Psoriasis by unknown
Psoriasis
Edited by Jennifer Soung and Bonnie Koo
Edited by Jennifer Soung and Bonnie Koo
We hope you enjoy and find the information provided in this book useful in 
your research or practice. We urge that you continue to keep abreast of the new 
developments in psoriasis and share your knowledge so that we may advance 
treatment and cures of psoriasis.

















Edited by Jennifer Soung and Bonnie Koo
Contributors
Peter Härle, Roxane Pouliot, Kaiming Zhang, Pierre-Dominique Ghislain, Ramón Martín-Brufau, Jorge C. Ulnik, F.J. 
Corbalan Berna, Carmen Brufau-Redondo, Farideh Zafari Zangeneh, Sebastiano Bucolo, Giuseppe Romano, Valerio 
Torre, Carmelo Quattrocchi, Maura Filidoro, Claudio Caldarelli, Eckart Haneke, Amra Osmancevic, Amedei Amedeo, 
Mario M. D’Elios, Anna Campanati, Annamaria Offidani, Giulia Liberati, Giulia Ganzetti, Anna Balato, Nicola Balato, 
Matteo Megna, Serena Lembo, Fabio Ayala, Maria Schiattarella, Edoardo Alesse, Daniela Verzella, Daria Capece, 
Valeria Iansante, Fausta Fischietti, Maria Concetta Fargnoli, Ketty Peris, Roberto Giacomelli, Francesca Zazzeroni, 
Amitava Mitra, Maria Lucia Diniz Araujo, Maria Goretti Pessoa De Araújo Burgos, Paulla Suylane Santos Fernandes 
Costa, Delia Colombo, Mark Boon Yang Tang, Chee Ren Ivan Lam, Ming Jie Tan, Yan Yih Goh, Nguan Soon Tan
© The Editor(s) and the Author(s) 2012
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2012 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Psoriasis
Edited by Jennifer Soung and Bonnie Koo
p. cm.
ISBN 978-953-307-878-6
eBook (PDF) ISBN 978-953-51-6743-3
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,100+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Dr. Jennifer Soung is a board certified dermatologist 
and Assistant Clinical Professor of Dermatology at 
the University of California, Irvine. As the director of 
Dermatology Clinical Research at UC Irvine, Dr. Soung 
has a broad interest in medical and cosmetic dermatolo-
gy as well as clinical research. Her clinical and research 
interest is the treatment of psoriasis. She is currently the 
Principal Investigator of two large clinical trials focused on examining new 
medications for the treatment of psoriasis. Besides psoriasis, Dr. Soung 
plans to explore new treatment options in rosacea and discoid lupus. Dr. 
Soung treats adult and pediatric skin conditions, including acne, eczema, 
rosacea, and skin cancer. She is well-versed in techniques for cosmetic reju-
venation of the aging face including Botox, lasers and chemical peels.
Dr. Soung received her Bachelor of Arts at Brown University and earned a 
medical degree from the Albert Einstein College of Medicine. She complet-
ed a medical internship at the West Los Angeles-UCLA Veterans Hospital 
and a dermatology residency at the University of California, Irvine. Dr. 
Soung also pursued advanced fellowship training in dermatopharmacol-
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Psoriasis has a worldwide distribution varying according to race and geographic 
location. This book presents the international experience of psoriasis from 
pathophysiology to clinical presentation and treatment strategies.   
The first section of the volume focuses on research related to the development of 
therapies for psoriasis. Experimental models and clinical results from immunologically 
directed therapies have demonstrated the important role and interaction of 
inflammatory cytokines, chemokines and immune cells in the pathogenesis of psoriasis. 
The next segment of the volume presents the varying, and often difficult to treat, 
clinical manifestations of psoriasis. The role of vitamin D in psoriasis is explored and 
the role of the metabolic syndrome in psoriasis is reviewed. 
The final segment of the volume is a discussion of therapy. The review of topical and 
biologic treatments discusses the spectrum of therapies available for psoriasis. The 
efficacy and safety of cyclosporine, a traditional systemic therapy, and the role of diet 
and nutrition is addressed.  
We hope you enjoy and find the information useful in your research or practice. We 
urge that you continue to keep abreast of the new developments in psoriasis and share 
your knowledge so that we may advance treatment and cures of psoriasis. 
Mona Malakouti (medical student) assisted with editing of the “UVB and Vitamin D 
in Psoriasis”chapter. 
Jennifer Soung, M.D. 
Assistant Professor & Director 
Dermatology Clinical Research 
University of California, Irvine 
USA 
Bonnie Koo, M.D. 
Clinical Research Specialist  









Psoriasis and Stem Cells 
Kaiming Zhang, Guohua Yin, Xinhua Li,  
Xuping Niu, Ruixia Hou, Ruifeng Liu and Junqin Li 
Taiyuan City Central Hospital Affiliated to Shanxi Medical University,  
1 Dong San Dao Xiang, Taiyuan, Shanxi Province, 
 China 
1. Introduction 
Psoriasis is a chronic inflammatory skin disorder characterized by hyper-proliferation of 
basal keratinocytes, thickened and scaly epidermis, and recruitment of inflammatory cells to 
the skin. It affects approximately 2% of the world’s population. The disease follows a 
pathogenic pathway involving various immunocytes and immune molecules. Activated T 
cells have been shown to trigger a chain of cellular and molecular reactions leading to the 
formation of psoriatic lesions. Fusion proteins that can block T cell activation or the function 
of anergized T cells, and cytokines and biologics that can inhibit T cell migration are 
effective in the treatment of psoriasis. Intradermal injection of T cells from psoriatic patients 
into human skin/severe combined immunodeficient (SCID) mice can induce spontaneous 
psoriatic conversion of skins from healthy human or non-lesional skin from psoriatic 
patients. Thus, it is widely accepted that psoriasis is a T lymphocyte-mediated autoimmune 
disease. Although the roles of T cells in psoriasis have been confirmed, the exact 
mechanisms of psoriasis and the origin of abnormal T cells are still unclear.  
Beside T cells, psoriatic patients have a wide variety of other immune abnormalities such as 
B cells, monocytes, neutrophils and erythrocytes. As the precursor of immune cells, bone 
marrow hematopoietic stem cells have been suggested to be responsible for immune 
dysregulation of T cells in psoriasis. Several recent studies have indicated that abnormal T 
cells may be closely related to anomalous hematopoietic stem cells (HSCs) determined by 
psoriatic hereditary background. In addition to HSCs, aberrant bone marrow mesenchymal 
stem cells have also been demonstrated in patients with psoriasis.  
2. The clinical cue of relationship between psoriasis and bone marrow cells  
Although various exogenous and endogenous factors are believed to activate the immune 
system leading to imbalance of the system and initiation of psoriasis, increasing evidences 
suggest that inherent and intrinsic rather than extrinsic factors are more important in 
psoriasis pathogenesis. These intrinsic factors may be involved in spontaneous T-cell 
activation or proliferation, regulation of cytokine production, hematopoietic cell 
development, and T-cell development in the thymus. Allogeneic bone marrow 
transplantations (BMT) have been reported to either eliminate or aggravate psoriasis. 
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Leukemia patients with psoriasis reportedly have long-term psoriasis remission or 
amelioration. On the other hand, non-psoriatic leukemia patients can develop psoriasis after 
transplanting bone marrow from psoriatic donors. These clinical reports indicate that 
psoriatic immune abnormalities transferred by BMT may have originated from bone 
marrow HSC. 
3. Bone marrow derived hematopoietic stem / progenitor cells from psoriatic 
patients are anomalously proliferative 
Based on the above evidence, many researchers begin to pay close attention to bone marrow 
abnormality of psoriatic patients. In vitro studies have shown that monocytopoietic activity 
is enhanced in psoriasis and functional bone marrow scintigraphy using 99Tcm-labelled 
human serum albumin millimicrospheres has shown hyperplasia of phagocytes in psoriasis. 
Bone marrow, with its rapidly renewing cell populations, is one of the most sensitive tissues 
to various stimulations of exogenous or endogenous factors. Once activated the pathogenic 
peripheral immunocytes in psoriasis and their released soluble factors, such as gamma-
interferon (IFN-γ), interleukin-2 (IL-2), IL-8 and tumor necrosis factor-alpha (TNF-α), may 
influence hematopoietic microenvironment, and even hematopoiesis. In vitro assessment 
using high proliferative potential colony-forming cell (HPP-CFCs) and colony formation 
units (CFU) is used as a surrogate marker of hematopoietic activity and can play a key role 
in linking hematopoiesis to psoriasis. Supernatant of in vitro cultured psoriatic peripheral 
blood mononuclear cells was found to suppress the proliferative activity of normal bone 
marrow HPP-CFCs, CFU-GM (granulocyte-macrophage colony-forming units) and CFU-E 
(erythroid colony-forming units). These results support the hypothesis that aberrant 
psoriatic peripheral immunocytes and cytokines can influence hematopoiesis. 
Recently, besides the influence of aberrant peripheral immunocytes and cytokines, 
researchers began to pay attention to the intrinsic deficiency of psoriatic bone marrow 
hematopoietic cells. Zhang et al. cultured psoriatic bone marrow mononuclear cells in 
methylcellulose semisolid medium and observed their colony formation ability in the 
presence of exogenous cytokine combinations. These studies show a decreased colony 
formation ability of HPP-CFC, CFU-GM but not CFU-E, implying that the proliferative 
activity of HSCs in patients with psoriasis may be intrinsically decreased. They further 
investigated the molecular mechanisms of abnormal proliferative activity of HSCs in 
psoriasis and found that promoter methylation of p15, p16 and p21 genes is significantly 
decreased and transcription levels of these genes are enhanced in ex vivo cultured bone 
marrow HPP-CFCs from psoriatic patients in comparison to those from healthy volunteers. 
The P15, P16 and P21 proteins belong to the INK4 kinase family of cyclin-dependent kinase 
inhibitors and can negatively regulate the cell cycle through competitive inhibition of cyclin-
dependent kinases 2, 4 and 6. Higher expression of these genes may contribute to the low 
proliferative activity of psoriatic hematopoietic cells.  
Expression of Notch receptors and their ligands in hematopoietic system has been widely 
reported, and Notch signaling has been shown to influence hematopoietic cell proliferation 
and differentiation at several stages. The activation of Notch signaling results in 
transcriptional activation of E(spl)/HES genes, which function as negative regulators of cell 
proliferation and differentiation. Moreover, Notch1 and Hes-1 expression is significantly 
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enhanced in psoriatic CD34+ bone marrow cells compared to normal controls. Beside HES 
genes, another transcription factor RUNX-1, which is essential for hematopoietic cell 
development, has long been suspected to be involved in the pathogenesis of psoriasis 
because loss of RUNX1 binding site located between the SLC9A3R1 and NAT9 genes at 
17q25 has been found increased expression in the psoriatic CD34+ cells. These studies 
suggest that the dysfunction of immune cells in psoriatic patients can be traced back to the 
early development of hematopoietic cells. 
4. T cells differentiated from bone marrow derived hematopoietic cells of 
psoriatic patients are functionally different from normal T cells  
Since T cells are derived from bone marrow hematopoietic cells, it is suggested that 
hematopoietic cells are partly relevant to the dysfunction of T cells in psoriasis. To 
demonstrate whether T cells are produced inherently dysfunctional from the immune 
system, Zhang et al. cultured bone marrow CD34+ cells from psoriatic patients and induced 
them to differentiate into T cells and CD4+CD25+ regulatory T cells in vitro. A further 
functional study revealed abnormal characters of these cells compared to normal bone 
marrow derived ones. 
The main hallmark of CD4+CD25+ T cells is their immune regulatory function by interacting 
with effector T cells. Several studies have reported that the CD4+CD25+ T-lymphocyte 
subpopulation in peripheral blood and lesional skin demonstrates a less inhibitory effect on 
effector T cells, leading to accelerated proliferation of pathogenic/effector T-cells in 
autoimmune diseases, especially in psoriasis. Although the proportion of CD4+CD25+ T cells 
and FOXP3 gene expression are comparable in both psoriatic and healthy samples, 
proliferation of psoriatic bone marrow derived CD4+CD25+ T cells is significantly attenuated 
and secretion of cytokines IL-2 and IL-10 is decreased compared to normal controls in 
response to streptococcal superantigen (Strep-A). In particular, CD4+CD25+ T cells 
differentiated from psoriatic CD34+ cells are functionally insufficient to restrain proliferation 
of activated effector T-cells. That is to say, the function of CD4+CD25+ T cells derived from 
psoriatic bone marrow CD34+ cells in vitro is similar to that of peripheral CD4+CD25+ T-
lymphocytes of psoriatic patient in vivo. 
In another study, bone marrow CD34+ hematopoietic cells from psoriatic patients with 
family history were induced into effector T cells and their functions such as in vitro 
proliferation ability, secretion of cytokines IL-4, IL-8 and IFN–γ, and their ability to 
induce human keratinocytes producing C-myc, Bcl-xL, and Ki67 proteins were compared 
with their counterpart from healthy objects. The differentiated T cells from CD34+ cells of 
psoriatic patients showed higher proliferative activity and stronger capacity to secret Th1 
cytokines in response to streptococcal superantigen and could induce expression of C-myc 
and Ki67, but not Bcl-XL in keratinocytes co-cultured with psoriatic differentiated T  
cells. 
These studies show that regulatory as well as effector T cells differentiated from CD34+ cells 
of psoriatic patients, but not normal controls, are functionally similar to those psoriatic 
circulating T cells and suggest that dysfunctional activity of T cells in psoriatic patients can 
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5. The bionomics of psoriatic bone marrow mesenchymal stem cells 
Mesenchymal stem cells, also referred as marrow stromal cells, are another important type 
of stem cells in bone marrow. Cytokines secreted by bone marrow mesenchymal stem cells 
(BMSCs) along with extracellular matrix compose the hematopoietic microenvironment and 
influence hematopoiesis. More than 30 hematopoietic cytokines and growth factors 
including TNF-a, IL-1, IL-6, IL-7, IL-8, IL-10, IL-12, IFN-γ and IL-18 are reportedly secreted 
by BMSCs and many of them could influence immune reaction of peripheral blood. 
Secretion of SCF, granulocyte colony-stimulating factor (G-CSF) and IL-6 is increased in in 
vitro cultured BMSCs from psoriatic patients, while that of IL-1a, IL-1b, IL-3, IL-8, epidermal 
growth factor (EGF), vascular endothelial growth factor (VEGF), TNF-a, leukaemia 
inhibitory factor (LIF), hepatocyte growth factor (HGF) and platelet-derived growth factor 
(PDGF) is decreased and the levels of GM-CSF, IL-11 or IL-7 is not altered. Pearson 
correlation analysis demonstrates that those cytokine levels are not correlated with PASI 
scores, indicating that abnormal secretion of cytokines is due to anomaly of BMMSCs 
themselves rather than systemic inflammatory response.   
On the other hand, BMSCs are also characterized by their ability to differentiate into 
multiple mesenchymal lineages, including osteocytes, chondrocytes, adipocytes, endothelial 
cells and skeletal muscle cells under controlled in vitro conditions. Studies have found that 
BMSCs from psoriatic patients have lower proliferative and passage ability and are more 
prone to differentiate into vascular endothelial cells (VEC) compared with those from 
healthy subjects under the same induction conditions. Moreover, this differentiation ability 
is paralleled with the disease severity. In addition, specimens from a patient whose parents 
also have psoriasis could spontaneously differentiate into VECs. Further studies on gene 
expression using RNA sequencing showed a total of 475 genes mostly enriched in 
prostaglandin (PG) and prostanoid metabolic process (unpublished data) are differentially 
expressed in this patient.  
Studies on differential gene expression of BMSCs from 4 psoriatic patients and 3 healthy 
subjects found a total of 1617 genes were differently expressed by more than 2-fold between 
the two groups, among which 324 genes were upregulated and 1293 genes were 
downregulated in psoriatic patients. GO analysis revealed the first five gene-enriched GO 
terms were immune response, inflammatory response, antigen processing and presentation 
of peptide, chemotaxis, and cell adhesion. While the first five highly enriched factor terms 
were positive regulation of CD4+CD25+ alpha-beta regulatory T cell differentiation, 
lipoprotein particle clearance, antigen processing and presentation of peptide, negative 
regulation of peptidase activity, and positive regulation of cholesterol storage (unpublished 
data). These terms have been confirmed to participate in the onset and development of 
psoriasis. 
Taken together, these studies suggest that BMSCs of psoriatic patients are abnormal in 
proliferation, differentiation, passage ability, secretion of multiple cytokines and gene 
expression, and may partly participate in the occurrence and development of psoriasis. In 
other words, psoriasis is a multi-system disease that involves not only the epidermis, but 
also the hematopoietic system, immune system, neuroendocrine system, and so on. With 
continued research, various stem cells may be confirmed to be involved in the generation 
and development of psoriasis. 
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5. The bionomics of psoriatic bone marrow mesenchymal stem cells 
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continued research, various stem cells may be confirmed to be involved in the generation 
and development of psoriasis. 
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1. Introduction  
Psoriasis is a chronic, inflammatory skin disease affecting 2 to 3% of the white population 
(Gudjonsson & Elder, 2007). It is a multifactorial disease since its development depends on a 
complex interplay of genetic and environmental factors. As no pathogen has been 
consistently identified within psoriatic plaques (indeed skin infections are rare in lesions 
because of antimicrobial peptides) (Nomura et al., 2003), an autoimmune basis for the 
chronic inflammation is the dogma for this complex disorder. Psoriasis is characterized by 
macroscopic (clinical) and corresponding microscopic (histological) skin alterations and 
leads to considerable impairment of the quality of life of the affected patients. Special forms 
of psoriasis (e.g. arthropathic form) can be accompanied by severe extra-cutaneous changes.  
2. Psoriasis pathogenesis 
Psoriasis is usually identified by erythematous, raised, scaly skin lesions. These clinical 
features are explained by impressive growth and dilation of superficial blood vessels 
(elongated/hyperplastic capillaries in the papillary dermal region) and equally impressive 
hyperplasia of the epidermis. Epidermal growth occurs in a pattern termed ‘‘psoriasiform’’ 
hyperplasia, which describes both elongated rete pegs, thickening (acanthosis), and 
differentiation changes (Krueger & Bowcock, 2005). In psoriatic epidermis, keratinocytes 
proliferate and mature rapidly so that terminal differentiation, normally occurring in 
granular keratinocytes and then squamous corneocytes, is incomplete. Hence, squamous 
keratinocytes aberrantly retain intact nuclei (parakeratosis) and release few extracellular 
lipids that normally cement adhesions of corneocytes. The failure of psoriatic corneocytes to 
stack normally and to secrete extracellular lipids cause scaling and a break in the protective 
barrier whereas marked dilation of blood vessels in the dermis causes the visible redness of 
psoriatic skin lesions. The extensive infiltration of mononuclear immune cells in the dermis 
and epidermis (T cells and dendritic cells in the dermis and polymorphonuclear leucocytes 
such as neutrophils within small foci in the stratum corneum) is another defining feature of 
psoriasis histopathology and a key point of its pathogenesis. The pathogenesis of psoriasis is 
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genetic background. According to this view, the presence of a yet unknown (auto)-antigen 
causes the generation of effector T-cells that infiltrate the skin and initiate the inflammatory 
process (Wolk et al., 2009a). Over its course, cutaneous infiltration of various immune cell 
populations and, subsequently, an activation of numerous immune and tissue cells in the 
skin take place. Secreted cytokines from activated cells then induce keratinocyte alterations 
such as excessive growth and aberrant differentiation forming the basis of the epidermal 
acanthosis, hyperkeratosis and parakeratosis which characterize psoriasis plaques. The 
trigger of keratinocyte response is thought to be the activation of the cellular immune 
system, with T cells, dendritic cells  and various immune-related cytokines and chemokines 
implicated in pathogenesis. Rather than viewing psoriasis as a disease caused by a single 
cell type or a single inflammatory cytokine, it is probably best to conceptualize the disease 
pathogenesis as linked to many interactive responses among infiltrating leucocytes, resident 
skin cells, and an array of pro-inflammatory cytokines, chemokines, and chemical mediators 
produced in the skin (Lowes et al., 2007). Fundamentally two different cell types interact in 
the formation of a psoriatic lesion: keratinocytes and mononuclear leukocytes. Whereas 
keratinocytes might be viewed only as bystander cells in terms of immune activation, it is 
more likely that they are active participants in the recruitment and activation of leukocytes  
in psoriatic lesions. Thus, there are two sets of interactive cellular responses in the psoriatic 
lesion that potentially create a ying/yang relationship; the balance between the activation of 
innate and acquired immune cell types, and the factors produced by epidermal 
keratinocytes that directly affect T cells and dendritic cells, and vice versa. Psoriasis is 
considered a T helper 1 (Th1) condition, characterized by the production of interferon-
gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) under the influence of interleukin-
12 (IL-12). However, there is increasing evidence of the importance of a novel T cell 
population, Th17 cells, in this inflammatory disease. Th17 cells are stimulated by IL-23 
(which shares the p40 subunit with IL-12) to produce IL-17 and also IL-22, which has 
recently been shown to be a major driver of acanthosis in psoriasis, and so is a novel target 
for treatment. Effector cells of innate immunity including neutrophils, plasmacytoid 
dendritic cells (plasmocytoid DCs) and CD11c+ dendritic cells (myeloid DCs) are involved 
and present in psoriatic lesions creating a very intricate and complex network of interactions 
which is the base of the pathogenetic process of psoriasis (Nograles et al., 2010). An 
interplay between environmental and genetic factors sets the scene for disease-initiating 
events. Initial triggers such as physical trauma or bacterial products start a cascade of events 
that include the formation of DNA-LL-37 complexes, activation of plasmocytoid dendritic 
cells and secretion of interferon-α (IFN-α). IFN-α secreted by plasmocytoid dendritic cells 
promotes the activation of myeloid dendritic cells (Nestle et al., 2005). Activated myeloid 
dendritic cells migrate into draining lymph nodes and induce the differentiation of naive T 
cells into effector cells such as Th17 or type 17 cytotoxic T cells (Tc17) and Th1 or type 1 
cytotoxic T cells (Tc1) (Nestle et al., 2010). Effector cells recirculate and slow down in skin 
capillaries in the presence of selectin-guided and integrin-guided receptor-ligand 
interactions. Immune cells expressing the chemokine receptors CCR6, CCR4, and CXCR3 
emigrate into skin tissue along chemokine gradients. Dendritic cells and T cells form 
perivascular clusters and lymphoid-like structures around blood vessels in the presence of 
chemokines such as CCL19 produced by macrophages. A key checkpoint is the migration of 
T cells from the dermis into the epidermis; this migration is controlled through the 
interaction of α1β1 integrin (very late antigen 1 [VLA-1]) on T cells and collagen IV at the 
basement membrane (Conrad et al., 2007). Unconventional T cells, including natural killer T 
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cells (NKT), contribute to the disease process. Key processes during disease maintenance are 
the presentation of putative (auto)-antigens to T cells, the release of IL-23 by dermal 
dendritic cells, the production of pro-inflammatory mediators such as IL-17A, IL-17F, IL-22 
by Th17 and Tc17 cells and IFN-y and TNF-α by Th1 and Tc1 cells. These mediators act on 
keratinocytes leading to the activation, proliferation and production of antimicrobial 
peptides (AMPs) (e.g., LL-37 cathelicidin and β-defensins) and chemokines (e.g., CXCL1, 
CXCL9 through CXCL11 and CCL20), and S100 proteins (e.g., S100A7-9) (Nestle et al., 2010). 
These soluble mediators feed back into the pro-inflammatory disease cycle and shape the 
inflammatory infiltrate (Fig.1). In fact keratinocyte products influence immune activation, 
and products of activated lymphocytes alter keratinocyte responses, including the induction 
of new adhesion molecules for T cells. However although intrinsic alterations in 
keratinocytes are crucial for the development of psoriatic lesions, a deregulated function of 
other resident skin cells, such as fibroblasts and endothelial cells, may also contribute to the 
pathogenesis of psoriasis. Epidermal-dermal cell interaction is a determinant for the 
maintenance of the psoriatic phenotype because it guarantees the local production of growth 
factors and cytokines stimulating keratinocyte proliferation. An important paracrine loop  
 





genetic background. According to this view, the presence of a yet unknown (auto)-antigen 
causes the generation of effector T-cells that infiltrate the skin and initiate the inflammatory 
process (Wolk et al., 2009a). Over its course, cutaneous infiltration of various immune cell 
populations and, subsequently, an activation of numerous immune and tissue cells in the 
skin take place. Secreted cytokines from activated cells then induce keratinocyte alterations 
such as excessive growth and aberrant differentiation forming the basis of the epidermal 
acanthosis, hyperkeratosis and parakeratosis which characterize psoriasis plaques. The 
trigger of keratinocyte response is thought to be the activation of the cellular immune 
system, with T cells, dendritic cells  and various immune-related cytokines and chemokines 
implicated in pathogenesis. Rather than viewing psoriasis as a disease caused by a single 
cell type or a single inflammatory cytokine, it is probably best to conceptualize the disease 
pathogenesis as linked to many interactive responses among infiltrating leucocytes, resident 
skin cells, and an array of pro-inflammatory cytokines, chemokines, and chemical mediators 
produced in the skin (Lowes et al., 2007). Fundamentally two different cell types interact in 
the formation of a psoriatic lesion: keratinocytes and mononuclear leukocytes. Whereas 
keratinocytes might be viewed only as bystander cells in terms of immune activation, it is 
more likely that they are active participants in the recruitment and activation of leukocytes  
in psoriatic lesions. Thus, there are two sets of interactive cellular responses in the psoriatic 
lesion that potentially create a ying/yang relationship; the balance between the activation of 
innate and acquired immune cell types, and the factors produced by epidermal 
keratinocytes that directly affect T cells and dendritic cells, and vice versa. Psoriasis is 
considered a T helper 1 (Th1) condition, characterized by the production of interferon-
gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) under the influence of interleukin-
12 (IL-12). However, there is increasing evidence of the importance of a novel T cell 
population, Th17 cells, in this inflammatory disease. Th17 cells are stimulated by IL-23 
(which shares the p40 subunit with IL-12) to produce IL-17 and also IL-22, which has 
recently been shown to be a major driver of acanthosis in psoriasis, and so is a novel target 
for treatment. Effector cells of innate immunity including neutrophils, plasmacytoid 
dendritic cells (plasmocytoid DCs) and CD11c+ dendritic cells (myeloid DCs) are involved 
and present in psoriatic lesions creating a very intricate and complex network of interactions 
which is the base of the pathogenetic process of psoriasis (Nograles et al., 2010). An 
interplay between environmental and genetic factors sets the scene for disease-initiating 
events. Initial triggers such as physical trauma or bacterial products start a cascade of events 
that include the formation of DNA-LL-37 complexes, activation of plasmocytoid dendritic 
cells and secretion of interferon-α (IFN-α). IFN-α secreted by plasmocytoid dendritic cells 
promotes the activation of myeloid dendritic cells (Nestle et al., 2005). Activated myeloid 
dendritic cells migrate into draining lymph nodes and induce the differentiation of naive T 
cells into effector cells such as Th17 or type 17 cytotoxic T cells (Tc17) and Th1 or type 1 
cytotoxic T cells (Tc1) (Nestle et al., 2010). Effector cells recirculate and slow down in skin 
capillaries in the presence of selectin-guided and integrin-guided receptor-ligand 
interactions. Immune cells expressing the chemokine receptors CCR6, CCR4, and CXCR3 
emigrate into skin tissue along chemokine gradients. Dendritic cells and T cells form 
perivascular clusters and lymphoid-like structures around blood vessels in the presence of 
chemokines such as CCL19 produced by macrophages. A key checkpoint is the migration of 
T cells from the dermis into the epidermis; this migration is controlled through the 
interaction of α1β1 integrin (very late antigen 1 [VLA-1]) on T cells and collagen IV at the 
basement membrane (Conrad et al., 2007). Unconventional T cells, including natural killer T 
 
Pathogenesis of Psoriasis: The Role of Pro-Inflammatory Cytokines Produced by Keratinocytes 
 
11 
cells (NKT), contribute to the disease process. Key processes during disease maintenance are 
the presentation of putative (auto)-antigens to T cells, the release of IL-23 by dermal 
dendritic cells, the production of pro-inflammatory mediators such as IL-17A, IL-17F, IL-22 
by Th17 and Tc17 cells and IFN-y and TNF-α by Th1 and Tc1 cells. These mediators act on 
keratinocytes leading to the activation, proliferation and production of antimicrobial 
peptides (AMPs) (e.g., LL-37 cathelicidin and β-defensins) and chemokines (e.g., CXCL1, 
CXCL9 through CXCL11 and CCL20), and S100 proteins (e.g., S100A7-9) (Nestle et al., 2010). 
These soluble mediators feed back into the pro-inflammatory disease cycle and shape the 
inflammatory infiltrate (Fig.1). In fact keratinocyte products influence immune activation, 
and products of activated lymphocytes alter keratinocyte responses, including the induction 
of new adhesion molecules for T cells. However although intrinsic alterations in 
keratinocytes are crucial for the development of psoriatic lesions, a deregulated function of 
other resident skin cells, such as fibroblasts and endothelial cells, may also contribute to the 
pathogenesis of psoriasis. Epidermal-dermal cell interaction is a determinant for the 
maintenance of the psoriatic phenotype because it guarantees the local production of growth 
factors and cytokines stimulating keratinocyte proliferation. An important paracrine loop  
 





operating between keratinocytes and fibroblasts that culminates with keratinocyte 
proliferation is triggered by IL-1: IL-1α and IL-1β neutralization and IL-1 receptor antagonist 
significantly reduced keratinocyte growth through the abrogation of keratinocyte growth 
factor (KGF) production by fibroblasts. However, IL-1 is unlikely to be the only regulator of 
KGF production by fibroblasts, and indeed other keratinocyte-derived factors, such as 
parathyroid hormone–related protein (PTHrP), induce KGF expression. In addition 
fibroblast growth factor (FGF) family members and granulocyte-macrophage colony 
stimulating factor (GM-CSF) also play a particularly important role in the fibroblast-driven 
regulation of keratinocyte proliferation (Albanesi et al., 2007). Moreover, the activated 
phenotype of lesional endothelial cells are believed to play a central role in the pathogenesis 
of psoriasis and are determined by the expression of a variety of membrane and soluble 
factors mainly responsible for T-cell recruitment in the skin like adhesion molecule 1 
(ICAM-1). A key point is the endothelium expression of certain chemokines involved in the 
arrest of circulating T lymphocytes at inflammatory sites: upon exposure to inflammatory 
signals, mainly represented by TNF-α and IL-1, endothelial cells express a broad array of 
chemokines, including CCL20/MIP-3α, CXCL12/SDF-1, CCL21/SLC, CCL17/TARC, 
CCL2/MCP-1, CXCL10/IL-8, CCL5/RANTES, CXCL1/Gro-α, and CCL4/MIP-1β 
(Girolomoni et al., 2004).   
In summary, feedback loops involving keratinocytes, fibroblast and endothelial cells 
contribute to tissue reorganization with endothelial cell activation and proliferation and 
deposition of extracellular matrix. The hypothesis of cytokine/chemokine network in 
psoriasis proposed a central role of pro-inflammatory cytokines, including TNF-α. 
3. A special look at the pathogenetic functions of keratinocytes  
Besides erythema, impressive hyperkeratosis manifesting as large, silvery scales, is clinically 
the most visible pathology and represents a hallmark of psoriasis. This typical and 
characteristic epidermal involvement has in the past led to discussions on whether 
hyperproliferation and altered differentiation of epidermal keratinocytes occur indeed only 
in response to skin inflammation or whether keratinocytes themselves have their share in 
initiation and/or propagation of psoriasis. Whereas it is widely accepted today that 
keratinocytes have the potential to actively participate and modulate immune reactions in 
the skin their role as initiators or amplifiers of the inflammatory reaction in psoriasis is still 
not so clear (Tschachler, 2007). Some evidence indicates that the exposure of altered auto-
antigens by keratinocytes could be directly responsible for the activation and expansion of 
certain T-cell subpopulations in psoriatic skin (Bos et al., 2005). A keratinocyte-derived 
candidate auto-antigen is keratin 17. Patients with active psoriasis have an increased 
frequency of circulating Th1 cells reacting to peptides from keratin 17 that shares ALEEAN 
aminoacidic sequence with the streptococcus M-protein. Using a new approach termed 
SErological identification of Recombinant EXpressed antigens (SEREX), new auto-antigens 
were found in the serum of patients with psoriasis (Jones et al., 2004). Keratin 13, 
heterogeneous ribonucleprotein-A1, and a previously uncharacterized protein, FLJ00294, 
were identified by SEREX as representative antigens in psoriatic patients, although auto-
reactivity for these proteins was also detected in control subjects without psoriasis. 
Keratinocytes could be indirectly responsible for the activation of pathogenetic T cells 
through the exposure to viral or bacterial products. Under the influence of IL-17 and IL-22, 
keratinocytes, are able to produce AMPs like human beta defensin 2, and S100 proteins 
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(Nograles et al., 2008). The expression of another antimicrobial peptide, LL-37 cathelicidin, 
can also be enhanced by IL-17 in the presence of vitamin D3 (Peric et al., 2008). These 
proteins may function as key inflammation inducers in psoriasis, and at the same time 
decrease skin infections under conditions of a dysfunctional epidermal barrier. Infections or 
injury to the skin can promote lesion formation in susceptible individuals and these triggers 
have been shown to stimulate keratinocyte production of the antimicrobial LL-37 
cathelicidin that, when complexed with self-DNA, binds to TLR9 on plasmocytoid DCs. 
These cells produce massive amounts of IFN-α and are implicated in the initiation of psoriasis 
lesions (Lande et al., 2007). Accordingly, patients treated with a topical plasmocytoid DCs 
agonist, imiquimod, up-regulate IFN-α and experience exacerbations in psoriasis. In addition 
to stimulating plasmocytoid DCs, LL-37 has been shown to complex with self-RNA to trigger 
the activation of myeloid dendritic cells (myeloid DCs) through TLR8. This leads to production 
of TNF-α and IL-6, and promotes their differentiation into mature dendritic cells (Ganguly et 
al., 2009). Because myeloid DCs in psoriasis have been shown to produce IL-23 it is plausible 
that self-RNA complexes might potentially initiate the inflammatory cascade leading to 
expansion and activation of Th17 cells (Nograles et al., 2010).  
Recent investigations identified high levels of osteopontin (OPN) in psoriatic plaques 
(Buommino et al., 2009). Osteopontin is produced by both keratinocytes and activated T 
cells. It is a phosphorylated acidic glycoprotein of pleiotropic properties and has been 
recently recognized as a potential inflammatory cytokine. A model for the role of OPN in 
Th1  Th17 psoriatic disease was so suggested. After activation of myeloid DCs that express 
OPN, they migrate to skin draining lymph nodes and polarize naive T cells towards a Th1 
and Th17 phenotype. In addition OPN secreted by keratinocytes attracts additional 
inflammatory cells. Moreover OPN inhibits keratinocyte apoptosis thereby supporting 
enhanced epidermal proliferation, and, through a pro-angiogenic effect on microvascular 
endothelial cells, OPN also promotes vessel formation subsequently supporting the influx of 
inflammatory cells (Buback et al., 2009).  
3.1 Keratinocytes and cytokines 
Cutaneous and systemic over-expression of various pro-inflammatory cytokines has been 
demonstrated in psoriasis. Psoriatic keratinocytes are able to produce and release IL-1α, IL-
1β, IL-6, IL-15, IL-18 and IL-20, all of them involved in the development of different 
alterations which compose the complex and intricate net of psoriasis pathogenesis (Tab. 
1).The cellular composition of the inflammatory infiltrate within the psoriatic plaques as 
well as hyperproliferation of keratinocytes and so the whole pathogenetic process of 
psoriasis appears to be mediated by these cytokines (Wojas-Pelc et al., 2006).  
3.1.1 Keratinocytes and IL-1α & IL-1β 
IL-1 is a pro-inflammatory cytokine stimulating, among others, IL-2 and IFN-γ production 
through activated T cells. IL-1 activates neutrophils, monocytes, eosinophils and 
basophils, triggers production of TNF-α, IL-6, IL-8 by macrophages, and in autocrine 
fashion, IL-1 synthesis. IL-1 promotes proliferation of bone marrow cells, B lymphocytes, 
neutrophils, macrophages and platelets (Dinariello, 2002). In psoriasis, keratinocytes are 
the main source of IL-1α and IL-1β in the skin stored in the form of precursor particles 
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can also be enhanced by IL-17 in the presence of vitamin D3 (Peric et al., 2008). These 
proteins may function as key inflammation inducers in psoriasis, and at the same time 
decrease skin infections under conditions of a dysfunctional epidermal barrier. Infections or 
injury to the skin can promote lesion formation in susceptible individuals and these triggers 
have been shown to stimulate keratinocyte production of the antimicrobial LL-37 
cathelicidin that, when complexed with self-DNA, binds to TLR9 on plasmocytoid DCs. 
These cells produce massive amounts of IFN-α and are implicated in the initiation of psoriasis 
lesions (Lande et al., 2007). Accordingly, patients treated with a topical plasmocytoid DCs 
agonist, imiquimod, up-regulate IFN-α and experience exacerbations in psoriasis. In addition 
to stimulating plasmocytoid DCs, LL-37 has been shown to complex with self-RNA to trigger 
the activation of myeloid dendritic cells (myeloid DCs) through TLR8. This leads to production 
of TNF-α and IL-6, and promotes their differentiation into mature dendritic cells (Ganguly et 
al., 2009). Because myeloid DCs in psoriasis have been shown to produce IL-23 it is plausible 
that self-RNA complexes might potentially initiate the inflammatory cascade leading to 
expansion and activation of Th17 cells (Nograles et al., 2010).  
Recent investigations identified high levels of osteopontin (OPN) in psoriatic plaques 
(Buommino et al., 2009). Osteopontin is produced by both keratinocytes and activated T 
cells. It is a phosphorylated acidic glycoprotein of pleiotropic properties and has been 
recently recognized as a potential inflammatory cytokine. A model for the role of OPN in 
Th1  Th17 psoriatic disease was so suggested. After activation of myeloid DCs that express 
OPN, they migrate to skin draining lymph nodes and polarize naive T cells towards a Th1 
and Th17 phenotype. In addition OPN secreted by keratinocytes attracts additional 
inflammatory cells. Moreover OPN inhibits keratinocyte apoptosis thereby supporting 
enhanced epidermal proliferation, and, through a pro-angiogenic effect on microvascular 
endothelial cells, OPN also promotes vessel formation subsequently supporting the influx of 
inflammatory cells (Buback et al., 2009).  
3.1 Keratinocytes and cytokines 
Cutaneous and systemic over-expression of various pro-inflammatory cytokines has been 
demonstrated in psoriasis. Psoriatic keratinocytes are able to produce and release IL-1α, IL-
1β, IL-6, IL-15, IL-18 and IL-20, all of them involved in the development of different 
alterations which compose the complex and intricate net of psoriasis pathogenesis (Tab. 
1).The cellular composition of the inflammatory infiltrate within the psoriatic plaques as 
well as hyperproliferation of keratinocytes and so the whole pathogenetic process of 
psoriasis appears to be mediated by these cytokines (Wojas-Pelc et al., 2006).  
3.1.1 Keratinocytes and IL-1α & IL-1β 
IL-1 is a pro-inflammatory cytokine stimulating, among others, IL-2 and IFN-γ production 
through activated T cells. IL-1 activates neutrophils, monocytes, eosinophils and 
basophils, triggers production of TNF-α, IL-6, IL-8 by macrophages, and in autocrine 
fashion, IL-1 synthesis. IL-1 promotes proliferation of bone marrow cells, B lymphocytes, 
neutrophils, macrophages and platelets (Dinariello, 2002). In psoriasis, keratinocytes are 
the main source of IL-1α and IL-1β in the skin stored in the form of precursor particles 





Langerhans cells (LCs) are additional IL-1 sources (Yoshinaga et al., 1995). Normal 
keratinocytes do not contain a biologically active form of interleukin 1β-converting 
enzyme (ICE), and almost all IL-1 activity in the healthy epidermis results from the 
activity of IL-1α. In transgenic mouse models, IL-1α production in the basal layer of the 
epidermis leads to development of inflammatory lesions characterized by erythema and 
histology resembling psoriasis  (Groves et al., 1995). Although IL-1 expression in the 
psoriatic epidermis appears altered, data on this finding are often conflicting. Some 
studies showed that IL-1α levels in psoriatic lesions were decreased or below detection 
limits in comparison to non-lesional and healthy skin (Okubo & Koga, 1998), whereas 
others demonstrated increased levels of IL-1β (Debets et al., 1997). Serum levels of IL-1α 
and IL-1β were low both in patients and in healthy controls. Increased levels of IL-1α and 
IL-1β were noted in supernatants of monocyte cultures obtained from patients with 
psoriasis (Okubo & Koga, 1998). Peripheral blood mononuclear cells (PBMCs) of inactive 
psoriasis patients produced lower levels of IL-1α and IL-1β than the cells obtained from 
patients with active psoriasis, although still higher than those of healthy controls. The 
production of IL-1β by PBMCs from psoriatic patients positively correlated with disease 
severity (Mizutani et al., 1997). Higher levels of IL-1β in blister fluid than in serum 
support the hypothesis that this cytokine is locally produced in psoriatic lesions. Despite 
fairly strong arguments for the key role of IL-1 in the activation of psoriasis, there is 
scarcity of data on the use of IL-1 antagonists in psoriasis treatment.  
 
Cytokines Role in psoriasis 
IL-1 Stimulation of IL-2 and IFN-γ production 
through activated T cells and of TNF-α, IL-
6, IL-8 by macrophages, and in autocrine 
fashion, of IL-1 synthesis. 
IL-6 Regulation of growth and differentiation of 
epidermal cells and stimulation of Th17 
cells  differentiation. 
IL-15 Anti-apoptotic effects on lymphocytes and 
keratinocytes; stimulation of IL-17 
expression, promotion of T cell and 
monocyte activation, production of 
cytokines implicated in the pathogenesis of 
psoriasis, including IFN-γ and TNF-α. 
IL-18 Induction of several chemokines in 
fibroblasts and neutrophils, increased T-
cell adhesion to extracellular matrix 
ligands, induction of angiogenesis, 
induction of chemotaxis in plasmacytoid 
dendritic cells. 
IL-20 Inhibition of normal terminal 
differentiation of keratinocytes, induction 
of anti-bacterial proteins. 
Table 1. Roles of cytokines released by psoriatic keratinocytes. 
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3.1.2 Keratinocytes and IL-6 
IL-6 is involved in the growth and differentiation of dermal and epidermal cells (Hirano, 
1998), growth and differentiation of cytotoxic cells, activation of natural killer cells (NK) and 
maturation of hematopoietic stem cells (Pietrzak et al., 1999). Furthermore it acts as a 
chemotactic factor for T cells, and thus can directly stimulate T-cell migration to the 
epidermis. Increased levels of mRNA of IL-6 and its receptor were observed in psoriatic  
lesions, suction blister fluid and in keratinocytes (Krasowska et al., 1998). Previous studies 
have also shown a high level of IL-6 in plasma/serum of patients with psoriasis (Galadari & 
Sheriff, 2005; Grossman et al., 1989). Higher IL-6 levels were observed in psoriatic lesions 
compared to non-lesional and normal healthy skin (Chang et al., 1992; Grossman et al., 
1989). Classical anti-psoriatic therapies such as phototherapy (PUVA, UVB), systemic 
corticosteroids and methothrexate lead to normalization of IL-6 levels (Mizutani et al., 1997). 
Both non-lesional and lesional psoriatic keratinocytes produce IL-6 (Grossman et al., 1989; 
Krasowska et al., 1998; Zalewska et al., 2006). IL-1 and TNF-α activate keratinocytes to 
produce IL-6. Koebner phenomenon is likely to result from the increased activity of IL-6 and 
its receptor in psoriasis (Grossman et al., 1989). Many studies show that IL-17F is able to 
induce IL-6 production both in normal human epidermal keratinocytes and in mouse skin 
(Fujishima et al., 2010). Moreover CD4+ T cells in skin from psoriasis patients express IL-17F 
and recent studies have demonstrated increased expression of IL-6 in IL-17F-overexpressing 
mice, thus further supporting a role of IL-17F in the induction of IL-6 (Hurst et al., 2002; 
Yang et al., 2008). IL-6 could directly contribute to the epidermal hyperplasia seen in 
psoriatic epithelium as well as affecting the function of dermal inflammatory cells. 
Moreover, it has been demonstrated that IL-6 induces Th17 cell differentiation in humans 
(Ishigame et al., 2009). Taken together, all these data suggest that IL-17F-induced IL-6 
produced by keratinocytes promotes the development of Th17 cells as an autocrine 
regulator. Thus, the IL-17F/IL-6 axis may enhance inflammation of the lesional skin in 
psoriasis (Fujishima et al., 2010).  
3.1.3 Keratinocytes and IL-15 
IL-15 is a pro-inflammatory cytokine involved in chronic inflammatory processes. It is a key 
factor controlling the activation, proliferation and survival of NK cells (Fehniger & Caligiuri, 
2001; Liu et al., 2000). IL-15 is also a strong chemotactic factor for leukocytes. This cytokine 
triggers angiogenesis and exerts strong anti-apoptotic effects, especially on lymphocytes, 
hepatocytes and keratinocytes (Berard et al., 2003; Rückert et al., 2000). Furthermore, it 
stimulates the expression of IL-17 by T cells (Elder, 2007). Elevated levels of IL-15 were 
noted in the lesional psoriatic skin (Elder, 2007; Rückert et al., 2000; Yano et al., 2003). 
Monocytes and macrophages represent the main source of IL-15 (Fehniger & Caligiuri, 2001; 
Musso et al., 1999) in lesional psoriatic skin, as well as keratinocytes (McInnes & Gracie, 2004; 
Yano et al., 2003). Lesional keratinocytes are strong producers of IL-15, which not only appears 
critical in the promotion of T cell and monocyte activation and, hence, in the maintenance of 
the local pro-inflammatory milieu, but also in the keratinocyte self-protection from apoptosis 
(Rückert et al., 2000); the pathogenic effect of this cytokine in psoriasis probably results from 
the stimulation of proliferation and activation of T cells and pro-inflammatory cytokines 
release (including TNF-α). Recent genetic studies (Elder, 2007) further supported the role of IL-
15 as an important factor in psoriasis pathogenesis: IL-15 acts as a growth factor for CD8+ T 
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1998), growth and differentiation of cytotoxic cells, activation of natural killer cells (NK) and 
maturation of hematopoietic stem cells (Pietrzak et al., 1999). Furthermore it acts as a 
chemotactic factor for T cells, and thus can directly stimulate T-cell migration to the 
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have also shown a high level of IL-6 in plasma/serum of patients with psoriasis (Galadari & 
Sheriff, 2005; Grossman et al., 1989). Higher IL-6 levels were observed in psoriatic lesions 
compared to non-lesional and normal healthy skin (Chang et al., 1992; Grossman et al., 
1989). Classical anti-psoriatic therapies such as phototherapy (PUVA, UVB), systemic 
corticosteroids and methothrexate lead to normalization of IL-6 levels (Mizutani et al., 1997). 
Both non-lesional and lesional psoriatic keratinocytes produce IL-6 (Grossman et al., 1989; 
Krasowska et al., 1998; Zalewska et al., 2006). IL-1 and TNF-α activate keratinocytes to 
produce IL-6. Koebner phenomenon is likely to result from the increased activity of IL-6 and 
its receptor in psoriasis (Grossman et al., 1989). Many studies show that IL-17F is able to 
induce IL-6 production both in normal human epidermal keratinocytes and in mouse skin 
(Fujishima et al., 2010). Moreover CD4+ T cells in skin from psoriasis patients express IL-17F 
and recent studies have demonstrated increased expression of IL-6 in IL-17F-overexpressing 
mice, thus further supporting a role of IL-17F in the induction of IL-6 (Hurst et al., 2002; 
Yang et al., 2008). IL-6 could directly contribute to the epidermal hyperplasia seen in 
psoriatic epithelium as well as affecting the function of dermal inflammatory cells. 
Moreover, it has been demonstrated that IL-6 induces Th17 cell differentiation in humans 
(Ishigame et al., 2009). Taken together, all these data suggest that IL-17F-induced IL-6 
produced by keratinocytes promotes the development of Th17 cells as an autocrine 
regulator. Thus, the IL-17F/IL-6 axis may enhance inflammation of the lesional skin in 
psoriasis (Fujishima et al., 2010).  
3.1.3 Keratinocytes and IL-15 
IL-15 is a pro-inflammatory cytokine involved in chronic inflammatory processes. It is a key 
factor controlling the activation, proliferation and survival of NK cells (Fehniger & Caligiuri, 
2001; Liu et al., 2000). IL-15 is also a strong chemotactic factor for leukocytes. This cytokine 
triggers angiogenesis and exerts strong anti-apoptotic effects, especially on lymphocytes, 
hepatocytes and keratinocytes (Berard et al., 2003; Rückert et al., 2000). Furthermore, it 
stimulates the expression of IL-17 by T cells (Elder, 2007). Elevated levels of IL-15 were 
noted in the lesional psoriatic skin (Elder, 2007; Rückert et al., 2000; Yano et al., 2003). 
Monocytes and macrophages represent the main source of IL-15 (Fehniger & Caligiuri, 2001; 
Musso et al., 1999) in lesional psoriatic skin, as well as keratinocytes (McInnes & Gracie, 2004; 
Yano et al., 2003). Lesional keratinocytes are strong producers of IL-15, which not only appears 
critical in the promotion of T cell and monocyte activation and, hence, in the maintenance of 
the local pro-inflammatory milieu, but also in the keratinocyte self-protection from apoptosis 
(Rückert et al., 2000); the pathogenic effect of this cytokine in psoriasis probably results from 
the stimulation of proliferation and activation of T cells and pro-inflammatory cytokines 
release (including TNF-α). Recent genetic studies (Elder, 2007) further supported the role of IL-
15 as an important factor in psoriasis pathogenesis: IL-15 acts as a growth factor for CD8+ T 





inflammatory cell recruitment, angiogenesis, and production of other cytokines implicated in 
the pathogenesis of psoriasis, including IFN-γ and TNF-α.  
3.1.4 Keratinocytes and IL-18 
IL-18 exerts its activity on the human defense system in inflammatory, infectious and 
autoimmune diseases (Dinarello, 2006). IL-18 over-production stimulates the recruitment of 
dendritic cells to the site of inflammation (Gutzmer et al., 2003). IL-18, especially together 
with IL-12, triggers the production of IFN-γ in many immunocompetent cells, including NK 
cells, T helper and cytotoxic cells. Subsequently, IFN-γ decreases Th2 response and enhances 
Th1 response by stimulating cytotoxic T cells (Ericson et al., 2004). Thus, IL-18 possesses the 
capacity to stimulate innate immunity as well as Th1-mediated responses (Nakanishi et al., 
2001). IL-18 overproduction is characteristic for many diseases including psoriasis 
(Nakanishi et al., 2001). The role of IL-18 in psoriasis has not been fully elucidated. It is 
speculated that IL-18 produced by human keratinocytes enhances IFN-γ production in 
inflammation and thus IL-18 seems to be a promising target in Th1-type inflammatory 
diseases, like psoriasis (McKenzie et al., 2002; Ohta et al., 2001). Its expression in psoriasis is 
significantly enhanced in supra-basal keratinocytes (Flisiak et al., 2006; McKenzie et al., 
2002; Ohta et al., 2001). Reverse transcription polymerase chain reaction (RT-PCR) revealed IL-
18 mRNA levels to be two to eight times higher in psoriatic skin biopsies than in the non-
lesional psoriatic skin and healthy controls. Overexpression of IL-18 was observed in 
keratinocytes of the whole epidermis in psoriatic lesions and in the basal layer of non-lesional 
epidermis compared to only slight IL-18 expression in the epidermis of healthy controls 
(McKenzie et al., 2002). McKenzie et al. reported six to eight-fold higher levels of the IL-18 
receptor mRNA in the epidermis of psoriatic lesions compared to non-lesional and healthy 
control skin. Moreover total IL-18 protein levels were found to be 3.5 times higher in the active 
and progressive psoriatic epidermis compared to the normal and stable, plaque-type psoriatic 
epidermis. To date, there are only a few studies on IL-18 in the blood of psoriatic patients 
(Flisiak et al., 2006, Gangemi et al., 2003), which revealed increased plasma IL-18 levels in 
psoriatic patients in comparison to controls. IL-18 might act in the early phases of psoriasis via 
IFN-γ independent routes, such as: a) induction of several chemokines in fibroblasts and 
neutrophils (Leung et al., 2001; Morel et al., 2001); b) increased T-cell adhesion to extracellular 
matrix ligands (Ariel et al., 2002); c) induction of angiogenesis (Park et al., 2001); d) induction 
of chemotaxis in plasmacytoid dendritic cells (Kaser et al., 2004). Thus, IL-18 could be involved 
in the regulation of early inflammatory events by promoting the recruitment and adhesion of 
the immune system cells to the inflamed sites. However, whether IFN-γ-dependent or 
independent mechanisms are responsible for the IL-18 activity in early stages of psoriatic 
plaque development remains to be elucidated.  
3.1.5 Keratinocytes and IL-20 
IL-20 was demonstrated to promote hyperproliferation of keratinocytes by activating IL-20 
receptor to modulate skin inflammation. It was also reported that IL-20 induced IL-6 and TNF-
α in monocytes, stimulated the expression of keratinocytes growth factor (KGF), IL-6, TNF-α 
and reactive oxygen species (ROS) in CD8+ T cells (Wei et al., 2006). In psoriasis, the two most 
important effects of IL-20 are the inhibition of normal terminal differentiation of keratinocytes 
and the induction of anti-bacterial proteins (Wolk et al., 2009a). Keratinocyte terminal 
differentiation is the apoptosis-like process that generates corneocytes for the desquaming 
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stratum corneum from living keratinocytes of the upper (granular) epidermis layer (Candi et 
al., 2005). In psoriatic lesions, which contain high levels of IL-20, this process is altered. 
Furthermore, IL-20 simultaneously enhance the K16 expression, a keratin known to be up-
regulated in psoriatic lesions and associated with keratinocyte regeneration (Wolk et al., 2006, 
2009b). Apart from the inhibition of normal terminal differentiation of keratinocytes, IL-20 in 
addition to other mediators (Kanda & Watanabe, 2008), induce a state of enhanced 
antimicrobial defence of the epidermis by inducing a range of antimicrobial proteins (Sa et al., 
2007; Wolk et al., 2004, 2006). In psoriatic lesions IL-20 expression was found preferentially in 
basal and supra-basal keratinocytes above the dermal papillae (Romer et al., 2003; Wolk et al., 
2009a). Most interestingly, IL-17 and TNF- amplified the IL-22 induced production of IL-20 in 
keratinocytes. In summary, the T/NK cell cytokine IL-22 induces the keratinocyte secretion of 
IL-20 as a second mediator that has very similar effects to its own. IL-20, therefore, may, to 
some extent, further amplify and/or prolong the IL-22 action on the keratinocyte 
differentiation that leads to the characteristic epidermal changes observed in psoriasis.  
3.1.6 Keratinocytes and other cytokines 
TNF-α is a key pro-inflammatory cytokine with an important pathogenetic role in psoriasis 
and psoriatic arthritis. The evidence includes further observations that a variety of anti-
TNF-α approaches such as monoclonal antibodies and fusion proteins of soluble TNF-α 
receptors are effective therapies both in psoriasis and psoriatic arthritis. As for TNF-α itself, 
production of this cytokine is mainly attributed to immune cells (Lowes et al., 2007); 
however, it is noteworthy that keratinocytes are also able to elaborate TNF-α (Gottlieb at al., 
2005). In psoriasis, the inflammatory response to TNF-α could be self-sustaining: activated 
dendritic cells are the major source of TNF-α in psoriasis lesions (Boyman et al., 2004) and at 
the same time TNF-α mRNA is induced in keratinocytes after TNF-α exposure (Gottlieb et 
al., 2005). Low level of TNF-α is present in the upper layer of the healthy epidermis, but its 
synthesis and release from keratinocytes are greatly augmented by injury, infection and UV 
irradiation. Of the two distinct cell-surface receptors for TNF-α, TNFR1 and TNFR2, 
keratinocytes mainly express TNFR1 (Kondo & Sauder, 1997). The binding of TNF-α to 
TNFR1 triggers a series of intracellular events resulting in the activation of transcription 
factors, including NF-KB, AP-1, CCAAT enhancer-binding protein-β, and others, which are 
responsible for the induction of genes important for diverse biological processes, including 
cell growth and death and immune, inflammatory, and stress responses (Banno et al., 2004). 
TNF-α activates the immune responses through inducing the production of additional 
signals, such as IL-1 and IL-8, transforming growth factor type-β (TGF-β) and ICAM-1. 
Psoriatic keratinocytes are also an important source of IL-7. Increased IL-7 levels were 
observed in both the psoriatic skin and serum of psoriatic patients (Bonifati et al., 1997; 
Pietrzak et al., 2008). However, no correlation between IL-7 levels and psoriasis area severity 
index (PASI) score was observed. In addition, IL-7 levels did not decrease after effective 
anti-psoriatic treatment, which suggests that this cytokine could not be regarded as a marker 
of the disease activity. IL-7 is a pleiotropic cytokine playing an essential role in the 
development and differentiation of T cells. IL-7 regulates survival, proliferation and 
cytotoxicity of maturation of T cells at the periphery. Furthermore, IL-7 together with IL-2 
and IL-12, can induce the synthesis of IFN-γ, while, in turn, IFN-γ induces IL-7 secretion by 
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stratum corneum from living keratinocytes of the upper (granular) epidermis layer (Candi et 
al., 2005). In psoriatic lesions, which contain high levels of IL-20, this process is altered. 
Furthermore, IL-20 simultaneously enhance the K16 expression, a keratin known to be up-
regulated in psoriatic lesions and associated with keratinocyte regeneration (Wolk et al., 2006, 
2009b). Apart from the inhibition of normal terminal differentiation of keratinocytes, IL-20 in 
addition to other mediators (Kanda & Watanabe, 2008), induce a state of enhanced 
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2007; Wolk et al., 2004, 2006). In psoriatic lesions IL-20 expression was found preferentially in 
basal and supra-basal keratinocytes above the dermal papillae (Romer et al., 2003; Wolk et al., 
2009a). Most interestingly, IL-17 and TNF- amplified the IL-22 induced production of IL-20 in 
keratinocytes. In summary, the T/NK cell cytokine IL-22 induces the keratinocyte secretion of 
IL-20 as a second mediator that has very similar effects to its own. IL-20, therefore, may, to 
some extent, further amplify and/or prolong the IL-22 action on the keratinocyte 
differentiation that leads to the characteristic epidermal changes observed in psoriasis.  
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reciprocal interactions between epithelial cells (keratinocytes) and T-lymphocytes. The 
concomitant T-lymphocyte activation may be dependent on IL-7, and therefore the 
subsequent events driving toward the clinical expression and persistence of psoriasis may 
be IL-7 mediated (Bonifati et al., 1997). All these findings suggest an involvement of IL-7 in 
psoriasis, although further studies are warranted to elucidate the exact role of this molecule 
in the cytokine network of psoriasis pathogenesis. 
3.2 Keratinocytes and chemokines 
Keratinocytes produce many different types of chemokines involved in the recruitment of 
immune cells in the skin. For this reason epidermal cells can play a fundamental role in 
collecting all the immune cells which are implicated in the beginning of the cutaneous 
inflammation process that characterize psoriatic disease. Specifically, keratinocytes release 
IL-8 (CXCL8) and related chemokines which are responsible for the intra-epidermal 
collection of neutrophils and so to the formation of subcorneal microabscesses, a 
characteristic feature of psoriasis (Nickoloff & Turka, 1994); CCL2 (MCP-1), CCL5 
(RANTES), CXCL10 (IP-10), and other CXCR3 ligands are responsible to attract 
predominantly monocytes and Th1 cells, (Gillitzer et al., 1993; Gottlieb et al., 1998), whereas 
CCL20 (MIP-3α) recruits immature Langerhans cells, dendritic cells, and CLA+ T cells 
(Dieu-Nosjan et al., 2000; Homey et al., 2000) (Tab. 2).  
 
Chemokines Roles




Recruitment of monocytes and Th1 cells 
CCL20 (MIP-3α) Recruitment of dendritic cells, CLA+ T 
cells and immature Langherans cells 
Table 2. Roles of chemokines produced by psoriatic keratinocytes. 
3.3 Keratinocytes and other products 
Psoriatic keratinocytes are a reservoir of inflammatory mediators. Under the influence of 
pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-23, and IL-17, keratinocytes express a 
plethora of mediators, not only cytokines, thereby contributing to amplifying the 
inflammatory response implicated in the pathogenesis of psoriasis (Albanesi et al., 2005). 
Apart from pro-inflammatory cytokines as IL-1α, IL-1β, IL-6, IL-15, IL-18 and IL-20 psoriatic 
keratinocytes are able to produce other important factors involved in the development of the 
psoriatic process like vascular endothelial growth factor (VEGF) and CD1d (Tab. 3). 
 
Factors Functions
VEGF Stimulation of angiogenesis, enhancement 
of vascular permeability, induction of 
keratinocytes hyperproliferation in an 
autocrine manner.
CD1d Activation of CD161+ NK T cells and their 
stimulation to secrete IFN-γ.
Table 3. Roles of VEGF and CD1d in psoriasis. 
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3.3.1 Keratinocytes and VEGF 
The typical erythema of psoriatic lesions is due to the increased, dilated, and tortuous 
capillaries that extend between the epidermal columns protruding into the dermis. The 
formation of new blood vessels starts with early psoriatic changes and disappears with 
disease clearance. Several angiogenic mediators like VEGF, hypoxia inducible factors, 
angiopoietins and pro-angiogenic cytokines, such as TNF-α, IL-8 and IL- 17, are involved in 
psoriasis development (Heidenreich et al., 2009). Interestingly, already in uninvolved, non-
lesional skin significant over-expression of several VEGF isoforms was observed in patients 
as compared to healthy skin of normal volunteers (Henno et al., 2009). These findings 
suggest that angiogenesis is also one of the key features in the pathogenesis of psoriasis and 
various recent studies focused on the identification and role of pro-angiogenic mediators in 
psoriatic skin. In general, angiogenesis is tightly regulated by a balance between pro- and 
anti-angiogenic mediators (Heidenreich et al., 2009). VEGF, hypoxia-inducible factor-1α 
(HIF-1α), TNF-α, IL-8 and angiopoietins are considered to be the main players responsible 
for the increased vessel formation in psoriasis (Creamer et al., 2002; Heidenreich et al., 2008). 
Interestingly, several small molecules as well as modern biologics used for systemic therapy 
of psoriasis have been shown to provide not only immune regulatory effects but also 
influence endothelial cell biology (Heidenreich et al., 2008). Thus, direct targeting of 
angiogenesis could help both to dissect psoriasis pathogenesis and to develop new 
therapeutic strategies for psoriasis treatment by blocking angiogenic pathways driving 
cutaneous inflammation. Strongly increased production of VEGF by keratinocytes has been 
found in psoriasis (Detmar et al., 1994). Furthermore, over-expression of VEGF in the 
epidermis of mice triggered sub-epidermal angiogenesis and increased leukocyte adhesion 
to these vessels (Detmar et al., 1998), and later in life, these animals develop hyperkeratotic 
skin lesions with a resemblance to psoriasis (Xia et al., 2003). VEGF signaling often 
represents a critical rate-limiting step in physiological angiogenesis (Ferrara et al., 2003). 
Under physiological conditions, VEGF promotes growth of endothelial cells (ECs) derived 
from arteries, veins and lymphatic vessels. VEGF delivery also induces lympho-
angiogenesis in mice and it is known to be a survival factor for endothelial cells both in vitro 
and in vivo. However, VEGF is also known as a vascular permeability factor, based on its 
ability to induce vascular leakage. In the meantime it is well established that such 
permeability enhancing activity underlies significant roles of this molecule in inflammation 
and other pathological circumstances (Ferrara et al., 2003). Besides its potential role in 
causing aberrant angiogenesis and vascular leakage in the upper dermis, VEGF may also 
contribute to keratinocyte proliferation and epidermal barrier homeostasis (Elias et al., 2008; 
Heidenreich et al., 2009). In psoriatic skin, the VEGF receptors VEGFR-1 and -2 are 
detectable and functional in keratinocytes (Man et al., 2006). As VEGF is secreted by 
keratinocytes and induces VEGFR expression in the same cells, VEGF may also contribute to 
keratinocyte hyperproliferation in psoriasis in an autocrine manner. This could be relevant 
when psoriasis is triggered by external injury (Koebner phenomenon) and interestingly 
disruption of the epidermal barrier homeostasis induces VEGF expression (Elias et al., 2008). 
Further evidence for a role of VEGF in keratinocyte proliferation comes from transgenic 
mice deficient in epidermal VEGF: these animals have delayed permeability barrier recovery 
after acute perturbation, decreased density of dermal blood vessels and lack epidermal 
hyperplasia as well as angiogenesis in response to sustained barrier disruption (Elias et al., 
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differentiation and function of the epidermis (Heidenreich et al., 2009). Consequently, VEGF 
over-expression in psoriasis might contribute to the epidermal changes observed in this 
disease. Although immune cells are also able to secrete VEGF, the findings of VEGF over-
expression in psoriatic epidermis together with the data reported from the transgenic 
animals strongly suggest that VEGF derived from epidermal keratinocytes acts as a key 
cytokine driving angiogenesis in psoriasis and as a central paracrine growth factor 
contributing to the pathology seen in psoriasis. 
3.3.2 Keratinocytes and C1d 
The expression of CD1d by normal human skin and its pronounced over-expression in 
psoriatic skin lesions is well documented (Bonish et al., 2000) as well as the presence of 
NK-T cells in the epidermis of acute and chronic psoriatic plaques (Nickoloff & Wrone-
Smith, 1999; Nickoloff et al., 2000). A hallmark of NK-T cells is their expression of certain 
C-type lectin NK cell receptors (NKRs)4 such as CD94 and CD161. Classical NK-T cells 
may plan an immunoregulatory role for recognition of both self and foreign antigens and 
are implicated in the pathogenesis of autoimmune and inflammatory diseases like 
psoriasis. An important clue to the function of NK-T cells is provided by their interaction 
with professional antigen presenting cells (APCs) via CD1d (Huang et al., 1999). CD1d 
has some similarities in structure to the major histocompatibility complex class II (MHC 
II) molecules. While initially CD1d was believed to bind and present peptide antigens to T 
cells (Castano et al., 1995), more recent studies highlight its ability to present glycolipids 
and GPI-linked proteins (Huang et al., 1999). NK-T cells can become activated in a CD1d-
restricted fashion with subsequent proliferation and cytokine production, including IFN-γ 
and IL-4. Keratinocytes in vitro and in vivo synthesize and express CD1d, which is 
capable of triggering CD161+ NK-T cells to produce high levels of IFN-γ, but not IL-4. The 
stimulation by CD1d of T cells bearing NK receptors preferentially induces a cytokine 
switch to IFN-γ (Arase et al., 1996, 1997). Moreover, the differential induction of IFN-γ 
production, but not IL-4, after the NK-T cell clones recognized CD1d on keratinocytes has 
potentially important implications for psoriasis. Not only is there over-expression of 
CD1d by psoriatic epidermal keratinocytes and the presence of NK-T cells bearing CD94 
and CD161, but the cytokine IFN-γ has been shown to trigger psoriatic lesions (Fierlbeck 
et al., 1990). Therefore a positive feedback loop could be established in skin due to the 
presence of NK-T cells being activated to produce IFN-γ upon contact with CD1d-positive 
keratinocytes, leading to further CD1d expression and subsequent NK-T cell release of 
more IFN-γ. The lack of a proliferative response by NK-T cells to CD1d keratinocytes is 
also consistent with the general number and distribution of CD94- and CD161-positive 
NK-T cells in psoriasis. Thus, the NK-T cells are never observed in tight clusters or in very 
large numbers as might be expected if they were undergoing a local proliferative 
response; rather, they are found as more evenly distributed single cells throughout a 
psoriatic plaque. In normal human skin CD1d is generally restricted to the outermost 
keratinocyte layers in the stratum granulosum just beneath the lipid-rich stratum 
corneum. In addition to epidermal keratinocytes, CD1d is detected on upper dermal 
dendritic cells, endothelium, eccrine ducts, acrosyringium, and the pilo-sebaceous unit, 
except for the dermal papillae and hair matrix cells. In psoriatic plaques CD1d expression 
was increased compared with that in normal and symptomless skin, beginning in the 
supra-basilar layer and extending to the outermost keratinocytes immediately beneath the 
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parakeratotic layer juxtaposed to the stratum corneum. CD161-positive T cells were 
frequently observed in direct contact with keratinocytes expressing CD1d in psoriatic 
plaques. Given this anatomical juxtaposition, it is possible for various types of glycolipids 
in the psoriatic scale to be directly exposed to the abundant keratinocyte cell surface 
CD1d. Moreover, given the large hydrophobic binding pockets in CD1d, the presence of 
CD1d on the outer layers of epidermis in psoriatic plaques opens up the possibility that 
various glycolipids present in the stratum corneum could play a role in triggering a 
response by NK-T cells or other T cell subsets capable of recognizing such glycolipids in 
the context of CD1d. During epidermal differentiation keratinocytes produce different 
amounts and types of various glycolipids, including glucosylceramides (Holleran et al., 
1993). Alterations in these glycolipids in the stratum corneum can have a significant 
impact on the barrier function of skin. However, it is also clear that barrier perturbation 
can initiate cytokine cascades and thus influence inflammatory and mononuclear cell 
activation (Nickoloff & Naidu, 1994). A cycle can be envisioned in which pathogenic NK-
T cells initiate barrier abnormality, which, in turn, would generate glycolipids that could 
be presented by keratinocyte CD1d and further activate CD161+ T cells in psoriasis 
(Kalish et al., 1994). Taken together, these findings support the idea that NK-T cells may 
play an important patho-physiological role in psoriasis. Besides the ability of 
keratinocytes to initiate (Barker et al., 1991), perpetuate (Nickoloff & Turka, 1994), and 
terminate (Guttierrez-Steil et al., 1998) immune reactions involving conventional T cell 
responses to nominal antigens and super-antigens, CD1d expression may also imbue the 
keratinocyte with the capacity to interact with NKR-bearing T cells. As a member of a 
non-classical, MHC independent, antigen-presenting system, CD1d expression as seen in 
psoriasis provides a novel opportunity for therapeutic targeting and for understanding 
the immunologic and genetic basis of psoriasis as well as the potential role for innate 
immunity in psoriasis (Nickoloff, 1999a, 1999b). 
4. Conclusion  
The pathogenesis of psoriasis is considered to be an immunologically mediated process that 
takes place upon a favourable genetic background. According to this view, the presence of a 
yet unknown (auto)-antigen causes the generation of effector T-cells that infiltrate the skin 
and initiate the inflammatory process. Over its course, cutaneous infiltration of various 
immune cell populations and, subsequently, an activation of numerous immune and tissue 
cells in the skin takes place. Two fundamentally different cell types interact in the formation 
of a psoriatic lesion: epidermal keratinocytes and mononuclear leukocytes. Whereas 
keratinocytes might be viewed only as bystander cells in terms of immune activation, it is 
more likely that they are active participants in the recruitment and activation of leukocytes 
in psoriatic lesions: the interplay between keratinocytes and immune cells can be considered 
the main feature of the psoriasis pathogenesis. In facts whatever the sequence of events that 
leads to the induction of the mentioned cytokines and mediators in epidermal keratinocytes, 
it is highly likely that they significantly contribute to the typical changes observed in 
psoriatic lesions; cytokine or growth factor secretion by epidermal keratinocytes can be 
sufficient to recruit immune cells into the skin and induce a hyperplastic epidermis with 
hyperkeratosis and reproduce features of psoriatic disease. Regulation of the inflammatory 
events initiated or perpetuated by keratinocytes could so represent an important strategy for 
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(Kalish et al., 1994). Taken together, these findings support the idea that NK-T cells may 
play an important patho-physiological role in psoriasis. Besides the ability of 
keratinocytes to initiate (Barker et al., 1991), perpetuate (Nickoloff & Turka, 1994), and 
terminate (Guttierrez-Steil et al., 1998) immune reactions involving conventional T cell 
responses to nominal antigens and super-antigens, CD1d expression may also imbue the 
keratinocyte with the capacity to interact with NKR-bearing T cells. As a member of a 
non-classical, MHC independent, antigen-presenting system, CD1d expression as seen in 
psoriasis provides a novel opportunity for therapeutic targeting and for understanding 
the immunologic and genetic basis of psoriasis as well as the potential role for innate 
immunity in psoriasis (Nickoloff, 1999a, 1999b). 
4. Conclusion  
The pathogenesis of psoriasis is considered to be an immunologically mediated process that 
takes place upon a favourable genetic background. According to this view, the presence of a 
yet unknown (auto)-antigen causes the generation of effector T-cells that infiltrate the skin 
and initiate the inflammatory process. Over its course, cutaneous infiltration of various 
immune cell populations and, subsequently, an activation of numerous immune and tissue 
cells in the skin takes place. Two fundamentally different cell types interact in the formation 
of a psoriatic lesion: epidermal keratinocytes and mononuclear leukocytes. Whereas 
keratinocytes might be viewed only as bystander cells in terms of immune activation, it is 
more likely that they are active participants in the recruitment and activation of leukocytes 
in psoriatic lesions: the interplay between keratinocytes and immune cells can be considered 
the main feature of the psoriasis pathogenesis. In facts whatever the sequence of events that 
leads to the induction of the mentioned cytokines and mediators in epidermal keratinocytes, 
it is highly likely that they significantly contribute to the typical changes observed in 
psoriatic lesions; cytokine or growth factor secretion by epidermal keratinocytes can be 
sufficient to recruit immune cells into the skin and induce a hyperplastic epidermis with 
hyperkeratosis and reproduce features of psoriatic disease. Regulation of the inflammatory 
events initiated or perpetuated by keratinocytes could so represent an important strategy for 
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1. Introduction  
Psoriasis, a chronic relapsing inflammatory skin disease with a disturbing global incidence 
of approximately 2%, is an afflicting and disfiguring skin disease with high morbidity 
(Lomholt, 1964). The disease is characterized by the well-demarcated erythematous plaques 
with silvery white scales and a predilection for body areas such as the elbows, knees, 
umbilicus and lumbar area (Schön & Boehncke, 2005). In contrast to normal skin, the dermal 
vasculature in psoriasis dermis is dramatically increased with large, tortuous blood vessels, 
accounting for the erythematous appearance or redness of the affected skin 
regions/psoriatic plaques (Nestle et al, 2009). In addition, the psoriatic epidermis is 
significantly thickened and acanthotic, due to hyperproliferative keratinocytes with an 
approximate seven-fold increase in the number of dividing cells in the basal and suprabasal 
epidermal layers (Castelijns et al, 2000). Keratinocytes of the psoriatic skin are prematurely 
differentiated, as evident in the incomplete cornification of the stratum corneum, 
characterized by the retention of nuclei (i.e., parakeratosis) and the loss of the granular 
layer. The stratum corneum of psoriasiform skin is also thickened (i.e., hyperkeratosis). This 
heavy disruption of epidermal differentiation and skin barrier homeostasis coupled with 
altered levels of intercellular adhesion molecules result in the widespread scaling of 
psoriatic lesions (Christensen et al, 2006). While psoriasis primarily affects the epidermis, the 
disease has a strong immunopathological basis, with the psoriatic skin being significantly 
infiltrated with immune cells. Notably, this immune infiltrate has a characteristic 
distribution and is composed mainly of dendritic cells and macrophages in the dermis, 
neutrophils in the epidermis and T cells in both layers. Another immunologic feature of the 
disease is its extracutaneous manifestation of an arthritic condition, which affects 
approximately 5% of the population and approximately 20% of psoriasis patients (Zachariae 
et al, 2002; Hueber & McInnes, 2007). However, the direct involvement of the skin and 
immune system in psoriasiform features complicates and confounds studies of psoriasis. 
Therefore, despite the detailed documented pathological observations of psoriasis and the 
vast research efforts aimed at understanding the disease, a key question remains 
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It is well accepted that the pathology of psoriasis involves the participation of both the 
immune system and skin tissue; therefore a rational research approach would include 
studying the disease from an in vivo rather than an in vitro perspective. Hence, most 
psoriasis studies have been in the context of animal models which continue to serve as an 
invaluable platform for drug testing and development. While there is an absolute need for 
an in vivo platform, an ideal animal model is still lacking as no naturally and frequently 
occurring animal disease is known to exhibit every complex disease feature of psoriasis 
(Schön, 1999). Hence the study of psoriasis is narrowly limited to the artificial induction of 
the disease in laboratory animals. Nevertheless, several animal models have been developed 
in recent decades to meet the demands of psoriasis research. Study approaches include 
spontaneous mutants, T cell transfer models and xenografts.  
2.1 Spontaneous mutants 
The earliest psoriasis models were laboratory-bred mutant mice that were found to manifest 
skin lesions resembling psoriasis. These animals were spontaneous mutants of known allelic 
mutations. One such mutant strain was mice carrying the homozygous asebia mutation 
(Scd1ab/ Scd1ab). The skin of the asebia mouse is typified by hair loss (i.e., alopecia) and the 
complete absence of sebaceous glands. Like psoriatic human skin, asebia mouse skin 
displayed hyperkeratosis, epidermal acanthosis, increased dermal vascularity and an 
immune cell infiltrate (Gates & Karasek, 1965). However, unlike human psoriatic skin, the 
leukocytic infiltrate of asebia mouse skin was devoid of neutrophils and T cells. Because the 
immune system is strongly believed to account for a substantial portion of the pathogenesis 
of psoriasis, this difference in the inflammatory response in asebia mouse skin reduces the 
reliability of this disease model. Moreover, lipid metabolism in asebia mouse skin was 
significantly altered, implying a distinctly different disease mechanism from psoriasis, 
which further undermined its value as a psoriasis model (Wilkinson & Karasek, 1966). Two 
other homozygous mouse mutants, chronic proliferative dermatitis (cpd) and the flaky skin 
(fsn), also display a hyperproliferative epidermis, increased dermal vascularity and a mixed 
immune cell infiltrate including neutrophils in micro-abscesses of lesions. These similarities 
with human psoriatic skin make these animal models slightly superior to the asebia mouse 
model as disease models for psoriasis (Morita et al, 1995). However, the psoriasiform-like 
phenotype of both fsn and cpd critically lack a T cell-based immunopathogenesis. This was 
demonstrated by the ability of glucocorticosteroid treatment to improve the fsn lesions, 
which targets the innate immune response, but not with cyclosporine A, a licensed psoriasis 
drug which inhibits T cell-mediated immune responses (Sundberg et al, 1994). Cyclosporin 
A treatment also did not improve cpd skin lesions (HogenEsch et al, 1994). Fsn mice that 
were double homozygous for the severe combined immunodeficiency mutation (scid/scid) 
and lacked mature T and B lymphocytes also developed skin lesions nonetheless (Sundberg 
et al, 1994). Furthermore, the transfer of hemopoietic T cell precursors from cpd to syngeneic 
recipients did not pass on the psoriasiform condition (HogenEsch et al, 1994). Cpd and fsn 
are also far more complex than psoriasis; both involve pathologies that extend to other 
organ systems. This complexity confounds the study of psoriasis when these models are 
used. Critically, the psoriasiform-like phenotype of cpd and fsn could both develop without 
the participation of T cells, which are known key effectors in psoriasis (HogenEsch et al, 
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1994; Sundberg et al, 1994). Given these limitations, spontaneous mutants still fall short of 
being an ideal psoriasis model. The greatest concern about using this type of animal model 
for psoriasis research is that researchers are essentially deriving conclusions about the 
causes of psoriasis from diseases with another unknown basis. 
2.2 T cell transfer models 
The disqualification of the early animal models (i.e., fsn and cpd) as psoriatic models 
highlights the strong growing recognition of psoriasis as a T cell-mediated disease. Several 
clinical observations support this theory, including how psoriasis can be significantly 
improved with drugs targeting T cell-mediated immunity (Weinshenker et al, 1989). 
Streptococcal infection of the upper respiratory tract, which is remote from the skin, is 
known to trigger psoriasis via T cell-mediated responses to bacterial superantigens that 
mimic keratins. This process initiates a pseudo-autoimmune reaction responsible for the 
psoriasiform outcome (Prinz et al, 1991; Leung et al, 1995; Valdimarsson et al, 2009). 
Interestingly, psoriasis was shown to be transferrable when the bone marrow of an 
affected individual was transplanted into a previously unaffected recipient (Snowden & 
Heaton, 1997). Conversely, psoriasis in a previously affected individual was completely 
cured after bone marrow ablation prior to transplant (Eedy et al, 1990). While phagocytic 
immune cells (i.e., neutrophils, macrophage and dendritic cells) are responsible for 
indiscriminate immune functions such as the engulfment of pathogens or cellular debris 
and antigen presentation (Delves & Roitt, 2000), T cells have a more specific molecular 
recognition role in the immune system. In summary, every cytotoxic CD8 T cell clone 
possesses antigen specificity, allowing it to recognize a unique antigen presented on the 
major histocompatibility complex (MHC) of non-immune cells. For example, this antigen 
could be a viral peptide in the context of an infected cell, a foreign peptide in the context 
of an allograft, or a self peptide in the event of an autoimmune response. In any of these 
cases, CD8 T cells would mount a cytotoxic response against the target cell. The CD8 T 
cells can mediate a necrotic cell killing through the targeted secretion of lytic proteins, 
perforin and granzyme, onto the target cells. These proteins drastically destabilize the 
target cell membrane, eventually leading to osmotic stress and colloid osmotic lysis 
(Delves & Roitt, 2000).  
The classic study of tissue graft rejection showed that the adoptive transfer of normal T cells 
into nude mice scid would lead to an immune rejection of the host animal’s skin (Roopenian 
& Anderson, 1988). An experimental proof of T cell pathogenesis for psoriasis would require 
a T cell-mediated response directed against skin cells. Using principles of tissue graft 
rejection, MHC compatible naïve CD4+/CD45RBHi T lymphocytes that were minor 
histocompatibility complex mismatched were transplanted into scid/scid mice. The minor 
histocompatibility mismatch was aimed at minimizing the severity of the immune response 
and hence prolonging the rejection process. Without fail, this procedure led to the 
development of clinically consistent psoriasiform skin within 4-8 weeks. The resulting 
mouse skin lesions were markedly similar to those of human psoriatic skin; they shared the 
key histopathological features of acanthosis, parakeratosis, leukocytic infiltrate and dermal 
angiogenesis. Remarkably, pro-inflammatory cytokine expression in the lesional skin was 
also similar to that of human psoriatic skin, with elevated expressions of tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6), interferon-γ and granulocyte macrophage colony 
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A treatment also did not improve cpd skin lesions (HogenEsch et al, 1994). Fsn mice that 
were double homozygous for the severe combined immunodeficiency mutation (scid/scid) 
and lacked mature T and B lymphocytes also developed skin lesions nonetheless (Sundberg 
et al, 1994). Furthermore, the transfer of hemopoietic T cell precursors from cpd to syngeneic 
recipients did not pass on the psoriasiform condition (HogenEsch et al, 1994). Cpd and fsn 
are also far more complex than psoriasis; both involve pathologies that extend to other 
organ systems. This complexity confounds the study of psoriasis when these models are 
used. Critically, the psoriasiform-like phenotype of cpd and fsn could both develop without 
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1994; Sundberg et al, 1994). Given these limitations, spontaneous mutants still fall short of 
being an ideal psoriasis model. The greatest concern about using this type of animal model 
for psoriasis research is that researchers are essentially deriving conclusions about the 
causes of psoriasis from diseases with another unknown basis. 
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The disqualification of the early animal models (i.e., fsn and cpd) as psoriatic models 
highlights the strong growing recognition of psoriasis as a T cell-mediated disease. Several 
clinical observations support this theory, including how psoriasis can be significantly 
improved with drugs targeting T cell-mediated immunity (Weinshenker et al, 1989). 
Streptococcal infection of the upper respiratory tract, which is remote from the skin, is 
known to trigger psoriasis via T cell-mediated responses to bacterial superantigens that 
mimic keratins. This process initiates a pseudo-autoimmune reaction responsible for the 
psoriasiform outcome (Prinz et al, 1991; Leung et al, 1995; Valdimarsson et al, 2009). 
Interestingly, psoriasis was shown to be transferrable when the bone marrow of an 
affected individual was transplanted into a previously unaffected recipient (Snowden & 
Heaton, 1997). Conversely, psoriasis in a previously affected individual was completely 
cured after bone marrow ablation prior to transplant (Eedy et al, 1990). While phagocytic 
immune cells (i.e., neutrophils, macrophage and dendritic cells) are responsible for 
indiscriminate immune functions such as the engulfment of pathogens or cellular debris 
and antigen presentation (Delves & Roitt, 2000), T cells have a more specific molecular 
recognition role in the immune system. In summary, every cytotoxic CD8 T cell clone 
possesses antigen specificity, allowing it to recognize a unique antigen presented on the 
major histocompatibility complex (MHC) of non-immune cells. For example, this antigen 
could be a viral peptide in the context of an infected cell, a foreign peptide in the context 
of an allograft, or a self peptide in the event of an autoimmune response. In any of these 
cases, CD8 T cells would mount a cytotoxic response against the target cell. The CD8 T 
cells can mediate a necrotic cell killing through the targeted secretion of lytic proteins, 
perforin and granzyme, onto the target cells. These proteins drastically destabilize the 
target cell membrane, eventually leading to osmotic stress and colloid osmotic lysis 
(Delves & Roitt, 2000).  
The classic study of tissue graft rejection showed that the adoptive transfer of normal T cells 
into nude mice scid would lead to an immune rejection of the host animal’s skin (Roopenian 
& Anderson, 1988). An experimental proof of T cell pathogenesis for psoriasis would require 
a T cell-mediated response directed against skin cells. Using principles of tissue graft 
rejection, MHC compatible naïve CD4+/CD45RBHi T lymphocytes that were minor 
histocompatibility complex mismatched were transplanted into scid/scid mice. The minor 
histocompatibility mismatch was aimed at minimizing the severity of the immune response 
and hence prolonging the rejection process. Without fail, this procedure led to the 
development of clinically consistent psoriasiform skin within 4-8 weeks. The resulting 
mouse skin lesions were markedly similar to those of human psoriatic skin; they shared the 
key histopathological features of acanthosis, parakeratosis, leukocytic infiltrate and dermal 
angiogenesis. Remarkably, pro-inflammatory cytokine expression in the lesional skin was 
also similar to that of human psoriatic skin, with elevated expressions of tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6), interferon-γ and granulocyte macrophage colony 





treatments such as cyclosporine A and ultraviolet B (310 nm) phototherapy (Schön et al, 
1997). Taken together, these features suggest that an epidermal abnormality is unnecessary 
for the formation of psoriatic lesions and that a T cell-invoked immune response results in 
psoriasiform skin. However, this model cannot rule out the involvement of an epidermal 
trigger, as T cells were deliberately mismatched to the host skin cells. Hence, this T cell 
transfer model can only be used to study cutaneous psoriatic events post-T cell activation 
and not those processes preceding T cell activation.  
2.3 Xenografts 
Although animal and T cell transfer models offer a convenient bench approach to studying 
psoriasis, they still do not reflect the genuine pathogenesis of the disease. Animal models 
may have typical psoriasiform-like skin lesions but closer analysis has revealed critical 
cellular differences from the human disease. In addition, T cell transfer models exhibit only 
the immune aspects of psoriasis after T cell activation, and they lack all aspects of the 
preliminary events leading to T cell activation. Furthermore, the vast differences between 
mouse and human skin further complicate the ability to extrapolate animal models to the 
actual human disease (Gudjonsson et al, 2007). Hence, another approach is to study every in 
situ event of human psoriatic skin in vivo. This has been made possible by 
xenotransplantation, whereby human diseased skin is grafted across species to an 
immunocompromised murine host. With xenotransplantation, psoriatic features of diseased 
human skin can be maintained for more than 2 months, providing sufficient study time 
(Krueger et al, 1975). Apart from T cells originating in the systemic circulation, resident T 
cells and other immune cells in psoriatic skin may also contribute to pathogenesis, which is 
not possible using T cell models.  Xenotransplantation models circumvent this shortcoming, 
as all forms of resident immune cells in the transplanted diseased skin may be continually 
studied post-transplantation (Boehncke & Schön, 2007). Altogether, xenotransplantation 
models allow the study of in situ events in the context of actual human psoriatic skin. This 
approach has helped elucidate the role of resident T cells in disease pathogenesis and 
helped identify the molecules involved in the epidermal recruitment of T cells, such as 
integrin α1β1 (Conrad et al, 2007). Importantly, the xenotransplantation method allows for 
comparisons between involved and uninvolved skin (Boehncke et al, 1994; Nickoloff et al, 
1995). Xenotransplantation models may also be used to study other components of the 
immune system, such as the role of natural killer cells in psoriasis. The immune background 
of the host could be modified by cross-breeding mouse strains that carry mutations to 
different immunity-related genes. For example, non-obese diabetic (NOD) mice with 
impaired natural killer and antigen presenting cells could be combined with scid through 
cross-breeding to generate a host animal with a modified immune background to enhance 
the study of natural killer cells in psoriasis (Roder & Duwe, 1979;  Shultz et al, 1995). With 
this concept, many other combinations of immune backgrounds have since been innovated 
to support novel studies. Regarding drug discovery studies, xenotransplantation models 
facilitate the testing of human directed antibodies or biologics because of the limited cross-
species reactivity (Boehncke, 2005). However, xenotransplantation models do have their 
own shortcomings and limitations, including the challenge of assessing T cell homing 
processes since human T cells in the transplanted xenograft may not transit normally to 
mouse lymph nodes in the hybrid natured “two-species-systems” (Garcia et al, 1997).  Also, 
xenotransplantation is limited by a lack of diseased skin donors. In response to this issue, a 
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bioengineered skin-humanized mouse model was recently developed. Healthy human skin 
biopsies were engrafted onto mice and allowed to regenerate. T cells isolated from blood 
samples of the same donors were cultured in vitro and transfected with recombinant IL-17 
and IL-22 expression vectors. The regenerated skin graft was then reconstituted with this T 
cell population through intradermal injections. The stratum corneum surface of the graft 
was also removed by mild abrasion, which then triggered psoriasiform features. The 
bioengineered skin was claimed to accurately represent human psoriatic skin (Guerrero-
Aspizua et al, 2010).  
2.4 Transgenic animal models 
With the advent of genetic engineering, another approach using transgenic expression of 
individual molecules in the mouse epidermis has allowed scientists to identify possible 
psoriatic triggers. To assess the relevance of a protein factor, researchers induce an 
overexpression of the factor in the epidermis. By varying the promoter used, scientists can 
localize and target the epidermal overexpression to either the basal or the suprabasal layer, 
taking advantage of distinct promoters found in the different skin layers. For example, there 
is exclusive expression of keratin 14 in the basal layer and involucrin in the suprabasal 
keratinocytes. Epidermal overexpression helps enhance the presence of the protein of 
interest in the skin which enables investigations of the effects of the proteins on the immune 
system (Schön, 2008). To date, most of the proteins shortlisted for studies are related to the 
immune system or angiogenesis (e.g., TNF-α, IL-1α, IL-6, IL-8, IFN-γ, ICAM-1, VEGF, etc.). 
Comparatively few proteins studied are of epidermal origin (i.e., TGF-α, KGF, etc.) because 
previous studies using animal or T cell transfer models have identified a more 
immunological etiology of psoriasis (Schön, 1999). While the compilation of these studies 
suggests a strong immunopathogenic basis for psoriasis, an epidermal trigger of psoriasis 
cannot be completely discounted, as these in vivo disease models also involve the immune 
and cutaneous systems of animal models. 
3. New players in psoriasis identified from wound repair studies 
While the current evidence suggests that dysregulation of the immune system, particularly 
abnormal Th1 and Th17 immune responses, is the primary and predominant pathogenic 
basis for psoriasis, it is still debatable how epidermal barrier dysfunction contributes as a 
primary and secondary etiological factor in psoriasis. It is noteworthy that psoriasis 
susceptibility has been linked to a large number of genes, including those involving 
epidermal and immunological functions. While psoriasis has been associated with key 
adaptive immune genes like the PSORS1 MHC locus antigen cluster (Allen et al, 2005), it has 
also been linked to epidermal proteins like the S100 proteins (Wolf et al, 2010). These genetic 
associations reinforce the mechanistic complexity of psoriasis, which cannot be reduced 
simply to either an epidermal or immunological mode of causation. This uneven balance of 
research attention could also stem from the natural difficulty of studying cutaneous factors 
in animal models. While immune cells can be studied by their transfer into an in vivo system, 
the same cannot be said for keratinocytes. Moreover, immune responses are always obligate 
and inseparable from the in vivo context of an animal model. Skin grafting, for example, 
inevitably leads to wounding and subsequent inflammation in the grafted skin region. In 
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actual human disease (Gudjonsson et al, 2007). Hence, another approach is to study every in 
situ event of human psoriatic skin in vivo. This has been made possible by 
xenotransplantation, whereby human diseased skin is grafted across species to an 
immunocompromised murine host. With xenotransplantation, psoriatic features of diseased 
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as all forms of resident immune cells in the transplanted diseased skin may be continually 
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models allow the study of in situ events in the context of actual human psoriatic skin. This 
approach has helped elucidate the role of resident T cells in disease pathogenesis and 
helped identify the molecules involved in the epidermal recruitment of T cells, such as 
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1995). Xenotransplantation models may also be used to study other components of the 
immune system, such as the role of natural killer cells in psoriasis. The immune background 
of the host could be modified by cross-breeding mouse strains that carry mutations to 
different immunity-related genes. For example, non-obese diabetic (NOD) mice with 
impaired natural killer and antigen presenting cells could be combined with scid through 
cross-breeding to generate a host animal with a modified immune background to enhance 
the study of natural killer cells in psoriasis (Roder & Duwe, 1979;  Shultz et al, 1995). With 
this concept, many other combinations of immune backgrounds have since been innovated 
to support novel studies. Regarding drug discovery studies, xenotransplantation models 
facilitate the testing of human directed antibodies or biologics because of the limited cross-
species reactivity (Boehncke, 2005). However, xenotransplantation models do have their 
own shortcomings and limitations, including the challenge of assessing T cell homing 
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and IL-22 expression vectors. The regenerated skin graft was then reconstituted with this T 
cell population through intradermal injections. The stratum corneum surface of the graft 
was also removed by mild abrasion, which then triggered psoriasiform features. The 
bioengineered skin was claimed to accurately represent human psoriatic skin (Guerrero-
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With the advent of genetic engineering, another approach using transgenic expression of 
individual molecules in the mouse epidermis has allowed scientists to identify possible 
psoriatic triggers. To assess the relevance of a protein factor, researchers induce an 
overexpression of the factor in the epidermis. By varying the promoter used, scientists can 
localize and target the epidermal overexpression to either the basal or the suprabasal layer, 
taking advantage of distinct promoters found in the different skin layers. For example, there 
is exclusive expression of keratin 14 in the basal layer and involucrin in the suprabasal 
keratinocytes. Epidermal overexpression helps enhance the presence of the protein of 
interest in the skin which enables investigations of the effects of the proteins on the immune 
system (Schön, 2008). To date, most of the proteins shortlisted for studies are related to the 
immune system or angiogenesis (e.g., TNF-α, IL-1α, IL-6, IL-8, IFN-γ, ICAM-1, VEGF, etc.). 
Comparatively few proteins studied are of epidermal origin (i.e., TGF-α, KGF, etc.) because 
previous studies using animal or T cell transfer models have identified a more 
immunological etiology of psoriasis (Schön, 1999). While the compilation of these studies 
suggests a strong immunopathogenic basis for psoriasis, an epidermal trigger of psoriasis 
cannot be completely discounted, as these in vivo disease models also involve the immune 
and cutaneous systems of animal models. 
3. New players in psoriasis identified from wound repair studies 
While the current evidence suggests that dysregulation of the immune system, particularly 
abnormal Th1 and Th17 immune responses, is the primary and predominant pathogenic 
basis for psoriasis, it is still debatable how epidermal barrier dysfunction contributes as a 
primary and secondary etiological factor in psoriasis. It is noteworthy that psoriasis 
susceptibility has been linked to a large number of genes, including those involving 
epidermal and immunological functions. While psoriasis has been associated with key 
adaptive immune genes like the PSORS1 MHC locus antigen cluster (Allen et al, 2005), it has 
also been linked to epidermal proteins like the S100 proteins (Wolf et al, 2010). These genetic 
associations reinforce the mechanistic complexity of psoriasis, which cannot be reduced 
simply to either an epidermal or immunological mode of causation. This uneven balance of 
research attention could also stem from the natural difficulty of studying cutaneous factors 
in animal models. While immune cells can be studied by their transfer into an in vivo system, 
the same cannot be said for keratinocytes. Moreover, immune responses are always obligate 
and inseparable from the in vivo context of an animal model. Skin grafting, for example, 
inevitably leads to wounding and subsequent inflammation in the grafted skin region. In 





manipulation or perturbation of the epidermal barrier. The heavy influx of immune 
responses and their corresponding mediators would obscure any genuine causal triggers, 
especially if the cause may be of a subtle epidermal origin. A similar obfuscation of 
epidermal causes could happen in the actual human disease, confounding the continual 
search for an initiating factor. Moreover, the concept of skin as a immunological tissue has 
gradually gained importance over the last two decades, supported by the notion of skin-
associated lymphoid tissue (SALT) that was conceptualized in the early eighties. This SALT 
concept supports a specialized exclusive circulation of immune cells between the skin, the 
draining lymph nodes and the systemic circulation, which facilitates the priming of the T 
cell-mediated response in the skin (Streilein, 1983; Streilein, 1989). This helps highlight the 
importance of the adaptive immune response in psoriasis. Furthermore, to effectively 
safeguard the extensive cutaneous barrier against the external environment, 
immunosurveillance of the skin cannot rely solely on skin-residing immune scavenger cells 
(i.e., Langerhans cell). Rather, the average keratinocyte can capably assume the versatile role 
of an immune sentinel in the epidermis (Nestle et al, 2009). Armed with Toll-like receptors 
(TLRs) on their surfaces, keratinocytes recognize pathogen-associated molecular patterns on 
invading microorganisms and activate both cell-mediated immune responses and the 
production of type I interferons (IFNs) (Baker et al, 2003; Mempel et al, 2003; Pivarcsi et al, 
2004). Keratinocytes are also constitutive producers of pro-inflammatory cytokines (i.e., IL-1, 
TNF-α, IL-6, IL-10, etc.) (Pivarcsi et al, 2004; Nestle et al, 2009) and can express MHC class II 
molecules (Nickoloff & Turka, 1994). It is thus feasible for keratinocytes to serve as adjunct 
antigen-presenting cells (Nickoloff & Turka, 1994). As such, the keratinocyte, despite being a 
non immune cell, can trigger both the innate and adaptive immune responses, suggesting 
that it can act as a peripheral extension of the immune system. Importantly, the role of 
epidermal barrier dysfunction in psoriasis should not be overlooked given the inextricable 
relationship between the skin and the immune system.  
3.1 A neglected aspect of psoriasis research: The relevance of wound healing 
3.1.1 Koebner phenomenon 
Although psoriasis is strongly believed to have an underlying genetic predisposition, 
psoriatic plaque formation is demarcated and usually does not cover or affect the patient’s 
entire skin area (Schön & Boehncke, 2005). The unexpected outbreak of psoriatic lesions in 
most patients gives the impression of an unpredictable skin condition and has greatly 
complicated the study of psoriasis. With an unknown trigger for psoriasis, it is difficult to 
rationally attribute a direct or indirect causation to either the epidermal or the immune 
systems. Thus, to understand the epidermal role in psoriasis, it is advantageous to trigger 
psoriatic plaque formation on uninvolved skin with a specific epidermal perturbation and 
subsequently study the molecular changes in keratinocytes corresponding to the known 
perturbation. This is, however, impossible in animal models in which psoriasis does not 
naturally occur (Schön, 1999). 
The Koebner phenomenon is a well recognized clinical finding in psoriasis, whereby new 
psoriastic lesions can be induced in previously uninvolved skin after skin wounding or 
trauma. Such psoriatic lesions usually form within 10-20 days of the wounding event, 
coinciding with the duration of the wound healing phase. This strongly suggests that skin in 
predisposed individuals may still develop normally until substantial triggering by key 
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epidermal perturbations (Weiss et al, 2002). Wounding stands out as the only known 
epidermal perturbation with the predictable ability to trigger psoriasis, thus offering a 
unique opportunity to study pathogenetic mechanisms in psoriasis. While the molecular 
basis for koebnerized psoriasis remains largely unexamined (Weiss et al, 2002), wound 
healing studies have been comparatively well established. Considering the obligate 
coincidence and connection between wounding and psoriasis, an adequate understanding of 
koebnerized psoriasis requires a solid understanding of wound healing. The Koebner 
phenomenon was initially described after animal bite wounds and incision wounds. 
However, with accumulated observation and documentation, the Koebner phenomenon 
was later broadened to more accurately and extensively include psoriasis arising from all 
other forms of skin injury such as insect bites, friction, pressure wounds, excoriations, burns, 
contact dermatitis, chemical irritation, infections, tattoo and sunburns (Sagi & Trau, 2011). 
Some interesting exceptions were also made and accordingly, not every form of trauma 
resulted in koebnerization. Some interesting exceptions have been observed that did not 
result in koebnerization, such as experimentally inflicted knife blade injury to the dermis 
that did not produce psoriatic lesions on the overlying epidermis above the wounded 
dermal portion, but only at the incisional point where the epidermis was damaged (Farber 
et al, 1965). Likewise, the dermal injection of potent inflammatory stimulators like 
hyaluronidase and chymotrypsin did not initiate a Koebner response (Farber et al, 1965). 
The key conclusion from both experiments was that koebnerization must involve epidermal 
traumatic damage (Farber et al, 1965). This finding was further confirmed by suction 
blistering experiments, resulting in epidermal and dermal separation without epidermal 
rupture, which did not induce koebnerization (Miller, 1982; Pedace et al, 1969). The criterion 
of an epidermal rupture needed for koebnerization is crucial and on a microscopic level, 
necrotic damage of keratinocytes will activate the innate inflammatory cascade leading to 
psoriasis (Chen et al, 2007). Thus, it is conceivable that some forms of wounds, perturbations 
and traumas to the skin are not as visibly obvious as others. These subtle forms of epidermal 
injuries could lead to koebnerized psoriasis but still display the misleading outward 
appearance and impression of a spontaneous psoriatic outbreak. This revelation will shed 
light on many of our clinical and scientific observations concerning psoriasis. As mentioned 
earlier, adoptive T cell transfer experiments in scid mice have demonstrated the independent 
ability of T cells to promote the complex pathogenesis of psoriasis (Schön et al, 1997). It is 
likely that transplanted minor histocompatibility complex mismatched T cells would direct 
a T cell-mediated cytotoxic response against host keratinocyte cells leading to widespread 
necrotic epidermal damage, hence fueling the onset of koebnerized psoriasis. Furthermore, 
the injured epidermis may expose putative self antigens to the adaptive immune system, 
triggering an autoimmune inflammatory reaction. The importance of undetected, insidious 
micro-trauma to the skin as a possible initiating and aggravating factor in psoriasis cannot 
be over-emphasized and may explain the predilection for psoriasis over sites of frequent 
trauma such as the knees and elbows (Schön & Boehncke, 2005).  Recent advances in wound 
healing research has enhanced our understanding and allowed better insight into the role of 
wound healing in the pathogenesis of psoriasis.  
3.2 Events in wounding 
Wounding or skin injury results in keratinocyte disruption leading to an epidermal gap that 
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epidermal perturbations (Weiss et al, 2002). Wounding stands out as the only known 
epidermal perturbation with the predictable ability to trigger psoriasis, thus offering a 
unique opportunity to study pathogenetic mechanisms in psoriasis. While the molecular 
basis for koebnerized psoriasis remains largely unexamined (Weiss et al, 2002), wound 
healing studies have been comparatively well established. Considering the obligate 
coincidence and connection between wounding and psoriasis, an adequate understanding of 
koebnerized psoriasis requires a solid understanding of wound healing. The Koebner 
phenomenon was initially described after animal bite wounds and incision wounds. 
However, with accumulated observation and documentation, the Koebner phenomenon 
was later broadened to more accurately and extensively include psoriasis arising from all 
other forms of skin injury such as insect bites, friction, pressure wounds, excoriations, burns, 
contact dermatitis, chemical irritation, infections, tattoo and sunburns (Sagi & Trau, 2011). 
Some interesting exceptions were also made and accordingly, not every form of trauma 
resulted in koebnerization. Some interesting exceptions have been observed that did not 
result in koebnerization, such as experimentally inflicted knife blade injury to the dermis 
that did not produce psoriatic lesions on the overlying epidermis above the wounded 
dermal portion, but only at the incisional point where the epidermis was damaged (Farber 
et al, 1965). Likewise, the dermal injection of potent inflammatory stimulators like 
hyaluronidase and chymotrypsin did not initiate a Koebner response (Farber et al, 1965). 
The key conclusion from both experiments was that koebnerization must involve epidermal 
traumatic damage (Farber et al, 1965). This finding was further confirmed by suction 
blistering experiments, resulting in epidermal and dermal separation without epidermal 
rupture, which did not induce koebnerization (Miller, 1982; Pedace et al, 1969). The criterion 
of an epidermal rupture needed for koebnerization is crucial and on a microscopic level, 
necrotic damage of keratinocytes will activate the innate inflammatory cascade leading to 
psoriasis (Chen et al, 2007). Thus, it is conceivable that some forms of wounds, perturbations 
and traumas to the skin are not as visibly obvious as others. These subtle forms of epidermal 
injuries could lead to koebnerized psoriasis but still display the misleading outward 
appearance and impression of a spontaneous psoriatic outbreak. This revelation will shed 
light on many of our clinical and scientific observations concerning psoriasis. As mentioned 
earlier, adoptive T cell transfer experiments in scid mice have demonstrated the independent 
ability of T cells to promote the complex pathogenesis of psoriasis (Schön et al, 1997). It is 
likely that transplanted minor histocompatibility complex mismatched T cells would direct 
a T cell-mediated cytotoxic response against host keratinocyte cells leading to widespread 
necrotic epidermal damage, hence fueling the onset of koebnerized psoriasis. Furthermore, 
the injured epidermis may expose putative self antigens to the adaptive immune system, 
triggering an autoimmune inflammatory reaction. The importance of undetected, insidious 
micro-trauma to the skin as a possible initiating and aggravating factor in psoriasis cannot 
be over-emphasized and may explain the predilection for psoriasis over sites of frequent 
trauma such as the knees and elbows (Schön & Boehncke, 2005).  Recent advances in wound 
healing research has enhanced our understanding and allowed better insight into the role of 
wound healing in the pathogenesis of psoriasis.  
3.2 Events in wounding 
Wounding or skin injury results in keratinocyte disruption leading to an epidermal gap that 





protective barrier against various insults of the external environment, re-epithelialization of 
the breached epidermis is an urgent priority to close the wound gap and restore epidermal 
integrity. Keratinocytes at the edge of the wound are required to proliferate and migrate to 
fill up the epidermal gap to effectively seal it (Stadelmann et al, 1998).  
The wound and psoriatic lesional microenvironment in the initial stages appear to be largely 
similar in terms of the abundant production of pro-inflammatory cytokines, such as TNF-α, 
IFN-γ and IL-1 (Nickoloff et al, 2006). Keratinocytes in wound sites and psoriatic lesions are 
also similarly differentiated; both express keratin 6 (K6), keratin 16 (K16) and keratin 17 
(K17) instead of the standard keratin 1 (K1) and keratin 10 (K10) expressed by normal 
differentiating suprabasal keratinocytes (de Jong et al, 1991; Mommers et al, 2000; Wang & 
Chang, 2003). This suggests that transcriptional regulation responsible for both wound 
healing and psoriasis are similar. It is thus relevant to identify the key transcriptional 
regulators responsible for wound healing to evaluate its impact on psoriatic skin. 
3.3 Nuclear hormone receptors as prospective transcriptional regulators in wounded 
skin 
Among transcriptional regulators, nuclear hormone receptors are of particular interest. 
Nuclear hormone receptors (NRs), such as the retinoid acid receptors, are  one of the largest 
known classes of transcription factors, several have significant transcriptional activities in 
the skin and are responsible for skin homeostasis (Redfern & Todd, 1992). In humans, this 
superfamily comprises 48 ligand-dependent or “orphan” transcription factors (Robinson-
Rechavi et al, 2003). Unlike conventional transmembrane receptors, NRs are intracellular 
and locked in an inactive conformation by means of a bound chaperone (i.e., heat shock 
proteins, immunophilins) (Young & Hartl, 2002). Upon ligand binding in the cytosol, the 
chaperone is displaced, and the nuclear receptor is freed to undergo an active conformation, 
enabling its translocation into the nucleus where it subsequently binds specific DNA 
recognition elements present in the promoter sequence of target genes, inducing their 
transcription (Gronemeyer et al, 2004). As such, NRs are dual functional, serving as both a 
receptor and a transcription factor. The active conformation of NRs possesses a hydrophobic 
pocket as the ligand-binding site (Gronemeyer et al, 2004). Hence, ligands of NRs are 
necessarily small hydrophobic molecules (e.g., fatty acids, steroid hormones, thyroid 
hormones, vitamin D, retinoids, etc.), which eases their diffusion-based passage through the 
hydrophobic cell membrane and their subsequent binding to intracellular receptors 
(Friedmann et al, 2005). Furthermore, the skin is increasingly recognized as an endocrine 
tissue because it synthesizes and modifies steroidal hormones, which subsequently has 
autocrine, paracrine or endocrine signaling functions (Zouboulis, 2009). As such, significant 
research attention has been paid to NRs and their transcriptional regulatory role in the skin. 
Agonist and antagonist drugs that target the NR family constitute one of the largest and 
most potent groups of pharmaceuticals currently in use, and thus hold great potential for 
use in improved wound treatment strategies (Sladek, 2003). 
3.3.1 PPAR as wound healing transcription regulator and psoriasis trigger 
Recent research by various groups including our laboratory has highlighted the crucial role 
of a distinct member group of the NR superfamily, the peroxisome proliferator-activated 
receptors (PPARs), in wound healing (Tan et al, 2004). PPARs consist of three isotypes, 
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namely α, β/δ and γ (Tan et al, 2004). Specifically, studies of adult murine skin wounds 
have shown that wounding rapidly elevates the expression of PPAR β/δ from an initially 
undetectable range to very high levels in wound-edge keratinocytes located at the 
interfollicular regions of the epidermis (Tan et al, 2004). Apart from the epidermis, dermal 
PPAR β/δ levels were also up-regulated (Tan et al, 2004). In addition to wounding, the up-
regulation of PPAR β/δ in interfollicular keratinocytes was also observed upon hair 
plucking and treatment with chemical irritants like phorbol esters, which can induce skin 
inflammation, epidermal hyperplasia and act as tumor promoting agents (TPAs) 
(Fürstenberger et al, 1981; Tan et al, 2003). The common underlying theme of these three 
skin perturbation events is that they all involve a preliminary phase of inflammation 
followed by epidermal proliferation. Wounding and hair plucking which are examples of 
koebnerization, both involve damage to the epidermis that initiate inflammation, followed 
by keratinocyte proliferation in order to re-epithelialize the breached epidermis. 
Inflammation and a hyperproliferative epidermis are also hallmark features of psoriasis, 
thus suggesting the possible involvement of PPAR β/δ in the transcription regulatory 
process of psoriasis. We conducted in vitro studies on mouse primary keratinocytes to 
evaluate the means of PPAR β/δ up-regulation during wounding. A mixed leukocyte 
reactions (MLR) procedure was used to mimic the inflammatory environment in the wound. 
MLR involves exposing immature bone marrow-derived dendritic cells (DCs) and T cells to 
a necrotic cellular mixture of minced skin. DCs activated by the necrotic cellular mixture 
will induce T cells to synergistically produce pro-inflammatory cytokines equivalent to 
those produced in a wound environment (i.e., TNF-α, IFN-γ, IL-1, etc.). Incubation of 
keratinocytes with the conditioned MLR media led to the up-regulation of PPAR β/δ. In 
fact, TNF-α and IFN-γ were confirmed to be the signaling inducers responsible for this 
PPAR β/δ up-regulation. TNF-α and IFN-γ were also found to up-regulate the endogenous 
ligand of PPAR β/δ, hence enhancing the transcriptional activity of PPAR β/δ in the 
wounded skin. Without this production of the ligand, transcription through PPAR β/δ 
would have been futile despite a deliberate overexpression of PPAR β/δ (Tan et al, 2001). 
In summary, wounding and skin injury lead to epidermal damage, which trigger innate skin 
inflammation. Excessive pro-inflammatory cytokines in the inflamed skin induce the up-
regulation of PPAR β/δ and its endogenous ligand, which subsequently counter the 
apoptotic consequences of inflammation, favoring epidermal hyperproliferation (Tan et al, 
2001). This relationship was first established in wounding studies and bears clear 
resemblances to the pathological manifestation of psoriasis. This insight into PPAR β/δ’s 
involvement in wound healing prompted further investigation into its probable role in 
psoriasis. Immunohistochemistry and expression profiling studies have revealed that PPAR 
β/δ is overexpressed in the psoriatic lesions of most patients (Romanowska et al, 2010). The 
overexpression of PPAR β/δ in mouse skin also resulted in an inflammatory skin disease 
that was phenotypically similar to psoriasis (Romanowska et al, 2010). 
Other epidermal factors have also been linked to psoriasis. One emerging area of interest is 
the S100 proteins, a multigene family of low molecular weight calcium binding proteins 
encoded within a well known psoriasis susceptibility locus (PSOR4) on chromosome 1q21 
(Semprini et al, 2002). S100A7 (psoriasin) and S100A15 (koebnerisin), prominent members of 
this protein family, are up-regulated in skin inflammation and psoriasis (Semprini et al, 
2002). Uninvolved psoriatic skin was found to have more constitutively enhanced 
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level of S100A7/A15 was further elevated, suggesting its significant role in the disease. This 
up-regulated S100A7/A15 expression was also retained when psoriatic keratinocytes were 
isolated and cultured in vitro (Wolf et al, 2010). S100A7/A15 was found to prime psoriatic 
keratinocytes, thereby increasing their susceptibility to inflammation (Wolf et al, 2010). This 
has been largely attributed to its autocrine effect on keratinocytes with recent studies 
confirming the intracellular presence of S100A7 (Broome et al, 2003). Moreover, S100A7 
expression was also correlated with epidermal fatty acid binding protein (E-FABP), a 
keratinocyte protein that is distinctly up-regulated in psoriasis (Ruse et al, 2003). As it is 
difficult for lipophilic ligands to traverse through the hydrophilic cytosolic environment 
enroute the nucleus,  E-FABP eases this transition by binding the endogenous ligands and 
transferring them to the PPAR β/δ receptor (Kannan-Thulasiraman et al, 2010). Notably, 
S100A7 has been found to bind and co-localize with E-FABP in keratinocytes (Broome et al, 
2003). This interaction effectually stabilizes intracellular E-FABP levels (Broome et al, 2003).  
Hence, E-FABP is necessary for PPAR β/δ to stabilize and function effectively as a nuclear 
receptor (Kannan-Thulasiraman et al, 2010). This relationship explains how increased levels 
of S100A7 predisposes keratinocytes to inflammation and psoriasis, possibly via the 
stabilization of PPAR β/δ receptors for their relevant transcriptional activity. As S100 
proteins interact with their target proteins in a calcium-dependent manner, it is also possible 
that calcium released from the endoplasmic reticulum during inflammation activates 
S100A7 which acts together with PPAR β/δ to induce transcription of anti-apoptotic 
features in psoriatic keratinocytes. Herein, the role of PPAR β/δ in psoriasis is reinforced. 
3.4 ROS-induced oxidative damage of keratinocytes as initiating event of psoriasis 
Psoriatic lesions are associated with up-regulated levels of reactive oxygen species (ROS) 
(Zhou et al, 2009). Using dichlorodihydrofluorescein diacetate (DCF) staining, we assessed 
levels of intracellular ROS in mouse wounds and found ROS levels in wound epithelial 
tissue peaking at 3-7 days post-injury (Lam et al, 2011). This ROS up-regulation is likely 
secondary to the strong pro-inflammatory wound microenvironment, supported by TNF-α, 
which can up-regulate cellular ROS (Kim et al, 2010). ROS-induced oxidative damage can 
trigger both apoptotic and necrotic cell death through multiple mechanisms including DNA 
fragmentation (Higuchi, 2003) and mitochondria cytochrome c release (Kirkland & Franklin, 
2001). While all previously mentioned forms of skin trauma involve external perturbation to 
the epidermis, this endogenous ROS-triggered necrotic cell death secondary to epidermal 
trauma may theoretically be the initializing cause of koebnerized psoriasis. Such an ROS-
triggered skin trauma could arise in apparently unwounded psoriatic skin based on 
intracellular signaling dysregulation and could help explain the spontaneous occurrence of 
psoriatic lesions. However, key questions remain as to how this death-promoting ROS 
signal is regulated.   
Interestingly, we have found that the wound expression of transforming growth factor-β 
(TGF-β) activated kinase 1 (TAK1), a downstream signaling player of TNF-α, coincides with 
the pattern of ROS production, with peak expression also at 3-7 days post-injury (Lam et al, 
2011). Like PPARβ/δ, TAK1 activity is most likely affected by TNF-α induction in 
wounding. A known signal transducer in the innate immune response, TAK1 in 
keratinocytes may serve as both an epidermal and an immune factor responsible for the 
pathogenesis of psoriasis. Another separate study reported that mice with an epidermal 
specific deletion of TAK1 suffered massive keratinocyte death attributed to elevated ROS 
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levels which subsequently resulted in severe psoriasiform-like skin inflammation (Omori et 
al, 2008). These findings strongly suggest that the dysregulation of epidermal homeostasis 
could trigger inflammation and initiate/sustain psoriasis of the skin and death by the 7th 
post-natal day (Omori et al, 2008). This precise role of TAK1 in psoriasis needs further 
elucidation.  
To circumvent the limitations of in vivo models, we generated lentiviral-mediated TAK1 
knockdown (TAK1 kd) human keratinocytes and cultured them in organotypic co-cultures 
(OTC). OTC consists of seeded keratinocytes cultured on a dermal-like fibroblast embedded 
collagen layer. The bottom fibroblast/collagen dermal layer contacts the OTC medium, 
while the top keratinocyte layer is exposed to the air. This mimics the in vivo positions of 
keratinocytes and fibroblasts in the intact skin, whereby nutrients are solely supplied to the 
dermis through the dermal blood circulation with nutrients reaching the epidermal layer 
only through diffusion (Stark et al, 2004). The advantage of using OTC models in the study 
of psoriasis is that it allows us to study the behavior and development of keratinocytes at 
the tissue level without the confounding influences of the immune system. This is especially 
useful in psoriasis research so that epidermal factors can be isolated and studied alone, 
without any immune related effects. Using this setup, we found that TAK1 kd OTC 
epidermis displayed significantly higher ROS levels with an increased incidence of 
keratinocyte cell death (Lam et al, 2011). This suggests that TAK1 kd keratinocytes 
succumbed to ROS-induced keratinocyte death even in normal tissue development. A 
unique feature of keratinocytes is that they are naturally subjected to anoikis-induced death 
after detachment from the basement membrane during skin homeostasis. Through flow 
cytometric analyses of DCF and annexin V staining, we found that either TNF-α induction 
or anoikis could enhance ROS production and subsequently induce cell death in TAK1 kd 
keratinocytes (Lam et al, 2011). 
Importantly, we found that TAK1 protects healthy keratinocytes from ROS-mediated death 
by inducing epidermal expression of stem cell factor (SCF) through transcription factor c-
Jun. SCF is secreted in an autocrine manner to bind and activate its c-Kit receptor on 
neighboring keratinocytes (Lam et al, 2011). The activation of c-Kit further leads to the 
activation of phosphoinositide-3 kinase (PI3K)/protein kinase B (PKB)α to initiate cell 
survival and anti-apoptotic effects (Lam et al, 2011). Incidentally, epidermal deletion of c-
Jun in mice has been shown to produce a realistic psoriatic model (Zenz et al, 2005), further 
substantiating the role of TAK1 in psoriasis pathogenesis. As the skin is frequently exposed 
to oxidative stress from the external environment (Zhou et al, 2009), additional protection of 
keratinocytes is necessary to ensure that epidermal cells do not succumb to a fatal, massive 
cell death fate, similar to mice with epidermal specific TAK 1 deletion (Omori et al, 2008). 
Likewise, the constant microbial insults the skin confronts may lead to inflammatory 
responses like TNF-α induction, which will enhance ROS production in keratinocytes 
(Omori et al, 2008). Without the protective effects of TAK1, the epidermis may undergo 
necrotic degeneration especially during episodes of skin infection. We postulate that the 
pathogenesis of psoriasis may involve the suppression of TAK1 mediated protective 
mechanisms against ROS in psoriatic keratinocytes, leading to keratinocyte death and 
inflammation. The degree of this suppression may vary with the severity of psoriasis, with 
mild cases having lower levels of suppression compared to severe cases. Keratinocytes with 
strong suppression would undergo anoikis-triggered ROS elevation and necrotic cell death, 
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(Zhou et al, 2009). Using dichlorodihydrofluorescein diacetate (DCF) staining, we assessed 
levels of intracellular ROS in mouse wounds and found ROS levels in wound epithelial 
tissue peaking at 3-7 days post-injury (Lam et al, 2011). This ROS up-regulation is likely 
secondary to the strong pro-inflammatory wound microenvironment, supported by TNF-α, 
which can up-regulate cellular ROS (Kim et al, 2010). ROS-induced oxidative damage can 
trigger both apoptotic and necrotic cell death through multiple mechanisms including DNA 
fragmentation (Higuchi, 2003) and mitochondria cytochrome c release (Kirkland & Franklin, 
2001). While all previously mentioned forms of skin trauma involve external perturbation to 
the epidermis, this endogenous ROS-triggered necrotic cell death secondary to epidermal 
trauma may theoretically be the initializing cause of koebnerized psoriasis. Such an ROS-
triggered skin trauma could arise in apparently unwounded psoriatic skin based on 
intracellular signaling dysregulation and could help explain the spontaneous occurrence of 
psoriatic lesions. However, key questions remain as to how this death-promoting ROS 
signal is regulated.   
Interestingly, we have found that the wound expression of transforming growth factor-β 
(TGF-β) activated kinase 1 (TAK1), a downstream signaling player of TNF-α, coincides with 
the pattern of ROS production, with peak expression also at 3-7 days post-injury (Lam et al, 
2011). Like PPARβ/δ, TAK1 activity is most likely affected by TNF-α induction in 
wounding. A known signal transducer in the innate immune response, TAK1 in 
keratinocytes may serve as both an epidermal and an immune factor responsible for the 
pathogenesis of psoriasis. Another separate study reported that mice with an epidermal 
specific deletion of TAK1 suffered massive keratinocyte death attributed to elevated ROS 
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levels which subsequently resulted in severe psoriasiform-like skin inflammation (Omori et 
al, 2008). These findings strongly suggest that the dysregulation of epidermal homeostasis 
could trigger inflammation and initiate/sustain psoriasis of the skin and death by the 7th 
post-natal day (Omori et al, 2008). This precise role of TAK1 in psoriasis needs further 
elucidation.  
To circumvent the limitations of in vivo models, we generated lentiviral-mediated TAK1 
knockdown (TAK1 kd) human keratinocytes and cultured them in organotypic co-cultures 
(OTC). OTC consists of seeded keratinocytes cultured on a dermal-like fibroblast embedded 
collagen layer. The bottom fibroblast/collagen dermal layer contacts the OTC medium, 
while the top keratinocyte layer is exposed to the air. This mimics the in vivo positions of 
keratinocytes and fibroblasts in the intact skin, whereby nutrients are solely supplied to the 
dermis through the dermal blood circulation with nutrients reaching the epidermal layer 
only through diffusion (Stark et al, 2004). The advantage of using OTC models in the study 
of psoriasis is that it allows us to study the behavior and development of keratinocytes at 
the tissue level without the confounding influences of the immune system. This is especially 
useful in psoriasis research so that epidermal factors can be isolated and studied alone, 
without any immune related effects. Using this setup, we found that TAK1 kd OTC 
epidermis displayed significantly higher ROS levels with an increased incidence of 
keratinocyte cell death (Lam et al, 2011). This suggests that TAK1 kd keratinocytes 
succumbed to ROS-induced keratinocyte death even in normal tissue development. A 
unique feature of keratinocytes is that they are naturally subjected to anoikis-induced death 
after detachment from the basement membrane during skin homeostasis. Through flow 
cytometric analyses of DCF and annexin V staining, we found that either TNF-α induction 
or anoikis could enhance ROS production and subsequently induce cell death in TAK1 kd 
keratinocytes (Lam et al, 2011). 
Importantly, we found that TAK1 protects healthy keratinocytes from ROS-mediated death 
by inducing epidermal expression of stem cell factor (SCF) through transcription factor c-
Jun. SCF is secreted in an autocrine manner to bind and activate its c-Kit receptor on 
neighboring keratinocytes (Lam et al, 2011). The activation of c-Kit further leads to the 
activation of phosphoinositide-3 kinase (PI3K)/protein kinase B (PKB)α to initiate cell 
survival and anti-apoptotic effects (Lam et al, 2011). Incidentally, epidermal deletion of c-
Jun in mice has been shown to produce a realistic psoriatic model (Zenz et al, 2005), further 
substantiating the role of TAK1 in psoriasis pathogenesis. As the skin is frequently exposed 
to oxidative stress from the external environment (Zhou et al, 2009), additional protection of 
keratinocytes is necessary to ensure that epidermal cells do not succumb to a fatal, massive 
cell death fate, similar to mice with epidermal specific TAK 1 deletion (Omori et al, 2008). 
Likewise, the constant microbial insults the skin confronts may lead to inflammatory 
responses like TNF-α induction, which will enhance ROS production in keratinocytes 
(Omori et al, 2008). Without the protective effects of TAK1, the epidermis may undergo 
necrotic degeneration especially during episodes of skin infection. We postulate that the 
pathogenesis of psoriasis may involve the suppression of TAK1 mediated protective 
mechanisms against ROS in psoriatic keratinocytes, leading to keratinocyte death and 
inflammation. The degree of this suppression may vary with the severity of psoriasis, with 
mild cases having lower levels of suppression compared to severe cases. Keratinocytes with 
strong suppression would undergo anoikis-triggered ROS elevation and necrotic cell death, 





psoriasis drugs have been found to have a therapeutic effect on ROS-induced oxidative 
stress, further favoring the ROS aspect of psoriasis pathogenesis (Zhou et al, 2009). A 
primary example is dimethylfumarate (DMF), which is known to up-regulate glutathione 
(Ghashghaeinia et al, 2010) and the induction of NADPH:quinine oxidoreductase 1 (NQO1) 
(Begleiter et al, 2004), two antioxidative pathways in the cell. Vitamin D analogues also 
increase the production and activity of glucose-6-phosphate dehydrogenase (G6PD), which 
reduces ROS-induced oxidative stress (Bao et al, 2008). 
4. Conclusion 
Chronic psoriasis has a complex pathogenesis, involving both epidermal barrier and 
immune mediated dysfunction. While much of the recent advances have been in the area of 
the immunopathogenesis of psoriasis, the role of epidermal disruption as an initiating event 
and perpetuating cause of psoriasis certainly warrants further investigation and 
understanding. In this chapter, we have highlighted wound healing studies that support the 
key role of epidermal dysfunction in psoriasis and the koebner phenomenon. In particular, 
the role of nuclear receptor S100 proteins and the protective role of TAK1 against ROS 
induced stress were highlighted and discussed. It is noteworthy that the wound healing 
studies using novel organotypic skin cocultures have been crucial in further enhancing our 
understanding of the epidermal dysfunction in psoriasis and complementing existing in vivo 
models. 
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Skin is composed of three layers: epidermis, dermis and hypodermis (Sugihara et al., 1991). 
Epidermis is divided into five layers namely, stratum basale, spinosum, granulosum, lucidum, 
and corneum (Bragulla & Homberger, 2009, Nagarajan et al., 2009). The differentiation 
process implies that keratinocytes are transformed through the different cell layers to reach 
their complete maturation in the stratum corneum (Harding, 2004). In this process, various 
proliferation and differentiation markers are expressed in a well-orchestrated sequence of 
events (Fig. 1). When the differentiation process is negatively affected, skin pathologies such 
as psoriasis can appear (Rashmi et al., 2009, Karlsson et al., 2004). 
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Psoriasis is a severe skin disease affecting men and women worldwide. It affects about 2 % 
of the world population (Baker et al., 2008, Wippel-Slupetzky & Stingl, 2009). Previous 
studies have demonstrated that psoriasis prevalence varies as a result of two factors: (1) 
geographical localization and (2) ethnic group. Firstly, psoriasis shows a significant 
geographical variability with the lowest incidence seen at the equator and increasing 
frequency towards the poles (Kormeili et al., 2004, Krueger & Bowcock, 2005, Lowes et 
al., 2007) (Fig. 2). Secondly, even if psoriasis is universal, it does not affect all ethnic 
groups in a similar way. In fact, various studies have demonstrated that psoriasis 
prevalence can be modified in function of ethnic factors. They established that, in the 
United States, the prevalence was of 0.5 to 0.7 % in African population compared with 
1.4 to 4.6 % for Caucasian population (Schon & Boehncke, 2005). Furthermore, some 
populations, such as Samoan population (Polynesia), are exempt from psoriasis, whereas 
other ethnic groups show a high percentage of affected peoples such as observed in 


































Fig. 2. Worldwide psoriasis prevalence 
Psoriasis prevalence shows a significant geographical variability. A lower incidence can be 
observed at the equator while the frequency increases towards the poles. Studies suggest 
that the incidence may be related with the time and/or the intensity exposure to the 
ultraviolet wavelengths of sunlight (Menter & Stoff, 2010). 
 




Psoriatic skin is characterized by remarkable hyperplasia of the epidermis (acanthosis), loss 
of the granular layer, increased vascularization in the dermis, and thickening of the 
cornified layer (hyperkeratosis). Additionally, the incomplete keratinocyte differentiation 
(parakeratosis) and the leukocyte infiltration in skin are hallmarks of this disease (Tonel & 
Conrad, 2009).   
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psoriatic phenotype (Boyman et al., 2004, Conrad et al., 2007). Thus, psoriatic lesions could 
be initiated by an initial trigger which activates dendritic cells (DCs) and induces their 
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Furthermore, migration of T cells in the epidermis seems to be connected with the 
disturbances of desmosome connection between keratinocytes, thereby contributing to the 
disruption of epidermal integrity (Krueger, 2002). That could be interpreted by 
keratinocytes as an injury with a further wound repair response, and the release of cytokines 
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Psoriasis is considered to be an immune-mediated disease characterized by a predominantly 
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tumour necrosis factor-alpha (TNF-α), IL-12, and IL-18, among others. Thus, the secretion of 
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immune system are considered to be one of the earliest events leading to psoriasis (Nestle et 
al., 2005). Cytokines released by T cells, DCs, macrophages and neutrophils such as IL-1, IL-
6 and INF-γ have been shown to directly induce epidermal hyperplasia (Krueger, 2002). 
Additionally, other inflammatory cytokines such as IL-23, have gained attention for their 
role in psoriasis pathogenesis. IL-23 leads to the production of IL-17 and IL-22, contributing 
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Fig. 2. Worldwide psoriasis prevalence 
Psoriasis prevalence shows a significant geographical variability. A lower incidence can be 
observed at the equator while the frequency increases towards the poles. Studies suggest 
that the incidence may be related with the time and/or the intensity exposure to the 
ultraviolet wavelengths of sunlight (Menter & Stoff, 2010). 
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(Chan et al., 2006, Wolk et al., 2004). Intradermal injection of this IL-23 contributes to the 
development of epidermal acanthosis in mice (Chan et al., 2006, Zheng et al., 2007). Other 
evidence supporting its role in psoriasis includes the clinical efficacy of anti-p40 monoclonal 
antibody (Krueger et al., 2007).  
Overall, psoriasis involves a complex interplay between various cells of the immune system 
and skin, including dendritic cells, T cells, neutrophils, and keratinocytes, which leads to the 
release of numerous cytokines and chemokines that signal keratinocytes to hyperproliferate 
and undergo abnormal differentiation (Gottlieb et al., 2003).   
1.2.3 Treatment satisfaction: Results of worldwide surveys 
Previous worldwide surveys of psoriasis affected individuals have revealed widespread 
dissatisfaction with available treatments, as well as frustration with current management 
strategies, thereby demonstrating the need for more appropriate forms of therapy (Nijsten et 
al., 2005, Stern et al., 2004) and the importance for an improved access for patients to health 
care services (Klotz et al., 2005, Simpson et al., 2006). 
In 1998, a self-administered questionnaire was mailed to the entire membership of the 
National Psoriasis Foundation in the United States (n=40,350) and followed by a telephone 
survey of patients with severe psoriasis. Of the 40,350 questionnaires mailed out, a response 
rate of 43 % was realized. Although 48 % of responders were very or fairly satisfied with 
psoriasis treatments, a nearly similar number of patients (49 %) reported that they were only 
somewhat or not at all satisfied (Krueger et al., 2001). Additionally, 46 % of patients 
responded that their treatment functioned “just somewhat well” or “not well at all” and a 
high degree of dissatisfaction with the capacity of treatments to control the symptoms was 
reported. In the case of patients with severe disease, 78 % reported that their treatment did 
not function well enough, thereby leading them to a frustration with their medications 
(Krueger et al., 2001). In fact, 32 % of these patients replied that the treatment they received 
was not aggressive enough. As a consequence, many of the responders (43 %) had tried 
over-the-counter medications or alternative therapies such as herbs, relaxation or 
acupuncture in order to control their psoriasis (Krueger et al., 2001). Another survey, 
conducted with 77 psoriatic patients in Israel also demonstrated that 62 % of patients used 
complementary and alternative medicines including herbal medicines and nutritional 
treatments followed by homeopathy and traditional Chinese medicine. The main reasons for 
complementary and alternative medicines were: the less toxic indications, disappointment 
with conventional treatments and stress reduction (Ben-Arye et al., 2003).    
In order to assess the satisfaction of psoriatic patients with four systemic medications 
(methotrexate, PUVA-therapy, cyclosporin and acitretin), 1,197 patients were interviewed in 
the United States between 2001 and 2002 (Nijsten et al., 2005). Of these patients, only 26 % 
(n=311) indicated the use of these systemic treatments for their psoriasis. Less than 40 % of 
these patients were very satisfied with their treatment, while a comparable proportion 
indicated being dissatisfied. Low levels of satisfaction were related with treatment 
resistance, toxicity, convenience, costs and unrealistic patients’ expectations (Nijsten et al., 
2005). Patients were more satisfied with methotrexate and PUVA-therapy than with acitretin 
and cyclosporine. Furthermore, PUVA-therapy had the highest satisfaction rate and 
cyclosporine the lowest compared with other therapies.   
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In 2002, the European Federation of Psoriasis Patient Associations (EUROPSO) carried out a 
Europe-wide survey investigating quality of life of psoriatic patients, as well as their 
satisfaction with available treatments (Dubertret et al., 2006). Self-administered 
questionnaires were thus mailed to members of psoriasis associations in Germany, Belgium, 
Finland, France, Czech Republic, Italy and Netherlands. From 18,386 responders, 17,990 had 
psoriasis. At the time of the survey, 32 % of all participants used a topical treatment, 17 % a 
systemic treatment and 13 % phototherapy treatment. Although many patients were 
satisfied with the information and care offered by their physicians (40 % highly satisfied), 
available treatment modalities were less satisfactory, with over 70 % reporting low or 
moderate satisfaction. Higher satisfaction (score of 8–10) was observed for treatments with 
methotrexate (30 %), cyclosporin (28 %) and fumarates (26 %) followed by PUVA-therapy 
(38 %). Lower satisfaction (score of 1–4) was observed for tazarotene (42 %) and etretinate 
(38 %).  Responders (50 %) reported that the time consumed during therapies was the most 
troublesome aspect, followed by ineffectiveness of treatments (32 %). Patients with severe 
psoriasis reported side effects as a problem (31 %), whereas only 23 % of patients with mild 
psoriasis considered this aspect (Dubertret et al., 2006). Furthermore, another survey 
conducted in 2003 with 301 psoriatic patients in Europe, also demonstrated that 42 % of 
patients were dissatisfied with their treatment (Christophers et al., 2006). Lack of satisfaction 
was lower among the patients receiving treatment with more than one agent, and in those 
who had more frequent psoriasis relapses, demonstrating the high need for safe and 
effective therapies for management of this disease (Christophers et al., 2006).  
Patients diagnosed with psoriasis in the United States between 2006 and 2007 were 
contacted to complete an online survey ("Psoriasis Patient Study Wave 1") related to their 
psoriasis diagnosis, treatment and treatment satisfaction (total of patients=1,006). Of those 
who had ever taken a prescription (topical, phototherapy, systemic oral or biologics, n=557), 
31.8 % (n=177) reported that their current treatment was not able to satisfactorily clear their 
psoriasis. When patients were separated by treatment, 20.8 % (n=33) of those using 
biologics, 31.1 % (n=33) of those using systemic oral, 46.4 % (n=13) of those using 
phototherapy, and 34.2 % (n=163) of those using topical treatments reported that their 
current treatment was not able to satisfactorily clear their psoriasis. Patients with severe 
disease were less satisfied than those with mild and moderate disease (47.9 % vs. 32.9 % vs. 
27.6 % respectively) (DiBonaventura et al., 2010). 
An online Canadian survey conducted in December 2007 with 514 patients diagnosed with 
moderate, severe and very severe plaque psoriasis demonstrated that awareness of available 
treatment options ranged from 98 % for topical treatments to 75 % for phototherapies, 49 % 
for oral treatments and 35 % for injectable medications. Satisfaction with treatments were 
generally low, and only 24 % of patients reported to be “very satisfied” with their current 
therapy. Satisfaction decreased with the increase of psoriasis severity, 39 % of patients with 
mild/very mild psoriasis reported to be ‘‘very satisfied’’, compared with 16 % of those 
diagnosed with moderate/severe/very severe psoriasis (Wasel et al., 2009). In this survey, 
dissatisfaction with the efficacy of antipsoriatic treatment was highlighted by the majority of 
patients (68 %) reporting that ‘‘No medication works really well for my psoriasis’’. 
Additionally, patients with severe psoriasis more frequently complained that “medication 
was very ineffective for my psoriasis” compared to those less affected (49 %, 69 % and 77 % 
for respondents with 0–2 %, > 3%, and > 10% of body surface area (BSA) involvement, 
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side effects from medication to treat psoriasis (54 %, 64 % and 69 % of psoriatic patients with 
0–2 %, > 3% and > 10% BSA involvement, respectively). Patients also manifested that the 
reasons for treatment discontinuation were as following: lack of efficacy (60 %), 
inconvenience (23 %) and improvement of symptoms (22 %), side effects (20 %), cost (14 %) 
and doctor’s advice (14 %) (Poulin et al., 2010).  
Overall, results of worldwide surveys demonstrate that a substantial proportion of psoriatic 
patients are highly dissatisfied with current therapies, particularly those with greater 
psoriasis severity. A perceived lack of efficacy of available treatments suggests the 
importance of the development of more relevant treatments, in order to allow the 
establishment of more individualized therapies.   
2. Challenges for antipsoriatic drug development 
The most significant challenge for antipsoriatic drug development is to provide safe and 
effective long-term management of this disease. In general, a conventional vision of this 
process starts with the study of disease in relevant model systems, in order to determine 
cellular and molecular mechanisms involved in pathogenesis. Afterwards, new therapeutic 
approaches are developed in these models before clinical trials in humans (Guttman-Yassky & 
Krueger, 2007). The comprehension that psoriasis is an immune-mediated disease, which 
involves a complex interplay of T cells, natural killer cells, dendritic cells, macrophages and 
other leukocytes, has led to the development of new biological treatments. The positive results 
obtained with these agents have expanded our understanding on psoriasis pathogenesis. 
However, many questions remain regarding psoriasis pathogenesis, and other medications 
should be developed to offer individualized treatments able to improve patient’s quality of 
life. Some of the challenges for this field include the improvement of efficacy and safety of new 
drugs, the solution of problems related to formulation/administration/costs of new agents, 
and the development of more relevant psoriatic skin models.  
2.1 Efficacy 
Many psoriatic patients are unresponsive to current therapies or have aggressive disease 
that is not addressed by current approaches. The determination of relevant biomarkers 
directly related to psoriasis pathogenesis to be targeted with effective treatments could 
allow quantitative assessment of treatment response (Rashmi et al., 2009).  
2.2 Safety 
The challenge of improving the safety of new antipsoriatic drugs is a very important aspect 
for long-term therapies, and can be overcome through the understanding of the toxicity 
mechanisms of new agents at early stages of drug development. Unfortunately, this is not 
always feasible during the drug development process, and the “safety question” should 
respond to what constitutes an acceptable risk. Thus, it is important to carefully analyse the 
risk/benefit rate of new antipsoriatic agents, mainly in the case of severe disease.  
2.3 Practical issues 
In the case of drugs approved for clinical use, their specific immunogenicity, costs, patient 
access and inconveniences for administration should be considerate. Other challenges 
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include the optimization of the new drug delivery to give maximum effects to its intended 
biological targets.   
2.4 Development of more relevant psoriatic skin models 
Maybe the most important challenge for antipsoriatic drug development is the inexistence of 
validated in vivo and in vitro skin models. Psoriasis is a complex disease in which 
interactions with 30 or more upregulated cytokines and chemokines implies the formation 
of interactive circuits that are not completely reproduced by in vivo and in vitro models. In 
the case of animal models, which are very important in pre-clinic stages of drug 
development, no one can fully mimic the genomic signature of this disease in which 
expression than more of 1,300 genes is altered (Guttman-Yassky & Krueger, 2007). Other 
problems are related to the fact that murine skin is different from human skin, and often 
the immune infiltrates are less intense and contain different mixtures of leucocytes 
compared with psoriatic plaques (Gudjonsson et al., 2007). Furthermore, animal models of 
epidermal hyperplasia are not selective enough, being also used for the study of other 
diseases, such as atopic dermatitis, even when different inflammatory genes are implied 
in these two diseases. Thus, it is not a surprise that targeted therapies such as the 
antibody efalizumab, are effective in both diseases (Farshidi & Sadeghi, 2006). The lack of 
representative in vivo and in vitro skin models could also be related to failures of clinical 
trials at late stages. Hence, some psoriatic models are of questionable value for the 
development of selective antipsoriatic treatments. A detailed explanation of these models 
will be provided in subsequent sections.   
3. In vivo and in vitro psoriatic skin models 
3.1 In vivo models 
3.1.1 Spontaneous mutations 
Psoriasis is a typical human skin disease. Even if spontaneous mutation models do not 
exhibit every features found in psoriasis, various pathology-like characteristics can be 
observed, including hyperkeratosis and scaly formation (Mizutani et al., 2003). Hundred of 
these spontaneous mutation models have been described in the literature (Sundberg et al., 
1990), but no one shows all the characteristics of psoriasis. However, these models can be 
really practical for studying individual characteristics such as hyperkeratosis (Schon, 2008). 
A comparison between the characteristics observed in the three major models of 
spontaneous mutations is presented in table 1. 
3.1.2 Xenotransplantation 
Animal models based on transgenic technology have been used extensively to study the 
pathogenesis of various skin diseases, including psoriasis (Raychaudhuri et al., 2001, Jean & 
Pouliot, 2010). Xenotransplantation approach consists of grafting a piece of in vivo psoriatic 
skin (or an in vitro psoriatic substitute) on a genetically modified mouse. Currently, three 
major models are used: athymic nude mice (Fraki et al., 1983), severe combined 
immunodeficient mice (SCID) (Raychaudhuri et al., 2001), and spontaneous AGR129 model 
(Boyman et al., 2004). The main difference between each model is the immunological 
potential of the immune system. Athymic nude mice have no thymus and therefore no T 
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Table 1. Examples of spontaneous mutation models and their characteristics 
(Raychaudhuri et al., 2001). As for AGR129 model, it is characterized by the absence of T and 
B cells and by the presence of immature natural killer (NK) cells, less cytotoxic than mature 
NK cells (Boyman et al., 2004). A weaker system is potent to dwell skin transplants for a 
longer time on a compromised mouse upon rejection. Thus, the amount of transplant 
rejection is reduced in the AGR129 model compared to the others. Boyman et al. 
demonstrated that human uninvolved psoriatic skin grafted onto AGR129 mice 
spontaneously developed psoriatic plaques without the injection of any activated immune 
cells or any other exogenous factor, suggesting that uninvolved psoriatic skin is not exactly 
comparable to the normal human skin of healthy patients (Boyman et al., 2004, Gudjonsson 
et al., 2007, Jean & Pouliot, 2010). However, the absence of an inflammatory system could be 
a significant weakness of these models, since the importance of the immunology has been 
described by many research groups. 
3.1.3 Genetically modified models 
Development of rat and mouse transgenic models was an important step in the field of in 
vivo models. These genetically modified animals allow the observation of psoriasis-like 
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characteristics in rodents following the overexpression or underexpression of cytokines (or 
enzymes) (Bullard et al., 1996, Danilenko, 2008, Keith et al., 2005). It is important to note that 
psoriasis is a multisystemic skin disease, and that transgenic models consider only a single 
gene at the time. Thus, even if these models are interesting to observe isolated psoriasis-like 
features, they do not allow the study of all the characteristics of the pathology. There exist a 
broad variety of genetically modified in vivo models. An exhaustive list can be seen in table 





























































Targeting the immune system  
HLA-B27/β2 microglobulin rat + + + + (Keith et al., 2005, Breban et al., 1996) 
Hypomorphic CD18 + + + + (Bullard et al., 1996, Kess et al., 2003) 
E (CD103) + + ? + (Schon et al., 2000) 
K14/p40 + ? ? + (Kopp et al., 2001) 
 
Targeting vascular endothelium
pTek-tTA/Tie2 + + + + (Voskas et al., 2005) 
K14/VEGF + + + + (Xia et al., 2003) 
 
Targeting epidermal proteins
K5/Stat3C + + + + (Sano et al., 2005) 
IKK2 + + ? - (Pasparakis et al., 2002) 
c-Jun/JunB + + + + (Zenz et al., 2005) 
K14/KGF + + + - (Guo et al., 1993) 
K14/TGF- + + ? Some animals (Vassar & Fuchs, 1991) 
K14/IL-20 + + - - (Blumberg et al., 2001) 
K14/amphiregulin + + + + (Cook et al., 1997) 
K14/IL-1 + + - ? (Groves et al., 1995) 
K14/IL-6 + - - - (Turksen et al., 1992) 
K10/BMP-6 + + + + (Blessing et al., 1996) 
Involucrin/integrins + + + + (Carroll et al., 1995) 
Involucrin/MEK1 + + ? + (Hobbs et al., 2004) 
Involucrin/amphiregulin + + + + (Cook et al., 2004) 
Involucrin/IFN- + + + - (Carroll et al., 1997) 
Chymotryptic enzyme + + ? + (Hansson et al., 2002) 
Table 2. In vivo genetically modified models of psoriasis 
Reproduced and modified from Jean et al., 2010 according to the copyright policy of the 
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3.2 In vitro models  
3.2.1 Monolayer 
By using only a small skin biopsy, monolayer techniques allow the attainment of a large 
number of cells (normal or pathological) supporting the production of many experiments. In 
monolayer models, only one cell type is studied. Thus, keratinocytes (or fibroblasts) can be 
used to test different conditions or to observe psoriatic skin features such as 
hyperproliferation or abnormal differentiation of keratinocytes. These models allow the 
isolation of one cell type for step by step dissection of the implied mechanisms. Even if it 
was not possible to observe direct interaction between cell types, these models allowed the 
discovery of many interesting facts about psoriasis, and favoured a better understanding of 
the pathology (Jean & Pouliot, 2010). 
3.2.2 Collagen gels 
Despite the absence of a complete in vitro model allowing the observation of interactions 
between different cell types, such as keratinocytes and fibroblasts, some teams have 
developed specialized techniques which imply an exogenous matrix: the collagen gel. 
3.2.2.1 Organ culture 
Some teams decided to put down complete skin biopsies on collagen gel, containing 
fibroblasts, to observe cell proliferation. Total surface recovered by keratinocytes was used 
to calculate cell proliferation percentage (Saiag et al., 1985). Higher keratinocyte proliferation 
values were obtained in the presence of psoriatic fibroblasts (Saiag et al., 1985). Furthermore, 
this model led to the conclusion that normal fibroblasts are unable to suppress the 
hyperproliferative growth of psoriatic keratinocytes, and that hyperproliferation of normal 
epidermis can be induced both by uninvolved and involved psoriatic fibroblasts (Saiag et al., 
1985, Jean & Pouliot, 2010). 
3.2.2.2 Models using many cellular types 
Other teams developed skin substitutes composed of two cell types, in order to observe 
the effects of psoriatic keratinocytes on fibroblasts and vice versa. In a global way, these 
models consist of isolating normal and pathological cells from a small biopsy. Fibroblasts 
are extracted from dermis, expanded and seeded in collagen gel. Keratinocytes are 
extracted in a similar way and are placed on the pre-prepared collagen gel (Konstantinova 
et al., 1996). Barker et al. developed and characterized an in vitro psoriatic skin model 
using collagen gel. This model was very representative of the pathology (Barker et al., 
2004). In fact, they have demonstrated that the model kept many characteristics of 
psoriasis such as hyperproliferation and abnormal differentiation of keratinocytes, 
augmentation of the interleukin 6 and 8 concentrations, as well as the overexpression or 
underexpression of some proliferation, differentiation and inflammatory markers 
observed in psoriatic skin. Researchers concluded that involved and uninvolved skins 
seem to have the same pathological characteristics as psoriatic human skin (Barker et al., 
2004, Jean & Pouliot, 2010). Barker, Konstantinova and Saiag models are interesting in 
vitro models for studying psoriasis, but they are produced with a contractile exogenous 
material (collagen gel). 
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3.2.3 Self-assembly approach 
Facing the absence of exogenous material-free models, our group developed a new 
pathological skin model to study psoriasis in vitro by using the self-assembly approach 
(Michel et al., 1999) (Fig. 3). Briefly, normal and pathological fibroblasts are thawed and 
cultured with ascorbic acid for a period of time of four weeks. Then, dermal sheets are 
produced and removed from flasks. Two fibroblast sheets are superimposed to form a new 
dermal equivalent. Seven days later, normal or pathological keratinocytes are seeded on the 
dermal equivalent to obtain a new epidermal equivalent. After another 7 days of culture, the 
substitutes are raised to the air–liquid interface to favour cell differentiation and 
stratification. Finally, biopsies are taken after 21 days of culture at the air–liquid interface, 
and samples are analyzed using histological, immunohistochemical, physico-chemical or 
permeability techniques (Jean et al., 2009). 
Fig. 3. The self-assembly approach for the production of skin substitutes 
Schematic representation of the various steps of skin substitutes production in function of 
time. Reproduced and modified from Jean et al., 2010 according to the copyright policy of 
the publisher.  2010 InTech. 
In 2009, Jean et al. showed that self-assembled skin substitutes partially maintained 
psoriasis-like features such as a thick epidermis, hyperproliferation as well as abnormal cell 
differentiation of epidermal cells (Jean et al., 2009). In 2011, they demonstrated for the first 
time that pathological substitutes produced by the self-assembly approach can be treated 
with an anti-psoriatic molecule and react positively to the treatment such as observed in 
psoriatic skin in vivo. This functional study suggests that the self-assembled skin substitutes 
could be useful to better understand the mechanisms through which retinoic acid regulates 
cellular physiology in psoriatic skin, and could become an effective and innovative 
dermopharmaceutical tool for the screening of new treatments (Jean et al., 2011). 
4. Conclusion  
Psoriasis is characterized by the presence of physical and psychological pains, which can 
severely affect the quality of life of psoriatic patients. Currently, a broad spectrum of anti-
psoriatic treatments, both topical and systemic, is available for the management of psoriasis. 
These treatments only allow to control psoriasis without curing it. Challenges for 
antipsoriatic-drugs development are numerous, and the pharmaceutical industry strongly 
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needs highly predictive in vivo and in vitro models to improve the success rate of the 
development of new drugs. Effectively, the lack of representative in vivo and in vitro models 
could be related with failures of clinical trials. Thus, the elaboration of these models 
represents a key component in the fight against psoriasis.  
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1. Introduction 
Psoriatic arthritis (PsA) was first recognized as a specific rheumatic entity in 1964 by the 
American Rheumatism Association (later American College of Rheumatology) (Blumberg, 
1964). In the forthcoming years it has become clear that PsA belongs to the spondyloarthritis 
(SpA) family that comprises several heterogeneous clinical conditions. These are Ankylosing 
Spondylitis, Reactive Arthritis (which occurs after bacterial infections), Spondyloarthritis 
associated to Chronic Inflammatory Bowel Diseases (Crohn´s disease and Ulcerative 
Colitis), Undifferentiated Spondyloarthritis, and juvenile forms (figure 1). The term 
spondyloarthritis relates to inflammatory manifestations of peripheral and spinal joint 
structures. The Spondyloarthitides are defined by classification criteria (Sieper, 2009; Zeidler 
2011, Rudwaleit 2011). The main clinical manifestation will trigger the main group for each 
disease entity may have varying degrees of articular, spinal, and extraaticular 
manifestations. Furthermore, extraarticular inflammatory manifestations may also occur at 
different intensity levels. However, it needs to emphasized that classification criteria are not 
diagnostic criteria. Classification criteria were developed for clinical studies in order to 
include rather homogenous disease manifestations. In daily clinical practice it may occur 
that although the classification criteria are not fully met, the patient still may be allocated to 




Spinal manifestations Extra-articular Manifestations 
Arthritis Spondylitis Uveitis, Scleritis, Conjunctivitis 
Enthesitis Enthesitis Psoriasis
Bursitis Sacroiliac joint arthritis Urethritis
Tendosynovitis Facet joint arthritis Inflammatory bowel disease 
Erosive-proliferative joint 
destruction 
Bony ankylosis Periodontitis with dental loss 
Table 1. Clinical manifestation of the Spondyloarthritides, which may be present in all the 
different disease entities (Fig. 1). 
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Fig. 1. Clinical entities of Spondyloarthritis. The overall disease group is the 
Spondyloarthritis, which comprises 6 distinct diseases. Psoriasis Arthritis is one disease 
entity of the group. Common abbreviations are given in parenthesis. 
In clinical practice, articular and extraarticular manifestations overlap quite frequently 
among the SpA diseases. Initially, the clinical manifestations of PsA were collected and a set 
of manifestations was proposed as classification criteria by Moll and Wright in 1973 (Moll, 
1973). These described clinical features were considered to be “Psoriatic Arthritis”. 
However, over the following years, 6 modified classification criteria for PsA (Bennet, 1979; 
Dougados, 1991; Fournie, 1999; Gladman, 1987; McGonagle, 1999; Vasey, 1984) have been 
proposed by different research groups in order to differentiate between the different disease 
entities (Taylor, 2002). As in the Moll and Wright criteria proposal, these criteria mainly 
have been established in groups of patients with classical and fully developed disease 
manifestations. The validity of these criteria have never been formally proven in studies. 
Formal prove of PsA criteria was done in 2006 with the publication of the CASPAR 
(Classification of Psoriasis Arthritis Study Group)-Criteria (Taylor, 2006) as a joint project of 
the EUAR and ACR. As with the other above mentioned 7 criteria sets, the CASPAR criteria 
also were established in a group of patients with long standing psoriasis arthritis (mean 
disease duration of greater than 10 years (Taylor, 2006). As we know that chronic 
inflammatory arthritis like Rheumatoid Arthritis (RA) and PsA can destroy joints and cause 
significant disability (see Tab. 1) we need to diagnose arthritis before destruction of tissue 
has taken place. For this reason, in RA, arthritis classification criteria have just been revised 
to also classify early RA (Aletaha, 2010). Next to the new RA early classification criteria, the 
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diagnostics of the sacroiliac joints (Rudwaleit, 2009). Bone marrow edema around the 
sacroiliac joints seen in MRI in water sensitive squences, i.e. STIR (short tau inversion 
recovery, T1 plus contrast media) detects inflammatory processes significantly earlier than 
actual joint destruction can be seen on conventional X-ray films. 
However, we still do not have validated early PsA criteria and early PsA most times does 
not present with the classical, fully developed clinical picture as is described in our 
textbooks.  
This book chapter is dedicated to discuss why we need to detect PsA early and will answer 
the question of how patients with psoriasis can be screened for possible early peripheral and 
spinal arthritis manifestations. Suggestions on how cooperation between dermatologists and 
rheumatologists can be effectively set up will be given at the end. 
2. Why is early detection of inflammatory processes important? 
2.1 The earlier the better or time is joint function 
Early detection and treatment of chronic inflammatory joint disease has been shown in 
numerous reports to correlate with better long-term outcome in rheumatoid arthritis (van 
der Bijl, 2007; Verstappen, 2007). Severity of joint destruction and loss of quality of life in 
PsA has been shown to be similar to RA (Husted, 2001; Rahman, 2001). Therefore, many 
aspects in PsA may be compared with aspects in RA. As depicted in figure 2, the chronic 
inflammatory process begins with an undulating situation of clinical and subclinical 
manifestations of joint pain with or without swelling. A trigger event then sets off the 
clinical manifest chronic inflammatory course. Joint destruction begins very early after this 
event. If the inflammatory process is not stopped, the natural disease course will occur with 
more or less destruction of joint structures.  
 
Fig. 2. Time course of the development of PsA. The earlier detection and treatment of 
arthritis takes place, the better the outcome in the following years will be, adapted according 
to (Machold, 1998).  
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However, if we treat to the target of remission and control the inflammatory process, it is 
possible to prevent or slow down the destructive process. We have plenty of evidence for 
this targeted approach for RA as reviewed elsewhere (Schoels, 2010). Furthermore, 
recommendations for physicians (Smolen, 2010) and patients (de Wit, 2011) on how to treat 
to the target of remission have recently been published. Very likely, the targeted approach is 
also true for PsA, because PsA also shows destructive disease courses and we use the same 
outcome measures than for RA. However, this has not yet been formally proven as has been 
for RA.  
Inflammation of articular structures always is coupled with loss of function. Early in the 
disease course inflammation and loss of function correlate very well. This means, if 
inflammation is suppressed, function is completely regained. However, the longer the 
inflammatory process goes on, the more fibrotic and destructive changes occur which are 
not reversible (Aletaha, 2006). This implies that effective suppression of inflammation will 
not result in full regain of function anymore (figure 3). Furthermore, fibrotic tissue may 
cause destruction by itself thus uncoupling the destructive process from classic immune 
mediated mechanisms (Neumann, 2006). 
 
Fig. 3. Correlation of inflammation (black), loss of function (yellow) and joint destruction 
(blue) with time. Very early in the inflammatory process loss of joint function is tightly 
correlated with the degree of inflammation. In this phase, complete reduction of joint 
inflammation will restore joint function. However, the longer the inflammatory process goes 
on, the more destruction of joint structures will occur along with continuously more 
irreversible loss of function and destruction. Finally, there may occur an uncoupling of 
inflammation and irreversible joint destruction with loss of function, adapted according to 
(Kirwan, 2001). 
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is Important and How Dermatologists and Rheumatologists Can Successfully Cooperate? 69 
2.2 Chronic inflammation confers a cardiovascular risk factor by itself  
An upcoming discussion is that chronic inflammatory processes enhance the cardiovascular 
risk to a similar extend like the classical known risk factors diabetes, hypertension, 
hyperlipidemia, obesity, smoking and genetics (van Halm, 2009). This implies that treatment 
of inflammation may be similar important to the treatment of the classical cardiocascular 
risk factors in order to reduce the overall cardiovascular risk. Prospective studies on 
reduction of cardiovascular risk by anti-inflammatory treatment are still pending but it was 
shown retrospectively that effective reduction of inflammation with combination therapy of 
methotrexate and anti-TNF (Tumor Necrosis Factor) medication may reduce the risk for the 
first cardiovascular event (Cugno, 2010). 
As in RA the cytokine TNF plays an important role in the pathophysiological mechanism of 
Ps and PsA. The prothrombotic effects of TNF in cardiovascular disease are discussed in a 
recent review and may play an important role in the about 4 fold enhanced cardiovascular 
risk compared with the normal population (Jacobsson, 2005). However, Ps and PsA patients 
seem to additionally have an increased prevalence of cardiovascular risk factors such as 
smoking, hypertension, raised levels of homocysteine, excessive alcohol consumption and 
metabolic syndrome compared to the normal population (Tobin, 2010). Therefore, it cannot 
be finally answered to what extend chronic inflammation of the skin, joints, and spine in 
Ps/PsA add to an enhanced cardiovascular risk. 
2.3 Health care costs of PsA are high 
Another reason for early detection of PsA is health care costs. PsA shows increasing costs 
with the duration of the disease. This seems to mainly be due to the rising risk of work 
disability. However, the association of work disability and disease duration has not very 
well been studied up to day. Only 3 studies were published on this topic (Mau, 2005; 
Verstappen, 2010) and one review gets to the conclusion that the data is too heterogeneous 
to draw hard conclusions (Tillett, 2011). Nevertheless the study of Mau et al. describes a 
reduction of the standard employment rate in PsA patients from 0,94 to 0,7 within 5 years. 
Functional status seems to be the most important factor to predict total costs. Zink et al. 
summarize that patients with a poor functional status of 50% (HAQ of more than 1,7) cost 
more than double compared to patients with a good functional status (functional status of 
70% or HAQ less than 1,2) (Zink, 2006).  
2.4 Psychosomatic comorbidity is important to consider 
Finally, the psychological and psychiatric comorbidities resulting from the cutaneous 
stigmatization and the painful, debilitating arthritic manifestations of joint and spine add to 
the disease burden of PsA (Devrimci-Ozguven, 2000; Esposito, 2006). There seems to be no 
difference in depression rate among sex and age of patients with PsA. Effective therapy of 
cutaneous manifestations and arthritis may reduce depressive disorders, which will 
significantly reduce health costs and therefore needs to be balanced against the high costs of 
modern treatment with biologics. 
3. How can patients with PsA be identified in daily clinical routine? 
In clinical practice, psoriatic patients with a dominant skin manifestation primarily consult 
dermatologists and patients with a dominant peripheral or spinal manifestation primarily 
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3. How can patients with PsA be identified in daily clinical routine? 
In clinical practice, psoriatic patients with a dominant skin manifestation primarily consult 
dermatologists and patients with a dominant peripheral or spinal manifestation primarily 
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consult rheumatologists or orthopedics. However, the vast majority of Ps patients gather 
within the dermatology setting. Therefore, it seems rational to screen patients for arthritic 
manifestations in the dermatology setting.  
From July 2005 until October 2008, we validated and established the self-administered 
patient-screening questionnaire GEPARD (GErman Psoriasis ARthritis Diagnostic 
questionnaire) to detect PsA in psoriatic patients seeking primarily dermatologic care 
(Härle, 2010) (Tab. 2 and www.kkm-mainz.de/rheumatologie). In order to keep the 
questionnaire simple, only dichotomous answers (yes/no) were used. The twelve questions 
were derived from discussions about appropriate questions among the authors and 
additional advice provided by other experienced rheumatologists. Questions number 1 to 4 
relate to clinical signs of arthritis but do not necessarily impose a momentary active state of 
arthritis by asking if the patient ever had these signs. It was considered that these questions 
take into account the remitting and relapsing nature of PsA. We considered the detection of 
these patients being especially important in the context of a longitudinal follow-up of 
fluctuating arthritis, which might eventually lead to establishing prognostic parameters for 
PsA. Questions number 5 to 8 pertain to arthritis in a more indirect way by relating to the 
discomfort caused by joint pain or dysfunction. Questions number 9 to 13 relate to the 
clinical signs of inflammatory back pain which can be associated with PsA. An additional  
 
# Question Yes No 
1 Have you ever had joint pain accompanied by swelling?   
2 Have you ever had a completely swollen digit or toe?   
3 Have you ever had joint pain accompanied by redness of that 
joint? 
  
4 Do your joints feel stiff after waking up in the morning?   
5 Have you ever thought of having a joint disease?   
6 Have you ever consulted a doctor because of your joint 
problems? 
  
7 Have you ever received the diagnosis of "arthritis"?   
8 Do you take pain medication for your joint pain?   
9 Do you suffer from back- or buttock pain? If yes, does/is this 
pain…. (please, answer questions 8a to 8d) 
  
10 … most intense in the early morning hours?   
11 … improve through exercising or moving around?   
12 … persist while resting?   
13 … accompanied by back stiffness in the morning hours?   
14 If you answered one of the above questions with “YES”: 















Table 2. The GEPARD questionnaire targets arthritic complaints of peripheral joints and 
spinal manifestations in addition of duration of arthritic symptoms thus enableing early 
detection of PsA. The patient alone answers the questionnaire. The physician or assistant 
counts the positive answers. The cut-off value of equal or more than 4 positive answers 
showed a sensitivity of 89% and a specificity of 73% to detect PsA in Ps patients 
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question related to the time period since the first occurrence of complaints lasting from one 
week up to more than 5 years in order to detect early PsA manifestations. In the statistical 
evaluation of the study, we calculated a cut-off value of greater than or equal to 4 positive 
answered questions. This cut-off showed a sensitivity of 89% and a specificity of 73% to 
detect PsA in Ps patients (Härle, 2010). 
In the final evaluation, we clinically evaluated 54 patients. These patients were selected by 
the GEPARD questionnaire from dermatology outpatient clinics. We found 43 patients who 
had some arthritic manifestations according to clinical examination, ultrasound, x-ray, MRI, 
and Technecium-Szintigraphy. This accounts for 79,6% patients being positive for PsA 
manifestation. This percentage of PsA among patients with Ps is in line with earlier 
publications (Sadek, 2007). Furthermore, 23 patients were first diagnosed as having PsA.  
According to the time duration of arthritic complaints we found 57% suffering over 4 years 
but 43% of patients below 4 years (figure 4) which may still be considered as being early 
arthritis. From these patients with complaints of less than 4 years 80% could be classified for 
PsA just by clinical examination according the CASPAR criteria without the use of 
sonography, x-ray, MRI, or szintigraphy (figure 5). Considering that the initial screening 
process was exclusively based on patients’ answers, without evaluation by a physician, the 
GEPARD patient - questionnaire is well suited for routine clinical usage. In addition, the 
screening tool does not consume additional time from the dermatologist but still enables 
him to identify patients who need to be referred to a rheumatologist for further evaluation 
of arthritic manifestation.  
 
Fig. 4. Pie chart of arthritis duration according to the GEPARD patient-questionnaire. Forty-
three percent suffered of symptoms of less than 4 years. Less than 4 years is considered to be 
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Fig. 5. Distribution of arthritis, arthralgia and no complaints in percent of GEPARD patient-
questionnaire early arthritis patients (≤ 4 years). According to the CASPAR classification 
criteria, eighty percent were classified as having PsA. 
4. How could the cooperation between dermatologist and rheumatologist be 
set up? 
As described in the previous paragraphs screening of patients with Ps can easily be done by 
using the GEPARD patient self-administered questionnaire. In the case of equal or more 
than 4 positive answers in the questionnaire, the dermatologist may refer the patient to a 
cooperating rheumatologist. Since the end of the 90s most rheumatologists have set up an 
early arthritis schedule. With the GEPARD questionnaire the patient is already screened for 
arthritis and is more likely to have an arthritic manifestation. After the rheumatologic 
assessment the decision has to be made which discipline is advantageous to take the lead in 
guidance and treatment of the patient. Usually a cooperative way is chosen, taken into 
consideration that the general practitioner is the stearing physician for the other comorbid 
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In the case of leading arthritis, the consultation of the dermatologist is necessary to confirm 
the diagnosis of Ps by clinical means or by biopsy in unclear situations (figure 7). 
Furthermore, topical treatment may be instituted if systemic therapy of PsA does not lead to 
full treatment success of the skin. The same treatment cycle as described before is necessary 
















Fig. 6. Flow chart of possible cooperation among the medical disciplines. Screening starts 
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Fig. 7. Flow chart of possible cooperation among the medical disciplines. In the case of 
suspected psoriatic manifestation or in the case of suboptimal treatment response of Ps by 
systemic therapy the rheumatologist confers the patient to the dermatologist for further 
evaluation. 
5. Summary 
Considering all the many facets of PsA and the different diagnostic and therapeutic 
strategies is the art of modern medicine and good clinical practice. We need to understand 
the context of inflammatory skin, joint, and spine manifestations with mental health, extra 
articular problems and economical considerations. This can only be accomplished by good 
cooperation between dermatologist and rheumatologist in addition to the comprehensive 
care by the general practitioner, internist, and psychological disciplines (figure 8). 
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Fig. 8. Interdisciplinary, holistic view of Ps and PsA. 
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1. Introduction   
Psoriasis is an immuno-mediated condition whose pathogenesis is still unclear and that in 
head and neck area presents six specific aspects that justify the title of this chapter: 1) 
visibility of the lesions and their impact on quality of life (QOL); 2) the very common 
involvement of the scalp; 3) the difficulty of the treatment; 4) the aberrant epidermal-
mesenchymal interactions theory; 5) the rare mucous occurrence and the PPP-tonsil-related 
disease; 6) the significantly increased risk of head and neck cancer in men with Psoriasis. 
2. Visibility and the impact on quality of life  
Visibility of head and neck Psoriasis has a considerable impact on patients’ QOL. The 
differential diagnosis for pustular skin disorders is extensive but facial Psoriasis more 
commonly affects eyebrows, the skin between the nose and  the upper lip, the upper 
forehead and the hairline. Scalp Psoriasis is very common. Multiple instruments have been 
used to determine the severity of scalp Psoriasis and tools for patient self-assessment have 
also been developed (Psoriasis Area and Severity Index or PASI, Psoriasis Scalp Severity 
Index or PSSI, Body Surface Area or BSA, Physicians' Global Assessment or PGA, Lattice 
Physician Global Assessment or LS-PGA, and Self-assessed Psoriasis Area and Severity 
Index or SAPASI) but none of the severity scores used for Psoriasis meets all of the 
validation criteria required for an ideal score. However the PASI score is the most 
extensively studied (Puzenat & al, 2010). 
While head represents only 10% of the whole body’s surface, consequences of scalp Psoriasis 
are disproportionate to its extension as it can be seriously debilitating inducing important 
social and emotional distress. 
Although it is unclear why initial scalp involvement is so common, scalp tissue has unique 
features that may promote its vulnerability to psoriatic lesions. For example, its high 
follicular density provides a dark, warm and moist environment that reduces environmental 
UV exposure which normally would limit lesion development. In addition, inflammation-
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promoting microorganisms flourish in the sebum-rich setting of the scalp and, as seen in one 
study, an association with the severity of scalp disease was suggested to be related to 
isolation of Malassezia globosa yeast from patients scalp (Gupta & al., 2004).  
Additional inflammation may be triggered or exacerbated by frequent friction and trauma 
to the scalp (Koebner phenomenon: psoriatic lesions as consequence of trauma in psoriatic 
patients) from brushing or use of styling implements. 
Psoriasis of the eye is extremely rare.  When it does occur, it can cause inflammation, 
dryness and discomfort. It may cause vision impairment. When Psoriasis affects the eyelids, 
scales may cover lashes and topical antibiotics may be used to treat infection.  
Psoriasis generally affects the external auditory canal without involvement of the ear or 
behind the eardrum but can cause scale buildup that can block the auditory canal with 
subsequent temporary hearing loss. 
Rarely Psoriasis appears on the gums, the tongue, inside the cheek and the nose or on the 
lips. The lesions in these areas are usually white or gray and can be relatively uncomfortable 
as they can cause chewing and swallowing discomfort. 
When Psoriasis involves the face, it can be much more disabling and can severily decrease 
patient’s QOL. Facial Psoriasis is difficult to treat and is associated with severe cutaneous 
disease. In fact, patients who have a long history of Psoriasis or an early age of onset are 
more likely to suffer from facial involvement. Facial Psoriasis may also be associated with 
pruritus, psoriatic arthritis, and with a family history of Psoriasis. 
Various clinical manifestations of Psoriasis make it more than a dermatological nuisance, as 
it interferes with many normal daily activities, such as use of hands, walking, sleeping, and 
sexual activity. At least 30% of patients contemplate suicide, which places Psoriasis on par 
with other major medical diseases such as depression, heart disease and diabetes (Krueger, 
2001). 
Alexithymia was originally defined as the inability to recognize and verbalize emotions. It is 
characterized by an emptiness of feelings, poverty of imagination or of a life fantasy and by 
difficulties in communicating with other peoples, as well as lack of positive emotions and a 
high prevalence of negative emotions. Its presence has been incriminated in genesis and 
maintenance of various psychosomatic pathologies.  
As patient’s psychological dimension seems to be related to the onset of the illness, to its 
evolution and to its prognosis, Psoriasis is classified among psychosomatic pathologies too.  
In this perspective Alexithymia does not appear to be simply a condition related to 
Psoriasis, but a worsening of patient’s condition, exposing him to other psychosomatic 
diseases and alcoholism and to a worsening of his global prognosis. That’s why 
psychological approach in treatment favouring expression of patient’s emotions and 
opening a symbolic dimension is as important as the biological approach and is necessary 
for improvement (Masmoudi, 2009). 
A recent cohort study (Gelfand & al., 2011) has also shown that severe Psoriasis (defined as 
Psoriasis patients with a history of systemic therapy) is associated with an increased risk of 
mortality as male and female patients in the study died 3.5 and 4.4 years younger 
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respectively than those without Psoriasis (even after adjustment for classical risk factors of 
mortality). Hence Psoriasis is a major public health problem.  
The data analysis suggests that a minimum of two summary scores (one for skin and one for 
joints), and potentially a third for nails, are required to accurately assess severity across the 
full spectrum of psoriatic disease. The optimal design of such assessment tools remains the 
objective of many research projects, with efforts continuing to identify the most meaningful 
contributing elements that define the full spectrum of the psoriatic disease state (Wittkowski 
& al., 2011). 
2.1 Addictions and Psoriasis 
Association between Psoriasis and addictive disorders is a longtime suspect and several 
studies are supporting association of Psoriasis and alcohol, and of Psoriasis and tobacco. 
Association between Psoriasis and alcohol seems not to be influenced by gender and shows 
a dose-effect relation. The most striking link between cigarette smoking and Psoriasis has 
been established in Palmo-Plantar Pustulosis (PPP). This link also seems to exist for other 
forms of Psoriasis with a dose-effect relation.  
The relationship between cigarette smoking and Psoriasis has been the subject of several 
studies. It was showed that cigarette smoking represents a significant risk factor for 
appearance of Psoriasis, especially in women, in a case about five, and it has been pointed 
out  that risk increases with the number of cigarettes consumed per day and increases in 
those who smoke 20 or more daily. The risk would increase further in those who have a 
family history of this disease. Also for PPP seems to be a relation to cigarette smoking, with 
a risk factor 7.2 times higher in smokers than in non smokers. The report is based on 
leukocyte neutrophil counts: PPP is a neutrophilic dermatosis and cigarette smoke increases 
peripheral neutrophil counts and alters it in morphological and functional way.  
Cigarette smoking may be involved in the high prevalence of lung and oral cancer and 
cardio-vascular disorders in psoriatic patients. The association between alcohol and 
development of plaque-type Psoriasis is complex and confusing because many of the initial 
studies did not control for confounding factors such as tobacco use.   
There are a number of difficulties in the assessment of the correlation between Psoriasis, 
cigarette smoking and alcohol, and even more so in establishing a causal or etiologic 
relationship between the three because of several confusing factors (Meyer &al., 2008).  
Alcohol-controlled studies suggest that women who are smokers have an up to 3.3-fold 
increased risk of developing plaque-type Psoriasis. Men who are smokers do not exhibit 
such an increased risk, but studies have shown that smoking more than 10 cigarettes per 
day by men who are Psoriasis patients may be associated with a more severe expression of 
disease in their extremities. In addition, smoking among both men and women who are 
Psoriasis patients has been shown to reduce improvement rates.  
Dermatologists are not only the sentinels for early diagnosis of psoriatic arthritis, but also 
for metabolic complications such as dyslipidemia or diabetes. Moreover, they need to keep 
in mind interactions between (systemic) anti-psoriatic drugs and the co-medication of their 
patients as well as possible consequences of these co-medications on the course of Psoriasis 
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The association between Psoriasis and alcoholism represents one of the major 
psychodermatological issues where a multidisciplinary approach (including dermatologist, 
psychiatrist, psychologist and others) is crucial for optimal outcome. Psoriasis is associated 
with an increased risk of comorbidity and mortality compared to the general population. It 
appears that patients with Psoriasis have a higher prevalence of metabolic disorders such as 
diabetes, hypertension, obesity, and hyperlipidemia, as well as a higher frequency of 
cigarette smoking. These concomitant diseases can complicate the treatment of Psoriasis. 
3. The very common involvement of the scalp 
The estimated prevalence of Psoriasis worldwide is 0.3-5%, depending on ethnic origin 
(Naldi, 1994; Valdimarsson, 2007). In a retrospective analysis in children was present scalp 
involvement in 48% on 125 patients by Stefanaki & al. (2011) and in 50.3% on 137 patients 
(most common initial site affected) by Wu & al. (2010) . 
Psoriasis of the scalp is estimated to occur in 40-90% of patients with Psoriasis. Up to 79% of 
patients with chronic plaque Psoriasis may have scalp involvement (Farber & Nall, 1992). It 
can be mild to severe, frequently itchy and so cosmetically embarrassing to affect patient’s 
QOL adversely. Treatment is often prolonged for a long period of time and can be another 
cause of worsening of patient’s QOL because of hair staining, face irritating, messy, time-
consuming and cosmetically unacceptable applications prescribed. 
As with Psoriasis elsewhere on the body, skin cells grow too quickly on the scalp and cause 
red lesions to be covered with scales. Scalp Psoriasis can be very mild with slight and fine 
scaling but can also be severe with thick, crusted plaques covering the entire scalp. Psoriasis 
can extend beyond the hairline onto the forehead, the back of the neck and around the ears.  
The scalp is frequently involved in patients with Psoriasis vulgaris but rarely it is the only 
site affected. Lesions look like an erythematous crown with net margins covered by dry 
silvery-white scales. They are located at the hairline in the fronto-temporal, parietal or 
occipital areas (where, often, the erythematous component is more pronounced) and are 
associated to scaling-scratching squamous lesions. In the fronto-temporal regions, 
particularly in young subjects, the spots extend beyond the scalp involving the skin of the 
forehead and ear. In patients with a long history of scalp Psoriasis the confluence of many 
spots and the scant evidence of the erythematous component leads to the formation of a real 
shell that can cover the entire scalp. In other cases, silvery-white scales are seen on a 
widespread dry pityriasiform furfuracea-like desquamation, sometimes showing follicles. 
The spots do not produce alopecia and hairs are not incorporated by squamous heaps but in 
the less restrictive forms the pseudotinea amiantacea can be seen. This lesion, once 
considered a variant of impetigo, is characterized by the presence of small opaque white 
adherent scales similar to asbestos, that incorporate the proximal part of the hair shaft. 
Psoriasiform lesions localized to the face often represent the extension of scalp lesions to the 
brow, the temporal regions, the ears and the retroauricular fold where it is observed a 
tendency to fissures. The involvement of the face in the course of Psoriasis is considered an 
index of extended or severe disease as in the case of erythrodermic Psoriasis. Rarely small 
droplike lesion in the face can be seen in case of eruptive Psoriasis; in case of mild forms of 
Psoriasis Vulgaris (minimal Psoriasis) instead, the eyelid involvement by small patches of 
whitish scales is characteristic. Psoriasis of the ear is characterized not only by the 
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involvement of the auricle but also by the involvement of external auditory canal by heaps 
of scales that can stamp it. Diagnosis of SeboPsoriasis, that is characterised by the presence 
of yellowish-white unctuous scales can be put when psoriasiform lesions are localized 
exclusively in seborrheic areas of the face (naso-labial fold, glabella and eyebrows, auricle 
and retroauricular fold) and are associated with similar lesions of the hairline and the 
presternal area. This clinic form, on the border between Psoriasis Vulgaris and Seborrheic 
Dermatitis, is considered  a Psoriasis arisen on patches of Seborrheic Dermatitis because of 
the Koebner phenomenon.  
Family history may predispose patients to scalp Psoriasis. In an analysis of Psoriasis genes 
in an Icelandic patient population, 296 of 1,000 Psoriasis patients experienced onset of 
Psoriasis on the scalp. Cluster analysis (Karason & al., 2005) of this subset of patients 
determined that 198 patients fit within 79 families and determined a linkage to 
chromosome 10. The familial nature of Psoriasis has long been recognized with evident 
intra and interfamilial variability. Thirty nine individual with Psoriasis (25 men and 14 
women) from 9 Tunisian unrelated multiplex families (in Tunisian population the 
estimated prevalence of Psoriasis is of 3%) were investigated during a study period of 1 
year (Ammar & al., 2009). The common form of Psoriasis was discovered in 37 cases. The 
nails, the scalp, the mucous membranes were involved respectively in 21, 12 and 13 cases. 
The Psoriasis was severe in 11 cases. 
Methods used to diagnose scalp Psoriasis vary in sensitivity, reproducibility, and 
invasiveness. Recently has been introduced a videodermoscopy scalp Psoriasis severity 
index (VSCAPSI) for evaluation of scalp Psoriasis (Rossi &al., 2011). This index is 
particularly useful in mild and moderate forms that often are not clinically appreciable. 
VSCAPSI takes into account extension of the area of the scalp affected, the presence and 
morphology of vascular patterns, erythema and desquamation. Videodermoscopy images 
obtained between November 2009 to June 2010 from 900 participants with various scalp and 
hair disorders were reviewed for distinguishing features. During the 2010 Italian congress 
on Psoriasis, in order to assess the reproducibility and efficacy of the VSCAPSI, 146 
dermatologists were asked to evaluate 16 videodermoscopy images of scalp Psoriasis using 
the VSCAPSI. Of the 900 patients, 85 new cases of scalp Psoriasis were diagnosed. The other 
815 patients were found to be suffering from different scalp and hair diseases. Of 146 
dermatologists, 28 did not recognize erythema, 15 desquamation and 7 the vascular 
patterns. The VSCAPSI provides an important tool for early diagnosis, differential diagnosis 
and follow-up and screening. 
3.1 Histology of head and neck Psoriasis: Gross findings 
Head and neck Psoriasis (in the form of the so-called Psoriasis vulgaris or plaque type of 
Psoriasis and guttate Psoriasis) commonly involves the skin surface of the scalp and the face 
(eyebrow, nose, upper lip, forehead, and hairline) and presents as papules, well-demarcated 
erythematous plaques with a scaly surface or as papulo-squamous lesions covered by fine 
silvery-white and loosely adherent scales. The amount and thickness of the scales is variable 
such are the plaques, ranging in size from few to several centimeters, with coalescence of 
smaller plaques into larger and sometimes fissured lesions. On the other hand, less thick 
plaques and less scaly lesions are commonly encountered in children with face psoriatic 
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face as annular or circinnate and pustular lesions on an erythematous background with an 
acute, subacute or chronic clinical course. Pustular eruptions are frequently associated with 
a classic form of skin Psoriasis, and both hair loss and involvement of tongue mucosal 
surface may be appreciated. Oral localizations, less commonly observed in children than in 
adults, appear as pustular and hyperemic lesions within a geographic and fissured tongue. 
In such a localization, infections, smoking and physical agents all may affect the course and 
duration of Psoriasis and may cause dysphagia. Unusual mucosal (nose, oral cavity) or 
ocular localizations are commonly described in patients with otherwise usual skin psoriatic 
dermatitis. Mucosal lesions show a non-specific macroscopic appearance ranging from 
erythematous and slightly raised lesions to a white annular, serpiginous and ulcerated 
pattern that may disappear quickly, with no obvious clinical symptoms, or may have 
exacerbations and remissions similar to skin lesions. Pustular forms, mixed white and 
erythematous lesions, ulcerative, vescicular and indurated lesions, multiple annular coin-
sized lesions, gray, yellowish, translucent and silvery-white forms are described with 
macroscopic findings similar to several so-called psoriasiform benign and malignant 
conditions involving the oral cavity. In this setting, the diagnosis mainly rely on an 
interdisciplinary clinical and histological approach with a crucial role played by the 
microscopic findings on mucosal biopsy. Psoriasis vulgaris may also be associated to oral 
localizations such as the case of geographic tongue and the stomatitis areata migrans. 
Patients with Psoriasis rarely develop uncommon ocular manifestations such as uveitis, 
blepharitis and conjunctivitis as a result of changes, alterations and dysfunctions of 
conjunctival surface, tear film and meibomiam gland changes. 
3.2 Microscopic findings 
Variabilities in clinical macroscopic findings of Psoriasis reflect different histologic pictures 
with relation to the stage of the disease. Generally, early stages show more typical and 
pathognomonic microscopic clues to the diagnosis than that of the advanced and fully 
developed lesions. Moreover, histologic differences could also be noted in psoriatic lesions 
affecting mucosal surfaces. 
In its classic histologic appearance, cutaneous Psoriasis shows achantosis (thickened of 
epidermal layers) and parakeratosis (retention of cell nuclei in stratum corneum) of the 
epidermis, with thin or loss of granular cell layer, downward elongation of rete ridges and 
thinning of the epidermis overlying the dermal papillae that shows edema and small vessels 
close to the epidermis. The latter condition underlies the so-called Auspitz sign: when the 
silvery scales (parakeratotic layers) are removed from the plaque (epidermal achantosis), 
small pinpoint bleeding (from dermal capillaries) is seen. 
The inflammatory cutaneous infiltrate of Psoriasis is characterized by neutrophils and 
lymphocytes throughout the superficial papillary dermis. Activated CD3+ T cells are mainly 
observed around small papillary vessels and are admixed with neutrophils and 
macrophages. Neutrophils and lymphocytes can migrate upwards from the dermis to the 
epidermis and in parakeratotic layers (exocytosis). Collections of intraepithelial neutrophils 
(Munro abscesses) and those arranged in the epidermis in a network of degenerated 
keratinocytes (spongiform pustule of Kogoj) are characteristics of Psoriasis but not always 
present nor specific to the disease. 
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In the pustular form of Psoriasis, such a collection of neutrophils occurs as characteristic 
macropustules (abscesses), while epidermal and dermal changes are similar to those seen in 
Psoriasis vulgaris. The so-called eruptive or guttate Psoriasis, with small and numerous red 
papules and an acute onset on clinical examination, shows similar microscopic findings to 
that of early Psoriasis vulgaris lesions unless the same degree of achantosis.  
Mucosal localizations show a more variable histological presentation ranging from classic 
hyperparakeratotic lesions, with thinning of the suprapapillary plate and mixed 
inflammatory infiltrate with neutrophils exocytosis to mild and quickly self-limited 
erythematous inflammatory conditions with capillaries engorgement but without 
microabscess formation. Similar microscopic characteristic are shared by different 
inflammatory mucosal diseases generally known as psoriasiform mucositis or psoriasiform 
lesions. In such instances, histological distinction between Psoriasis and other inflammatory 
mucosal entities cannot be made with confidence unless mucosal lesions are associated to or 
are coincident with cutaneous psoriatic dermatitis and additional data (family history, HLA 
typing) are available. 
3.3 Differential diagnosis 
Although the diagnosis of Psoriasis mainly rely on clinical settings, histological 
evaluation should be used to confirm the diagnosis as well as to evaluate unusual clinical 
lesions and to exclude benign and malignant conditions that may mimic Psoriasis or may 
be associated to it. 
On the other hand, microscopic findings alone should pose problems in differential 
diagnosis with other inflammatory disorders as well as in the evaluation of the phase of 
Psoriasis normally evolving through early, advanced and later lesions with a different 
microscopic variability with lesion’s age and activity. 
Skin psoriatic manifestations should sometimes require a differential diagnosis from 
dermatoses such as lichen planopilaris, florid seborrheic dermatitis and discoid lupus 
erythematosus.  
On the other hand, differential diagnosis of oral localization of Psoriasis could also consider 
Reiter’s syndrome, erythema migrans, benign migratory glossitis, oral lichen planus and 
other inflammatory conditions generally described as psoriasiform lesions. 
Clinical data alone may be inadequate such as the case of Koebner phenomenon that could 
be present in lichen planus.  
In this settings, the macroscopic characteristics of cutaneous psoriatic lesions (well defined 
elevated lesions, with silvery-white or micaceous scale), the clinical data (symmetrical 
distribution, Auspitz sign, patient’s history reporting itchy, skin scaling and peeling, lesions 
at site of injury or trauma) and the classic histologic findings may all contribute to a 
definitive diagnosis of Psoriasis.  
Oral lichen planus, mainly occurring in adults, appears as bilateral plaques, papules and 
erythematous-atrophic or ulcerated lesions on the oral mucosa, gingivae (desquamative 
gingivitis) and tongue. Oral white striations (so-called Wickham striae) may coincide with 
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conjunctival lesions. Skin involvement of the scalp (lichen plano-pilaris) appears as scarring 
alopecia and violaceous and erythematous papules with hair loss. On histologic 
examination, more irregular acanthosis, prominent granular cell layer and dense sub-
epithelial T-cell CD8+ inflammatory infiltrate along with damage of basal keratinocytes 
represent clues to the diagnosis in contrast to Psoriasis. Moreover, since patients with oral 
lichen planus could develop oral squamous cell carcinoma and commonly show a 
significant local morbidity with negative impact on QOL, a proper diagnosis based on 
clinical and histological findings is mandatory. 
Discoid lupus erythematosus may sometimes be responsible for unusual manifestations in 
head and neck localizations that can mimic several skin diseases (Psoriasis, acne rosacea, 
lichen planopilaris) or be associated with liken planus-like lesions and Psoriasis. 
Nonetheless, clinical findings are usually characteristic as erythematous papules and 
plaques that progress to scaling lesions with pigmentary changes (central hypopigmentation 
and peripheral hyperpigmentation) in a centrifugal spread. Cutaneous scalp lesions may 
result in permanent alopecia with atrophy and scarring (localized form of discoid lupus 
erythematosus) with histologic picture similar to that of lichen planopilaris. Rare mucosal 
involvement are described with clinical and microscopic characteristic that may simulate 
lichen planus lesions. In this setting, laboratory data (hematologic and serologic 
abnormalities frequently observed in widespread discoid lupus erythematosus) along with 
meticulous clinical attention and microscopic findings (essentially dependent on familiarity 
with these lesions) can pose a correct diagnosis.  
Psoriatic lesions may also not look much different from those caused by seborrheic 
dermatitis, a papulo-squamous disease of the scalp, face and trunk. In its facial localization, 
the disease may be associated with squamous blepharitis, a chronic inflammation of the lid 
margins with small white scales accumulated among the lashes, or may present as mild 
scaling to widespread crust adherent to the skin of the scalp, forehead, neck and 
postauricolar skin. Secondary infections may occur as eczematoid dermatitis. Microscopic 
picture shows a more irregular acanthosis than that seen in psoriatic lesions along with 
spongiosis and follicular ostia involvement.  
The guttate variety of Psoriasis may appears as an acute exanthema in young adults, often 
associated to streptococcal pharyngitis, with papules on the face similar to those seen in 
psoriasiform drug eruption. The latter condition is also known as localized drug reactions 
related to medications and usually involving the face, chest and back with a papulo-
erythematous or vescicular and pustular appearance. Similarly, psychogenic and emotional 
factors, infections and environmental factors may all contribute to the development of 
cutaneous lesions similar to those seen in Psoriasis or may be related to increase in Psoriasis 
activity and severity. 
Histologic overlapping in such cases, with lacking of microscopic characteristic features, 
require a correct clinical evaluation in the differential diagnosis of these conditions.  
Differential diagnosis of head and neck Psoriasis, in both cutaneous and mucosal 
localizations, should also consider preneoplastic and neoplastic conditions. Since head and 
neck Psoriasis is more often a chronic and long standing process, frequently associated with 
severe cutaneous disease and difficult treatment, a significant risk of cancer has been noted. 
Such an association could be related to the reactive epidermal hyperproliferation seen in 
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psoriatic lesions along with keratinocytes activation and expression of molecules involved in 
cell proliferation. In particular, basal cell and squamous cell carcinomas are frequently 
reported and should be taken into account when evaluating psoriatic patients. 
Moreover, malignant conditions should be ruled out as is the case of the rare acrokeratosis 
paraneoplastica (Bazex syndrome). The disease can be associated with head and neck and 
upper aerodigestive tract squamous cell carcinomas and differs from Psoriasis in its 
localizations (erythematous squamous plaques or scaly patches of earlobes, helices and tip 
of the nose along with similar lesions in the extremities and nail dystrophy) and lack of 
histological findings typical of Psoriasis. 
Investigators use several physical examination measures to assess clinical features and 
severity of Psoriasis and psoriatic arthritis (PsA) in clinical trials, clinical registries, and 
clinical practice; however, no relevant training modules are widely available to teach and 
standardize the performance of these measures. At a GRAPPA (Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis) meeting adjacent to the 2009 International 
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teaching points, demonstration video of examination where applicable, and an optional 
examination at the end. Future plans include evaluating the modules for their influence on 
interrater and intrarater reliability and development of additional modules (Callis Duffin & 
Mease, 2011). 
4. The difficulty of the treatment  
Head and neck Psoriasis treatment is still a challenge because its difficult to get topical 
agents through hair to be absorbed by the scalp. In fact, scalp is not susceptible to many 
topical Psoriasis treatment or phototherapy because hair prevent adequate contact with the 
affected tissue. Moreover current therapies can only bring some relief to the symptoms 
without any cure to the disease and treatments can carry important side effects in face of 
high therapeutic costs. 
Medications for scalp Psoriasis include those to be left on the scalp and wash off products. 
Left on products are gels, lotions and ointments containing steroids, coal tar, salicylic acid or 
vitamin D analogs.  
Wash off products are shampoos containing coal tar, salicylic acid, sulfur, selenium, 
ketoconazole or zinc pyrithione. Recently, Handa (2010) proposed a treatment algorithm for 
scalp Psoriasis (see Tab. 1), dividing a first line and a second line therapies.  
In 2009 van de Kerkhof & al. divided treatment of scalp Psoriasis into four phases. First 





conjunctival lesions. Skin involvement of the scalp (lichen plano-pilaris) appears as scarring 
alopecia and violaceous and erythematous papules with hair loss. On histologic 
examination, more irregular acanthosis, prominent granular cell layer and dense sub-
epithelial T-cell CD8+ inflammatory infiltrate along with damage of basal keratinocytes 
represent clues to the diagnosis in contrast to Psoriasis. Moreover, since patients with oral 
lichen planus could develop oral squamous cell carcinoma and commonly show a 
significant local morbidity with negative impact on QOL, a proper diagnosis based on 
clinical and histological findings is mandatory. 
Discoid lupus erythematosus may sometimes be responsible for unusual manifestations in 
head and neck localizations that can mimic several skin diseases (Psoriasis, acne rosacea, 
lichen planopilaris) or be associated with liken planus-like lesions and Psoriasis. 
Nonetheless, clinical findings are usually characteristic as erythematous papules and 
plaques that progress to scaling lesions with pigmentary changes (central hypopigmentation 
and peripheral hyperpigmentation) in a centrifugal spread. Cutaneous scalp lesions may 
result in permanent alopecia with atrophy and scarring (localized form of discoid lupus 
erythematosus) with histologic picture similar to that of lichen planopilaris. Rare mucosal 
involvement are described with clinical and microscopic characteristic that may simulate 
lichen planus lesions. In this setting, laboratory data (hematologic and serologic 
abnormalities frequently observed in widespread discoid lupus erythematosus) along with 
meticulous clinical attention and microscopic findings (essentially dependent on familiarity 
with these lesions) can pose a correct diagnosis.  
Psoriatic lesions may also not look much different from those caused by seborrheic 
dermatitis, a papulo-squamous disease of the scalp, face and trunk. In its facial localization, 
the disease may be associated with squamous blepharitis, a chronic inflammation of the lid 
margins with small white scales accumulated among the lashes, or may present as mild 
scaling to widespread crust adherent to the skin of the scalp, forehead, neck and 
postauricolar skin. Secondary infections may occur as eczematoid dermatitis. Microscopic 
picture shows a more irregular acanthosis than that seen in psoriatic lesions along with 
spongiosis and follicular ostia involvement.  
The guttate variety of Psoriasis may appears as an acute exanthema in young adults, often 
associated to streptococcal pharyngitis, with papules on the face similar to those seen in 
psoriasiform drug eruption. The latter condition is also known as localized drug reactions 
related to medications and usually involving the face, chest and back with a papulo-
erythematous or vescicular and pustular appearance. Similarly, psychogenic and emotional 
factors, infections and environmental factors may all contribute to the development of 
cutaneous lesions similar to those seen in Psoriasis or may be related to increase in Psoriasis 
activity and severity. 
Histologic overlapping in such cases, with lacking of microscopic characteristic features, 
require a correct clinical evaluation in the differential diagnosis of these conditions.  
Differential diagnosis of head and neck Psoriasis, in both cutaneous and mucosal 
localizations, should also consider preneoplastic and neoplastic conditions. Since head and 
neck Psoriasis is more often a chronic and long standing process, frequently associated with 
severe cutaneous disease and difficult treatment, a significant risk of cancer has been noted. 
Such an association could be related to the reactive epidermal hyperproliferation seen in 
 
Head and Neck Psoriasis 
 
87 
psoriatic lesions along with keratinocytes activation and expression of molecules involved in 
cell proliferation. In particular, basal cell and squamous cell carcinomas are frequently 
reported and should be taken into account when evaluating psoriatic patients. 
Moreover, malignant conditions should be ruled out as is the case of the rare acrokeratosis 
paraneoplastica (Bazex syndrome). The disease can be associated with head and neck and 
upper aerodigestive tract squamous cell carcinomas and differs from Psoriasis in its 
localizations (erythematous squamous plaques or scaly patches of earlobes, helices and tip 
of the nose along with similar lesions in the extremities and nail dystrophy) and lack of 
histological findings typical of Psoriasis. 
Investigators use several physical examination measures to assess clinical features and 
severity of Psoriasis and psoriatic arthritis (PsA) in clinical trials, clinical registries, and 
clinical practice; however, no relevant training modules are widely available to teach and 
standardize the performance of these measures. At a GRAPPA (Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis) meeting adjacent to the 2009 International 
Federation of Psoriasis Associations in Stockholm, members were updated on the 
development status of online training videos of Psoriasis and PsA examination measures. 
Dermatology assessment modules include the PASI, the PGA, the BSA, the original and 
modified Nail Psoriasis Severity Index (NPSI), the Palmar-Plantar Pustular Psoriasis Area 
and Severity Index (PPP-PASI), and the PSSI. Rheumatology modules include assessment of 
tender and swollen joint counts used in the American College of Rheumatology criteria, 
Disease Activity Score, and other composite arthritis scores; enthesitis assessment used in 
various enthesitis scoring systems; dactylitis; and spine disease. Each module will include 
background information for each measure, diagrams and photographs to emphasize 
teaching points, demonstration video of examination where applicable, and an optional 
examination at the end. Future plans include evaluating the modules for their influence on 
interrater and intrarater reliability and development of additional modules (Callis Duffin & 
Mease, 2011). 
4. The difficulty of the treatment  
Head and neck Psoriasis treatment is still a challenge because its difficult to get topical 
agents through hair to be absorbed by the scalp. In fact, scalp is not susceptible to many 
topical Psoriasis treatment or phototherapy because hair prevent adequate contact with the 
affected tissue. Moreover current therapies can only bring some relief to the symptoms 
without any cure to the disease and treatments can carry important side effects in face of 
high therapeutic costs. 
Medications for scalp Psoriasis include those to be left on the scalp and wash off products. 
Left on products are gels, lotions and ointments containing steroids, coal tar, salicylic acid or 
vitamin D analogs.  
Wash off products are shampoos containing coal tar, salicylic acid, sulfur, selenium, 
ketoconazole or zinc pyrithione. Recently, Handa (2010) proposed a treatment algorithm for 
scalp Psoriasis (see Tab. 1), dividing a first line and a second line therapies.  
In 2009 van de Kerkhof & al. divided treatment of scalp Psoriasis into four phases. First 





clearing phase in which topical corticosteroids, vitamin D analogs, tar, dithranol, antifungal 
treatment, ultraviolet B light therapy or systemic treatment are used. The third phase is 
stabilization using a steroid-sparing vitamin D analog during the week and a super potent 
topical corticosteroid at weekends. Finally, the fourth phase is maintenance, using a vitamin 
D analog alone or with a tar shampoo. 
 
First line therapies 
Salicylic acid/Urea 
Topical corticosteroids (short term use) 
Calcipotriol 
Dithranol/Anthralin 
Coal tar (Shampoo/pomade) 
Tazarotene 
Combination therapies 
Second line therapies (for recalcitrant or severe disease) 
Phototherapy 
Systemic drugs (Methotrexate, Acitretin, Cyclosporine) 
Biologics 
Table 1. Treatment algorithm for scalp Psoriasis (from Hanna S., 2010) 
4.1 Corticosteroids 
Topical corticosteroids are the recommended first-line therapy for short-term use. Response 
to treatment is quick but high potential for side effects, such as atrophy, striae, 
telangiectasias and tachyphylaxis, limits the period of use. These side effects are virtually 
never seen in the scalp. Use of potent steroids (twice a day) should be limited to 4 weeks. 
The choice of preparation such as ointment, cream, gel, lotion, foam, spray or shampoo 
should be patient oriented.  
In any single patient the lowest strength preparation that allows clinical clearing should be 
used for the shortest time, in order to minimize side effects and tachyphylaxis. Nevertheless, 
long-term use of mid-potency preparations or intermittent use of potent steroids is more 
commonly practiced by physicians. Clobetasol propionate (CP) 0.05% and betamethasone 
dipropionate 0.05% are the most potent topical corticosteroid preparations currently used. 
Exceptionally intralesional corticosteroids can be used for one or two localized patches not 
responding to topical steroids. Foam vehicles are the new alternatives to traditional topical 
preparations because of the advantage of minimal residue and increased ease of application. 
They are absorbed more rapidly, have a higher bioavailability, are not associated with 
suppression of the hypothalamic pituitary adrenal (HPA) axis and once-daily 
administration has been seen to be as effective as twice daily administration. They are also 
associated with better patient compliance. CP foam 0.05% is generally as effective as CP 
solution for scalp Psoriasis and may produce superior results against scaling. Dose is limited 
to 50 g/week. Mid-potency corticosteroid betamethasone valerate (BMV) has also become 
available in a new thermolabile, low-residue foam vehicle, BMV 0.12% foam. In a recent 
study BMV foam produced greater improvement in the primary signs of scalp Psoriasis than 
BMV lotion, placebo or other standard topical therapies (Stein, 2005). Shampoo preparations 
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are another new development. When clobetasol shampoo 0.05% was tried in a patient 
experience program, 50% of the patients said that the shampoo was easy to use and did not 
interfere with their daily routine. Almost 90% of patients found the shampoo better than 
other prescriptions they had used before for their scalp Psoriasis.  
Medication used to treat facial Psoriasis should be applied carefully and sparingly; creams 
and ointments can irritate eyes. Because facial skin is delicate, prolonged use of steroids may 
cause it to become thin, shiny and/or prone to enlarged capillaries. Treatment with steroids 
is safe if a careful treatment schedule is followed. 
4.2 Non steroidal topical preparations 
This group includes: Calcipotriene/calcipotriol, Anthralin, Coal Tar, Tazarotene. 
4.2.1 Calcipotriene/calcipotriol 
These are vitamin D 3 derivatives used for chronic, moderately/severe Psoriasis of the scalp. 
The 0.005% solution is applied to the affected area and rubbed gently onto the scalp twice a 
day. Response to therapy takes about 8 weeks. It is not recommended in patients with acute 
psoriatic eruptions on the scalp, those with hypercalcemia or hypervitaminosis D. The main 
side effects are burning, itching, irritation and dryness. Irritation tends to decrease with 
time. Clearance has been observed even with 8 weeks of once a day treatment in up to 60% 
of patients. 
4.2.2 Anthralin 
Anthralin 0.1-3% cream has been used for long-term treatment of scalp Psoriasis. 
Concentration should be gradually increased according to body response and tolerance of 
the patient. Anthralin is applied in a thin layer to the psoriatic area once a day, rubbed in 
well and left on the scalp for 5-10 minutes before washing with a shampoo and rinsing well. 
It is not used for acutely inflamed scalp Psoriasis. Redness or irritation of the treated scalp is 
common. Anthralin may temporarily stain the fingernails, gray/white hair, skin and fabrics. 
Caution is advised in patients having history of allergy to anthralin or to condoms (e.g., 
parabens). 
4.2.3 Coal tar  
Coal tar is an effective and cheap treatment modality for scalp Psoriasis but staining and an 
acrid smell associated with its use may have an important impact on patients QOL. Topical 
tar solution (liquor picis carbonis-LPC,  or liquor carbonis detergens-LCD) is widely 
available and commonly used for scalp Psoriasis. Newer preparations specifically meant for 
scalp include coconut oil compound ointment (coal tar solution with precipitated sulfur, 
salicylic acid, coconut oil, yellow soft paraffin and emulsifying wax) and tar pomades 
(contain LCD, Tween 20 and salicylic acid in a hydrophilic ointment). Compound ointment 
should be applied once at night and washed off the next morning with a coal tar shampoo. 
Coal tar shampoos contain 1-20% coal tar extract. They are used twice a week. A tar blend 
1% shampoo Polytar (Steifel, Johannesburg, South Africa) is made of coal tar, juniper tar 
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and CP 0.05% shampoo (Clobex, Galderma, Ft. Worth, USA), the corticosteroid shampoo 
was significantly more effective and showed a better patient’s compliance too. 
Coal tar has been a very popular traditional treatment for various types of Psoriasis for over 
a century and still it’s the first-line treatment for scalp, hand, and foot Psoriasis. However, 
application of coal tar on hair invariably causes staining, which results in a high degree of 
patient non-compliance, especially in patients with non-black hair. Thus, treatment of scalp 
Psoriasis with a topical coal tar formulation requires that special concern to be paid to 
product esthetics. A novel lecithinized coal tar (LCT) formulation seems to be less likely to 
stain hair and thus has excellent potential to be exploited in treatment of scalp Psoriasis 
(Bhatia & al. 2011). 
4.2.4 Tazarotene 
There are no controlled studies on the use of tazarotene in scalp Psoriasis. Response to 
tazarotene (0.1%) compared to topical calcipotriol or steroids is less effective but relapse 
rates are reported to be minor as well. Dryness and irritation are common side effects. 
4.3 Combination therapies 
Combining different treatment allows enhanced efficacy and minimizes toxicity. 
Corticosteroids, when combined with vitamin D analogs, require a minor total amount of 
dose and induce less skin irritation. In treatment of moderate to severe plaque Psoriasis of 
the scalp, the fixed-combination suspension containing betamethasone 0.05% and 
calcipotriene 0.005% is used once a day. In a randomized double-blind controlled trial 
over 8 weeks, 71.2% patients achieved "absent" or "very mild" disease with the two-
compound scalp formulation, compared to 64% treated with betamethasone dipropionate, 
36.8% with calcipotriene and only 22.8% with the vehicle alone. Pruritus was the only 
adverse event reported. 
Topical steroids with Puvasol gave better results: 37.3% clearance versus 13.3% with Puvasol 
alone. LPC 10% along with 2% salicylic acid in a cream base along with Puvasol for 8 weeks 
gave a much better clearance rate than Puvasol alone. Tazarotene has also been found to be 
efficacious in combination with topical steroids and calcipotriol.  
In a prospective non-interventional trial in German dermatological practices, 721 patients 
with scalp Psoriasis received Xamiol(®) gel (calcipotriol 50 μg/g, betamethasone 0,5 mg/g) 
topically for 4 weeks. Severity was assessed by physician’s global assessment (PGA) and 
QOL was assessed by using a scalp-specific questionnaire at the beginning of the study and 
after 4 weeks treatment. The mean disease severity of scalp Psoriasis (PGA) improved from 
4.26 to 2.49 (-41.8 %, p < 0.0001) during 4 weeks treatment and QOL improved from 10.57 to 
3.22 (-69.5 %, p < 0.0001). Among patients with pre-treatment 89.5% of patients and 87.9% of 
dermatologists judged treatment response to Xamiol(®) gel as better/much better compared 
to previous therapy. Tolerability of Xamiol(®) gel was rated good/very good by 98 % of 
dermatologists and patients, respectively. The use of Xamiol(®) gel was found easy/very 
easy by 90.4 % of the patients (Mrowietz, 2011).  
McCormack (2001) reviewed the efficacy and tolerability of calcipotriol/betamethasone 
dipropionate in patients with Psoriasis vulgaris summarizing its pharmacological 
 
Head and Neck Psoriasis 
 
91 
properties. Calcipotriol/betamethasone dipropionate showed low systemic absorption and 
displayed local anti-inflammatory and immunoregulatory properties. It reduced 
hyperproliferation of keratinocytes and helped normalize keratinocyte differentiation. In 
large, well designed clinical trials, calcipotriol/betamethasone dipropionate, either as the 
ointment or the gel formulation, applied once a day for 4-8 weeks, was more effective than 
placebo, calcipotriol and tacalcitol, as well as betamethasone dipropionate in most instances, 
for the topical, symptomatic treatment of Psoriasis vulgaris of the trunk/limbs. Likewise, 
calcipotriol/betamethasone dipropionate gel applied once daily for 8 weeks was more 
effective than placebo or either component alone in the topical, symptomatic treatment of 
Psoriasis vulgaris of the scalp. Long-term, once a day, when required therapy with 
calcipotriol/betamethasone dipropionate for 52 weeks was more effective than calcipotriol 
alone for the treatment of scalp Psoriasis and was at least as effective as switching to 
calcipotriol for 48 weeks after 4 weeks of calcipotriol/betamethasone dipropionate or 
alternating between calcipotriol/betamethasone dipropionate and calcipotriol every 4 
weeks for 52 weeks in the treatment of Psoriasis vulgaris of the trunk/limbs. 
Calcipotriol/betamethasone dipropionate also improved health-related QOL.  
Calcipotriol/betamethasone dipropionate was generally well tolerated, with most 
adverse drug reactions being lesional or perilesional effects of mild or moderate severity 
(see Fig. 1).  
Calcipotriol/betamethasone dipropionate was often associated with fewer lesional/ 
perilesional adverse reactions than calcipotriol or tacalcitol and did not appear to be  
 
Fig. 1. Scalp Psoriasis after treatment with calcipotriol/betamethasone dipropionate gel 





and CP 0.05% shampoo (Clobex, Galderma, Ft. Worth, USA), the corticosteroid shampoo 
was significantly more effective and showed a better patient’s compliance too. 
Coal tar has been a very popular traditional treatment for various types of Psoriasis for over 
a century and still it’s the first-line treatment for scalp, hand, and foot Psoriasis. However, 
application of coal tar on hair invariably causes staining, which results in a high degree of 
patient non-compliance, especially in patients with non-black hair. Thus, treatment of scalp 
Psoriasis with a topical coal tar formulation requires that special concern to be paid to 
product esthetics. A novel lecithinized coal tar (LCT) formulation seems to be less likely to 
stain hair and thus has excellent potential to be exploited in treatment of scalp Psoriasis 
(Bhatia & al. 2011). 
4.2.4 Tazarotene 
There are no controlled studies on the use of tazarotene in scalp Psoriasis. Response to 
tazarotene (0.1%) compared to topical calcipotriol or steroids is less effective but relapse 
rates are reported to be minor as well. Dryness and irritation are common side effects. 
4.3 Combination therapies 
Combining different treatment allows enhanced efficacy and minimizes toxicity. 
Corticosteroids, when combined with vitamin D analogs, require a minor total amount of 
dose and induce less skin irritation. In treatment of moderate to severe plaque Psoriasis of 
the scalp, the fixed-combination suspension containing betamethasone 0.05% and 
calcipotriene 0.005% is used once a day. In a randomized double-blind controlled trial 
over 8 weeks, 71.2% patients achieved "absent" or "very mild" disease with the two-
compound scalp formulation, compared to 64% treated with betamethasone dipropionate, 
36.8% with calcipotriene and only 22.8% with the vehicle alone. Pruritus was the only 
adverse event reported. 
Topical steroids with Puvasol gave better results: 37.3% clearance versus 13.3% with Puvasol 
alone. LPC 10% along with 2% salicylic acid in a cream base along with Puvasol for 8 weeks 
gave a much better clearance rate than Puvasol alone. Tazarotene has also been found to be 
efficacious in combination with topical steroids and calcipotriol.  
In a prospective non-interventional trial in German dermatological practices, 721 patients 
with scalp Psoriasis received Xamiol(®) gel (calcipotriol 50 μg/g, betamethasone 0,5 mg/g) 
topically for 4 weeks. Severity was assessed by physician’s global assessment (PGA) and 
QOL was assessed by using a scalp-specific questionnaire at the beginning of the study and 
after 4 weeks treatment. The mean disease severity of scalp Psoriasis (PGA) improved from 
4.26 to 2.49 (-41.8 %, p < 0.0001) during 4 weeks treatment and QOL improved from 10.57 to 
3.22 (-69.5 %, p < 0.0001). Among patients with pre-treatment 89.5% of patients and 87.9% of 
dermatologists judged treatment response to Xamiol(®) gel as better/much better compared 
to previous therapy. Tolerability of Xamiol(®) gel was rated good/very good by 98 % of 
dermatologists and patients, respectively. The use of Xamiol(®) gel was found easy/very 
easy by 90.4 % of the patients (Mrowietz, 2011).  
McCormack (2001) reviewed the efficacy and tolerability of calcipotriol/betamethasone 
dipropionate in patients with Psoriasis vulgaris summarizing its pharmacological 
 
Head and Neck Psoriasis 
 
91 
properties. Calcipotriol/betamethasone dipropionate showed low systemic absorption and 
displayed local anti-inflammatory and immunoregulatory properties. It reduced 
hyperproliferation of keratinocytes and helped normalize keratinocyte differentiation. In 
large, well designed clinical trials, calcipotriol/betamethasone dipropionate, either as the 
ointment or the gel formulation, applied once a day for 4-8 weeks, was more effective than 
placebo, calcipotriol and tacalcitol, as well as betamethasone dipropionate in most instances, 
for the topical, symptomatic treatment of Psoriasis vulgaris of the trunk/limbs. Likewise, 
calcipotriol/betamethasone dipropionate gel applied once daily for 8 weeks was more 
effective than placebo or either component alone in the topical, symptomatic treatment of 
Psoriasis vulgaris of the scalp. Long-term, once a day, when required therapy with 
calcipotriol/betamethasone dipropionate for 52 weeks was more effective than calcipotriol 
alone for the treatment of scalp Psoriasis and was at least as effective as switching to 
calcipotriol for 48 weeks after 4 weeks of calcipotriol/betamethasone dipropionate or 
alternating between calcipotriol/betamethasone dipropionate and calcipotriol every 4 
weeks for 52 weeks in the treatment of Psoriasis vulgaris of the trunk/limbs. 
Calcipotriol/betamethasone dipropionate also improved health-related QOL.  
Calcipotriol/betamethasone dipropionate was generally well tolerated, with most 
adverse drug reactions being lesional or perilesional effects of mild or moderate severity 
(see Fig. 1).  
Calcipotriol/betamethasone dipropionate was often associated with fewer lesional/ 
perilesional adverse reactions than calcipotriol or tacalcitol and did not appear to be  
 
Fig. 1. Scalp Psoriasis after treatment with calcipotriol/betamethasone dipropionate gel 





associated with a higher incidence of corticosteroid-related adverse events during long-term 
therapy. Pharmaco-economic analyses predicted calcipotriol/betamethasone dipropionate 
to be more cost effective than other topical therapies. 
Puig & al. (2010) reported the recommendations developed by an expert panel using the 
Delphi process to reach a consensus and then ratified by the members of the Psoriasis Group 
of the Spanish Academy of Dermatology and Venereology. The recommended induction 
therapy for scalp Psoriasis is either a topical corticosteroid or a topical treatment combining 
calcipotriol and betamethasone. The choice of an appropriate vehicle is crucial in improving 
effectiveness and patient adherence to treatment. The only formulations that have been 
studied in long-term treatment of scalp Psoriasis are a combination of calcipotriol and 
betamethasone in gel and calcipotriol alone in solution. 
4.4 Second line treatments for recalcitrant disease 
These are used when all topical treatments fail. No controlled studies exist regarding their use 
and include phototherapy and systemic drugs like methotrexate, retinoids, cyclosporine and 
biologics. They are used based on physician experience, choice and risk versus benefit ratio. 
4.4.1 Phototherapy 
Hair blocks adequate penetration of ultraviolet light. Better results are achieved with 
conventional UV units, if hair is parted in many rows or if the patient has thin hair or if the 
head is shaved. Hand-held devices (UV combs) deliver a higher intensity of UV light. There 
are reports of the use of targeted phototherapy with excimer laser which provides 
narrowband ultraviolet B (NB-UVB) (308 nm) phototherapy with a very high irradiance, 
allowing for a shorter treatment time.   
4.4.2 Biologics 
The emergence of biologic therapies as an effective modality for treatment of plaque 
Psoriasis may provide another option for patients.  The biological agents employed in 
therapy of Psoriasis are classified into three groups (see Tab. 2). 
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Ustekinumab 
Briakinumab 
T-cell modulating agents 
Alefacept 
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Recent findings suggest that Efalizumab may be effective for treatment of head and neck 
Psoriasis (Krell & al., 2008). Katsambas (2009) recorded a PSSI score for 1150 patients at 
baseline and by week 12; there had been a median improvement in PSSI score of 73.3% (IQR 
33.3–94.3) compared with baseline. At week 12, PSSI 50 and PSSI 75 responses were 
achieved by 62.4% (718/1150) and 44.7% (514/1150) of patients, respectively. In many cases, 
a response to Efalizumab was apparent early in treatment, with over half of the patients 
classified as PSSI 50 responders at week 12 having already achieved this response by week 4 
(n = 425).  
However, Efalizumab has now been recommended for withdrawal in European market due 
to adverse effects. European Medicines Agency evaluated all safety data in light of post-
marketing surveillance of patients with Psoriasis receiving Efalizumab continuously for 
more than 3 years that showed opportunistic infections and, in particular, cases of JC virus 
infection (polyomavirus) resulting in progressive multifocal leucoencephalopathy (PML). It 
was concluded that the benefits of Efalizumab treatment no longer outweighed the risks 
associated with the drug and was recommended suspension of marketing authorization on 
19 February 2009. The drug has also been voluntarily withdrawn from the US market. 
Adalimumab, a monoclonal humanized tumor necrosis factor alpha inhibitor proved to be 
successful in treatment of severe facial Psoriasis (Noiles & Vender, 2008).  
Accumulating evidence supports efficacy and safety of ustekinumab for treatment of 
moderate to severe Psoriasis. There is some suggestion from head-to-head comparisons that 
ustekinumab may offer some advantage over TNF-α inhibitors. However, there is a need for 
larger and longer-term studies to assess the safety profile, cost-effectiveness and advantages 
of anti-interleukin 12 and 23 activity in the modern era of biological therapy (Garcia- 
Valladares & al., 2011). 
4.5 Miscellaneous agents 
Salicylic acid 5-10% is combined with other topical therapies as a keratolytic. Many topical 
treatments do not work well until thick scales that reduce drug penetration are removed. 
Urea 10% and lactic acid 10% have been used as scalp moisturizers. In resistant cases topical 
imidazole derivatives are used to control the overgrowth of Pityrosporum in scalp Psoriasis. 
Kircik (2011) stated that Salicylic acid 6% emollient foam provides a useful option that is 
highly effective, well tolerated and acceptable to patients. Efficacy, tolerability and patient 
acceptability of salicylic acid 6% emollient foam were assessed in an open-label pilot study 
of 10 subjects with scalp Psoriasis. All Psoriasis severity parameters were reduced with a 
significant decrease in PSSI score from 15.3 to 3.0 after four weeks of monotherapy 
(P<0.001). Sixty percent of subjects were either "completely cleared" or "almost cleared" from 
their Psoriasis. No adverse events were reported.  
Psoriasis skin lesions can be secondarily infected with bacteria according with Brook (Brook 
& al., 1999). In this report the predominant aerobic and facultative bacteria were S. aureus, 
group D Enterococcus and Escherichia coli while the predominant anaerobes were 
Peptostreptococcus spp. and Bacteroides spp., Propionibacterium acnes and pigmented 
Prevotella spp. in two each. Nineteen of the micro-organisms isolated from 78% patients 
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The U.S. Food and Drug Administration (FDA) has approved two drugs, Protopic and 
Elidel, for treatment of eczema which many dermatologists have found to work well in 
treating Psoriasis of the face or of other sensitive areas.   
5. The aberrant epidermal-mesenchymal interactions theory   
The normal adult epidermis is a self-renewing tissue consisting of 10 to 20 layers in which 
cell proliferation is primarily restricted to the basal layer. Orthokeratinized epithelium 
similar to that in skin is seen in the hard palate, whereas other regions are either 
parakeratinized (gingiva) or nonkeratinized (buccal mucosa) (Squier & al., 1976). Injury to 
the epidermis activates a homeostatic response resulting in inflammation, re-
epithelialization, followed by tissue remodelling (Martin, 1997). Several studies have 
suggested release of interleukin-1 from keratinocytes at the wound site as the initial trigger 
for the inflammatory reaction. This serves as an autocrine signal to surrounding 
keratinocytes and paracrine signal to other cells, such as fibroblasts, endothelial cells, and 
lymphocytes resulting in a pleiotropic effect on them (Freedberg & al., 2001). The changes in 
gene expression that accompany re-epithelialization are similar to those seen in other 
disorders associated with hyperproliferation such as Psoriasis, contact dermatitis, and 
squamous cell carcinoma (SCC) suggesting considerable overlap in the signaling cascades. 
The development of a normal scar is dependent on the reversal of expression of these genes 
at the wound site. However, in some cases the inflammatory and proliferative signals persist 
even after wound closure resulting in pathological scars, such as hypertrophic (HTS) and 
keloid scars. Although most previous studies have considered these scars as dermal 
phenomena (Akagi & al., 1999), others have identified abnormalities associated with 
epidermal keratinocytes in HTS perhaps as a result of aberrant epidermal-mesenchymal 
interaction (Niessen & al., 2001). One of the most sensitive biochemical markers of 
terminal differentiation in keratinocytes is the keratin protein family that constitutes the 
major cytoskeletal architecture of all epithelia. In humans, the family consists of  30 
polypeptides (including trichocytic keratins of hair and nail) that are divided into two 
types; type I is acidic and includes K9 to K20; type II is basic/neutral and includes K1 to 
K8. The normal expression of K2e in the upper spinous and granular layers of 
interfollicular epidermis is increased in keloid scars but showed distinct down-regulation 
in Psoriasis and hypertrophic scars where keratinocytes are known to undergo activation. 
Unlike normal and psoriatic skin, K2e expression in hypertrophic and keloid scars began 
in the deepest suprabasal layer. In cutaneous basal and squamous cell carcinomas, K2e 
was absent in most tumor islands but the overlying epidermis showed strong expression. 
In mild-to-moderate oral dysplasia with orthokeratinization, K2e was highly expressed 
compared with parakeratinized areas but in severe dysplasia as well as in oral squamous 
cell carcinoma, K2e expression was undetectable. Taken together, the data suggest that 
K2e expression in skin is sensitive to keratinocyte activation but its up-regulation in oral 
lesions is a reflection of the degree of orthokeratinization (Bloor & al., 2003). K 15 protein 
and mRNA are primarily located in the basal keratinocytes of stratified tissues (Waseem 
al., 1999) and the k 15 gene is upregulated in human subjects where both alleles for k 14 
have beeen inactivated.  In hyperproliferating epidermis, such as in Psoriasis, K 15 
expression, both protein and mRNA, is downregulated, suggesting that K 15 expression 
may not be compatible with the activated phenotype. 
 
Head and Neck Psoriasis 
 
95 
6. The rare mucous occurrence and the PPP-tonsil-related disease 
6.1 Mucous membrane localization 
The occurrence of true psoriatic lesions on mucous membranes is disputed. For many years 
it has been claimed that this disease does not affect oral mucosa. Today it is thought that 
involvement of the oral cavity is rare but does exist. Oppenheim (1903) was the first to 
describe oral Psoriasis in a biopsy after histological examination. In a review of English-
language and European non-English literature Younai and Phelan (1997) identified only 57 
cases of oral Psoriasis. Since then, few new cases have been reported bringing the total to 
less than 100 cases described. The reports described a number of oral sites affected, such as 
lips, buccal mucosa, gums, palate, tongue and floor of the mouth. In the cases reviewed by 
Younai and Phelan, clinical  presentation was a white intraoral lesion in 44% of patients, 
erythematous in 24% and red and white mixed in 13%. The remaining lesions appeared 
ulcerative, vesicular, pustular, or indurated. The histopathological findings in oral mucous 
membranes are assumed to be similar to those found in skin lesions. Epithelial 
parakeratosis, elongated rete ridges and the presence of an inflammatory infiltrate of the 
upper dermis were described in most cases. Differential diagnosis from other oral diseases 
such as benign migratory glossitis, fissured tongue, oral candidosis and the oral lesions of 
Reiter’s syndrome may be subtle. The diagnosis is easily made when the clinical features of 
oral lesions parallels that of skin lesions and it is supported by histological investigation 
(Weathers et al., 1974; Younai and Phelan, 1997; Bruce and Rogers, 2003).  
6.2 Recurrent streptococcal infection theory in pathogenesis of psoriasis 
Recent immunological studies have shown that hyperactivation of tonsillar T cells is caused 
by a hyperimmune response to α-streptococci; recruitment of the T cells to lesions may be 
involved in the pathogenesis of PPP. ß1 integrin, expressed on T cells, not only provides a 
co-stimulatory signal for T-cell activation but also facilitates the accumulation of T cells in 
inflammatory skin lesions. In this study was found that expression of ß1 integrin on both 
tonsillar and peripheral blood CD4-positive T cells was higher in PPP patients than in non-
PPP patients. It was demonstrated that ß1 integrin may play a key role in the pathogenesis 
of PPP (Ueda & al., 2010).  
Psoriasis is a T-cell-mediated disease that can be triggered by group A beta-haemolytic 
streptococci infection. 
The results of many experimental studies provide evidence that Psoriasis is largely a T-cell 
mediated disorder. It may result from antigen-specific activation of T cells in the skin of 
genetically predisposed individuals. These T cells apparently have a particular functional 
differentiation and promote the psoriatic skin changes by secreting a certain set of cytokines. 
Based on the fact that streptococcal throat infections are a trigger of guttate Psoriasis, the 
putative psoriatic antigens are assumed to be in keratinocyte proteins that share structural 
homologies with streptococcal proteins and thus induce cross-reactive responses of 
antibacterial T cells against skin components. Together with the particular phenotype of 
psoriatic skin lesions these findings can suggest that Psoriasis represents a sterile 
antibacterial tissue reaction, which is mediated by streptococci-specific T cells that cross-
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Psoriasis is strongly associated with streptococcal throat infection and patients have 
increased occurrence of such infections. Psoriatic lesional T cells are oligoclonal, and T cells 
recognizing determinants common to streptococcal M-protein and keratin have been 
detected in patients’ blood. The streptococcal association might reflect the concurrence of 
superantigen production promoting skin-homing of tonsil T cells, M-protein mimicking 
keratin determinants, and adjuvant effects of the peptidoglycan. Accordingly, improvement 
of Psoriasis after tonsillectomy should be associated with fewer T cells that recognize keratin 
and streptococcal determinants (Valdimarsson & al., 2009). 
6.3 Tonsillectomy and antistreptococcal antibiotic therapy 
Tonsillectomy may be a successful treatment modality in selected patients with recalcitrant 
guttate or chronic plaque Psoriasis. In the study of Hone & al.  (1996) Psoriasis was cleared 
completely after tonsillectomy in five out of six patients (83%) with guttate Psoriasis and 
was improved in one patient. Two out of seven patients with plaque Psoriasis (29%) were 
cleared, two (29%) were improved and three (42%) were unchanged. 
Numerous studies implicate subclinical or recurrent streptococcal infection as a trigger or 
maintenance factor in the pathogenesis of Psoriasis in children but the study of Wilson & al. 
(2003) stated that the available evidence does not demonstrate the efficacy of either 
antibiotic therapy or tonsillectomy in treatment of childhood Psoriasis. Clinical trials 
assessing the efficacy of antibiotics or tonsillectomy as treatments for childhood Psoriasis 
were identified with a search of the medical literature and the results were compared. Only 
one controlled clinical trial was identified and it did not find a significant effect of antibiotic 
treatment on Psoriasis. In other studies, the percentage of Psoriasis patients who 
experienced a disease clearance with antibiotic therapy ranged from 0% to 55%, with no 
patients experiencing disease worsening during treatment. No controlled trials of 
tonsillectomy for Psoriasis were identified. The percentage of patients who experienced a 
disease clearance after tonsillectomy in uncontrolled trials ranged from 32% to 53% and a 
similar percentage reported significant improvement in their Psoriasis, with a maximum of 
7% noting worsening of the disease after operation.  
Owen & al. (2000) agreed on the previous conclusions. They searched the Cochrane Clinical 
Trials Register (Cochrane Library, Issue 3, 1999), Medline (1966- September 1999), Embase 
(1988-September 1999), the Salford Database of Psoriasis Trials (to November 1999) and the 
European Dermato-Epidemiology Network (EDEN) Psoriasis Trials Database (to November 
1999) for terms [STREPTOCOCC* or ANTIBIOTIC* or TONSIL*] and PSORIASIS using the 
Cochrane Skin Group search strategy. The only one eligible trial identified compared the use 
of two oral antibiotic schedules in 20 Psoriasis patients, predominantly of guttate type, who 
had evidence of beta-haemolytic streptococcal colonisation. Either rifampicin or placebo was 
added to the end of a standard course of antistreptococcal antibiotic 
(phenoxymethylpenicillin or erythromycin). No patient in either arm of the study improved 
during the observation period. No randomised trials of tonsillectomy for Psoriasis were 
identified. Although both antibiotics and tonsillectomy have frequently been advocated for 
patients with recurrent guttate Psoriasis or chronic plaque Psoriasis, there is no good 
evidence that either intervention is beneficial to date. 
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Because these treatments are relatively benign compared to other treatments for severe 
Psoriasis, the use of antibiotic therapy or tonsillectomy may still be worth considering, 
especially for those patients with recurrent streptococcal infections that seem to trigger or 
maintain their skin disease. 
6.4 Psoriasis as T cell-mediated disease and correlation with PPP 
Another item of correlation between Psoriasis and inflammatory disease of the upper 
aerodigestive tract is represented by PPP.  PPP is a tonsil-related disease and tonsillectomy 
is somewhat effective in treating the condition. However, aetiological association between 
tonsils disease and PPP has not been elucidated fully. Recently, some chemokines and 
chemokine receptors, including CC chemokine receptor (CCR) 4, CCR6 and CX chemokine 
receptor (CXCR) 3, have been reported to play important roles in the development of 
Psoriasis, which is related closely to PPP. Chemokines and chemokine receptors have been 
known to play a crucial role in directing the movement of mononuclear cells throughout the 
body, contributing to the pathogenesis of several skin diseases. In the skin lesions of PPP 
and/or Psoriasis, IL-8 and regulated upon activation normal T cell expressed and secreted 
are reported to be up-regulated on epidermal keratinocytes, suggesting that such 
chemokines may play an important role for migration of leucocytes and T cells.  
Yoshizaki & al.(2009) have demonstrated that: (1) CCR6 expression was up-regulated in 
both tonsillar and peripheral blood T cells; (2) CCR6 expression on tonsillar T cells was 
enhanced by in vitro stimulus with a-streptococcal antigens; (3) tonsillar T cells exhibit more 
intense chemotactic responses to CCL20; (4) the number of CCR6-positive peripheral blood 
T cells decreased after tonsillectomy and this reduction was correlated with an improvement 
in skin lesions; and (5) CCR6 expression of T cells and CCL20 expression of epidermal cells 
were up-regulated in PPP skin lesions.  
These results indicate that CCR6 may be induced by a novel immune response to α-
streptococci in tonsillar T cells in PPP patients. CCR6-positive tonsillar T cells may be 
recruited to the skin via peripheral blood circulation and then attracted to keratinocytes 
expressing CCL20 in the epidermis. Therefore, CCR6 may act as an important factor, 
bridging the tonsils and PPP. CCR6-positive tonsillar T cells may move and circulate in the 
peripheral blood, being recruited ultimately to the skin lesions of PPP patients. The 
mechanism underlying the manner in which CCR6-expressing tonsillar T cells are recruited 
to the skin lesions of PPP patients remains obscure; the skin-specific homing receptor CLA 
may play an important role. 
The pathogenic role of T lymphocytes and immune cross-reaction between human-HSP60 
and bacterial-HSP65 in PPP was also revealed (Hayashi & al. 2009). 
The evidence that T lymphocytes play a key role in the pathogenesis of Psoriasis is now 
compelling. Eruption of psoriatic skin lesions coincides with epidermal infiltration and 
activation of T cells and spontaneous or treatment-induced resolution of the lesions is 
preceded by the reduction or disappearance of epidermal T cells. An up-regulation has 
also been demonstrated for various molecules associated with T-cell mediated 
inflammation and treatments selectively directed against T cells have proved to be very 
effective. Infections with group A beta-haemolytic streptococci have been associated with 
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Because these treatments are relatively benign compared to other treatments for severe 
Psoriasis, the use of antibiotic therapy or tonsillectomy may still be worth considering, 
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maintain their skin disease. 
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chemokines may play an important role for migration of leucocytes and T cells.  
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mechanism underlying the manner in which CCR6-expressing tonsillar T cells are recruited 
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may play an important role. 
The pathogenic role of T lymphocytes and immune cross-reaction between human-HSP60 
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frequently accompanied by erythematous skin rashes. Also, recent reports indicate that 
streptococcal superantigens can induce expression of cutaneous lymphocyte antigens 
(CLA), believed to play a major role in enabling T cells to migrate to the skin.  A novel 
immune response to alpha-streptococci may enhance CLA expression on tonsillar T-cells 
through TGF-beta production in patients with PPP, resulting in moving of CLA-positive 
tonsillar T-cells to skin and tissue damages. This may play a key role in pathogenesis of 
PPP (Nozawa & al., 2005).  
Helper T-cells are frequently activated in tonsils from PPP patients and this activation may 
be related to unresponsiveness of TGF-beta1 by overexpression of Smad7. Such hyper-
activation of T-cell may increase the risk of elicitation of self-reactive T-cell, being associated 
with pathogenesis of PPP (Takahara & al., 2005). 
Furthermore, T-cell lines isolated from psoriatic lesions may show strong reactivity to 
streptococcal antigens. It was demonstrated that active Psoriasis is associated with a Th1 
type response to short peptides with epitopes shared by streptococcal M-protein and 
keratin. This is consistent with the hypothesis that Psoriasis may be induced and 
exacerbated in susceptible individuals by M-protein-specific Th1-like cells that cross-react 
with human epidermal keratin (Valdimarsson & al., 1997). 
6.5 Interaction between epidermal keratinocytes and the immune system 
Psoriasis is associated with an increase of Th17 cytokines, such as IL-17, IL-22, IL-21, and 
TNF-α, which are produced by Th 17 cells. Adipokines are peptide hormones or cytokines 
secreted from adipose tissues and involved in the pathogenesis of metabolic syndrome. 
Psoriasis patients have a high prevalence of metabolic syndrome. Increased serum levels of 
IL-22 and adiponectin were positively correlated with PASI. In contrast, serum high 
molecular weight adiponectin levels were decreased in Psoriasis and negatively correlated 
with PASI (Nakajima & al. 2011). 
Th 17 cells have crucial functions in host defense and dysregulated Th17 responses mediate 
a variety of autoimmune and inflammatory conditions. Th17 cells coexpress interleukin-22 
and its receptor is expressed on epidermal keratinocytes. IL-17 and IL-22 cooperatively 
enhance some immunological responses. A close relationship between IL-17 and the 
cutaneous milieu has been suggested by a number of observations. IL-17 induces the 
production of certain cytokines, chemokines and antimicrobial peptides by keratinocytes, 
and its cooperation with IL-22 has been documented. Recent findings have suggested that 
Th17 cells profoundly participate in the pathogenesis of certain skin disorders, in particular, 
Psoriasis. The concept of the subsets of T cells responsible for Psoriasis has been modified in 
the order of Th1, T cytotoxic 1, and again Thl, and Thl7 cells. IL-22 is the strongest cytokine 
in the keratinocyte-proliferative ability. Since IL-22 is produced by Th17 cells, they are 
crucial for the proliferation of keratinocytes. Furthermore, IL-22 with the help of IL-17 can 
induce the critical events of Psoriasis, including signal transducer and activator of 
transcription 3 (STAT3) activation, cytokine/chemokine (IL-8 etc.) production, and 
antimicrobial peptide elaboration. For maintaining Th17 cells, IL-23 is required and is 
released from tumor necrosis factor-alpha (TNF-alpha) and inducible nitric oxide synthetase 
(iNOS)-producing dendritic cells (TIP-DCs). TIP-DCs are activated via an autocrine 
mechanism by virtue of TNF-alpha.  
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The above cytokine network in the pathogenesis of Psoriasis has been proven by the 
therapeutic effectiveness of cytokine-blocking biologics. Antibodies against TNF-alpha or its 
soluble receptor have already been widely used in the treatment of Psoriasis.  
The involvement of Th17 cells has also been shown in allergen-specific immune responses. 
The percentage of Th17 cells is increased in the peripheral blood of patients with atopic 
dermatitis (AD) and associated with the severity of AD. Drug eruption is another disease 
where Th17 cells are involved in the pathogenesis. The percentage of circulating Th17 cells 
are increased in drug-induced hypersensitivity syndrome, etc. Th17 cells and IL-22 are 
increased in patients with acute generalized exanthematous pustulosis. Since IL-17 and IL-
22 cooperatively stimulate keratinocytes to produce IL-8, keratinocyte-derived IL-8 
contributes to the accumulation of neutrophils in the lesional epidermis of this drug 
eruption (Tokura & al., 2010). 
In conclusion, more recent data suggest that Psoriasis is caused by an interaction between 
epidermal keratinocytes and the immune system and that one possible candidate linking the 
immune system and epidermal keratinocytes is IL-22, a T-cell-derived cytokine that is 
produced by Th17 polarized T cells that are stimulated by IL-23, but that acts on epidermal 
keratinocytes to induce acanthosis and differentiation toward a psoriatic phenotype. 
Regardless of the specific underlying pathogenesis, Psoriasis is characterized by a 
disregulated epidermal acanthosis, dermal and epidermal leukocytic infiltration, and 
dilatation of dermal blood vessels—lesions that are maintained by the complex interplay  
between T cells and their cytokines, other leukocytes, vascular endothelium, and epidermal 
keratinocytes. As noted above, epidermal keratinocytes as well as vascular endothelial cells 
are active participants in the psoriatic inflammatory process via secretion of cytokines and 
growth factors, and the up regulation of signaling and adhesion molecules on their surfaces 
(Danilenko, 2008). 
6.6 SAPHO syndrome and CMRO 
SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome and CMRO (chronic 
recurrent multifocal osteomyelitis) represent pathologic entities related to Psoriasis and PPP 
in regard to the relationship between infection and autoimmunity. In genetically susceptible 
individuals, environmental factors (mainly infections) play a critical role in the pathogenesis 
of autoimmune diseases. Molecular similarity of microbial and host antigens has recently 
been proposed as a promoting factor for pathogen expansion when microbial agents are not 
recognized as alien and not completely eliminated (Rozin, 2009). 
SAPHO syndrome is now recognized as a distinct medical entity: a reactive infectious 
osteitis. Infectious agents isolated from SAPHO patients have gained special attention for 
many years. Their possible etiological role is supported by the pathogen isolation from 
different sites: anterior chest wall, spine, synovial fluid, bone tissue and skin pustules. A 
range of pathogens have been found, including Staphylococcus aureus, Hemophilus 
parainfluenzae, Actinomyces, and even Treponema pallidum (Arnson, 2008). 
Propionibacterium acnes is a much more frequent pathogen and plays a particular role. 
Multiple affected members who segregated a SAPHO syndrome-like phenotype had 
neutrophil dysfunction and reduced internal oxydant production (Ferguson & al., 2008). 
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affected sites and justifies long-term or permanent antibiotic therapy (Rozin, 2009; 
Magrey, 2009). Treatment of SAPHO syndrome remains empirical as the underlying 
aetiopathogenesis is unclear. 
A growing body of literature has identified the association between neutrophilic dermatoses 
and multifocal, aseptic bone lesions in children, termed chronic recurrent multifocal 
osteomyelitis (CRMO). Classically, patients present with swelling, pain, and impaired 
mobility of the affected area, with skin lesions developing concurrently or in the future. 
Bone biopsy reveals inflammatory changes consistent with infectious osteomyelitis, but 
cultures and histologic staining invariably fail to identify an infectious source. Patients are 
refractory to antibiotic therapy, but dramatically respond to systemic steroids and may need 
to be maintained on low-dose steroids to prevent relapse. Numerous authors have 
suggested that CRMO and SAPHO syndrome lie along the same clinical spectrum (Tlougan, 
2009; Shilling, 2000). 
7. Psoriasis and tumours in head and neck area 
Overexpression of S100A7 (psoriasin), a small calcium-binding protein, has been associated 
with the development of Psoriasis and carcinomas in different types of epithelia but its 
precise functions are still unknown. Using human tissue specimens, cultured cell lines and a 
mouse model it was found (Zhou & al., 2008) that S100A7 is highly expressed in 
preinvasive, well-differentiated and early staged human squamous cell carcinoma of the 
oral cavity (SCCOC), but little or no expression was found in poorly differentiated, later-
staged invasive tumors. Interestingly those researchers showed that S100A7 inhibits both 
SCCOC cell proliferation in vitro and tumor growth/invasion in vivo. Furthermore, they 
demonstrated that S100A7 is associated with the beta-catenin complex, and inhibits beta-
catenin signaling by targeting beta-catenin degradation via a non canonical mechanism that 
is independent of GSK3beta-mediated phosphorylation. More importantly their studies also 
indicated that beta-catenin signaling negatively regulates S100A7 expression. Thus, this 
reciprocal negative regulation between S100A7 and beta-catenin signaling implies their 
important roles in tumor development and progression. Despite its high levels of expression 
in early stage of SCCOC tumorigenesis, S100A7 actually inhibits SCCOC tumor 
growth/invasion as well as tumor progression. Downregulation of S100A7 in later stages of 
tumorigenesis increases beta-catenin signaling, leading to promotion of tumor growth and 
tumor progression. 
Significantly increased risk of cancer was demonstrated in patients with Psoriasis at an 
average of 9.3 years after discharge from hospital. This risk, amounting to 1.4 times that in 
the general population, is mainly relative to skin and lung cancer in both sexes and to 
pharynx and larynx cancer in men. Still this data are not definitive as no studies have been 
published with bias correction for smoke and alcohol consumption. Non-melanoma skin 
cancer is the most common malignancy, occurring in 196 of 795 patients with cancer: 
standardized incidence ratio 2.4 for men and 2.6 for women. This means an overall lifetime 
risk (up to the age of 75 years) of 14.1%. Women run the highest risk of basal cell carcinoma 
in the age range 20-40 years, while men in the age range 30-60 years run a particularly high 
risk of squamous cell carcinoma (Frentz & Olsen, 1999).  
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Standardized incidence ratios (SIR) was found to be 2.80 (95% CI 1.96, 3.87) for oral cavity 
and pharynx cancer in a nationwide series of psoriasis patients from Sweden with a 
hospital discharge diagnosis of psoriasis made during 1965–83, who were alive and free 
from malignancy 1 year after first discharge, compared with the national population 
(Boffetta & al., 2001). Psoriasis was associated with a significantly increased prevalence 
ratio of lip, oral cavity and pharynx cancer (1.49; [1.22, 1.80]), in a national database in 
Taiwan (Tsai & al. 2011). 
8. Conclusion 
Psoriasis is a disease treated near exclusively from dermatologists.  Nevertheless some 
factors indicate the need for a new attention by the head and neck area specialists, especially 
by the otorhinolaringologists and maxillofacial surgeons.   
Recent literature focuses on relationship between autoimmunity and infection, the latter 
representing the prince environmental factor that could play a critical role in the 
pathogenesis of autoimmune diseases in susceptible individuals with the production of 
cross-reacting antibodies and the induction of the inflammatory second hit. When infectious 
agents  are not recognized as alien and not completely eliminated, pathogen expansion 
could be promoted by molecular similarity  of microbial and host antigens.  
As above mentioned important relationship has been demonstrated between tonsillar T cells 
and skin lesion in PPP patients with immune response to α-streptococci.  
Further investigations with translation from bench research to clinical knowledge and vice 
versa and with interrelation between dermatologists and head and neck specialists could 
result in considerable progress in understanding immunopathogenesis of Psoriasis and 
other immuno-mediated diseases.  
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1. Introduction  
Psoriasis is a chronic inflammatory disease affecting about 3% of the worldwide population 
(Gottlieb A et al, 2007). 
Recent findings have shown that the previous concept “ psoriasis as a disease of healthy 
people” must be revisited into psoriasis as a complex entity with multisistemic involvement.   
Although the overall mortality attributed to psoriasis is about 0.64 deaths per 100 000 
psoriatic patients annually in the USA, erythrodermic and generalized pustular soriasis, are 
associated with a greater risk of mortality and morbidity (Boyd AS et al, 1989;  Prystowsky 
JH et al, 1995). 
Psoriasis can be associated with other disease, such as metabolic syndrome, which may have 
a major impact on quality of life, morbidity and mortality. 
The aim of this chapter is to focus on  two newly emergent comorbidities in psoriatic 
patients,  the cardiovascular disease (CVD) and the metabolic syndrome (MetS). 
2. The metabolic syndrome 
The metabolic syndrome  (MetS) is  a cluster of risk factors including obesity, atherogenic 
dyslipidaemia, hypertension, glucose intolerance and a proinflammatory and prothrombotic 
state  predisposing the patients to cardiovascular diseases (CVD),  type 2 diabetes (DM), 
renal failure and stroke (Gisondi et al, 2007). 
Furthermore, it has recently been suggested that the metabolic syndrome might be a risk 
factor for cancer, in particular colon cancer (Gottlieb A et al, 2007). 
The MetS prevalence in Western Europe population  ranges from  15% to  35% and  it 
strictly correlates with age, increasing sharply after the age of 60 (Gisondi et al, 2007).  
The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) 
have proposed the criteria for the metabolic syndrome diagnosis; other organizations, such 
as The World Health Organization (WHO) and the European Group on Insulin resistance, 
agree with it in the essential components, differing from it in the details and criteria (Chung 
CP et al, 2005). 
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 Abdominal obesity, defined as waist circumference ≥ 102 cm in men and ≥ 88 cm in 
women 
 Tryglicerides plasma levels ≥ 150 mg/dl 
 HDL cholesterol plasma levels less than 40 mg/dl in men and 50 mg/dl in women 
 Blood pressure more than 130 mmHg (systolic) and 85 mmHg (diastolic)  
 Fasting plasma glucose levels more than 100 mg/dL  [Grundy et al., 2005] 
It is now thought that non-alcoholic fatty liver disease (NAFLD)  is a component of 
metabolic syndrome, that may progress to steatoepatitis (NASH) with  complications of 
fibrosis and cirrhosis (Capeau J, 2008). 
Recent study have demonstrated that the prevalence of metabolic syndrome is 
significantly higher in psoriatic patients compared to controls after the age of 40 years  
and  psoriatic patients have an increased risk for the individual components of MetS 
(Gisondi et al, 2007). 
Moreover, the association between psoriasis and metabolic syndrome is also true for mild 
severity psoriasis and it is independent from the tendency of psoriatic patients to be obese 
( Mallbris L et al, 2006; Neimann AL et al, 2006; Sommer DM  et al, 2006). 
Although the link between psoriasis and metabolic syndrome is not completely elucidated, 
the pathophysiology of both these entities shows many shared cytokines contributing to the 
underlying chronic inflammatory status. 
It is known that both innate and adaptive immunity are involved in psoriatic 
pathogenesis and, in particular, NK cells appear crucial in the inflammatory process 
initiation, with an increased release of  proinflammatory cytokines, such as TNF-alpha 
and IFN-gamma and the subsequent interaction with TH1 and Th17 cells (Teunissen 
MBM et al , 2007). 
Dysregulation of T-cell antigen presenting cell interactions and overexpression of   
proinflammatory cytokines lead to the hyperproliferation of keratinocytes and the activation 
of neutrophils and endothelial cells until the development of the characteristic psoriatic skin 
lesions (Kimball AB et al, 2008). 
The molecular mechanisms involved in psoriasis-associated dysregulation of metabolic 
functions are believed to be due to an underlying low and persistent inflammatory status 
with increased levels of proinflammatory factors, such as tumor necrosis factor-alpha and 
IL-6 (Fig.1). 
TNF-alpha is a proinflammatory cytokine produced by many cell lines, such as 
keratinocites, T  cells,  NK cells, dendritic cells, neutrophils,  mast cells and adipocytes 
(Ronti T et al, 2006). 
It is expressed as a 26-kD cell surface trans-membrane protein that undergoes cleavage to 
produce a 17-kD soluble, biologically active form of TNF-α (Ronti T et al, 2006). 
IL-6, a pleiotropic circulating cytokine, shows multiple effects ranging from inflammation to 
host defence and tissue injury. It is secreted by many cell types, including immune cells, 
fibroblasts, endothelial cells, skeletal muscle and adipocytes (Ronti T et al, 2006). 
 
Metabolic Features in Psoriasis 109 
 
Fig. 1. The molecular mechanisms involved in psoriasis-associated dysregulation of 
metabolic function. 
3. Obesity and psoriasis 
Among different MetS components, the association between obesity and psoriasis is the best 
documented.  
Several studies have shown that the severity of PsO may be linked to obesity  and a 
population-based study of mild or severe PsO has demonstrated that the risk of obesity was 
significantly increased in PsO patients compared with healthy controls. Unlike in other 
inflammatory diseases, such as rheumatoid arthritis, the risk of obesity is strongly 
associated with disease severity (Sterry W et al, 2004). 
Although it is controversial if psoriasis is the result or the cause of obesity itself , recent data 
support the obesity is a consequence of psoriasis (Henseler T et al, 1995; Neimann AL  et al, 
2006; Herron MD et al. 2005). 
Obesity is considered  the main pathogenic factor in the metabolic syndrome and it is 
characterized by a low and persistent sistemic inflammatory status, whose mainstay is  the 
adipose tissue (Greenberg et al., 2006). 
Adipose tissue is principally divided into two compartments, subcutaneously and centrally: 
the central one is characterized by omental adipose tissue and other intra-abdominal fat 
sources such as mesenteric fat. Central adipose tissue, also called  visceral fat,  is considered 
more metabolically active than peripheral subcutaneous fat (Kershaw EE et al, 2004; Galic S 
et al, 2010). 
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The importance of adipose tissue location in terms of dysmetabolism risk is evident:  
patients with excess visceral fat (central obesity) show an higher risk of developing insulin 
resistance  and the features of the metabolic syndrome than patients with excess 
subcutaneous fat (Kissebach AH et al, 1982). 
One of the most commonly used antropometric indexes is BMI (Body mass index), which 
measures adiposity and body composition as weight in kilograms divided by the square 
ofthe height measurement in metres (kg/m2).  BMI have high specificity, but low sensitivity 
to identify adiposity and excess body fat (Okorodudu DO et al, 2010). 
Waist circumference (WC), alone or  in combination with BMI, has been shown to be an 
accurate predictor of visceral fat directly reflecting total abdominal fat mass but failing to 
quantify the visceral and subcutaneous fat compartments individually (Kashihara H et al, 
2009). 
The visceral adipose tissue is not only an energy storage organ, but also an important 
component of the immune system through the adipocytes’ expression of toll receptors and a 
real active endocrine organ producing  proinflammatory cytokines (TNF-alpha, IL-6), free 
fatty acids, procoagulant molecules and bioactive products called adipokines (Ronti et al, 
2006).  
Many adipokines have been identified, such as leptin, visfatin, resistin and adiponectin; they 
act in a communications network with other tissues and organs such as the skeletal muscle, 
adrenal cortex, brain and sympathetic nervous system and participate in appetite and 
energy balance, immunity, insulin sensitivity, angiogenesis, blood pressure, lipid 
metabolism and haemostasis (Ronti T et al, 2006). 
In particular, leptin and resistin appear to be two proinflammatory cytokines, while 
adiponectin has anti-inflammatory properties (Ronti T et al, 2006). 
Leptin, a 16-kD adipocyte-derived cytokine, is synthesized and released from fat cells in 
response to changes in body fat. Leptin circulates partially bound to plasma proteins and 
enters the CNS by diffusion through capillary junctures in the median eminence and by 
saturable receptor transport in the choroid plexus. In the hypothalamus, leptin binds to 
receptors that stimulate anorexigenic peptides such as proopiomelanocortin and cocaine- 
and amphetamine-regulated transcript and inhibit orexigenic peptides, such as 
neuropeptide Y. Leptin reduces intracellular lipid levels in skeletal muscle, liver and 
pancreatic beta cells, thereby improving insulin sensitivity. There is strong evidence 
showing that the dominant action of leptin is to act as a ‘starvation signal’: leptin declines 
rapidly during fasting.Therefore, leptin deficiency was perceived as a state of unmitigated 
starvation, leading to compensatory responses, such as hyperphagia, decreased metabolic 
rate and changes in hormone levels, designed to restore energy balance. The concept of 
‘leptin resistance’ was introduced when increased adipose leptin production was observed 
in obese individuals, who were not leptin-deficient. Moreovere, some studies suggest leptin 
may affect vascular structure with an angiogenic activity and contributes to arterial 
thrombosis through the platelet leptin receptor. Leptin also stimulates production of 
reactive oxygen species as a result of monocyte activation. Therefore, in an obese subject 
leptin may no longer be able to regulate caloric intake and energy balance, but may still 
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exert its angiogenic activity and production of reactive oxigen species, which affect vessel 
walls (Ronti T et al, 2006). 
Resistin is a dimeric protein. In murine models, obesity is associated with rises in 
circulating resistin concentrations. Resistin increases blood glucose and insulin 
concentrations and impairs hypoglycaemic response to insulin infusion. In obese mice, 
antiresistin antibodies decrease blood glucose and improve insulin sensitivity: these data 
support the hypothesis that in obese rodents, resistin induces insulin resistance and 
contributes to impaired insulin sensitivity. In humans, the physiological role of resistin 
must be elucidated and its role in obesity and insulin resistance and/or diabetes is 
controversial. In humans, as resistin is primarily produced in peripheral blood monocytes 
and its levels correlate with IL-6 concentrations. the question of its inflammatory role has 
been raised (Ronti et al, 2006). 
Four genes encode for resistin in the mouse and two in humans. Some genetic case 
control studies demonstrated genetic variations in the resistin gene are associated with 
insulin resistance and obesity in humans. Others show that the very low resistin mRNA 
expression in isolated human adipocytes does not correlate consistently with insulin 
resistance or obesity, making the role of human resistin in insulin resistance unclear. No 
differences have been observed in resistin expression in adipocytes from normal, insulin-
resistant, and type 2 diabetic individuals. Mc Ternan et al. reported greater resistin 
mRNA expression in fat depots in the abdomen than in the thigh, suggesting human 
resistin could play a role in obesity-related insulin resistance (McTernan et al, 2002; Ronti 
et al, 2006). 
Adiponectin is almost exclusively expressed in white adipose tissue, whose expression is 
inhibited by IL- 6 and TNF-α.   Unlike most adipokines, adiponectin expression and 
serum concentrations are reduced in obese and insulin-resistant states and,  in vivo, high 
plasma adiponectin levels are associated with reduced risk of myocardial infarction. 
Although further studies are needed to clarify whether adiponectin independently 
predicts coronary heart disease events, in men with type 2 diabetes, increased adiponectin 
levels are associated with a moderately decreased risk of coronary heart disease. The 
association seems to be mediated in part by the effects of adiponectin on high-density 
lipoprotein cholesterol (HDL), through parallel increases in both.  Moreover, it has been 
demonstrated that weight loss, caloric restriction and thiazoladinedione treatment 
increase adiponectin plasma levels and gene expression in white adipose tissue (Ronti et 
al, 2006). 
Recent studies have evidenced  a high leptin levels and  decreased serum levels of 
adiponectin in obesity, insulin-resistent PsO patients and they emphasized an inverse 
correlation between serum levels of adiponectin and IL-6 (Satapathy SK et al, 2004). 
The precise physiological events leading to the initiation of the inflammatory response in 
obesity remain incompletely understood. One theory underlined that the expansion of 
adipose tissue leads to adipocyte hypertrophy and hyperplasia with a consequent local 
oxygen supply, cell hypoxia and the activation of cellular stress pathways releasing 
proinflammatory cytokines and signals.  These proinflammatory chemokines attract pro-
 
Psoriasis 110 
The importance of adipose tissue location in terms of dysmetabolism risk is evident:  
patients with excess visceral fat (central obesity) show an higher risk of developing insulin 
resistance  and the features of the metabolic syndrome than patients with excess 
subcutaneous fat (Kissebach AH et al, 1982). 
One of the most commonly used antropometric indexes is BMI (Body mass index), which 
measures adiposity and body composition as weight in kilograms divided by the square 
ofthe height measurement in metres (kg/m2).  BMI have high specificity, but low sensitivity 
to identify adiposity and excess body fat (Okorodudu DO et al, 2010). 
Waist circumference (WC), alone or  in combination with BMI, has been shown to be an 
accurate predictor of visceral fat directly reflecting total abdominal fat mass but failing to 
quantify the visceral and subcutaneous fat compartments individually (Kashihara H et al, 
2009). 
The visceral adipose tissue is not only an energy storage organ, but also an important 
component of the immune system through the adipocytes’ expression of toll receptors and a 
real active endocrine organ producing  proinflammatory cytokines (TNF-alpha, IL-6), free 
fatty acids, procoagulant molecules and bioactive products called adipokines (Ronti et al, 
2006).  
Many adipokines have been identified, such as leptin, visfatin, resistin and adiponectin; they 
act in a communications network with other tissues and organs such as the skeletal muscle, 
adrenal cortex, brain and sympathetic nervous system and participate in appetite and 
energy balance, immunity, insulin sensitivity, angiogenesis, blood pressure, lipid 
metabolism and haemostasis (Ronti T et al, 2006). 
In particular, leptin and resistin appear to be two proinflammatory cytokines, while 
adiponectin has anti-inflammatory properties (Ronti T et al, 2006). 
Leptin, a 16-kD adipocyte-derived cytokine, is synthesized and released from fat cells in 
response to changes in body fat. Leptin circulates partially bound to plasma proteins and 
enters the CNS by diffusion through capillary junctures in the median eminence and by 
saturable receptor transport in the choroid plexus. In the hypothalamus, leptin binds to 
receptors that stimulate anorexigenic peptides such as proopiomelanocortin and cocaine- 
and amphetamine-regulated transcript and inhibit orexigenic peptides, such as 
neuropeptide Y. Leptin reduces intracellular lipid levels in skeletal muscle, liver and 
pancreatic beta cells, thereby improving insulin sensitivity. There is strong evidence 
showing that the dominant action of leptin is to act as a ‘starvation signal’: leptin declines 
rapidly during fasting.Therefore, leptin deficiency was perceived as a state of unmitigated 
starvation, leading to compensatory responses, such as hyperphagia, decreased metabolic 
rate and changes in hormone levels, designed to restore energy balance. The concept of 
‘leptin resistance’ was introduced when increased adipose leptin production was observed 
in obese individuals, who were not leptin-deficient. Moreovere, some studies suggest leptin 
may affect vascular structure with an angiogenic activity and contributes to arterial 
thrombosis through the platelet leptin receptor. Leptin also stimulates production of 
reactive oxygen species as a result of monocyte activation. Therefore, in an obese subject 
leptin may no longer be able to regulate caloric intake and energy balance, but may still 
 
Metabolic Features in Psoriasis 111 
exert its angiogenic activity and production of reactive oxigen species, which affect vessel 
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inflammatory macrophages into the adipose tissue with the creation of crown-like structures 
around hypertrophic dead or dying adipocytes. Furthermore, these macrophages release 
cytokines that stimulate an inflammation in neighboring adipocytes developing a vicious 
circle (Esposito K et al, 2004; Das UN, 2001). 
Thus, excess adipose tissue results in elevated levels of pro-inflammatory adipokines, 
resulting in an imbalance between increased inflammatory stimuli and decreased anti-
inflammatory mechanism leading to persistent low-grade inflammation (Wajchenberg BL et 
al, 2000; Esposito K et al, 2004; Das UN, 2001). 
Among proinflammatory cytokines, TNF-a and IL-6  represent  two  driving cytokines, 
which link psoriasis with many  MetS components, such as obesity-related insulin-resistance 
(Ronti T et al, 2006). 
In humans TNF-α is synthesized and secreted by adipocytes and stromovascular cells: 
adipose tissue TNF-α is not secreted in systemic circulation and acts in an autocrine and 
paracrine pathways. Adipose tissue TNF-α mRNA correlates with body mass index, 
percentage of body fat and hyperinsulinaemia; weight loss decreases TNF-α levels (Ronti T 
et al, 2006). 
TNF-α modifies the gene expression profile of adipocytes and liver with an increased release 
and production of FFAs, cholesterol and VLDL; elevated IL-6 levels appears  to be 
associated with decreased levels of HDL cholesterol, which  may contribute to a state of 
chronic inflammation (Gottlieb A et al, 2008). 
 
Fig. 2. The vicious circle linking obesity and hyperinsulinemia 
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Moreover, levels of soluble TNF-α receptors are directly  proportional to total and LDL 
cholesterol concentrations and inversely correlated with certain HDL cholesterol subfraction 
levels (Gottlieb A et al, 2008). 
Obesity-induced chronic inflammation is a key component in the pathogenesis of insulin 
resistance ( Fig.2). 
4. Insulin-resistance 
Several studies have demonstrated a potential association between PsO and increased 
serum fasting glucose levels, hyperinsulinemia, insulin-resistance, and type 2 diabetes. 
However, insulin resistance does not significantly correlate  with PsO disease severity and 
duration (Gottlieb A et al, 2008). 
Insulin resistance is a characteristic feature of most patients with Type 2 diabetes mellitus 
and is one of the MetS clinical features. Insulin is a pleiotropic hormone stimulating nutrient 
transport into cells, regulating gene expression, modifying enzymatic activity and 
regulating energy homeostasis (De Luca C et al, 2008). 
Insulin exerted to these multiple functions through  several intracellular signaling 
cascades, such as  the phosphatidylinositol 3-kinase (PI3K)-AKT (also called protein 
kinase B (PKB)) pathway and the Ras-mitogen activated protein kinase (MAPK) pathway. 
PI3K-AKT is largely responsible for insulin action on glucose uptake and in the 
suppression of gluconeogenesis, while MAPK mediates gene expression and controls cell 
growth and differentiation, interacting with the first pathway. The insulin action is 
evidenced on target tissue, such as liver, adipose tissue and skeletal muscle (De Luca C et 
al, 2008). 
In the liver, insulin regulates glucose metabolism depending on the meal or starvation, 
while in adipose tissue insulin signaling results in decreased hormone sensitive lipase 
activity and this anti-lipolytic effect inhibits free fatty acid efflux out of adipocytes (De Luca 
C et al, 2008). 
Increased levels of  TNF-alpha,  IL-6 and FFAs produced by excess visceral adipose tissue 
can cause insulin resistance in adipose tissue, skeletal muscle and liver by inhibiting insulin 
signal transduction and  they can determine the production of other inflammatory-related 
factors, such as CRP (Gottlieb A et al, 2008). 
TNF-alpha causes a decrease in the autophosphorylation of tyrosine residues of insulin 
receptor (IR) and phosphorylation of insulin receptor substrate 1 (IRS-1) (Hotamisligil GS, 
2003). 
Thus, in psoriasis obesity and insulin resistance have a proinflammatory effect perpetuated 
through a positive feedback loop in PsO patients. 
5. NAFLD  
The liver plays a central role in lipid metabolism, importing serum free fatty acids and 
manufacturing, storing and exporting lipids and lipoproteins (Adams LA et al, 2005). 
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NAFLD is the acronym for nonalcoholic fatty liver disease and it includes a wide spectrum 
of liver pathology, from hepatocellular steatosis to nonalcoholic steatohepatitis (NASH) 
(Browning JD et al, 2004). 
The prevalence of NAFLD is 10–25% in the western world and it is a an emergent condition 
now recognized as the most frequent cause of abnormal liver tests, especially in obese 
individuals (Papatheodoridis GV et al, 2007). 
NAFLD is considered the hepatic manifestation of the metabolic syndrome closely 
associated to visceral obesity and insulin resistance (Marchesini G et al, 2003; Tsochatzis EA 
et al, 2009). 
Adipocytokines, free fatty acids, mitochondrial dysfunction, bacterial endotoxin and 
vascular disturbance have all been implicated in the development of hepatic inflammation 
and fibrosis in patients with NAFLD (Adams LA et al, 2005). 
The pathogenesis of NAFLD is currently seen as a two steps process, initially characterized 
by the accumulation of liver fat followed by the development of necroinflammation and 
fibrosis (Day CP et al,1998).  
Insulin resistance results in both increased adipose tissue lipolysis and increased hepatic 
lipogenesis leading to lipid accumulation in the hepatocytes, mainly in the form of 
triglycerides and FFAs (Emmanuel A et al, 2009). 
The increased liver deposition of TG and FFAs contributes to lipotoxicity and predisposes 
hepatocytes to the second step: the mythocondrial disfunction and the oxidative stress 
(Emmanuel A et al, 2009). 
A recent study  has emphasized that NAFLD is highly prevalent among psoriasis patients 
and it seems that patients with NAFLD and psoriasis are at higher risk for severe liver 
fibrosis than their age, sex and BMI-matched counterparts with NAFLD without psoriasis 
(Marra M et al, 2007). 
Psoriasis, metabolic syndrome and NAFLD might share a common underlying mechanism 
characterized by a low level inflammatory status characterized by a pro-inflammatory 
cytokines generalized activation (Marra M et al, 2007). 
As in  obesity and insulin resistance, TNF-alpha seems to have a pivotal role: both serum 
and hepatic levels of TNF-alpha are elevated in patients with NAFLD and it is directly 
correlated considering the markers of liver damage (Marra M et al, 2007). 
AST, ALT and mostly AST/ALT ratio are considered important parameters of liver damage 
and they appear correlated to the severity of the hepatic damage to histological disease 
severity.[ Pulzi FBU et al, 2011] 
It has already demonstrated that psoriatic patients with NAFLD show a higher mean 
AST/ALT ratio, a parameter proved to be an independent predictor factor of liver fibrosis in 
NAFLD patients (Angulo P et al, 2007). 
AST serum levels increase more than those of ALT with the progression of the hepatic 
disease; therefore, an higher than 1 AST/ALT ratio may be one element of more advanced 
disease (Vanni E et al, 2010).   
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6. Atherogenic dyslipidemia 
Many evidences suggest a strong link between PsO and abnormalities in fatty acid 
metabolism: psoriatic patients show dyslipidemia with increased plasma cholesterol, 
triglycerides (TG), low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein 
(VLDL) cholesterol, and decreased HDL cholesterol and antioxidant capacity. In particular, 
a recent study has underlined that the dyslipidemic profile could precede the psoriasis 
manifestations (Gottlieb A et al, 2008). 
Studies on lipid profile in psoriatic patients have been conducted since 1994 focusing on the 
presence of a significant content in total cholesterol and of the cholesterol/protein ratio in 
low-density lipoproteins (LDL) and in high-density lipoproteins (HDL) of psoriatic children. 
The compositional changes were associated with alterations of fluidity in LDL and HDL of 
psoriatic patients (Offidani AM et al, 1994). 
In PsO patients, the detection of raised levels of LDL and low levels of HDL cholesterol is 
associated with coronary artery disease and with accelerated mortality for cardiovascular 
disease (Jones SM et al, 2000). 
7. Hypertension 
In  PsO patients a higher occurrence of hypertension compared with controls has been 
reported. The underlying mechanism of hypertension in psoriasis has been discussed and 
multiple hypothesis have been emerged on this topic (Gottlieb A et al, 2008). 
The pathogenesis of hypertension in psoriasis seems to be linked to increased production of 
angiotensinogen by adipose tissue, subsequently converted to angiotensin II through  
angiotensin converting enzyme (ACE) (Armstrong AW et al, 2011). 
ACE  serum levels are increased in psoriasis patients (Gottlieb A et al, 2008). 
Angiotensin II not only promotes salt retention by kidney but also it regulates vascular tone, 
acting a vasoconstrictor and stimulates T-cell proliferation promoting  inflammation and the 
development of atherosclerosis (Armstrong AW et al, 2011). 
The association between psoriasis and hypertension may also be attributed to the increased 
oxidative stress in psoriasis patients. Greater levels of reactive oxygen species can damage 
endothelium-dependent vasodilation (Armstrong AW et al, 2011). 
Other studies emphasized the role of endothelin-1 in hypertension development among PsO 
patients. Endothelin-1 is a protein produced by several different cell types including 
keratinocytes; it induces  blood vessels vasoconstriction increasing blood pressure. In PsO 
patients endothelin-1 expression appears to be altered in lesional skin and serum and 
correlated to psoriasis disease severity (Armstrong AW et al, 2011). 
8. Protrombotic state  
A proinflammatory and/or prothrombotic state has been associated with MetS and PsO, 
probably linked to elevated serum levels of PAI-1, fibrinogen and CRP. Elevated CRP levels 
are induced by IL-6 and they have been shown to be predictive of future CVD in initially 
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healthy individuals, and the risk of CVD in patients with either diabetes or MetS is 
significantly increased in the presence of elevated CRP levels (Gottlieb A et al, 2008). 
9. Anti-TNF-alpha in psoriasis and metabolic syndrome 
TNF-alpha is an inflammatory cytokine promoting inflammation via the activation and 
induction of proinflammatory cytokines (IL-1, IL-6, IL-8) and by the upregulation of 
adhesion molecules on endothelial cells leading to increased leukocyte extravasation 
(Channual J et al, 2009). 
Given that TNF-a show a pivotal role in many inflammatory conditions and that it 
represents one of possible link between psoriasis and metabolic syndrome, theoretically the 
TNF-alpha blockade might have a widespread potential in the treatment of both 
pathological entities (Channual J et al, 2009). 
Although it is well known the TNF-alpha inhibitors efficacy on PsO and Psoriatic arthritis 
(PsA), little is known about their effects on the MetS components in PsO patients. 
Currently, three available in the United States are approved for psoriasis and psoriatic 
arthritis (PsA): infliximab, etanercept, and adalimumab (Channual J et al, 2009). 
Infliximab is a chimeric monoclonal antibody binding the human tumor necrosis factor 
alpha (Staidle JP et al, 2011). 
Actually there are no data in literature about infliximab effect on insulin resistance or 
sensitivity in PsO patients. 
About lipid profiles, studies have shown that infliximab does not significantly modify total 
cholesterol, triglycerides and,  interestingly, the patient’s lipid profile reverted to baseline 
values after infliximab discontinuation (Gisondi P et al, 2008;  Antoniou KM et al, 2008). 
Studies investigating the effect of infliximab on body weight have reported significant 
increase in weight gain and in BMI, without  differences among males and females 
(Saraceno R et al, 2009). 
Etanercept is a fusion protein consisting of two molecules of extracellular domain of  human 
p75 TNF-alpha receptor attached to the Fc domain of  human immunoglobulin G1 (IgG1), 
that binds to TNF-alpha with greater affinity than natural receptor. The binding makes TNF-
alpha  biologically inactive, with consequent reduction of inflammation (Weinberg JM, 
2003). 
Although there are conflicting results on the effect of Etanercept in insulin-resistance, 
etanercept have shown an interesting action on reducing serum insulin levels and 
improving insulin sensitivity. Similar to Infliximab, Etanercept does not significantly modify 
lipid profiles; furthermore, PsO patients treated by etanercept gradually and progressively 
gain weight, in particular lean ones (Marra M et al, 2007). 
Adalimumab is human monoclonal antibody against TNF-alpha (Staidle JP et al, 2011). 
Although there are no reports in literature discussing about adalimumab effect on insulin 
resistance or sensitivity in PsO patients, a recent case revealed episodes of hyperglycemia in 
 
Metabolic Features in Psoriasis 117 
a PsO-PsA patient; these increased serum glucose levels resolved after adalimumab 
discontinuation (Wu JJ et al, 2008). 
Similar to Infliximab and Etanercept, Adalimumab does not modify lipid profiles and it 
increases BMI and weight gain (Saraceno R et al, 2009). 
10. Conclusion  
Despite further studies on anti-TNF-alpha drug effect on MetS syndrome are required, an 
examination of literature data suggest that the combined effects of improved insulin 
resistance and sensitivity and a significant reduction in systemic inflammation  may 
interrupt inflammatory cascade linking PsO and MetS. 
Taking into consideration the high potentiality of biological therapies to reduce the 
metabolic effect of TNF-alpha, the future goal might be to demonstrate a real in vivo 
preventing effect on development of cardiovascular comorbidities in Pso/PsA patients. For 
these reason other longitudinal long term clinical studies are needed.  
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Taking into consideration the high potentiality of biological therapies to reduce the 
metabolic effect of TNF-alpha, the future goal might be to demonstrate a real in vivo 
preventing effect on development of cardiovascular comorbidities in Pso/PsA patients. For 
these reason other longitudinal long term clinical studies are needed.  
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1. Introduction  
Psoriasis is a chronic, inflammatory disease affecting the skin and potentially the joints. Both 
genetic and environmental factors are important in the etiology of the disease. Psoriasis is 
characterized by keratinocyte hyperproliferation, abnormal keratinocyte differentiation, and 
immune-cell infiltration into the epidermis and dermis.  
Disease management is dependent on severity, psychosocial effects and the patient's 
lifestyle. Currently, psoriasis may be treated with phototherapy or by using various topical, 
systemic, and biologic drug treatments. Topical treatments include creams and ointments 
containing tar, dithranol, corticosteroids, salicylic acid or vitamin D-related compounds.  
Vitamin D3 analogs inhibit proliferation, induce terminal differentiation of human 
keratinocytes and exhibit immunomodulating properties. Several studies have shown 
vitamin D analogs to be a safe, efficacious and long-term treatment option for psoriasis. 
Vitamin D3 analogs are also used in combination with phototherapy. 
Phototherapy (broadband UVB, narrowband UVB (NBUVB) and heliotherapy – treatment 
with natural sunlight) is a commonly used treatment modality for widespread psoriasis. A 
similar wavelength spectrum of UVB (280-315 nm) is responsible for vitamin D synthesis in 
the skin. Vitamin D3, or cholecalciferol, is produced from 7-dehydrocholesterol in the basal 
epidermis when exposed to UVB, and is then hydroxylated in the liver into 25-
hydroxyvitamin D [25(OH)D], which is the major circulating metabolite. Further 
hydroxylation into 1,25-dihydroxyvitamin D [1,25(OH)2D] occurs primarily in the kidneys. 
Hydroxylation in the kidneys is stimulated by parathyroid hormone (PTH) and suppressed 
by phosphate. Homeostatic mechanisms include parathyroid activity, serum calcium and 
serum 1,25(OH)2D3 itself. Vitamin D is an essential steroid not only for calcium homeostasis 
and skeletal health, but also for regulation of cellular growth, cell proliferation and cell 
differentiation. Vitamin D is obtained by skin production in response to UVB or by intake of 
vitamin D rich food or supplements. Vitamin D status is measured by serum/blood 
concentration of its metabolite 25(OH)D.  
The wavelength spectrum of UVB responsible for vitamin D synthesis (broadband UVB, 
290-320 nm) has been used successfully for years to treat psoriasis and other chronic 
inflammatory skin disorders. This chapter aims to increase knowledge about the effects of 
UVB on vitamin D production during treatment with phototherapy in patients with 
psoriasis and to investigate the impact of UVB-induced vitamin D on psoriasis, bone, lipid 
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UVB on vitamin D production during treatment with phototherapy in patients with 





and carbohydrate status in psoriasis patients. A review of the published studies will be used 
to accomplish this task. In our previously published studies, the serum concentrations of 
25(OH)D, 1,25(OH)2D, PTH, calcium and creatinine were measured before and after 
phototherapy in Caucasian patients with moderate to severe active plaque psoriasis. Bone 
mineral density (BMD) was examined using dual-energy X-ray absorptiometry (DEXA) at 
the hip and lumbar spine in a group of postmenopausal women with psoriasis. Lipid and 
carbohydrate status were assessed in patients treated with heliotherapy. 
We found that UVB/heliotherapy improved the psoriasis score and lipid and carbohydrate 
status of the patients, increased serum 25(OH)D synthesis and reduced serum PTH 
concentrations. Vitamin D production in psoriasis patients increased less with narrowband 
UVB than with broadband UVB phototherapy. There was no correlation between the dose of 
UVB and the increase in 25(OH)D. The ratio of low density lipoprotein (LDL) and high 
density lipoprotein (HDL) cholesterol decreased, and the levels of glycosylated hemoglobin 
A1c (HbA1c) also decreased in psoriasis patients during heliotherapy. Postmenopausal 
women with psoriasis had higher BMD than age-matched controls, a finding that could be 
related to their higher body weight, levels of physical activity and UVB exposure.  
The changes in serum concentrations of vitamin D metabolite 25(OH)D were not related to 
the degree of improvement in psoriasis severity. This can be explained by the fact that 
25(OH)D is biologically inert. It is unclear if the serum 25(OH)D level is linked to the level of 
the active form of vitamin D3 (1,25(OH)2D) present in the skin. It has been suggested that 
cutaneous conversion of 25(OH)D to 1,25(OH)2D does not play a role because the amount of 
free 25(OH)D3 that penetrates the cell membrane of epidermal keratinocytes is too small to 
produce sufficient amounts of 1,25(OH)2D. Therefore, of great interest will be the study of 
UVB induced local effects on vitamin D synthesis and metabolism in psoriatic skin.  
2. Content 
2.1 Vitamin D, skin production and metabolism 
Vitamin D or calciferol refers to cholecalciferol or vitamin D3 and ergocalciferol or vitamin 
D2. D3 is produced in the skin as a result of ultraviolet irradiation of  7-dehydrocholesterol 
(7-DHC) and D2 is produced by ultraviolet irradiation of the plant sterol ergosterol(1). 
Vitamin D was discovered in the 1900's as a result of research efforts geared towards the 
treatment of the disease, rickets. Within the last decade, vitamin D has become a popular 
topic in medical research as investigators aim to elucidate the role it plays in both 
maintaining health and contributing to the onset of disease. 
Most people obtain their vitamin D requirement from sunlight exposure (2) in addition to 
smaller amounts obtained through the diet since very few foods naturally contain vitamin D.  
7-DHC absorbs ultraviolet B (UVB) radiation and optimum wavelengths for vitamin D3 
production are between 295 nm and 300 nm with a peak at 297 nm(3). Levels of 7-DHC have 
been observed to decline with age, which might negatively impact vitamin D3 synthesis in 
the skin (2). Vitamin D3 produced in the skin or ingested from the diet can be stored in body 
fat and later released into circulation. Vitamin D3 is sequestered deep into body fat, making 
it less bioavailable in obese individuals(4). Vitamin D is biologically inert and must be 
hydroxylated in the liver to form 25-hydroxyvitamin D [25(OH)D or calcidiol], which is the 
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major circulating metabolite. Further hydroxylation into 1,25-dihydroxyvitamin D 
[1,25(OH)2D or calcitriol] occurs primarily in the kidneys (Figure 1). Hydroxylation in the 
kidneys is stimulated by parathyroid hormone (PTH) and suppressed by phosphate. 
Homeostatic mechanisms include parathyroid activity, serum calcium and serum 
1,25(OH)2D itself. Conversion of vitamin D to 25(OH)D is mediated by the enzyme vitamin 
D-25-hydroxylase (CYP27A1). The synthesis and degradation of calcitriol are regulated by 
the enzymes 25(OH)D-1-α-hydroxylase (CYP27B1) and 25(OH)2D-24-hydroxylase 
(CYP24A1), respectively. The combined activity of these enzymes is an important factor in 
determining the circulating concentrations of 25(OH)D, and 1,25(OH)2D(1). In addition to 
the kidney, other tissues and cells, including keratinocytes and immune cells, contain these 
enzymes and are able to convert 25(OH)D to active 1,25(OH)2D(5). 
Besides being an essential steroid for calcium homeostasis and skeletal health, vitamin D 
also plays a role in regulation of cellular growth, cell proliferation and cell differentiation. 
Vitamin D also regulates the immune system, controls cancer cell growth and plays a role in 
the regulation of blood pressure(6). These effects are mediated through the intracellularly 
located vitamin D receptor (VDR). VDR is a member of the steroid, estrogen and retinoid 
receptor gene family of proteins that mediate transcriptional activities of the respective 
ligands. The VDR complex interacts with vitamin D responsive elements on the target gene. 
Alterations in calcitriol levels and polymorphisms of the VDR gene have been shown to be 
associated with several malignant and autoimmune diseases including psoriasis vulgaris(7).  
25(OH)D is used clinically to measure vitamin D status. The cut-off level for serum 
25(OH)D, which is used as a diagnostic marker for vitamin D deficiency, has varied over the 
years(8-10). The early biochemical changes in vitamin D insufficiency include a rise in serum 
PTH, which begins to increase as serum 25(OH)D levels fall below 30 ng/ml or 75 
nmol/l(9). This level of 25(OH)D has become the suggested cut-off point for vitamin D 
deficiency or inadequacy(9, 11-13). At the present time, there is no clear consensus regarding 
levels of 25(OH)D for optimal health but levels of  > 50 nmol/l (20 ng/ml)(14) and > 75 
nmol/l (30 ng/ml)  have been based on considering the outcomes of bone health, fracture 
prevention and colorectal cancer(15,16). Sun exposure is the strongest factor influencing 
25(OH)D. The serum concentrations of 25(OH)D vary seasonally, with maximum and 
minimum values in the late summer and  winter respectively(17). The extent of this seasonal 
variation depends on factors such as latitude, skin pigmentation, clothing, and the use of 
sunscreen(18).  
Currently, limited data is available on the role of vitamin D deficiency in the pathogenesis or 
outcomes of psoriasis. The lack of conclusive data combined with vitamin D’s 
immunomodulatory role, warrants further research investigating the role of vitamin D 
insufficiency in chronic diseases as well as monitoring 25(OH)D levels in children and 
adults of all ages as a part of routine physical examinations.  
2.2 The effects of vitamin D in psoriasis 
Vitamin D has pleotropic functions; it acts as a hormone by controlling calcium homeostasis 
as well as exerting autocrine/paracrine effects on tissues that express CYP27B1 and VDR. 
Besides its local effects, calcitriol may also act in psoriasis through its immunomodulatory 
properties by inhibiting T-cell proliferation and Th1 development, modulating antigen-
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major circulating metabolite. Further hydroxylation into 1,25-dihydroxyvitamin D 
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variation depends on factors such as latitude, skin pigmentation, clothing, and the use of 
sunscreen(18).  
Currently, limited data is available on the role of vitamin D deficiency in the pathogenesis or 
outcomes of psoriasis. The lack of conclusive data combined with vitamin D’s 
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2.2 The effects of vitamin D in psoriasis 
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as well as exerting autocrine/paracrine effects on tissues that express CYP27B1 and VDR. 
Besides its local effects, calcitriol may also act in psoriasis through its immunomodulatory 
properties by inhibiting T-cell proliferation and Th1 development, modulating antigen-





production of IL-2, IL-17, IL-8 and interferon-γ, increasing the production of IL-10 and 
regulatory T cells(19, 20). Calcitriol has also been suggested to reduce production of 
interferon-α in some cells(21). Calcitriol is involved in the regulation of antimicrobial 
peptides cathelicidin and human β-defensin 2 (HBD2), which both participate in the 
pathogenesis of psoriasis (22). Vitamin D’s role in psoriasis is further supported by studies 
that confirm the link between VDR polymorphism and psoriasis (23, 24). An association 
between VDR genotypes (Apa1) and the mean age at onset of psoriasis were previously 
observed (25). Since VDR gene polymorphisms show ethnic variability, concern arises on 
how to treat psoriasis patients of different populations according to their potentially varied 
treatment response (26). Moreover, it has been demonstrated that VDR gene polymorphisms 
may also play a role in partial resistance to calcipotriol therapy (24). 
There are few studies on high-dose vitamin D3 in the treatment of psoriasis while systemic 
administration of 1,25(OH)2D for the treatment of psoriasis might be limited by its toxicity. 
A number of small trials show the efficacy and safety of vitamin D metabolites in the 
treatment of psoriasis and psoriatic arthritis (27-29). Systemic calcitriol treatment had an 
immunomodulatory effect manifested by a short-term temporary decrease in type 1 immune 
responses and a decrease in disease activity in patients with psoriatic arthropathy (27). 
Administration of vitamin D3 could be a better option than calcitriol or alphacalcidol since it 
is safer and less expensive, although more studies are needed to assess its efficacy (21). 
However, the use of calcitiol in dermatology is hampered by its hypercalcemic activity. 
There is limited information on the role of vitamin D deficiency in the pathogenesis of 
psoriasis or the role of vitamin D deficiency in response to treatments with topical or 
systemic drugs. There is a report of resolution of anti-TNFα-induced psoriasiform lesions by 
high doses of vitamin D3, in a patient with rheumatoid arthritis and vitamin D deficiency 
(21). More studies are needed to assess the possible usefulness of high-dose vitamin D3 in 
the treatment of psoriasis.  
2.3 Effects of vitamin D3 analogues in psoriasis 
The observation that keratinocytes and T cells express VDR and that 1,25(OH)2D is a potent 
stimulator of keratinocyte differentiation provides a potential basis for the clinical use of 
VDR ligands for the treatment of psoriasis (30, 31). Clinical data that first supported the use 
of vitamin D analogs was obtained when a patient treated orally with 1-hydroxyvitamin D3 
for osteoporosis showed remarkable remission of psoriatic lesions(32). In addition, 
promising clinical results were obtained in studies using oral 1-hydroxyvitamin D3, oral and 
topical calcitriol which led to improvement of psoriatic lesions in approximately 70-80% of 
patients (33). Vitamin D3 analogs (calcipotriol (Dovonex), calcitriol (Silkis) or tacalcitol 
(Curatoderm)) inhibit proliferation, induce terminal differentiation of human keratinocytes 
and exhibit immunomodulating properties (33). Differentiation of keratinocytes results in 
the formation of a cornified envelope (CE) that provides the barrier function of the skin. The 
expression of involucrin, a component of the CE, and transglutaminase I (TGase I), the 
enzyme that cross-links the components of CE, was increased by calcitriol and other VDR 
ligands(35). Treatment of keratinocytes with a medium containing high calcium also 
stimulated keratinocyte differentiation by increasing the expression of involucrin and TGase 
I. 1,25(OH)2D also promoted keratinocyte differentiation, at least in part by increasing 
intracellular calcium and by increased expression of calcium receptors in keratinocytes(36). 
Calcitriol indirectly induces the expression of keratin 1, involucrin, TGase I, loricrin, and 
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filaggrin, which are required for CE formation. VDR ligands decreased the expression of 
proinflammatory cytokines IL-2, IFN-γ, IL-6, IL-8 (37-40) and proliferation of T lymphocytes 
and keratinocytes. Furthermore, topical calcipotriol increased anti-inflammatory cytokine 
IL-10 in psoriatic lesions(41), and  increased the expression of IL-10 receptor in 
keratinocytes(42).  
Antigen presenting cells (APCs), which play an important role in psoriasis, are one of the 
major targets of calcitriol-mediated immunosuppressive action (43). VDR ligands prevent 
the activation, differentiation, maturation and survival of APCs, leading to T cell 
hyporesponsiveness(44). Calcitriol also increased the expression of IL-10 and decreased the 
expression of IL-12, two major cytokines that are involved in Th1-Th2 balance(45).  
Several studies have shown that calcipotriol as well as calcitriol and tacalcitol are 
efficacious, safe and can be used on a long-term basis for psoriasis (43, 46-49). Vitamin D3 
analogs can be used in combination with phototherapy(50).  
2.4 Vitamin D status in patients with psoriasis 
Few studies on vitamin D status and its role in psoriasis have been performed or published. 
Low vitamin D status is associated with an increased risk of cancer, autoimmune, infectious, 
and inflammatory diseases, although the role of vitamin D status in the pathogenesis of 
psoriasis is unknown.  
3. The effects of phototherapy on vitamin D status in patients with psoriasis  
A similar wavelength spectrum of UVB is responsible for vitamin D synthesis (280-315 nm), 
which has been successfully used for years to treat psoriasis and other chronic inflammatory 
skin disorders. 
Phototherapy (broadband UVB, narrowband UVB and heliotherapy - treatment with natural 
sunlight) is an effective treatment, commonly used for widespread psoriasis. Therefore, 
phototherapy is an excellent option for patients with generalized psoriasis because of its 
superior systemic safety profile in comparison to systemic and biologic agents (51).  
In addition to standard broadband ultraviolet radiation B (BUVB), (280-315 nm), 
narrowband phototherapy (NBUVB) (monochromatic UV between 311-312 nm) and 
heliotherapy (treatment with natural sunlight) have become important treatment modalities 
for psoriasis. Research suggests that NBUVB is more effective than broadband UVB for 
reducing PASI scores, as well as being a safer and better tolerated option for patients in 
comparison to PUVA when taken at suberythemogenic doses (52). Furthermore, these 
advantages along with the handling ease of the NBUVB lamp led to a reduction in the usage 
of broadband UVB. However, one drawback of the new lamp is that the radiation times 
have almost doubled (54). Additionally, several studies indicate that combination therapy 
using both calcipotriol and UVB radiation illustrate more rapid healing of psoriasis when 
compared to monotherapy of either treatment (50,55).  
Serum levels of 25(OH)D increased during treatment with artificial UV (BUVB and  
NBUVB) and during heliotherapy(56-59). The increase in 25(OH)D was higher in the BUVB 
treated patients when compared to the NBUVB (p=0.008)  and heliotherapy (p=0.017) 
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advantages along with the handling ease of the NBUVB lamp led to a reduction in the usage 
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patients with psoriasis, atopic eczema and other skin disorders with low initial levels of 
25(OH)D(60, 61). Within the following intervention studies, age showed no correlation with 
the observed increase in 25(OH)D levels (57, 58, 62). This indicates the skin’s capacity to 
produce vitamin D3 during phototherapy of psoriasis is independent of the patient’s age or 
psoriasis severity. Phototherapy of psoriasis is the time-consuming procedure long enough 
to provide adequate cutaneous production of vitamin D even in elderly patients. The ability 
of the skin to produce vitamin D declines with age (63) due to insufficient sunlight exposure 
(11, 64) and a reduction in the functional production capacity of the skin(63, 65, 66). The 
increase in 25(OH)D3 was enhanced in patients with low baseline levels of vitamin D. 
Vitamin D production in patients with psoriasis increased less with NBUVB than with 
BUVB phototherapy(58). One explanation might be that the optimal wavelength for 
initiation of the vitamin D3 pathway was 300±5 nm in vitro and in vivo(67, 68) which is in 
the BUVB range (280-315 nm). The synthesis of vitamin D was stimulated by wavelengths 
between 290-315 nm, but not for wavelengths longer than 315 nm. One study (58) reported 
that a wavelength of 311 nm effectively induced vitamin D synthesis, but not to the same 
extent as wavelengths in the BUVB range. UVB treatment including NBUVB treatment of 
psoriasis was a sufficiently time-consuming procedure to increase vitamin D. The time 
required for NBUVB to have an effect can reduce the difference in the potential of vitamin D 
production between the two lamps. The treatment time correlated strongly with the type of 
lamp (patients treated with NBUVB required 4 times the exposure patients treated with 
BUVB needed). This is consistent with other studies demonstrating that the dose response of 
the erythemal spectra of NBUVB should be about 4.2 times that of BUVB(69). The dose of 
UVB also correlated with the type of lamp, but no correlation between the dose of UVB and 
the increase of 25(OH)D3 levels was found (58). This might be due to the fact that serum 
concentrations of 25(OH)D3 were measured at different time points and a plateau level was 
reached after three weeks, which was also seen in a previous study(70). An in vitro study 
demonstrated that the dose-response relationship of UV exposure and cholecalciferol 
synthesis was nonlinear. It was hypothesized that exposure to additional UV did not result 
in a proportional increase in vitamin D levels(71). This might be explained by 
autoregulation of the skin synthesis, storage, and slow, steady release of vitamin D3 from 
the skin into the circulation(3). Non-linear vitamin D synthesis is easily explained by the 
photo equilibrium that is set up as a result of continued exposure to ultraviolet radiation as 
reported by Holick et al(72). Vitamin D production is a unique, autoregulated mechanism 
which occurs at two levels. Excessive sun exposure does not lead to overdosing of vitamin 
D3 due to conversion of previtamin D3 to inactive photoproducts (lumisterol 3 and 
tachisterol 3) as well as conversion of vitamin D3 to its isomers in the skin (5,6-trans vitamin 
D3, suprasterol I, suprasterol II) which are thought to have a low calcemic effect at 
physiological concentrations. The synthesis of previtamin D3 reached a plateau at about 10 
to 15 percent of the original 7-dehydrocholesterol content(72). Vitamin D3 is synthesized in 
the skin and released steadily and slowly from the skin into the circulation(3).  
In a study by Ryan, the number of exposures to NBUVB was the sole predictor of an 
increase in serum 25(OH)D level, whereas prior phototherapy was the only predictor of 
baseline serum 25(OH)D levels in the group of psoriasis patients treated with 
phototherapy(73). 
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Patients with lower 25(OH)D levels at baseline responded better to sunlight and 
phototherapy which is consistent with other studies(3, 6, 57). All patients reached serum 
levels of 30 ng/ml (75 nmol/l) after two weeks of sun exposure(62). A circulating level of 
25(OH)D of >30 ng/ml, or >75 nmol/L, appears to be necessary to maximize the health 
benefits of vitamin D(6).  
Sun exposure is the major source of vitamin D for most humans(6). During the winter 
months vitamin D production is insufficient to meet the optimal requirements in both 
younger and older adults at Northern latitudes(74). Psoriasis lesions usually worsen during 
winter, and many patients are therefore given repeated UVB treatment during this season. 
In addition to healing psoriatic lesions, UVB therapy also provides these patients with 
vitamin D during the winter months, when levels of 25(OH)D in Northern countries are 
generally low. UVB therapy even increased serum 25(OH)D levels in patients taking vitamin 
D supplements. This is in line with previous studies, which reported that UV-induced 
vitamin D synthesis had a greater influence on the serum levels of circulating calcidiol than 
the per oral intake of supplements(75, 76).  
Skin pigment, sunscreen use, aging, time of day, season, and latitude all affect previtamin 
D3 synthesis(18). There was no difference in the increase of 25(OH)D between the different 
skin types in the present studies(59). This was most likely due to subjects being exposed to 
individually adjusted doses of UVB depending on skin phototype and erythemal response 
to therapy. All patients had previously experienced UVB therapy for their psoriasis disease. 
As expected, fair-skinned patients required lower doses of UVB (broadband and 
narrowband) than patients with skin type III and IV. This finding is consistent with other 
studies examining the effect of skin pigmentation on vitamin D synthesis(77). Melanin 
pigment in human skin competes with, and absorbs  UVB photons responsible for the 
vitamin D synthesis(77). 
The increase in 25(OH)D during the first two weeks of heliotherapy was very similar to the 
increase in 25(OH)D during treatment with BUVB and NBUVB for two to three months. The 
correlation between sunlight measures and serum 25(OH)D is evidently weak(78). Patients 
reached their plateau of daily sun exposure after the first week. It is likely that vitamin D 
production was most prominent during the first week, when the patients experienced 
redness and some of them even got sunburned(56).  
The increase in 25(OH)D during 15 days of climate therapy was significant even though 
patients used sunscreen on body sites susceptible to sunburn, and though the skin was 
affected by psoriasis lesions(56, 62). This indicates that short-term therapeutic UVB 
exposures are sufficient to increase vitamin D synthesis in psoriasis patients. SPF-8 
sunscreen has been observed to reduce the skin's production of vitamin D3 by 95%(79). 
Clothing also completely blocks all solar UVB radiation and thereby prevents vitamin D3 
production(79).  
Psoriasis improved in all patients, with a reduction in the PASI score of about 75% on all 
regimens(59, 73). Improvement in psoriasis correlated positively with the increase in 
25(OH)D3 levels in one (58) (p=0.047; the group of patients treated with BUVB and  
NBUVB) but not in the other studies (57, 61, 62, 73). There was no correlation between 
change in serum 25(OH)D levels and change in PASI or change in DLQI in the study of 
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Patients with lower 25(OH)D levels at baseline responded better to sunlight and 
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levels of 25(OH)D and psoriasis but a negative correlation was found between the severity 
of psoriasis and the basal serum level of 1,25(OH)2D(80).  
The skin is the only tissue yet known in which the complete UVB-induced pathway from 7-
DHC via intermediates (previtamin D3, vitamin D3, 25(OH)D) to the final product 
1,25(OH)2D, takes place under physiological conditions(81), (Figure 1). Levels of 
1,25(OH)2D tended to increase during phototherapy, but significant increases were noticed 
only during heliotherapy, and only in women with 25(OH)D3 below 30 ng/ml, and in ages 
≥ 70 years. One explanation might be that these patients had lower serum concentrations of 
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Fig. 1. Schematic outline of vitamin D metabolism and mechanism of action in psoriasis. 
It has been postulated that the synthesis of 1,25(OH)2D is tightly regulated, and that 
increases in 25(OH)D concentrations due to exposure to sunlight have no effect on serum 
1,25(OH)2D levels(6, 82). The observation that both 25(OH)D and 1,25(OH)2D increased in 
vitamin D deficient subjects following UVB exposure(83) or after vitamin D 
supplementation(84) has been reported previously. The increase of 1,25(OH)2D levels 
between patients treated with heliotherapy and patients treated with NBUVB differed 
(p=0.02). This might be explained by lower values of 25(OH)D at baseline in patients treated 
with heliotherapy(59). 
Keratinocytes are capable of producing a variety of vitamin D metabolites, including 
1,25(OH)2D, 24,25(OH)2D, 1,24,25(OH)3D(85) from exogenous and endogenous sources of 
25(OH)D. Thus, the local UVB-triggered production of calcitriol may primarily regulate 
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epidermal cellular functions in an auto- and paracrine manner, but this should not be crucial 
for systemic vitamin D effects (5) and systemic vitamin D deficiency does not stimulate 
epidermal synthesis of 1,25(OH)2D(86).  
Cutaneous production of 1,25(OH)2D3 may regulate growth, differentiation, apoptosis and 
other biological processes in the skin(87, 88). Therefore, topical vitamin D analogs have been 
used as a safe and effective treatment for psoriasis vulgaris(89, 90). The NBUVB has been 
shown to have less capacity to induce a local skin production of 1,25(OH)2D3 at 44% of the 
monochromatic irradiation at 300 ±2.5 nm(68). Nevertheless, the known therapeutic effect of 
UVB light therapy for the treatment of psoriasis may be mediated via UVB-induced 
production of 1,25(OH)2D(81). In vitro studies have shown that the substrate concentration 
of cholecalciferol in keratinocytes mainly determines the synthesis rate of 1,25(OH)2D in 
these cells(91). Thus, higher synthesis rates of cholecalciferol should result in a faster and 
more pronounced release of 1,25(OH)2D into the extracellular fluid. UVB-induced 
membrane damage to epidermal keratinocytes may also increase the outflow of newly 
synthesized calcitriol(92).  
It is not clear if the serum 25(OH)D level is linked to the level of the active form of vitamin 
D3 present in the skin. It has been suggested that cutaneous conversion of 25(OH)D to 
1,25(OH)2D does not play a role because the amount of free 25(OH)D3 that penetrates the 
cell membrane of epidermal keratinocytes is too small to produce sufficient amounts of 
1,25(OH)2D(88). The main form of circulating 25(OH)D is presented in a complex with 
vitamin D-binding protein (DBP) with only a very small amount (0.03%) available as the free 
form. Furthermore, the deeper layers of the epidermis are not vascularized, which further 
impairs the passage of the 25(OH)D3-DBP complex from blood to epidermal 
keratinocytes(88).  
The receptor for calcitriol and the production of 1,25(OH)2D vary with the differentiation 
in a manner suggesting feedback regulation, and both are reduced in the later stages of 
differentiation(93). 1,25(OH)2D increases involucrin, transglutaminase activity, and 
cornified envelope formation in preconfluent keratinocytes(94). NBUVB treatment 
increases cathelicidin and decreases HBD2 levels in healing skin lesions of psoriasis and 
atopic dermatitis(61). It has been shown that HBD2 and cathelicidin expression in 
psoriatic skin are higher in serum vitamin D sufficient patients than in serum vitamin D 
deficient psoriasis patients(95). 
The 1,25(OH)2D molecule and its analogs, as well as UVB phototherapy, exert 
antiproliferative, prodifferentiative, and immune-modulatory effects on keratinocytes that 
are of particular importance for the therapy of hyperproliferative skin diseases such as 
psoriasis vulgaris(5, 96). However, the full range of UVB and vitamin D3 effects is not 
completely understood.  
4. Serum PTH in psoriasis patients during treatment with phototherapy 
PTH decreased after the treatment with phototherapy(57). 25(OH)D concentrations below 30 
ng/ml (75 nmol/l) resulted in secondary hyperparathyroidism and a decrease in BMD(97). 
PTH increases with increasing age, possibly due to less sunlight exposure and/or reduced 
calcium/vitamin D intake(98). The clear concomitant decrease in serum PTH after UVB 
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older ages and with part of the skin covered by psoriatic lesions. Serum concentrations of 
calcium and creatinine were unaltered after phototherapy(58). 
5. Bone status in patients with psoriasis treated with UVB phototherapy 
Multiple risk factors that contribute to low serum 25(OH)D and osteoporosis have been 
identified. They include inadequate sun exposure(99), insufficient intake of fortified foods or 
vitamin D supplements(100), low body mass index, white ethnicity, lack of exercise, use of 
medications that accelerate vitamin D metabolism, diseases that alter vitamin D metabolism 
such as malabsorption syndromes, and chronic liver disease(9, 13, 101).  
Information regarding the prevalence of osteoporosis in addition to the epidemiological 
study of risk factors for developing osteoporosis among psoriasis patients has been sparse 
and controversial. Psoriasis patients with or without arthritis may suffer from 
osteoporosis(102). However, a previous study showed that patients with chronic plaque 
psoriasis had a low BMD despite risk factors, although the subgroup with joint involvement 
appeared to be at a higher risk of developing osteoporosis and therefore required 
prevention therapy(103). Reduced BMD has been linked to palmoplantar pustular 
psoriasis(104). The existence of less severe periarticular osteoporosis has also been 
reported(105). Psoriasis patients with peripheral arthritis with longer duration of joint 
disease(106) and patients with a greater number of affected joints are at a higher risk of 
developing osteoporosis(102).In a study by Pedreira, patients with psoriasis and psoriatic 
arthritis did not present with a lower BMD, but they had a higher prevalence of osteoporotic 
fractures and were at a higher risk of developing metabolic syndrome(107).  
Postmenopausal women with psoriasis treated with phototherapy had higher BMD of both 
the hip and lumbar spine compared with age-matched controls (57, 108). In the same 
study(108), patients with 25(OH)D levels below 30 ng/ml and secondary 
hyperparathyroidism had lower BMD in terms of both T and Z scores of the hip and the 
lumbar spine compared with those with higher vitamin D levels, consistent with another 
study(109). No relationship between psoriasis onset and bone status was found. Higher 
body weight and BMI are factors, which may have contributed to the higher BMD in 
patients(108) compared with controls 
In general, bone loss increases with age. BMD has been shown to be a predictive indicator 
for bone fractures in healthy subjects and in patients with osteoporosis(111). 
A family history of fractures, physical activity, smoking and estrogen substitution are 
important factors influencing bone mass(112-114). Low body weight is related to low 
skeletal muscle mass and an increased risk of fractures(114, 115). Muscle tissue and strength 
are important for body balance and the prevention of falls(116). Previous studies confirm the 
protective effect of weight gain against fractures(17).  
Physical activity correlated positively with BMD in psoriasis patients(108). Physical activity 
has been claimed to be beneficial for bone mass and protective against fractures(117). 
Regular walking in middle-aged and elderly women is associated with a reduced risk of 
vertebral deformity(118). Subjects who took a daily walk of at least 30 min had a 
significantly better climbing capacity, higher BMD and lower concentration of serum 
triglycerides than subjects who walked less(119). Lifetime exercise was also positively 
associated with BMD of the hip(120). 
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Vitamin D is important for bone metabolism(121). Vitamin D deficiency thus contributes to 
the pathogenesis of osteoporosis and hip fractures(122). Supplementation strategies 
involving calcium and vitamin D supplements are cost-effective for preventing osteoporotic 
fractures(123). 
The same range of UVB (290–315 nm) that induces vitamin D synthesis also improves 
psoriasis. Treatment with UVB in patients with psoriasis is most common during winter 
months when UVB is lacking, and levels of vitamin D are low in Northern countries(123). 
Furthermore, UVB therapy heals psoriasis and supplies these patients with vitamin D at 
levels similar to those of the general population(123), which might have positive effects on 
bone status as well. 
6. Blood glucose and lipid status in psoriasis patients during treatment with 
heliotherapy  
Psoriasis is considered a chronic and debilitating inflammatory disease associated with 
serious comorbidities (124, 125). Large epidemiological studies have shown that psoriasis 
and psoriatic arthritis are associated with metabolic diseases including obesity, dyslipidemia 
and diabetes(126). The chronic inflammation in psoriasis can predispose patients to other 
inflammatory conditions. The proinflammatory cytokines, such as tumor necrosis factor- 
(TNF-), and other factors that are overproduced in patients with psoriasis likely contribute 
to the increased risk for the development of metabolic syndrome(127, 128).  
Inflammatory factors have also been associated with insulin resistance and β-cell failure, 
both of which are key features of type 2 diabetes mellitus (129). There is evidence that 
vitamin D may stimulate pancreatic insulin secretion directly through nuclear receptors that 
are found in a wide variety of tissues, including T and B lymphocytes, skeletal muscle, and 
the pancreatic islet  β-cells(130). There is some evidence that suggests increased PTH activity 
is associated with, and possibly causes, reduced insulin sensitivity(130). The prevalence of 
impaired glucose tolerance and diabetes mellitus is increased in patients with primary 
hyperparathyroidism (131, 132). 
Vitamin D has a wide range of effects on the immune system: it promotes the differentiation of 
monocytes into macrophages thus increasing their cytotoxic activity; reduces the antigen-
presenting activity of macrophages to lymphocytes; prevents dendritic cell maturation; 
inhibits T lymphocyte-mediated immunoglobulin synthesis in B cells and inhibits delayed-
type hypersensitivity reactions(8, 133, 134). Furthermore vitamin D has been reported to 
down-regulate the production of several cytokines: IL-2, IL-6 and IL-12, interferon-γ, TNF-α, 
and TNF-β (134, 135). Alternations in vitamin D status and/or action may affect insulin 
sensitivity, β-cell function or both. Therefore, vitamin D may be involved in the pathogenesis 
of type 2 diabetes mellitus at both environmental and genetic levels(129). Psoriasis patients are 
more likely to be insulin resistant and to have impaired glucose tolerance, higher fasting 
insulin levels, and impaired β-cell function than non-psoriatic subjects(136).  
Heliotherapy improves lipid and carbohydrate status of psoriasis patients(56). Increases in 
high-density lipoprotein (HDL)-cholesterol and decreases in HbA1c during climate therapy 
could be explained by several factors. One possible mechanism could be a direct effect of 
vitamin D on insulin sensitivity(130). Another is that sun exposure usually implies greater 
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unrelated to serum 25(OH)D concentrations(130). Diet might also influence glucose and 
lipid metabolism. Although climate therapy did not change the basal glucose levels of the 
patients, the HbA1c levels decreased about 10 %, indicating improved insulin sensitivity 
(56). The observed associations between vitamin D, insulin, and glucose metabolism in 
humans have not yet been confirmed by intervention studies and, hence, a causal 
association has not been established(130).  
A high prevalence of atherosclerosis is also reported in psoriasis patients. High serum lipid 
levels have been suggested in the pathogenesis of atherosclerosis. High serum lipid levels 
are more common in psoriasis and may be responsible for an elevated prevalence of 
cardiovascular accidents in this group of patients(137). Patients with psoriasis exhibit a 
dyslipidemic profile, including increased levels of plasma cholesterol, triglycerides (TG), 
LDL, very low-density lipoprotein (VLDL) cholesterol and decreased levels of HDL 
cholesterol. Lipid abnormalities in psoriasis patients may be genetically determined(138). 
The ratio of low-density lipoprotein cholesterol (LDL) and high-density lipoprotein 
cholesterol (HDL) decreased, and the levels of hemoglobin A1c (HbA1c) also decreased in 
psoriasis patients during heliotherapy(56). Serum concentrations of 25(OH)D at baseline in 
psoriasis patients treated with heliotherapy correlated positively with serum HDL at 
baseline(56), consistent with a previously published study(139).  
Psoriasis is associated with obesity, which is a component of metabolic syndrome. Obesity 
has been shown to be an independent risk factor for the development of psoriasis, and is 
also associated with more severe psoriasis (140). Abdominal obesity is a proinflammatory 
state with the visceral adipose tissue providing a rich source of inflammatory molecules 
known as adipocytokines including leptin, adiponectin, visfatin and resistin. This may 
explain an important association between obesity, insulin resistance and related 
inflammatory disorders.  
Inflammation plays a key role in the pathogenesis of psoriasis and a number of chronic 
inflammatory systemic diseases listed above. Activated inflammatory cells and pro-
inflammatory cytokines, such as TNF-α and IL-1β, contribute to the development of 
psoriatic lesions and play an important role in atherosclerosis (141).  
7. Conclusion 
Recent literature has provided plenty of information concerning the preventive and 
therapeutic role of vitamin D in many inflammatory diseases including psoriasis. Vitamin D 
inhibits proinflammatory processes by suppressing the enhanced activity of immune cells 
that take part in the autoimmune reaction. Phototherapy (UVB and heliotherapy) improved 
psoriasis and lipid and carbohydrate status of the patients, increased serum 25(OH)D 
synthesis and reduced serum PTH concentrations. UVB therapy heals psoriasis and supplies 
these patients with vitamin D, which might have positive effects on bone status as well. 
The beneficial role of vitamin D for psoriasis might be due to both a skin and systemic increase 
in vitamin D metabolism. Cutaneous 1,25(OH)2D generated in psoriatic skin after UVB 
exposure develops a growth-inhibitory effect on proliferating epidermal keratinocytes similar 
to topically applicated calcitriol. It is unknown if skin affected by diseases such as psoriasis or 
eczema differ in vitamin D production compared to normal skin. Further research is needed to 
achieve a more comprehensive understanding of the synthesis of vitamin D in psoriatic skin 
and the role of vitamin D status in the prevention and treatment of psoriasis.  
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unrelated to serum 25(OH)D concentrations(130). Diet might also influence glucose and 
lipid metabolism. Although climate therapy did not change the basal glucose levels of the 
patients, the HbA1c levels decreased about 10 %, indicating improved insulin sensitivity 
(56). The observed associations between vitamin D, insulin, and glucose metabolism in 
humans have not yet been confirmed by intervention studies and, hence, a causal 
association has not been established(130).  
A high prevalence of atherosclerosis is also reported in psoriasis patients. High serum lipid 
levels have been suggested in the pathogenesis of atherosclerosis. High serum lipid levels 
are more common in psoriasis and may be responsible for an elevated prevalence of 
cardiovascular accidents in this group of patients(137). Patients with psoriasis exhibit a 
dyslipidemic profile, including increased levels of plasma cholesterol, triglycerides (TG), 
LDL, very low-density lipoprotein (VLDL) cholesterol and decreased levels of HDL 
cholesterol. Lipid abnormalities in psoriasis patients may be genetically determined(138). 
The ratio of low-density lipoprotein cholesterol (LDL) and high-density lipoprotein 
cholesterol (HDL) decreased, and the levels of hemoglobin A1c (HbA1c) also decreased in 
psoriasis patients during heliotherapy(56). Serum concentrations of 25(OH)D at baseline in 
psoriasis patients treated with heliotherapy correlated positively with serum HDL at 
baseline(56), consistent with a previously published study(139).  
Psoriasis is associated with obesity, which is a component of metabolic syndrome. Obesity 
has been shown to be an independent risk factor for the development of psoriasis, and is 
also associated with more severe psoriasis (140). Abdominal obesity is a proinflammatory 
state with the visceral adipose tissue providing a rich source of inflammatory molecules 
known as adipocytokines including leptin, adiponectin, visfatin and resistin. This may 
explain an important association between obesity, insulin resistance and related 
inflammatory disorders.  
Inflammation plays a key role in the pathogenesis of psoriasis and a number of chronic 
inflammatory systemic diseases listed above. Activated inflammatory cells and pro-
inflammatory cytokines, such as TNF-α and IL-1β, contribute to the development of 
psoriatic lesions and play an important role in atherosclerosis (141).  
7. Conclusion 
Recent literature has provided plenty of information concerning the preventive and 
therapeutic role of vitamin D in many inflammatory diseases including psoriasis. Vitamin D 
inhibits proinflammatory processes by suppressing the enhanced activity of immune cells 
that take part in the autoimmune reaction. Phototherapy (UVB and heliotherapy) improved 
psoriasis and lipid and carbohydrate status of the patients, increased serum 25(OH)D 
synthesis and reduced serum PTH concentrations. UVB therapy heals psoriasis and supplies 
these patients with vitamin D, which might have positive effects on bone status as well. 
The beneficial role of vitamin D for psoriasis might be due to both a skin and systemic increase 
in vitamin D metabolism. Cutaneous 1,25(OH)2D generated in psoriatic skin after UVB 
exposure develops a growth-inhibitory effect on proliferating epidermal keratinocytes similar 
to topically applicated calcitriol. It is unknown if skin affected by diseases such as psoriasis or 
eczema differ in vitamin D production compared to normal skin. Further research is needed to 
achieve a more comprehensive understanding of the synthesis of vitamin D in psoriatic skin 
and the role of vitamin D status in the prevention and treatment of psoriasis.  
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During the 8th gestational week, a condensation of cells develops on the distal dorsal aspect 
of the digital tip. At week 9, this migrates proximally to form a flat groove, the nail field. At 
week 11, an invagination develops from the proximal groove, which later forms the nail 
pocket or cul-de-sac, with the matrix at its bottom. Nail production starts around week 13. 
At the age of 20 weeks, the nail production is similar to that of an adult. From week 32 on, 
all nail components can be recognized (Lewis, 1954, Zaias, 1963). 
The nail apparatus consists of epithelial and connective tissue components and covers the 
tip of the fingers and toes (Figure 1) (Lewin, 1965, Morgan et al, 2001, Zook et al, 1980). Its 
functions are support, protection and maintenance of the digital tips as well as enhancement 
of the sensory functions of the digital pulps, and the nail is a tool for scratching, defense, 
fine manual work, etc. The cosmetic-aesthetic and social functions of the nail have attained a 
lot of attention in recent years. 
The nail has four epithelial components:  
 The matrix epithelium is the sole structure to produce the nail plate. It is commonly 
divided into the proximal, medial and distal matrix (Figure 2). The existence of a so-
called dorsal matrix is controversial. Most of the matrix is covered by the proximal nail 
fold. Under normal circumstances, its distal portion, the whitish lunula, is only seen in 
the thumb, index and middle finger as well as the great toe; however, manicure with 
pushing the free margin of the proximal nail fold back makes more of the matrix visible 
through the nail and lets the nail plate appear longer. 
The matrix epithelium consists of a basal compartment seen as cuboid basophilic cells that 
migrate up to form the more eosinophilic superficial compartment (Perrin et al, 2004). 
Whenever a nail is avulsed the superficial compartment remains attached to it. During 
onychotisation, the superficial cells undergo nuclear fragmentation. Under normal 
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During the 8th gestational week, a condensation of cells develops on the distal dorsal aspect 
of the digital tip. At week 9, this migrates proximally to form a flat groove, the nail field. At 
week 11, an invagination develops from the proximal groove, which later forms the nail 
pocket or cul-de-sac, with the matrix at its bottom. Nail production starts around week 13. 
At the age of 20 weeks, the nail production is similar to that of an adult. From week 32 on, 
all nail components can be recognized (Lewis, 1954, Zaias, 1963). 
The nail apparatus consists of epithelial and connective tissue components and covers the 
tip of the fingers and toes (Figure 1) (Lewin, 1965, Morgan et al, 2001, Zook et al, 1980). Its 
functions are support, protection and maintenance of the digital tips as well as enhancement 
of the sensory functions of the digital pulps, and the nail is a tool for scratching, defense, 
fine manual work, etc. The cosmetic-aesthetic and social functions of the nail have attained a 
lot of attention in recent years. 
The nail has four epithelial components:  
 The matrix epithelium is the sole structure to produce the nail plate. It is commonly 
divided into the proximal, medial and distal matrix (Figure 2). The existence of a so-
called dorsal matrix is controversial. Most of the matrix is covered by the proximal nail 
fold. Under normal circumstances, its distal portion, the whitish lunula, is only seen in 
the thumb, index and middle finger as well as the great toe; however, manicure with 
pushing the free margin of the proximal nail fold back makes more of the matrix visible 
through the nail and lets the nail plate appear longer. 
The matrix epithelium consists of a basal compartment seen as cuboid basophilic cells that 
migrate up to form the more eosinophilic superficial compartment (Perrin et al, 2004). 
Whenever a nail is avulsed the superficial compartment remains attached to it. During 
onychotisation, the superficial cells undergo nuclear fragmentation. Under normal 









Fig. 1. Anatomy of the nail apparatus. Oblique view (A) and sagittal section (B) through the 
distal phalanx. 
The matrix contains melanocytes most of which are located suprabasally. In light-skinned 
individuals, they remain functionally inactive. Independent from the skin type, the distal 
matrix contains more melanocytes than the proximal one (Tosti et al, 1994, Perrin et al, 
1997).  
The matrix connective tissue is relatively loose containing blood vessels and a considerable 
number of glomus bodies. Recent studies have found that matrix fibroblasts are CD 10+ 
similar to perifollicular fibroblasts (Lee et al, 2007- 2010). The matrix dermis has an 
important morphogenetic capacity allowing it to reproduce matrix epithelium when enough 
of it is left after trauma or superficial surgical removal. The distance from the most proximal 
matrix epithelium to the bone of the terminal phalanx is about 0.8 – 1 mm (Haneke, 2006, 
Kim et al, 2011). 
 The nail bed epithelium is a relatively thin layer of keratinocytes structurally similar to 
tricholemmal cells. It firmly attaches the nail to the underlying distal phalanx and 
produces a tiny amount of nail bed keratin, which allows the nail plate to virtually slide 
over the nail bed without being detached from it. The nail bed keratin is structurally 





and Angus, 1996, Nishi et al, 1996, Zaias and Alvarez, 1968) although this is also 
controversial (Johnson et al, 1991). A normal nail bed does not form a granular layer. 
The nail bed epithelium-connective tissue interface is characterized by unique longitudinal 
rete ridges, in which 3 to 6 layers of longitudinally running capillaries are arranged one 
above the other. Trauma to these capillaries may produce the characteristic splinter 
haemorrhages, which in nail psoriasis are equivalent to Auspitz’ phenomenon of the skin. 
The connective tissue of the nail bed is a firm layer directly attached to the bone without any 
subdermal fat. This and the abundance of nervous structures in the nail bed and matrix are 
probably the reason for the extraordinary pain elicited by trauma to the nail apparatus. 
 The hyponychium is localized at the distal end of the nail bed and forms a particular 
structure allowing the plate to get detached from the bed without injury. It seals the 
virtual space between the nail and the nail bed. The normal hyponychium shows a 
broad granular layer (Hanno et al, 1986, Perrin, 2008). Distal to it, digital pulp skin is 
present. 
 The eponychium is a thin layer of keratin produced by the undersurface of the proximal 
nail fold (PNF). Approximately halfway it divides into the true eponychium remaining 
firmly attached to the dorsal surface of the nail plate and the false eponychium attached 
to the epidermis of the PNF’s ventral surface. It forms the bulk of the cuticle, the 
function of which is to seal the cul-de-sac or nail pocket. 
Proximally and laterally, the nail is ensheathed by the proximal and two lateral nail folds, 
which form a frame leaving the distal margin of the nail plate free. This allows the nail plate 
to grow out and not up. The proximal nail fold is a continuation of the dorsal aspect of the 
skin of the tip of the digit, which folds on itself thereby producing a cover for most of the 
matrix. Its free margin forms an acute angle, which bears the cuticle. This is the most distal 
portion of the false eponychium. When the distal free margin of the proximal nail fold 
rounds up it loses its ability to form a cuticle, and within usually a relatively short period of 
time the undersurface of the proximal nailfold detaches from the underlying nail plate. 
The lateral nail folds are rolls of connective tissue covered with normal epithelium. Their 
border to the nail bed is the lateral nail groove. This is firmly attached to the nail plate 
preventing foreign substances from getting under the nail plate. The lateral grooves are 
important to guide the nails during their forward growth. 
The nail plate – commonly called “the nail” - is the product of the matrix. It is made up of 
keratin which is a sulfur-rich fibrous keratin embedded in a sulfur-rich amorphous matrix. 
The fibrous protein structure is seen clearly under polarized light. In contrast to hair, which 
is made up of exactly the same material, it has no special outer structure like a cuticle of 
scales and the nail grows continuously from birth to death without a cyclical pattern. The 
plate exhibits a slight longitudinal and a more pronounced transverse curvature, the degree 
of which varies between different fingers and toes, during age and some diseases, and has a 
concave border proximally and a convex free margin. The lunula border reflects the shape of 
the matrix as it runs parallel to the proximal border of the nail. Usually three layers of the 
nail plate are distinguished (Figure 2): dorsal (superficial), middle, and deep (ventral). The 
dorsal nail plate layer is produced by the proximal matrix. Its cells are considerably flatter 
and thus, despite its lesser thickness, it has approximately as many cell layers as the 
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responsible for the nail shine. The ventral layer is not true nail but keratin derived from the 
nail bed. Histologically, it is easily distinguished from nail plate. 
 
Fig. 2. Origin of the nail plate layers: The dorsal layer is produced by the proximal matrix 
(pink), the main intermediate and deep nail layer by the intermediate matrix (yellow) and 
the so-called ventral nail layer is the keratin produced by the nail bed (orange). 
The nail organ is an integral part of the functional and sensory finger tip unit (Morgan et al, 
2001). This is formed by the nail apparatus itself, all constituents of the finger tip, the distal 
interphalangeal joints with their capsule, tendons and ligaments. The entheses, insertion 
structures of bone with ligaments and tendons, play an important role for the functional and 
aesthetic integrity of the nail and have recently been found to be of utmost importance in 
psoriatic arthritis and nail psoriasis (McGonagle et al, 2010, 2011). The proximal tip of the 
matrix is just 0.8 to 1 mm from the bone of the terminal phalanx and also very close to the 
distal interphalangeal joint (Haneke, 2006). The joint capsule is enforced by the flexor and 
extensor tendons which form the dorsal and volar aponeuroses. They insert mostly at the 
base of the distal phalanx, but there are also fibers radiating to the more distal dorsal surface 
of the bone and into the connective tissue of the proximal nail fold (Frentz et al, 2000). This 
led some authors to call the nail a musculo-skeletal appendage (McGonagle et al, 2009a, b). 
Thus not only do the complex blood supply of the distal joint and nail, but also the anatomic 
vicinity of matrix and joint give a possible explanation why nail involvement is so frequent 
in psoriatic arthritis patients. 
Nails grow continuously, finger nails about 3 times faster than those of the toes. The 
middle finger of the dominant hand has the fastest growing nail, growing between 3 to 5 
mm per month. A big toenail grows about 1 mm per month. In summer and at daytime, 
the nails grow faster, during winter, at night, in high altitude slower. In psoriatic 
subjects, the nail growth rate is slightly increased. Some drugs also enhance nail growth, 
such as high-dose itraconazole and fluconazole, possibly also cyclosporine. Most 
cytostatic drugs including methotrexate, which is often used as a systemic drug for 
psoriasis treatment, slow down the nail growth rate. Fast growing nails are more prone 





2. Histopathologic nail reactions 
In contrast to skin, the nail demonstrates a variety of specific reactions that are sometimes 
opposite to the rest of the skin. Whereas irritation and a number of inflammatory reactions 
cause parakeratosis in skin they may induce a granular layer in the nail, some psoriatic 
reactions included. Several dermatoses that are not characterized by spongiosis, may exhibit 
marked intercellular oedema of matrix and nail bed epithelium, e.g. in ungual lichen planus 
and psoriasis. 
As the dorsal layer of the nail plate is produced by the most proximal portion of the matrix 
any alterations of the proximal matrix will translate into changes of the nail surface and 
uppermost layers. The bulk of the nail is produced by the middle matrix portion; alterations 
here will modify the nail plate both in its thickness as well as optical coherence. When the 
distal matrix is involved the resulting nail alterations will appear at the undersurface of the 
nail (Figure 2). All matrix-derived alterations will grow out with the nail. In contrast, nail 
bed alterations will be seen through the nail, but will not be integrated into the nail. As the 
nail bed keratin moves slower than the nail plate nail bed alterations remain longer or may 
even appear non-migratory. 
Psoriasis of the nails induces characteristic histopathological changes that are 
pathognomonic in the vast majority of cases; however, in the beginning and with less 
pronounced changes it may mimic a spongiotic dermatitis or may be indistinguishable from 
onychomycosis if there is no proof of fungal invasion.  
3. Histopathology of nail psoriasis 
Whereas the main criteria for psoriasis of the skin also apply for ungual psoriasis there are 
some differences and, above all, there are signs not seen in the rest of the skin. 
Pits are the most frequent lesions in nail psoriasis (Figs. 3, 4) with roughly 70% of the 
patients presenting at least some of these characteristic tiny depressions (Zaias, 1969, Tham 
et al, 1988). Histologically, their appearance varies slightly. In the distal nail plate, they are 
seen as a depression in the nail plate surface that may be lined by some parakeratotic nail 
cells. The more proximal the biopsy is taken, the more parakeratosis is left. Under the 
proximal nail fold there are not yet pits but saucer-shaped small areas of parakeratosis. 
When these do not break out as it most commonly happens tiny white spots remain visible 
giving rise to spotted nails. Usually the rest of the nail organ appears normal and only in 
rare circumstances is a tiny inflammatory psoriatic lesion seen at the proximal tip of the 
matrix. Whether or not the pits may also originate from the most proximal portion of the 
ventral surface of the proximal nail fold (Zaias, 1990) remains a matter of dispute. Anyhow, 
it is surprising how rarely the original inflammatory matrix lesions giving rise to spots and 
pits are seen in histopathological slides.  
Nail bed changes are the second most common ungual sign of psoriasis. They may present 
as salmon or oil spots, which represent a small psoriatic plaque of the nailbed entirely 
covered by the nail plate, as onycholysis when the psoriatic plaque extends to the 
hyponychium, or as subungual hyperkeratosis representing a hyperkeratotic psoriatic 
plaque. A typical salmon spot shows slight acanthosis of the nail bed epithelium, an 
inflammatory infiltrate mainly made up of lymphocytes that tend to migrate into the 
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rare circumstances is a tiny inflammatory psoriatic lesion seen at the proximal tip of the 
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covered by the nail plate, as onycholysis when the psoriatic plaque extends to the 
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inflammatory infiltrate mainly made up of lymphocytes that tend to migrate into the 





      
Fig. 3. Formation of psoriatic pits from a tiny inflammatory focus at the most proximal 
matrix. 
  
Fig. 4. Histological picture of an incipient pit, which is seen as a saucer-shaped mass of 
parakeratosis on the matrix epithelium. 
often contains neutrophils. In more pronounced acute lesions, Munro’s microabscesses may 
be seen. Typical for psoriasis is the arrangement of parakeratosis in obliquely ascending 
columns. This and the lack of fungal elements in PAS stained slides helps to distinguish this 
pattern from onychomycosis, which also often exhibits neutrophil collections as seen in 
Munro’s microabscesses. Psoriatic onycholysis is located more distally in the nail bed, but 
principally very similar to oil spots. The neutrophil exocytosis may be less pronounced, and 
in old lesions it may be difficult to make the diagnosis of nail psoriasis at all as the nailbed 
may develop a granular layer and layered orthokeratotic hyperkeratosis. Subungual 
hyperkeratosis in psoriasis may sometimes be extreme mimicking even pachyonychia 
congenita. Huge thickening of the keratosis with parakeratosis both in horizontal layers and 
oblique columns may be present along with serum inclusions. The latter may form large 
round to oval globules, but also present as very small longitudinal structures. These serum 





however, in contrast to fungal elements they are homogeneously positive and have no 
membrane staining like fungi. 
At the hyponychium, the normal granular layer is lost and the tight connection of the nail 
plate with the most distal portion of the nail bed is loosened. Parakeratosis develops 
without attachment with the nail plate. 
Both the matrix and nail bed may transform to an epidermis-like pattern of differentiation in 
old lesions with development of a granular layer and some orthokeratosis. 
Isolated involvement of the middle matrix appears to be less frequent. It leads to nail plate 
changes clinically often seen as psoriatic leukonychia. Histopathologically, the matrix shows 
acanthosis and spongiosis, a dense subepithelial inflammatory infiltrate mainly of 
lymphocytes that also migrate into the matrix epithelium. Neutrophils may be present and 
sometimes concentrate under the nail plate to form spongiform pustule-like collections. 
There may also be parakeratotic layers in the nail plate; these “paronychotic” cell layers are 
distinct from areas of  incomplete nuclear disintegration, which are not infrequently seen in 
avulsed nail strips of ingrown nails. These inclusions of parakeratosis in the nail plate give 
rise to the clinical picture of leukonychia (Fig. 5, 6, 7). 
 
Fig. 5. Psoriatic leukonychia is seen when there is a psoriatic lesion in the middle or distal 
matrix 
Splinter haemorrhages are a characteristic of nail psoriasis not seen in onychomycosis. They 
are analogous to Auspitz’ phenomenon of the skin. When the fragile thinned suprapapillary 
epithelial plate of a psoriasis lesion is traumatized a minute droplet of blood is seen to 
appear in a skin lesion because the epidermis has rete pegs and finger like dermal papillae. 
In contrast, the nail bed is unique to have rete ridges in parallel arrangement; when a 
microbleeding develops it forms a narrow stripe of haemorrhage, about 0.5 – 1mm wide and 
3 – maximally 10 mm long (Fig. 8, 9). They are soon included by newly produced nail bed 
keratin and seen as small blood lakes between the papillomatous appearing keratosis of the 
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Fig. 6. Munro’s microabscesses in the deep nail plate appear as leukonychic spots in the nail 
 
Fig. 7. This nail plate is irregular in its structure and contains many Munro’s microabscesses 
making it appear intransparent and grayish-white 
Acrodermatitis continua suppurativa is a particular form of pustular psoriasis; however,  
histopathologically three forms exist: with characteristic spongiform pustules, with 
marked spongiosis and even spongiotic vesicles, and a mixed form with spongiform 





In pustular psoriasis, spongiform pustule formation is usually seen with collection of 
neutrophils gradually increasing in density toward the superficial layers of both the matrix 




Fig. 8. Splinter haemorrhages develop when there  is haemorrhage in the papillary rete 
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Fig. 10. Acrodermatitis continua suppurativa of Hallopeau with massive spongiform 
pustule formation; a. Huge amounts of neutrophils are seen in the nail bed epithelium, b. 
Collections of neutrophils are embedded in a matrix of cornified nail bed keratinocytes.  
4. Frequency 
Psoriasis prevalence is about 2% in Central Europe and 1-3% worldwide. At any given time 
point, about 10 – 50% of the psoriatics present nail changes (Scher, 1985, Augustin et al, 
2010), but approximately 90% of all psoriatic subjects will have developed nail alterations 
during life time. The prevalence of nail psoriasis in men is about 11% higher than in women 





In a Swiss cohort of 1222 psoriasis patients, 9.4% suffered from nail involvement (Ruprecht 
et al, 2011). 
Whereas there is a striking difference in the frequency of familiar cases between psoriasis in 
Caucasian children (83%) as compared to Asian children (13.4%) ) nail psoriasis is 
insignificantly more frequent in Singaporean (35.8%) than in Dutch children (22.2%). Pitting 
is the most common nail sign (Chiam et al, 2011). The frequency of nail psoriasis appears to 
be similar in Indian children (Nanda et al, 1990). 
Nail psoriasis is more common in psoriatic arthritis, the prevalence is usually greater than 
80%. 
It appears that nail disease is relatively more frequent in males than in females (Wittkowski 
et al, 2011). 
5. Immunogenetics 
Psoriasis is a multifactorial disorder with a strong genetic background. Environmental co-
factors play an important role in its manifestation. Various psoriasis susceptibility 
(PSORS) factors have been identified, of which PSORS1 on chromosome 6p21 has been 
reproduced in all studies.  
Nail psoriasis has more frequently a positive family history as compared to psoriasis of 
the skin (52.7% vs. 43.8%), is more often associated with psoriatic arthritis (29.7% vs. 
11.5%), is more often linked to early onset psoriasis (74.1% vs. 65.5%) and is fewer positive 
for the HLA allele Cw*0602 (33% vs. 50.3%) (Armesto et al, 2011, Gudjonsson et al, 2006). 
It may also be speculated that the IL23R polymorphism that is a common susceptibility 
factor for psoriasis (Cargill et al, 2007) and is not or only rarely found in Han Chinese may 
account for the higher rate of familiarity of psoriasis in Caucasians as compared to Asians 
(Chiam et al, 2011). 
Nail psoriasis is associated with a higher frequency of psoriatic arthritis and a more 
progressive form of the disease (Williamson et al, 2004, Serarslan et al, 2007). The skin and 
nail lesion usually manifest before the arthritis (Mease , 2002). 
6. Clinical lesions of nail psoriasis 
Psoriasis patients with nail involvement have a longer disease duration, higher disease 
severity, more than double the frequency of psoriatic arthritis, more pronounced 
impairment of disease related quality of life, they were statistically significantly longer off 
work, and had a 2.5 fold higher rate of in-hospital treatments (Augustin et al, 2010).  
Nail psoriasis is characterized by pits, salmon spots, onycholysis, subungual hyperkeratosis 
and some more signs that are less frequent. The psoriatic nail changes may be classified 
according to their origin: Pitting, leukonychia, nail plate thickening, crumbling and red 
spots in the lunula originate in the matrix whereas oil drop discoloration (salmon spots), 
nail bed hyperkeratosis, onycholysis and splinter haemorrhages derive from the nail bed. 
Swelling of the proximal nail fold reflects paronychia and swelling of the distal 
interphalangeal joint is suggestive of psoriatic arthritis. Psoriatic pachydermoperiostosis 
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Pits are generally said to be the most frequent signs. They are small, well delimited 
depressions on the surface of the nail plate with usually equal size and depth (Figs 11-12).  




Fig. 11. Psoriatic pits are small depressions of the nail surface of equal size and depth. The 
pits in a are artificially stained by dithranol treatment, b shows distal onycholysis in 
addition. 
Analogous lesions are small white to yellowish spots that are mainly seen in the proximal 
nail plate when the parakeratosis does not break off the plate. This is called spotted nails 
(Tüpfelnägel in German), a term not commonly used in the Anglo-American literature. A 
number of ten or more pits per nail or more than 60 pits in all nails is commonly seen as 
proof of psoriasis (Baran & Haneke, 2007). Both pits and spots derive from tiny lesions in the 
most proximal matrix and possibly the most proximal part of the ventral surface of the 
proximal nail fold (Zaias, 1990). The length of a pit represents the length of time of the 
psoriatic matrix lesion, its width is indicative of  the width of the lesions and the depth 
either of the severity of the lesion or a lesion that extends a bit into the intermediate matrix. 
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b) 
Fig. 12. a - c. 16-year-old boy with marked nail psoriasis. Note that some nails are almost 
destroyed, other are much less involved. 
transverse rows. Longitudinal rows of pits are due to repeated minor trauma at exactly the 
same location of the proximal matrix whereas transverse ones may reflect a trauma that 
elicited a Köbner phenomenon at many spots at the same time. Rarely, shallow transverse 
lines are seen indicating a microtrauma to the entire width of the matrix. The variable 
arrangement of the pits may cause a clinical picture that varies within a relatively short 
period of time. It is now thought that pits may be due to microtrauma of the proximal 
matrix, which is the closest to the articulation, from the distal interphalangeal joint. Pits in 
horizontal rows are equivalent to Beau’s lines (Fig. 13). 
In pustular psoriasis, pits may occur that are much larger than usual pits (Fig. 14); they are 
also called elkonyxis.  
Salmon or oil spots represent circumscribed psoriasis plaques of the nail bed. Their specific 
colour is due to the fact that the psoriatic scales are compressed under the nail plate and 
imbibed with serum that makes them appear yellowish-reddish mimicking a drop of oil on 
a sheet of paper. Once a psoriatic plaque has reached the hyponychium or when it started at 
the hyponychium the scales are not or no longer compressed by the overlying nail plate and 
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Small lesions in the intermediate and distal matrix may appear as red spots whereas 






Fig. 13. Pits arranged in horizontal rows. On finger nails, which grow faster they are still 
identifiable as single pits (A) whereas on toenails, due to their slow growth rate they appear 
as transverse furrows and lines (B). 
Sometimes, psoriasis of the nail bed may cause important hyperkeratosis that may in 





there may also be a thickening of the nail plate itself. Clinically this looks like a rough nail 
with irregular surface and loss of transparency, which is mainly due to wavy arrangement 
of the nail lamellae as well as inclusion of serum and neutrophilic abscesses. 
 
Fig. 14. Nail involvement in pustular psoriasis of the palms and soles (Barber-Königsbeck 
type). Note the relatively large pits and some ivory-coloured spots. These large surface 
depressions are called elkonyxis. 
Small dark-brown to black longitudinal streaks in the nail bed, mainly in distal location, are 
called splinter haemorrages (Fig 16). They are due to thromboses of the dilated capillaries of 
the nail bed papillary ridges, which run all along the nail bed with 3 to 5 layers of capillaries 
one above the other. 
Psoriatic leukonychia is relatively rare. It usually represents a focus of parakeratosis in the 
intermediate nail layers. It is often associated with other signs of nail psoriasis and may be 
seen as an advancing edge in acute-onset nail psoriasis. 
Larger psoriatic lesions of the nail matrix cause crumbly nails, even complete nail 
destruction. They are often associated with psoriatic arthritis.  
Pustular psoriasis of the nails is seen in palmar plantar pustular psoriasis of Barber-
Königsbeck (Figures 14, 17), in generalized pustular psoriasis of von Zumbusch and in 
Hallopeau’s acrodermatitis continua suppurativa. In palmar plantar pustular psoriasis, nail 
involvement is commonly seen as yellow lakes of pus under the nail plate. This is often 
associated with elkonyxis. In generalized pustular psoriasis, nail involvement usually leads 
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Fig. 15. Subungual hyperkeratosis in distal nail bed psoriasis. A. Fingernails, B toe nails. 
Acrodermatitis continua suppurativa of Hallopeau is an insidiously developing disease of the 
tip of the finger commonly commencing dorsally and slowly involving the nail apparatus 
(Figs. 18, 19 a, b). The diagnosis is often only made late when there is already a certain degree 
of nail dystrophy. In very typical cases, the finger or toe tip rounds up, loses its nail, the skin is 
fiercely red with some tiny pustules. Radiographically, resorption of the corona unguicularis 






Fig. 16. Splinter haemorrhages in a nail with salmon spot 
  
Fig. 17. Psoriasis pustulosa of Barber-Königsbeck 
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Fig. 16. Splinter haemorrhages in a nail with salmon spot 
  
Fig. 17. Psoriasis pustulosa of Barber-Königsbeck 
 









Fig. 19. Acrodermatitis continua suppurativa. A. Pustules have been present for more than 
12 years in this elderly lady. B. Relatively acute onset of acrodermatitis continua 
suppurativa in a patient with bronchial carcinoma; whether this is a causal or accidental 
association is not clear. 
Psoriatic paronychia develops when the periungual skin is affected by psoriasis, but it is also 
commonly seen in psoriatic arthritis with nail involvement (Fig. 20). The chronic inflammation 
causes thickening of the free edge of the proximal nail fold with consecutive loss of the cuticle 
and later loss of attachment of the nail fold’s ventral surface to the underlying nail plate. This 
allows foreign material such as dirt, microorganisms or allergenic substances to enter the space 






Fig. 20. Psoriatic paronychia in a patient with psoriasis arthropathy. 
Psoriatic enthesitis of the distal interphalangeal joint is a painful inflammation of the 
insertions of tendons and ligaments mainly at the base of the distal phalanx. This may cause 
swelling of the distal joint with stiffness and loss of the dorsal creases of the distal 
interphalangeal joint and a shiny skin.  
Psoriatic pachydermoperiostosis is a rare event. It is associated with bone appositions which 
also lead to a widening of the base of the distal phalanx with consecutive widening of the 
nail plate. 
In almost a quarter of the patients with latent psoriatic arthritis, radiological assessment will 
detect changes not seen clinically (Khan et al, 2003). 
7. Quality of life 
Nail psoriasis has been shown to severely impair quality of life (see Scoring of nail 
psoriasis). Pain, cosmetic embarrassment, impaired function, loss of dexterity are just some 
of the complaints brought forward by the patients (De Jong et al, 1996). More than 90% of 
the patients consider their nail psoriasis to be a significant social problem affecting their 
professional work, and more than  half of them experienced pain (de Berker, 2009, Gupta 
and Cooper, 2009).   
7.1 Scoring of nail psoriasis 
To score the extent and severity of nail psoriasis the nail psoriasis severity index (NAPSI) 
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allows foreign material such as dirt, microorganisms or allergenic substances to enter the space 






Fig. 20. Psoriatic paronychia in a patient with psoriasis arthropathy. 
Psoriatic enthesitis of the distal interphalangeal joint is a painful inflammation of the 
insertions of tendons and ligaments mainly at the base of the distal phalanx. This may cause 
swelling of the distal joint with stiffness and loss of the dorsal creases of the distal 
interphalangeal joint and a shiny skin.  
Psoriatic pachydermoperiostosis is a rare event. It is associated with bone appositions which 
also lead to a widening of the base of the distal phalanx with consecutive widening of the 
nail plate. 
In almost a quarter of the patients with latent psoriatic arthritis, radiological assessment will 
detect changes not seen clinically (Khan et al, 2003). 
7. Quality of life 
Nail psoriasis has been shown to severely impair quality of life (see Scoring of nail 
psoriasis). Pain, cosmetic embarrassment, impaired function, loss of dexterity are just some 
of the complaints brought forward by the patients (De Jong et al, 1996). More than 90% of 
the patients consider their nail psoriasis to be a significant social problem affecting their 
professional work, and more than  half of them experienced pain (de Berker, 2009, Gupta 
and Cooper, 2009).   
7.1 Scoring of nail psoriasis 
To score the extent and severity of nail psoriasis the nail psoriasis severity index (NAPSI) 





and a vertical line. Nail matrix and nail bed are scored independently. Any of the matrix 
signs – pitting, leukonychia, red lunula spots and crumbling – as well as the nail bed  signs – 
onycholysis, salmon or oil spots, subungual hyperkeratosis, splinter hemorrhage – are 
counted. Absence is given 0, presence in one quadrant 1, presence in two quadrants 2 etc 
up to 4 quadrants receiving 4. Matrix and nail bed signs are added resulting in a 
maximum score of 8 per nail. All finger nails can have a maximum NAPSI score of 80, 
finger and toenails of 160. All of the 8 individual features of matrix and nail bed psoriasis 
are just given one score independent from their number per quadrant. For a target nail, 
the same technique can be used to evaluate all 8 parameters (pitting, leukonychia, red 
spots in lunula, crumbling, oil drop, onycholysis, hyperkeratosis, and splinter 
hemorrhages) in each quadrant of the nail, giving that one nail a score of 0-32. The NAPSI 
is a useful tool for nail evaluation in the course of therapeutic studies, both for the effect 
on all nails as well as for the judgment of a target nail (Rich and Scher, 2003). 
Interobserver reliability for the total NAPSI score is good whereas the nail score only 
shows moderate agreement (Aktan et al, 2006). 
The NAPSI has some limitations. It does not consider the number of pits or red spots of 
the lunula per quadrant nor the size of an oil spot or the thickness of subungual 
hyperkeratosis. This limits its use to assess improvement  in the course of a treatment 
(Parrish et al, 2004). Therefore, an additional gradation was proposed for each sign from 
absent (= 0), mild (= 1), moderate (= 2) and severe (=3) as a qualitative scale similar to that 
used in the Psoriasis Area and Severity Index (PASI). Nail crumbling is given the same 
score like a pit, but is considerably more severe. Pustular psoriasis and psoriatic arthritis 
are not included in the NAPSI. 
A modified NAPSI was developed for patients with psoriatic arthritis (Maejima et al, 2010). 
This modified NAPSI is higher in patients with psoriasis of the proximal nail fold, distal 
interphalangeal (DIP) joint arthritis whereas there was no correlation with the modified 
NAPSI and other systemic signs. Nail psoriasis was assumed to be related to the Koebner 
phenomenon and local inflammatory DIP joint arthritis in PsA patients, and nail 
involvement in PsA was suggested to be among the disorders indicative of distal phalanx 
enthesitis (Tan et al, 2007, Elder et al,2010). 
Nail psoriasis has both a physical and psychological impact on the patients negatively 
influencing their quality of life (QoL). A nail psoriasis quality of life index (NPQ10) was 
developed to measure life quality impairment due to nail psoriasis and its modification in 
the course of treatment (Ortonne et al, 2010). Again, psoriatic arthritis patients are not 
included in the NPQ10. Of the 17000 members of the French Association pour la lutte contre 
le psoriasis, 4000 were asked to fill in a questionnaire regarding the physical aspects of nail 
psoriasis. Roughly one third responded and 795 of them had nail psoriasis. The items were 
elaborated by physicians and patients alike. The patients rated their nail psoriasis as 
bothersome in 86%, as unsightly in 87%, and as painful in 59%. The number of nails 
involved significantly affected the pain, aesthetic and functional impairment. Whereas 86% 
received therapy, 72% were dissatisfied with their treatment. From these facts, 10 questions 
were created, only one of which concerned pain, the other 9 were related to functional 
handicaps in daily life. Answers are scored from 0 to 2 with 0 being ’no without hesitation’ 





without hesitation’ or ‘very painful’. Item 2 and 6 are specific for toe and finger nail 
psoriasis, respectively. Item 7 relates only to patients driving a car. Scores are transferred 
into percentages in order to be able to compare them always resulting in a maximum of 100. 
A test-retest questionnaire was sent out to a few patients yielding a very good 
reproducibility. NPQ10 scores are significantly higher in patients having both finger and toe 
nail psoriasis, in female psoriatics, and in patients with a shorter history of psoriasis 
(Ortonne et al, 2010). The NPQ10 score shows good correlation with the dermatology life 
quality index (DLQI) (Finlay and Khan, 1994). 
 
State the location of your psoriasis of the nails 
1. Fingernails  2. Toenails  3. Both 
1. Would you say that your psoriasis of the nails is mostly: 
          1. Very painful  2. Not very painful   3. Not painful 
2. Because of my psoriasis of the nails, I have difficulty putting my shoes on: 
          1. Always   2. Sometimes   3. Never 
3. Because of my psoriasis of the nails, I don’t do any of the jobs I usually do around the 
house: 
          1. Always    2. Sometimes    3. Never 
4. Because of my psoriasis of the nails, I get dressed more slowly than usual: 
          1. Always   2. Sometimes    3. Never 
5. Because of my psoriasis of the nails, I have trouble putting on my socks (or stockings 
or tights): 
          1. Always    2. Sometimes    3. Never 
6. Because of my psoriasis of the nails, I have trouble turning my door key: 
          1. Always    2. Sometimes    3. Never 
7. Because of my psoriasis of the nails, I have trouble driving my car: 
          1. Always   2. Sometimes    3. Never 
8. Because of my psoriasis of the nails, someone helps me to get dressed: 
          1. Always   2. Sometimes    3. Never 
9. Because of my psoriasis of the nails, I avoid doing big jobs around the house: 
          1. Always    2. Sometimes    3. Never 
10. Because of my psoriasis of the nails, I am more irritable than usual, and bad-
tempered with people: 
          1. Always    2. Sometimes    3. Never 
Table 1. Questionnaire of the NPQ10 (Ortonne et al, 2010) 
The psoriasis weighted extent and severity index (PWESI) evaluates the skin disease on a 
scale from 0 (none) to 4 (extensive) and severity of skin disease on a scale of 0 to 4 (intensely 
inflamed). Ten areas are assessed, among them hands/fingers/fingernails (Wittkowski et al, 
2011). 
The extended 10-area linear psoriasis area and severity index (XL-PASI) combines the 
PASI and PWESI scoring methods (Feldman and Krueger, 2005) and includes the 
assessment of surface area involved as well as dimension for scaling, erythema, thickness 
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is graded from 0 to 4 and body surface is divided into ten areas and each is quantified. The 
XL-PASI scale ranges from 0 to 148 (Wittkowski et al, 2011). 
8. Differential diagnosis of nail psoriasis 
There is a wide range of potential differential diagnoses, the most important of which are 
onychomycoses (Table 2) and nail dystrophies after minor trauma, in chronic venous 
insufficiency and impairment of the peripheral circulation. 
Onychomycoses are the most frequent nail disorders. Distal and distal-lateral subungual 
onychomycosis (DLSO) are mainly due to dermatophytes with Trichophyton rubrum being 
the most frequent pathogen although T mentagrophytes (interdigitale) also plays an 
important role. All other dermatophytes are rather rare and the role of most yeasts and non-
dermatophyte moulds as primary nail pathogens remains disputed. DLSO begins at the 
hyponychium from where the fungus slowly invades the nail bed in the direction toward 
the matrix. The infection apparently irritates the nail bed epithelium that produces a reactive 
hyperkeratosis, which harbours most of the fungal elements whereas the nail plate rather 
acts as a barrier. In contrast to psoriatic onycholysis that exhibits the classical salmon spot 
colour at its proximal margin, mycotic onycholysis has no reddish-brown margin (Fig 21 
a&b). Nail psoriasis and onychomycosis may coexist (Natarajan et al, 2010). 
 
 Onychomycosis Psoriasis 
Pits Rare Very frequent 
Onycholysis Frequent Frequent 
Discoloration Yellow – brown None - yellow 
Loss of nail 
transparency 
Frequent Less frequent 
Fungi Very frequent, depends on type of 
OM 
rare 
Transverse ridges Rare Rare 
Splinter haemorrhages Almost never Rare 
Leuconychia Depends on onychomycosis type:
Superficial white OM 
Proximal white subungual OM 
Rare 
Paronychia In onychomycoses due to moulds In psoriatic arthritis and 
periungual psoriasis 
Finger vs. toe 
involvement 
Toe nails 7 to 10 times more often 
infected 
Finger nails more often 
affected by psoriatic 
alterations 
Other skin lesions Tinea pedum and/or manuum Psoriasis elsewhere 
Heredity Autosomal dominant 
susceptibility to get a 
dermatophyte nail infection 
Frequent familiarity, 
particularly in early onset 
psoriasis and HLA-Cw6 
positive subjects 









Fig. 21. Psoriatic onycholysis demonstrates a livid-red proximal margin (A), which is not 
seen in mycotic onycholysis (B). 
There are also many histopathological signs in common of onychomycosis and nail psoriasis 
(Table 3). This may render the differential diagnosis between these two frequent nail 
conditions very difficult if not impossible. Furthermore, it is possible that both 
onychomycosis and psoriasis are present in the same subject in different digits as well as in 
the same nail (Fig.22). It is therefore self-evident that a specimen sent for histopathological 
diagnosis of nail psoriasis is also stained with periodic acid-Schiff (PAS) or another fungal 
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Fig. 22. This nail histopathology shows both psoriasis and onychomycosis: on the surface, 2 
pits are seen; the nail itself is a bit wavy and displays fungal hyphae seen as fine 
eosinophilic lines in the deep layer of the nail  in this haematoxylin & eosin stain section; at 
the undersurface of the nail there is loose keratin, which is mostly parakeratotic and 
contains several Munro’s  microabscesses. 
 




with accumulation of 
neutrophils and serum 
globules  
Marked hyperkeratosis 
with accumulation of 
neutrophils and serum 
globules  
Nail bed and matrix 
granulosis 
Patchy hypergranulosis Patchy hypergranulosis 
Nail bed hyperplasia Papillomatous hyperplasia 
of nail bed 
Papillomatous hyperplasia 
of nail bed 




Surface alterations Usually not present Cup-shaped depression of 
nail plate surface with 
parakeratosis: psoriatic pit  
Demonstration of fungi Hyphae and spores in 
subungual  hyperkeratosis 
and undersurface  of nail 
plate 
May be present in double 
pathology 





Reiter’s disease is an infrequent reactive arthritis with changes of the ocular, genital and oral 
mucosae such as conjunctivitis, blepharitis, scleritis or iridocyclitis, balanitis, vulvitis or 
stomatitis circinata, which are virtually indistinguishable from lingua geographica and its 
very rare extralingual analogues, and painful inflammation of joints and the vertebral 
column. Many patients are HLA-B27 positive. Nail changes often start with pits and salmon 
patches remaining indistinguishable for a long time from nail psoriasis (Pajarre et al, 1977, 
Lovy et al, 1980) before the nails become destroyed (Fig. 23) (Table 4). 
 
Fig. 23. Reiter’s disease of the nails (Courtesy T Ruzicka, Munich) 
 
 Psoriasis Reiter‘s disease 
Pitting Very frequent Less frequent 
Onycholysis Frequent Frequent 
Subungual keratosis Variable Pronounced 
Salmon patch Reddish More brown 
Nail destruction Rare Marked 
Skin lesions 
elsewhere 
Frequent Palmar and plantar lesions, joint changes, 
mucosal lesions 
Table 4. Differential diagnosis of nail psoriasis and nail changes in Reiter’s disease 
Onycholysis is often due to overzealous manicure, but psoriasis of the nails renders them 
more susceptible to develop onycholysis due to minor trauma. Again, psoriatic onycholysis 
has usually a reddish proximal margin, which is lacking in onycholysis semilunaris (Fig. 24). 
Eczema involving the nail apparatus usually causes pit-like depressions leading to a rough 
nail surface called trachyonychia as well as to irregular transverse lines. The depressions are 
commonly less deep and less regular in size than in psoriasis. Although these depressions 
are more common in allergic contact dermatitis and nummular eczema they are also seen in 
atopic eczema (Nnoruka et al, 2004). Despite the trachyonychia, the nail may still retain its 
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subungual hyperkeratosis and later onycholysis as well as loss of nail transparency  and 





Fig. 24. Onycholysis semilunaris (A) is characterized by its half-moon shape and clear 
border whereas psoriatic onycholysis has the typical appearance of an oil spot at its 
proximal margin (B). 
When many or even all nails are affected the condition is called twenty nail dystrophy; this 
may, however, be a manifestation of ungual lichen planus, alopecia areata, eczema or 






Irritant contact dermatitis was also estimated to mimic nail psoriasis (Takeuchi et al, 
2010). 
Alopecia areata is known to be associated with rough nails. The more extensive the 
alopecia areata is the more likely the patients also get nail changes. Most probably, 
isolated alopecia areata of the nails does exist (Tan et al, 2002, Nanda et al. 2002). Alopecia 
areata nails grow slower than psoriatic nails. They are often indistinguishable from 
eczema nails, and in fact, both have a microscopical spongiotic dermatitis in common. 
Serum is in the spongiotic vesicles and becomes included into the nail; when it is very 
superficial it may break out and leave a depression, but when the origin is in the 
intermediate matrix the dried serum will remain in the nail and be the reason for the loss 
of nail transparence, nail thickening and brittleness. 
When almost all nails are affected the so-called twenty-nail dystrophy is diagnosed 
(Samman, 1979). Even though this term does note denote a specific condition it is still 
widely used, particularly for 20-nail dystrophy of children (Horn and Odom, 1980, Baran 
and Dawber, 1987). 
9. Treatment of nail psoriasis 
Psoriasis of the nails is an often neglected or overlooked disease as is evidenced by the most 
recent 100-page strong guidelines on psoriasis treatment (Nast et al, 2011), and it has a 
serious impact on the individual’s daily life.  
The therapy of nail psoriasis is difficult, particularly that of isolated nail psoriasis as one 
usually hesitates to treat it systemically. In general, systemic treatment regimens that are 
effective in cutaneous psoriasis also improve nail lesions. There is a general lack of well-
documented studies and they are often not or difficult to compare (Jiaravuthisan et al, 2007) 
and few evidence-based treatments exist (Cassell and Kavanaugh, 2006). A standardized 
therapeutic approach does therefore not exist and preferred treatment regimens also differ 
between various countries. The treatment also depends on the nail structure involved, how 
severe the nail dystrophy is, whether there are extraungual lesions, the time needed for 
applying a specific therapy, and not the least also on its cost. 
9.1 Topical therapy 
Topical treatments are generally held not to be very effective. This has several simple 
reasons: Pits come from the depth of the nail pocket where the lesions are protected by the 
overlying proximal nail fold from being treated; lesions in the intermediate matrix are both 
hidden by the proximal nail fold and the nail plate; nail bed lesions are under the nail plate, 
which is a considerable obstacle to penetration of drugs. Ointments applied on finger nails 
may interfere with paper work. There are very few controlled studies on topical therapies. 
Urea (carbamide) is known for its keratolytic property. A paste containing 40% urea 
(Onyster®) softens fungus infected nails to a degree that it can be atraumatically removed; 
this may be a starting point for topical teatment. A 10% urea nail varnish was shown to 
improve the biophysical properties of the nail (Krüger et al, 2006). A 15% stable urea nail 
lacquer (Onypso®) is advertised as “the only specific topical treatment for nail psoriasis” as 
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Anthralin (dithranol, cignoline) suppresses cell proliferation, inhibits neutrophils and 
monocytes, neutrophile migration and lymphocyte proliferation. It exerts a strong 
antiproliferative action on keratinocytes (Schröder et al, 1985). It is an old, extremely safe 
and very effective psoriasis remedy. Anthraline 0.4 to 2% in petrolatum was used in a study 
of 20 patients over a period of approximately 5 months (Yamamoto et al, 1998). There was 
no response in 8 and little to fair response on onycholysis, subungual hyperkeratosis and 
pitting in 12 individuals. Anthraline is not popular because it stains skin and clothes. 
Therefore the patients washed the anthraline ointment off after 30 minutes and applied 10% 
triethanol amine. However, nail staining cannot be completely avoided making the lesions 
even more obvious and embarrassing. 
There are no studies on anthralin in combination with ultraviolet (Ingram regimen) or coal 
tar without or with UV (Goeckerman regimen) in nail psoriasis. 
5-Fluorouracil (5-FU) is a cytostatic agent inhibiting nucleic acid synthesis and thus 
reducing cellular renewal. It was mainly used for the treatment of actinic keratoses and 
superficial basal carcinomas, but the application under occlusion or twice daily until an 
erosive reaction was achieved did not make it popular amongst the patients. A prospective 
study on 20 patients with very long-standing psoriatic pitting, hyperkeratosis or onycholysis 
was conducted with 1% 5-FU solution twice daily. This had to be massaged into the skin 
immediately adjacent to the nail for 6 months. Seventeen of the 20 subjects experienced 
marked improvement in pitting and subungual hyperkeratosis (Fredriksson, 1974). One 
patient with onycholysis lost all affected nails that finally regrew but with the same 
onycholysis as before.  
In a double blind controlled study, 5-FU in a penetration enhancer consisting of urea and 
propylene glycol was compared to the penetration enhancer solution alone. The preparation 
was applied once daily over a period of 12 weeks. There was a statistically significant 
improvement of the total nail area severity (NAS) score comprised of the number of pits, 
degree of pitting, subungual hyperkeratosis, onycholysis and salmon spots, for both 
preparations with no superior results seen in the 5-FU group (de Jong et al, 1999). Six 
subjects in the 5-FU group experienced side effects such as pain, swelling, inflammation, 
discoloration, onycholysis, and nail perforations. 5-FU is not widely used anymore. 
Topical steroids have been and continue to be the most commonly used therapeutic agents 
for local treatment of nail psoriasis. They exert an anti-inflammatory and 
immunosuppressive action, inhibit leukocyte migration into the skin, decrease vascular 
permeability, reduce the effect of pro-inflammatory cytokines, and have an antiproliferative 
action. All these effects taken together make them a good treatment of nail psoriasis 
provided they can reach the psoriatic lesion of the nail. However, no standard therapeutic 
regimes exist for topical steroid  therapy of nail psoriasis (Jiaravuthisan et al, 2007) as there 
are very few controlled studies with their use in nail psoriasis. Generally, high-potency 
topical steroids are prescribed that are applied once or even twice daily to the nail folds and 
nail bed either as a cream, ointment or solution. Once an effect has been achieved the 
frequency of application is reduced until about twice weekly. A proactive treatment 
approach may be superior although there are no controlled studies in nail psoriasis. Side 
effects of long-term potent topical steroid use are hypopigmentation and skin atrophy with 
development of telangiectasiae. It may be wise to have the patient apply antiseptics once 





be considerable. Topical corticosteroid application has even been linked to tapering of the 
digits and to phalangeal bone resorption (Wolf et al, 1990). 
A study on 10 nail psoriasis patients with 8% clobetasol nail lacquer resulted in reduced 
pitting, onycholysis and salmon spots after only 3 months of treatment. The treatment was 
found to be safe, effective and cosmetically acceptable (Sanchéz Regaña et al, 2005). 
Betamethasone diproprionate – salicylic acid ointment over 3 to 9 months reduced the nail 
bed hyperkeratosis by about one half (Tosti et al, 1996), which was virtually identical to the 
effect of calcipotriol. The authors’ conclusion was that calcipotriol is a safe alternative to 
topical steroids in nail bed psoriasis.  
A combination treatment with calcipotriol cream and clobetasol cream was shown to reduce 
subungual keratosis by 72% after 6 months and 81% after 12 months in finger nails whereas 
the improvement was 70 and 72.5% in toe nails, respectively (Rigopoulos et al, 2002). For the 
first 6 months, calcipotriol cream was applied on weekday evenings and clobetasol cream on 
weekend evenings, the next 6 months only clobetasol cream was used. Side effects of 
calcipotriol in the treatment of nail psoriasis are rare and mild, they mainly consist of 
irritation, burning, erythema and diffuse urticaria (Tosti et al, 1996, Rigopoulos et al, 2002). 
Cyclosporine is an immunosuppressive calcineurin inhibitor ultimately decreasing T cell 
growth and migration (Baker et al, 1987). A 10% formulation in maize oil was used in three 
fingers of a patient (Tosti et al, 1990) with marked improvement after 2 months and almost 
complete clearing after 3 months. No adverse effects were observed. Cyclosporine is a 
hydrophobic, large molecule of 1.5 kD and difficult to incorporate into a topical preparation, 
but the newer calcineurin inhibitors tacrolimus and pimecrolimus are available as ointment 
or cream, respectively. Curiously, no controlled study with any of these two potent drugs 
has been conducted in nail psoriasis. Tacrolimus was found to be ineffective in plaque 
psoriasis, most probably due to insufficient penetration because of its large molecular 
weight of 802 Da, and this might have discouraged investigators to try it in nail psoriasis. 
Tazarotene is a third-generation topical retinoid for the treatment of acne and psoriasis. It 
binds to the nuclear retin acid receptors RAR- and RAR- exerting an effect on epidermal 
proliferation and differentiation. Its action in psoriasis is mainly normalization of abnormal 
keratinocyte proliferation and control of inflammation (Kang et al, 1996). In addition to 
some case reports on tazarotene use in periungual psoriasis, a double-blind controlled study 
was performed with the vehicle as the control. Both tazarotene 0.1% under occlusion as well 
as without occlusion yielded a statistically significant better reduction in onycholysis and 
pitting (Scher et al, 2001). Erythema, peeling of the paronychia, irritation of the finger skin 
and paronychia were the side effects seen in the tazarotene group whereas the vehicle was 
tolerated without adverse effects. 
Indigo naturalis is a dark-blue powder from the leaves of indigo-bearing plants. It inhibits 
proliferation, promotes differentiation of epidermal keratinocytes, inhibits neutrophil 
proinflammatory responses and suppresses TNF- induced vascular cell adhesion molecule 
1 expression in endothelial cells thereby exerting an antipsoriatic effect (Lin et al, 2009). Six 
patients with psoriasis who had been treated for 4 years with indigo naturalis ointment or 
systemic Chinese herbs and whose skin lesions had responded well whereas the nails 
remained unchanged were treated twice daily with 1 to 2 drops of indigo naturalis oil 
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in PASI was 51%, and two patients had even PASI reductions of 89 and 82%, respectively. 
No adverse side effects were noted (Lin, 2011). 
9.2 Intralesional treatments 
Intralesional injections of corticosteroids are widely used, either with an injection needle 
or by a high-pressure injector (Dermojet®, Port-O-Jet®). In most cases, crystal suspensions 
of triamcinolone acetonide are used with variable concentrations of 1 mg/mL (Zaias,1990) 
to 10 mg/mL (Scher and Daniels, 2003, de Berker and Lawrence 1998). Injections ranged 
from a single one (Gerstein, 1962) to once every 3 to 4 weeks for 4 to 6 months (Abell and 
Samman, 1973, Zaias, 1990) or monthly for the first 6 months and then 4 injections over 
the next 6 months followed by once every two months for the next 6 to 12 months 
(Norton, 1982). It appears that the number of affected nails may be a limiting factor as 
many patients complain of discomfort and pain. In our experience, even though most 
patients prefer the needle-less high pressure air gun they admitted that injection with a 
30-gauge needle is less painful (unpubl. observation). The sort of high pressure injector 
appears to be important as there are good results with some devices and disappointing 
ones with others. Side effects of high pressure devices are subungual haematomas, short-
term paraesthesias, atrophy at the injection site, epidermoid inclusion cysts (de Berker, 
2000), tattooing with minute rubber particles and blood splash back on the instrument  
and the physician. 
Most intralesional injections are given into the proximal nail fold, best one each into each 
side of it with sparing the central area where the extensor tendon inserts in order to avoid 
steroid-induced tendolysis. These injection sites are good for lesions originating from the 
matrix, i.e. pits, ridges and severe nail plate dystrophy whereas nail bed-derived lesions 
such as subungual hyperkeratosis and salmon spots profit from sub-nailbed injections. 
These are, however, even more painful and usually require an anaesthesia to be applied. 
The concentration of triamcinolon per mL does not appear to be critical as there are 
variations from 1mg/mL to 10 mg/mL in the literature. Higher concentrations allow 
smaller volumes to be injected, which then is less painful. It is still a matter of debate 
whether lidocaine or another local anaesthetic should be used to dilute the triamcinolone 
solution. In our opinion, it is both the needle prick and the pressure from the injection that 
are felt as uncomfortable to painful and no local anaesthetic can prevent this. Topical 
anaesthesia may be used, for instance with lidocaine-prilocain mixture (EMLA®), to 
alleviate the needle prick. 
Intralesional methotrexate (MTX) has recently been used in a single patient (Sarcaoglu et 
al, 2011). MTX is a folic acid analogue irreversibly binding to dehydrofolate reductase thus 
blocking deoxyribonucleic acid synthesis. In addition, it was shown to exhibit an anti-
inflammatory effect by inhibiting the polyamine pathway in autoimmune diseases. 
Intralesional MTX has been shown to be effective and safe in a variety of conditions 
(Agostini et al, 2007). This was the rationale to use it in a psoriatic patient with pitting and 
subungual hyperkeratosis of only one nail. MTX 2.5 mg was injected into each side of the 
proximal nail fold once weekly for 6 weeks. Pain was tolerable. During the 4-month follow-
up, the psoriatic nail alterations improved and no clinical or laboratory side effects were 





Although intralesional cyclosporine has shown good effects in cutaneous psoriasis there 
are no reports on intralesional cyclosporine in nail psoriasis. 
9.3 Physical treatment modalities 
9.3.1 Phototherapy and photochemotherapy 
Phototherapy has been used for psoriasis for more than 100 years. Ultraviolet (UV) is known 
to exert an immunosuppressive effect through an effect on local and circulating immune 
cells, particularly on dendritic cells. Narrow band UV B of 311 nm has been shown to be 
most effective. Photochemotherapy combines the use of UV, usually UV A, with the topical 
or systemic administration of a photosensitizing agent, most commonly a psoralen. In 
contrast to skin psoriasis, nail psoriasis barely responds. In a study with oral PUVA on 10 
patients, the skin of the proximal nail fold improved, but pitting did not improve. Nail plate 
crumbling cleared in three out of 4 individuals whereas onycholysis and oil drops improved 
slightly by approximately 50% (Marx and Scher, 1980). In contrast, in a retrospective study 
on the effect of different systemic treatments, PUVA improved the NAPSI score after 12, 24 
and 48 weeks by 21%, 51% and 69%,  Re-PUVA (combination of a retinoid with PUVA) by 
27%, 65%, and 85%,  ReNUVB (retinoid plus narrow-band UV B) by 21%, 48% and 64%, 
respectively, whereas narrow-band UV B alone had no beneficial effect (Regana et al, 2011). 
Topical PUVA resulted in clearing of 2 subjects with pitting and 2 with onycholysis 
improved substantially (Handfield-Jones et al, 1987). Even these results are surprising as the 
nail is a very efficient UV shield (Stern et al, 2011). 
9.3.2 Laser treatment 
Various studies have shown efficacy of laser treatments on cutaneous psoriasis. As 
angiogenesis was found to be one of the driving factors in psoriasis pathogenesis 
(Heidenreich et al, 2009) most studies were performed with the pulsed dye laser, which 
specifically targets blood vessels (Taibjee et al, 2005, Bovenschen et al, 2006). Two recent 
studies used the pulsed dye laser for nail psoriasis, one in comparison with photodynamic 
treatment (Fernández-Guarino et al, 2009), the other evaluated the effect of PDL on nail 
psoriasis (Oram et al, 2010). A third study not yet published (Treewittayapoom et al, in 
press) used two different pulse widths. All studies used a 595-nm pulsed dye laser with a 
spot size of 7 mm. The pulse duration in the Spanish study was 6 ms, in the Turkish one 1.5, 
and the Thai one compared the efficacy of 6 ms with 0.45 ms pulse width, fluences were 9, 8 
– 10, and 9 and 6 J/cm², respectively. Both the PDT and the PDL group showed a decrease in 
the NAPSI score with no difference between the two groups (Fernández-Guarino et al, 
2009). The Turkish study showed an improvement mainly of the nail bed NAPSI (Oram et 
al, 2010). The Thai study did not demonstrate a difference in treatment outcome between the 
long 6 ms pulse with 9 J/cm² group and the short 0.45 ms pulse duration with 6 J/cm² 
group; however, the pain was statistically significantly more intense in the longer pulse 
group (Treewittayapoom et al, in press). 
9.3.3 Ionising radiation 
Superficial radiotherapy delivers the radiation energy mainly to the skin surface. Three 
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month treatment interval the nails regrew normally in the following 8 to 14 months, and one 
patient had disease-free nails even 20 years after cessation of the irradiation (Finnerty, 1979). 
Another ten patients were treated in a randomized prospective double-blind study with 
twice fractioned doses of 150 cGy superficial radiotherapy each a week apart. One hand was 
treated and the other left for comparison. After 10 and 15 weeks posttreatment, the 
irradiated hand was significantly better concerning pitting, subungual hyperkeratosis, 
onycholysis, total nail destruction and nail thickness, but afte 20 weeks no difference was 
seen anymore between the treated and untreated hands (Yu and King, 1992). 
Grenz rays are very soft X-rays not penetrating the skin. In a randomized, double-blind 
study of 22 patients, 5 Gy of Grenz rays were applied in ten weekly courses to one hand 
only. Only 1 patient showed complete clearance, 7 mild improvement and 14 remained 
unchanged. Only non-hyperkeratotic lesions responded, which might have to be expected as 
Grenz rays do not penetrate the skin and hyperkeratosis. Six months after the irradiation, 2 
patients were improved, two had worsened, and 18 remained unchanged. Slight nail fold 
pigmentation was the only adverse effect (Lindelöf, 1989). 
Electron beam therapy was chosen by another group as the electrons are able to penetrate 
the nail bed (Kwang et al, 1995). Twelve patients were treated on one hand with a weekly 
dose of 750 cGy for a period of 8 weeks. Assessment at 3, 6 and 12 months showed 
improvement in 3 patients, slight improvement in 6 subjects, and a complete failure in 3 
individuals after 3 months. At 6 and 12 months, only one patient continued to improve, 9 
regressed to pretreatment conditions. A temporary deep brown-black discoloration of the 
treated nails was observed in some subjects.  
All ionizing treatments have to be used with utmost care as long-term side effects may 
occur, often so late that the patient does not remember to have been treated with this 
modality. 
9.3.4 Climatotherapy 
Climatotherapy, in particular balneotherapy in sunny regions, is very popular in countries 
with little sunshine. It often has a positive  effect on the skin and the emotional aspect of the 
patients. Although some patients claim that also their nails improve there are no systematic 
evaluations of the treatment modality on psoriatic nails. 
9.4 Systemic therapies 
Systemic treatments are indicated when there is wide-spread skin involvement. Isolated nail 
psoriasis is rarely seen as an indication for systemic therapy. All systemic treatments known 
to reduce skin lesions will also have a beneficial effect on nail lesions. Controlled studies are 
as a whole rather rare.  
9.4.1 Immunosupressive treatments 
Corticosteroids have for a long time given to psoriatics although their disadvantages such 
as general steroid adverse effects, tachyphylaxis and rebound phenomenon have been 





Cyclosporine is a powerful immunosuppressive agent used successfully in wide-spread 
psoriasis. Nail lesions usually also respond favorably. In a median dose of 2.5 mg/kg 
bodyweight daily, cyclosporine effectively reduces skin and nail psoriasis. In a comparative 
trial, cyclosporine versus etretinate were given to 210 patients two thirds of whom had nail 
involvement. At the end of 10 weeks, both groups showed slight improvement of their nails 
which continued in the group that continued with tapered cyclosporine (Mahrle et al, 1995). 
Another patient was treated for her severe nail psoriasis with cyclosporine 3mg/kg/d, and 
the dose was increased twice by one mg after 4 weeks each. After 16 weeks, both skin and 
nails had improved with the nail improvement having been considerably faster. “Proximal 
nail clearing” was observed to be 45 to 60%. The patient stopped cyclosporine on her own 
because of drug-induced hypertrichosis (Arnold et al, 1993). In a retrospective evaluation, 
cyclosporine was found to improve the NAPSI score after 12, 24 and 48 weeks by 40%, 72%, 
and 89%, respectively (Sánchez-Regaña et al, 2011).  
Cyclosporine adverse effects, such as gastrointestinal symptoms, fatigue, leg cramps, 
diastolic blood pressure increase, and peripheral oedema were more common than in the 
etretinate group that suffered more skin symptoms like dry skin, cheilitis, and dry mouth 
(Mahrle et al, 1995). 
Even though there are many reports on treatment of moderate to severe skin psoriasis 
with methotrexate, tacrolimus, mycophenolate mofetil, hydroxyurea, 6-thioguanine, 
sulfasalazine, fumaric esters, azathioprine, carbamazepine, calcitriol, and 
propylthiouracil, controlled studies concerning nail lesions in these patient cohorts are 
lacking. However, one may assume that they might also improve nail lesions when they 
are able to improve the skin. 
Methotrexate is still often administered for wide-spread skin psoriasis although lung, 
liver and kidney fibrosis are well documented adverse effects of long-term treatment. 
There is only one report specificially relating to MTX low dose therapy for 20-nail 
psoriasis (Lee, 2009). In an evaluation of patients with nail psoriasis treated systemically, 
MTX produced NAPSI score improvements of 7%, 31%, and 35%, respectively, after 12, 24 
and 48 weeks (Sánchez-Regaña et al, 2011). MTX as a classical cytostatic drug not only 
inhibits the inflammatory and hyperproliferative processes of psoriasis but may also slow 
down nail growth speed making it difficult to observe a positive effect in a reasonable 
time period. 
9.4.2 Retinoids 
Retinoids are vitamin A derivatives that are used for disorders of keratinisation. Their use 
in skin psoriasis is well documented with a number of studies. However, their potentials 
in nail psoriasis have not independently and systematically be studied (Tosti et al, 2009). 
In a comparative evaluation, acitretin was found to reduce the NAPSI score after 12, 24 
and 48 weeks by 19%, 41%, and 52%, respectively during the treatment of moderate to 
severe skin psoriasis (Sánchez-Regaña et al, 2011). Acitretin is a first-line drug in pustular 
psoriasis, reduces subungual hyperkeratosis  and improves symptoms in severe nail 
psoriasis (Duhard-Brohan, 1999, Piraccini et al, 2001, Tosti et al, 2009). Apart from the 
many potential side effects of retinoids, they may be onychodestructive in high doses as is 
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Nimesulide is a non-steroidal anti-inflammatory agent. After first positive experience 
(Piraccini e al 1994) it was given to 13 patients with pustular nail psoriasis of whom 4 
responded well to twice daily 100 mg. All these 4 responders relapsed after withdrawal of 
the drug (Piraccini et al 2001). It was judged as not being superior to other drugs.  
9.4.4 Biologics 
An increasing number of “biologics” have been developed in the last decade. They 
counteract extremely potent immunological targets such as tumor necrosis factor-α (TNF-α), 
T cells, B cells, various cytokines, some immunoglobulins and key enzymes. A variety of 
them has been used in psoriasis, often with astonishing success (Lawry, 2007). Also nail 
psoriasis was the object of some studies. This chapter is, however, not suited to discuss all  
as this will be discussed in the psoriasis treatment chapters. 
9.4.4.1 TNF-inhibitors 
TNF- promotes cytokine secretion, such as interleukin (IL)-1, IL-6, IL-8, by macrophages and 
other inflammatory cells, activates T cells and induces adhesion molecule expression by 
vascular endothelial cells which in turn promote angiogenesis and keratinocyte proliferation, 








Structure Chimaeric antibody Human monoclonal 
antibody 
Human fusion protein 
Application Intravenous infusion Subcutaneous Subcutaneous 
Dosage 5 mg/kg at weeks 0, 
2, 6, then every 8 
weeks 
Loading dose: week 0 
2x40 mg, week 1 40 
mg, then 40 mg every 
2 weeks 
50 mg/week, or 
2x50mg/week for 12 
weeks 






Table 5. Application, dosage and indications of the commonly used TNF- antagonists 
Infliximab (Remicade®) is an inhibitor of TNF-, which is a proinflammatory cytokine in 
psoriasis, psoriatic arthritis, ankylosing spondylitis, Reiter’s disease and several more 
chronic inflammatory diseases. Given as an intravenous infusion of 5 mg/kg at weeks 0, 
2, 6, and then every 8 weeks, infliximab, a chimeric monoclonal antibody, is effective in 
psoriasis, psoriatic nail lesions (Reich et al, 2005), psoriatic arthritis and Reiter’s disease 
including its nail changes (Gaylis, 2003). Many reports have described the dramatic 
infliximab-induced improvement of both psoriatic skin and nail lesions (Antoni et al, 
2005a, 2005b, Rich et al, 2008, Hussain et al, 2008,  Reich, 2009). Another study showed a 
reduction of the mean NAPSI of 55.8 at baseline to 29.8 at week 14 and 3.3 at 38 





24 and 48 weeks was 50%, 81%, and 92%, respectively (Sánchez-Regaña et al 2011). There 
appears to be general agreement that infliximab is the most potent antipsoriatic biologic 
(Noiles and Vender, 2009). 
Adalimumab (Humira®) is a human antibody. In an open study, significant NAPSI 
reductions were obtained for finger and toe nails both in patients with cutaneous psoriasis 
as well as with psoriatic arthritis (Rigopoulos et al, 2010). In a large cohort of 442 patients 
with psoriatic arthritis, the mean NAPSI was reduced by 44% (Van den Bosch et al, 2010). 
Nail psoriasis response may be rapid (Irla and Yawalkar, 2009) although some authors 
found skin lesions to respond less than articular inflammation (Otten et al, 2011). In a group 
of ankylosing spondylitis and psoriatic arthritis patients, the NAPSI score was demonstrated 
to be reduced by 6 points (Rudwaleit  et al, 2010). Adalimumab-induced improvement in 
nail psoriasis correlated with a good response in palmar plantar psoriasis (Langley et al, 
2011). In the Spanish study, NAPSI improvement after 12, 24 and 48 weeks was  37%, 73%, 
84%, respectively. Adalimumab was also beneficial for nail psoriasis after etanercept 
treatment (Puig et al, 2010). 
Etanercept, a fully human  TNF-α receptor fusion protein, binds TNF-α with greater 
affinity than natural receptors. The bound TNF-α is biologically inactive and many of the 
proinflammatory pathways responsible for initiation, maintenance, and recurrence of skin 
lesions in psoriasis are inhibited (Weinberg, 2003). The starting dose is twice weekly 50 
mg subcutaneously, which may be reduced to once weekly 50 mg or twice weekly 25 mg. 
In a comparison of systemic nail psoriasis treatments, NAPSI improvement after 12, 24 
and 48 weeks was 24%, 68%, and 87%, respectively (Sánchez-Regaña et al, 2011). The 
commonest adverse effect is an irritation reaction at the injection site. Infections and 
reactivations may occur as in infliximab treatment though probably less commonly. It 
should not be combined with systemic corticosteroids (Sanchez et al, 2006, Scheinfeld, 
2004). There are some otherwise rare skin diseases that have been observed during 
etanercept treatment, such as lupus erythematosus, vasculitis, eosinophilic cellulitis like 
inflammation and interstitial granulomatous dermatitis (Scheinfeld, 2004, Winfield et al, 
2006, Deng et al, 2006).  
Golimumab (Simponi®) is a new human monoclonal antibody against TNF- binding with 
high affinity and specificity to soluble and transmembrane TNF-. It was studied once in 
psoriasis and nail psoriasis and showed an improvement in the NAPSI score of 25% and 
43% after 14 weeks and 33% and 54% after 24 weeks in a dose of 50mg or 100 mg 
subcutaneously, respectively, at weeks 0, 4, 8, 12, 16, and 20 (Kavanaugh et al, 2009). 
Certulizumab (Cimzia®) has not been used in nail psoriasis (Gartlehner et al, 2009). 
All TNF- inhibitors were reported to have induced psoriasis or psoriasiform skin and nail 
lesions (Sfikakis et al, 2005, Wollina et al, 2010). The spectrum of conditions induced by 
TNF- is very wide and it apparently does not depend on the specific disease treated nor on 
the anti-TNF- agent used (Pine et al, 2010, Conrad et al, 2011; Lee et al 2011). In more than 
half of the cases, the TNF- induced skin lesions were successfully suppressed despite 
continuation of the drug. It is speculated that as TNF- blockade is one of the strongest 
inducers of interferon- production an unabated IFN- production by plasmocytoid 
dendritic cells might result in these paradoxical psoriasis flares under anti-TNF- treatment 
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24 and 48 weeks was 50%, 81%, and 92%, respectively (Sánchez-Regaña et al 2011). There 
appears to be general agreement that infliximab is the most potent antipsoriatic biologic 
(Noiles and Vender, 2009). 
Adalimumab (Humira®) is a human antibody. In an open study, significant NAPSI 
reductions were obtained for finger and toe nails both in patients with cutaneous psoriasis 
as well as with psoriatic arthritis (Rigopoulos et al, 2010). In a large cohort of 442 patients 
with psoriatic arthritis, the mean NAPSI was reduced by 44% (Van den Bosch et al, 2010). 
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84%, respectively. Adalimumab was also beneficial for nail psoriasis after etanercept 
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proinflammatory pathways responsible for initiation, maintenance, and recurrence of skin 
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TNF- is very wide and it apparently does not depend on the specific disease treated nor on 
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half of the cases, the TNF- induced skin lesions were successfully suppressed despite 
continuation of the drug. It is speculated that as TNF- blockade is one of the strongest 
inducers of interferon- production an unabated IFN- production by plasmocytoid 
dendritic cells might result in these paradoxical psoriasis flares under anti-TNF- treatment 





Serious adverse events of all TNF- inhibitors include the development of viral, bacterial, 
mycobacterial, and fungal infections (Lowther et al, 2007), reactivation of tuberculosis, 
hepatitis B and C, allergic infusion reactions, malignancies, autoantibody formation with 
lupus erythematosus, pancytopenia and aplastic anaemia, neurological disorders and 
worsening of congestive heart failure (Smolen and Emery, 2011). Experience in pregnancy 
is lacking. Further, infliximab comes with an information what to look for before starting 
a treatment. Paradoxical sarcoidosis while on anti-TNF- treatment was also reported 
(Pine et al, 2010) 
9.4.4.2 T cell inhibitors 
Alefacept (Amevive®) is a human recombinant fusion protein composed of LFA-3 with the 
Fc portion of human IgG. In psoriasis, the inflammatory response is amplified when LFA-3 
molecule-containing antigen presenting cells bind to the CD2+ receptor of T cells, the result 
being T cell activation and the release of proinflammatory cytokines. Alefacept binds to the 
CD2+ receptor of T cells via its LFA-3, thus blocking this interaction with antigen-presenting 
cells. Furthermore, alefacept triggers apoptosis of memory T cells. Through these two 
mechanisms, alefacept decreases the number of pathogenic T cells in psoriasis (Weinberg, 
2003, Lawry 2007). 
Alefacet is usually given in a dose of 15 mg per week for a period of 12 weeks; intravenous 
administration is also possible. At baseline, the CD4+ T cells should be monitored and then 
every 2 weeks. A CD4+ count below 250/µl should prompt to withhold the treatment until 
it has recovered. As alefacept has proven to be very safe the 2-weekly CD4 cell count may be 
delayed. Side effects include pruritus, headache, fatigue, nausea, viral upper respiratory 
infections, and arthralgias. Malignancy and serious infections do not appear to occur more 
frequently with alefacept use (Scheinfeld, 2005). 
There are few studies and reports on alefacept use in nail psoriasis (Körver et al, 2006, 
Parrish et al, 2006). In moderate nail psoriasis, 2 patients improved, 2 remained unchanged 
and one worsened (Körver et al, 2006). 
Efalizumab (Raptiva®) is a humanized  monoclonal antibody against the CD11 portion of 
the LFA-1 molecule on lymphocytes. LFA-1 usually binds to intercellular adhesion molecule 
and promotes lymphocyte migration. The binding of efalizumab to CD11a cells is reversible 
and does not deplete T cells, but it prevents them from migrating into the skin (Weinberg, 
2003). It has shown efficacy in the treatment of cutaneous and nail psoriasis but the 
European Medicines Agency (EMA) recommended its suspension of the marketing 
authorization after the occurrence of cases of progressive multifocal leukoencephalopathy 
(19 February 2009 Doc. Ref. EMEA/CHMP/20857/2009). 
Cytokine inhibitors 
Ustekinumab (Stelara®) is a new human IgG1k monoclonal antibody to the p40 epitope 
common to both IL-12 and IL-23. It blocks the differentiation and expansion of T helper cells 
1 and 17 (Leonardi et al, 2008). It is indicated in moderate-to-severe psoriasis resistant to 
other therapies or with contraindications or intolerance to other systemic treatments. 
Ustekinumab is given in a dose of 45 mg for individuals under 100 kg body weight. In a 





marked improvement of his nail signs was noted after 4 weeks. A complete cure was 
achieved 4 weeks later after the second injection (Rallis et al, 2010). 
Tocilizumab (Actemra®) is an IL-6 receptor inhibitor. No reports on nail psoriasis treatment 
have been published hitherto. 
T cell inhibitors 
Abatacept (Orencia®) is a soluble chimeric protein consisting of the extracellular domain of 
human CD152 linked to the modified Fc portion of human IgG1. By binding to B7-1 (CD80) 
and B7-2 (CD86) molecules on antigen presenting cells, CTLA4Ig blocks the CD28-mediated 
costimulatory signal for T cell activation. Success with abatacept has been noted in psoriasis. 
Abatacept was administered to two patients with refractory psoriasis and psoriatic arthritis 
after the patients had failed all conventional treatment methods. Both patients experienced 
very brief improvement in disease (Altmeyer et al, 2011). 
Rituximab, a B cell depleting chimeric antibody has no place in the treatment of nail 
psoriasis. 
9.5 Combined treatments 
In clinical routine, different treatments are often combined as one is either insufficient or too 
slow. The combination should always consist of drugs with different mechanisms of action. 
In contrast to skin psoriasis, there are almost no studies on the effect of combination therapy 
on nail psoriasis (Jiaravuthisan et al 2007). A single-blinded study on 54 patients with nail 
psoriasis examined the effects of cyclosporine monotherapy versus cyclosporine 
systemically plus calcipotiriol cream topically (Feliciani et al 2004). The cyclosporine dose 
was 3.5 to 4.5 mg/d, calcipotriol was applied twice daily. After 3 months, the combined 
treatment showed significant improvement of pitting, subungual hyperkeratosis and 
onycholysis in 79%, whereas the cyclosporine monotherapy group showed 48% marked 
improvement. Six months after treatment, the cyclosporine monotherapy group showed a 
relapse rate of 52.9% (9/17), whereas only 37% (10/27) of patients in the combined therapy 
group had any signs of recurrence. 
10. Conclusion 
Nail psoriasis is frequent in psoriatic subjects with about 50% of psoriasis patients 
presenting with nail changes at any time and a life-time prevalence of up to 90%. Nail 
psoriasis has a strong genetic background and a frequent association with psoriatic 
arthritis. The most frequent signs of nail matrix involvement are pitting, leukonychia, 
crumbling and red spots in the lunula, whereas salmon or oil spots, subungual 
hyperkeratosis, onycholysis and splinter haemorrages represent changes of nail bed 
involvement. Understanding the mechanism of psoriatic nail sign development requires 
some basic knowledge of the nail organ, its specific reaction patterns and of nail 
histopathology. Nail psoriasis has a serious impact on the quality of life interfering 
particularly with manual work but also being cosmetically embarrassing. Treatment of 
nail psoriasis is difficult as the matrix pathology is hidden by the proximal nail fold and 
the nail bed changes are protected against treatment by the overlying nail plate and nail 
bed hyperkeratosis. Progress has been made with the new biologic drugs, which are 
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mechanisms, alefacept decreases the number of pathogenic T cells in psoriasis (Weinberg, 
2003, Lawry 2007). 
Alefacet is usually given in a dose of 15 mg per week for a period of 12 weeks; intravenous 
administration is also possible. At baseline, the CD4+ T cells should be monitored and then 
every 2 weeks. A CD4+ count below 250/µl should prompt to withhold the treatment until 
it has recovered. As alefacept has proven to be very safe the 2-weekly CD4 cell count may be 
delayed. Side effects include pruritus, headache, fatigue, nausea, viral upper respiratory 
infections, and arthralgias. Malignancy and serious infections do not appear to occur more 
frequently with alefacept use (Scheinfeld, 2005). 
There are few studies and reports on alefacept use in nail psoriasis (Körver et al, 2006, 
Parrish et al, 2006). In moderate nail psoriasis, 2 patients improved, 2 remained unchanged 
and one worsened (Körver et al, 2006). 
Efalizumab (Raptiva®) is a humanized  monoclonal antibody against the CD11 portion of 
the LFA-1 molecule on lymphocytes. LFA-1 usually binds to intercellular adhesion molecule 
and promotes lymphocyte migration. The binding of efalizumab to CD11a cells is reversible 
and does not deplete T cells, but it prevents them from migrating into the skin (Weinberg, 
2003). It has shown efficacy in the treatment of cutaneous and nail psoriasis but the 
European Medicines Agency (EMA) recommended its suspension of the marketing 
authorization after the occurrence of cases of progressive multifocal leukoencephalopathy 
(19 February 2009 Doc. Ref. EMEA/CHMP/20857/2009). 
Cytokine inhibitors 
Ustekinumab (Stelara®) is a new human IgG1k monoclonal antibody to the p40 epitope 
common to both IL-12 and IL-23. It blocks the differentiation and expansion of T helper cells 
1 and 17 (Leonardi et al, 2008). It is indicated in moderate-to-severe psoriasis resistant to 
other therapies or with contraindications or intolerance to other systemic treatments. 
Ustekinumab is given in a dose of 45 mg for individuals under 100 kg body weight. In a 





marked improvement of his nail signs was noted after 4 weeks. A complete cure was 
achieved 4 weeks later after the second injection (Rallis et al, 2010). 
Tocilizumab (Actemra®) is an IL-6 receptor inhibitor. No reports on nail psoriasis treatment 
have been published hitherto. 
T cell inhibitors 
Abatacept (Orencia®) is a soluble chimeric protein consisting of the extracellular domain of 
human CD152 linked to the modified Fc portion of human IgG1. By binding to B7-1 (CD80) 
and B7-2 (CD86) molecules on antigen presenting cells, CTLA4Ig blocks the CD28-mediated 
costimulatory signal for T cell activation. Success with abatacept has been noted in psoriasis. 
Abatacept was administered to two patients with refractory psoriasis and psoriatic arthritis 
after the patients had failed all conventional treatment methods. Both patients experienced 
very brief improvement in disease (Altmeyer et al, 2011). 
Rituximab, a B cell depleting chimeric antibody has no place in the treatment of nail 
psoriasis. 
9.5 Combined treatments 
In clinical routine, different treatments are often combined as one is either insufficient or too 
slow. The combination should always consist of drugs with different mechanisms of action. 
In contrast to skin psoriasis, there are almost no studies on the effect of combination therapy 
on nail psoriasis (Jiaravuthisan et al 2007). A single-blinded study on 54 patients with nail 
psoriasis examined the effects of cyclosporine monotherapy versus cyclosporine 
systemically plus calcipotiriol cream topically (Feliciani et al 2004). The cyclosporine dose 
was 3.5 to 4.5 mg/d, calcipotriol was applied twice daily. After 3 months, the combined 
treatment showed significant improvement of pitting, subungual hyperkeratosis and 
onycholysis in 79%, whereas the cyclosporine monotherapy group showed 48% marked 
improvement. Six months after treatment, the cyclosporine monotherapy group showed a 
relapse rate of 52.9% (9/17), whereas only 37% (10/27) of patients in the combined therapy 
group had any signs of recurrence. 
10. Conclusion 
Nail psoriasis is frequent in psoriatic subjects with about 50% of psoriasis patients 
presenting with nail changes at any time and a life-time prevalence of up to 90%. Nail 
psoriasis has a strong genetic background and a frequent association with psoriatic 
arthritis. The most frequent signs of nail matrix involvement are pitting, leukonychia, 
crumbling and red spots in the lunula, whereas salmon or oil spots, subungual 
hyperkeratosis, onycholysis and splinter haemorrages represent changes of nail bed 
involvement. Understanding the mechanism of psoriatic nail sign development requires 
some basic knowledge of the nail organ, its specific reaction patterns and of nail 
histopathology. Nail psoriasis has a serious impact on the quality of life interfering 
particularly with manual work but also being cosmetically embarrassing. Treatment of 
nail psoriasis is difficult as the matrix pathology is hidden by the proximal nail fold and 
the nail bed changes are protected against treatment by the overlying nail plate and nail 
bed hyperkeratosis. Progress has been made with the new biologic drugs, which are 
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1. Introduction 
Nowadays stress is a normal part of everyday living and the physiological and behavioral 
consequences of exposure to stressful situations have been extensively studied for decades. 
The neuroendocrine stress response is a necessary mechanism but disrupts homeostatic 
process and it is subserved by a complex system located in both the central nervous system 
(CNS) and the periphery. Stressor-induced activation of the hypothalamus–pituitary–
adrenal (HPA) axis and the sympathetic nervous system (SNS) results in a series of neural 
and endocrine adaptations known as the "stress response" or "stress cascade." The stress 
cascade is responsible for allowing the body to make the necessary physiological and 
metabolic changes required to cope with the demands of a homeostatic challenge. In recent 
years, evidence has suggested that stress responses are not only under control of the CNS 
but are influenced by peripheral tissue, outside of the classical HPA axis. Corticotrophin-
releasing hormone (CRH) is a central component of the HPA axis and is an important 
coordinator of the systemic stress response with subsequent modulation of the 
inflammatory response. In peripheral sites, cutaneous CRH and CRH-receptor1 (CRH-R1) is 
believed to regulate various functions of the skin that are important for local homeostasis. 
Common inflammatory skin disorders such as atopic dermatitis and psoriasis exhibit 
decreased barrier function and recent studies suggest that the complex response of 
epidermal cells to barrier disruption may aggravate, maintain, or even initiate such 
conditions.   
2. Overview of the stress system 
2.1 Historical context  
The concept of stress is as old as medical history itself, dating back at least to the time of 
Hippocrates who referred both to the suffering associated with disease (pathos) and to the 
toil (ponos) — the fight of the body to restore itself to normalcy (Hippocrates, 1923) . In 
more recent history, both Walter Cannon (Cannon, 1939) and Claude Bernard (Bernard, 
1949) described the ability of all organisms to maintain a constancy of their internal milieu 
or homeostasis. 70 years ago Hans Selye, the pioneer of contemporary stress research, first 
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response to stressors when their action is prolonged (Selye, 1936). Therefore as pointed out 
for the first time by Hans Selye in Nature in 1936, stress or ‘noxious agents’ initiate a 
reaction in the body, which he called the ‘general adaptation syndrome’ (GAS). Selye 
distinguished three stages that the body passes when responding to stress in the GAS: 1) the 
first stage is an ‘alarm reaction’, in which the body prepares itself for ‘fight or flight’; 2) the 
second stage of adaptation (provided the organism survives the first stage), is one in which 
a resistance to the stress is built; and 3) finally, if the duration of the stress is sufficiently 
long, the body enters a stage of exhaustion, a sort of aging, due to ‘wear and tear’.  
2.2 Stress system & homeostasis 
Life exists by maintaining a complex dynamic equilibrium or homeostasis that is constantly 
challenged by intrinsic or extrinsic adverse forces, the stressors (Chrousos et al., 1992). Stress 
has been defined in many ways. To the physicist, the term refers to a force, strain or 
pressure applied to a system. However, when the stress response is excessive or in 
appropriate, it disrupts physiological homeostasis and body function and contributes to 
disease production (Burchfield, 1979). Although the stress response of the body is meant to 
maintain stability or homeostasis, long-term activation of the stress system can have a 
hazardous or even lethal effect on the body. For example it increases the risk of obesity, 
heart disease, depression, and a variety of other illnesses (Selye, 1998). According to Hans 
Sely, mental, psychologic or sociologic and metabolic stressors (Kvetnansky et al., 2009) tall 
the stable internal environment of the body, that may contribute directly to the production 
of disease or it can contribute to the development of certain behaviors that increases the risk 
of disease. The process that counteracts this disruption and maintains homeostasis is termed 
allostasis. Allostasis activates a wide range of both general and specific physiological 
systems and behavioral coping mechanisms. The amount of work carried out during 
allostasis is termed the allostatic load and represents the cost(s) to the animal of responding 
to the stimulus. Over the past decade, these terms have been introduced to human stress 
research to differentiate between adaptation, allostasis and the end result, homeostasis, with 
the aim of producing a measurement of allostatic load that can be used to compare the 
effects of a wide range of stimuli. Beyond the "flight-or-fight" response to acute stress, there 
are events in daily life that produce a type of chronic stress and lead over time to wear and 
tear on the body ("allostatic load"). Yet, hormones associated with stress protect the body in 
the short-run and promote adaptation ("allostasis").  
2.3 Stress system: Response & adaptation 
2.3.1 Transient adaptation: Allostasis 
Physiologic systems operate within a dynamic range of steady states and maintain internal 
balance, or homeostasis, in terms of blood pH and electrolyte concentration. When physical 
or psychologic stressors challenge the body, there is activation of sympathoadrenal and 
adrenocortical responses that promote adaptation and survival in the short term. This has 
been referred to as allostasis. For example, during exercise or emotional responses, there is 
transient activation of the hypothalamic-pituitary-adrenocortical (HPA) and 
sympathoadernomedulary (SAM) systems, resulting in the elevation of blood pressure, 
heart rate, and circulating catecholamines and glucocorticoids. The patterns of autonomic, 
neuroendocrine, and behavioral responses vary with the type of stress, the different 
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perceptions of stress by the subject, the extent of control on the stressful stimulus, and the 
active or passive coping mechanisms in response stress (Benarroch 2006). Stressor-induced 
activation of the HPA axis and the SAM results in a series of neural and endocrine 
adaptations known as the "stress response" or "stress cascade." The stress cascade is 
responsible for allowing the body to make the necessary physiological and metabolic 
changes required to cope with the demands of a homeostatic challenge (Miller et al., 2002). 
The strongest stressors produce specific and nonspecific responses. The specific stress 
responses alter an individual to the presence of the stressors, which involve neuroendocrine 
responses such as increased autonomic nervous system activity (Tsigos et al., 2005) (Gold et 
al., 1998). When faced with excessive stress, whether physical or emotional, a subject's 
adaptive responses attain a relatively stereotypic nonspecific nature, referred to by Selye as 
“the general adaptation syndrome.” We now know that the adaptive responses have some 
specificity toward the stressor that generates them, which, however, is progressively lost as 
the severity of the stressor increases. The adaptive response of an individual to stress is 
determined by a multiplicity of genetic, environmental and developmental factors 
(Chrousos et al., 1992) and prenatal life, infancy, childhood and adolescence are critical 
periods characterized by increased vulnerability to stressors (Charmandari et al., 2005).  
2.3.2 Regulation of the stress response  
The orchestrated interplay of several neurotransmitter systems in the brain underlies the 
characteristic phenomenology of behavioral, endocrine, autonomic and immune responses 
to stress (Chrousos, 1998). Stress mediators such as adrenocorticotropic hormone, adrenaline 
and noradrenaline are subsequently released in specific patterns, reflecting the degree of  
HPA, adrenomedullary, and sympathetic nervous system activation (Goldstein et al., 2008). 
All stress responses are centrally integrated in the paraventricular nucleus (PVN) of the 
hypothalamus (Herman et al., 1997 and 2008) and the adrenal glands are their major 
peripheral effectors (Goldstein et al., 2008). Hypophysiotropic CRH neurons of the PVN are 
well known to serve as the origin of the final common pathway of glucocorticoid secretion. 
The powerful and far reaching action of these steroids (including effects upon metabolic, 
inflammatory, immune functions and on mood and behavior) has led to intensive 
investigation into regulatory mechanisms controlling glucocorticoid secretion (Cullinan et 
al., 2000). This hypothalamic neurohormone (CRH) plays a central role in the regulation of 
the HPA-axis, i.e., the final common pathway in the stress response. The activation of CRH 
neurons, increasing both adrenocorticotropic hormone (ACTH) biosynthesis and the best 
marker in  ACTH which reaches a maximum in the first hour, which cortisol is highest 
during the second hour of stress (Dobson et al., 2000). ACTH may play a crucial, perhaps 
direct, role in the regulation of catecholamine biosynthetic enzymes in sympathetic nervous 
system, especially during stress. CRH-R1 is the most abundant subtype found in the anterior 
pituitary and is also widely distributed in the brain (Wong et al., 1994).  Other possible 
factors that may regulate CRH1 receptor mRNA expression in the PVN of rats are 
catecholamine and glucocorticoids. Regarding catecholaminergic regulation, studies show 
that brainstem hemi section, which damaged the ascending noradrenergic bundle at least, 
attenuated the immobilization stress-induced increase in CRH1 receptor mRNA ipsilaterally 
in the PVN. This previous finding may reflect up-regulation of CRH1 receptor mRNA in the 
PVN by noradrenergic input from brainstem nuclei, such as the locus coerulus (LC), during 
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Fig. 1. Multiple feedback loops activating CRH systems during chronic stress. Stress initially 
activates the hypothalamic CRH system (i.e., CRH in the PVN), resulting in the hyper 
secretion of glucocorticoids from the adrenal gland. In addition, the psychological 
component of the stressor stimulates the amygdaloid CRH system (i.e., CRH in the central 
nucleus of the amygdala). Glucocorticoids exert GR-mediated negative feedback effects on 
the biosynthesis and release of CRH in the PVN and ACTH in the anterior pituitary (AP) 
directly or indirectly through the brainstem catecholaminergic nuclei such as the LC, 
resulting in the termination of stress-induced HPA axis activation. In the chronic phase of 
stress, down-regulation of GR in the PVN and other brain structures such as the LC fails to 
restrain hyper function of the HPA axis. Increased CRH in the PVN also induces a putative 
ultra short positive feedback effects on its own biosynthesis through up-regulation of PVN 
CRHr-1. The persistent activation of the HPA axis further up-regulates the amygdaloid CRH 
system involved in the expression of fear and anxiety, and the amygdala may have 
stimulatory effects on the HPA axis. Thus, the hypothalamic and the amygdaloid CRH 
systems cooperatively constitute stress-responsive, anxiety-producing neurocircuitry during 
chronic stress (Makino et al., 2002).  
3. Overview of the HPA axis 
3.1 Historical context of HPAC 
In 1936, Hans Selye reported a historic series of studies on severe stress in rats. Exposure to 
bacterial infection, toxic chemicals, and other life threatening insults consistently caused 
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adrenal gland enlargement with high levels of corticosterone secretion, atrophy of the 
immune organs, and gastric ulcers. All three components of this nonspecific stress response 
are caused by prolonged activation of corticosteroids in the hypothalamic-pituitary-adrenal 
axis (HPAC), resulting in secretion of stress levels of ACTH and glucocorticoids. In spite of 
these harmful effects, glucocorticoids in normal levels are necessary for sustaining life 
(Munck et al., 1984). Here we discuss the key elements of the HPA axis and the 
neuroendocrine response to systemic and local stress.   
3.2 HPA axis-CRH (homeostatic balance) 
CRH, synthesized in the PVN of the hypothalamus, represents the main driving force 
controlling HPA axis activation, the major hormone system responsible to maintain 
homeostatic balance in response to stressful stimuli (Tsigos et al., 1994).  
3.2.1 HPA axis & CRH: Response to systemic stress 
The HPA axis originates from the CRH neurons in the parvocellular subdivision of the PVN 
of hypothalamus, while the sympathetic nervous system is under the regulation of 
brainstem locus coeruleus (LC), clustered with noradrenaline neurons. Morphological and 
immunocytochemical studies have demonstrated that reciprocal projections exist between 
PVN–CRH neurons and LC–NE neurons, forming a CRH–NE–CRH loop, which plays an 
important role in the stressful responses (Maier, 2003) (Pacak et al., 1998) (Pacak et al., 1995). 
Central CRH, via glucocorticoids and catecholamines, inhibits the inflammatory reaction, 
while directly secreted by peripheral nerves CRH stimulates local inflammation (immune 
CRH) (Tsigos et al., 2002). The gene for CRH is expressed, not only in the brain, but also in 
extracranial tissues, (Orth, 1992) (Owens et al., 1991) including normal mammalian skin 
(Slominski et al., 1995) (aSlominski et al., 1993) (bSlominski et al., 1993) (Ermak et al., 1997) 
(Slominski et al., 1998). It has been proposed that an equivalent to the hypothalamic-
pituitary-adrenal axis functions in mammalian skin, in response to local stress (aSlominski 
et al., 1996).  
3.2.2 HPA axis & CRH: Response to local stress  
It has been known for several years that the CRH/ POMC skin system fulfils analogous 
(pro-opiomelanocortin) functions to the HPA stress axis. CRH is the central trigger of HPA 
axis, and together with related peptides urocortin I–III that are the most important elements 
of the body response to stress. These elements regulate behavioral, autonomic, endocrine, 
reproductive, cardiovascular, gastro-intestinal, metabolic and immune systemic functions 
(Aguilera et al., 2001) (Grammatopoulos et al., 2002). Other actions of CRH include local 
immunomodulatory (predominantly proinflammatory) effects (Karalis et al., 1991) 
(Slominski et al., 2003), differing from a central immunosuppressive activity (through the 
HPA axis) (Chrousos 1995). Moreover, expression of CRH and regulated activity of CRH 
receptor type 1 (CRH1) can also play an important role in regulation of local stress response 
in peripheral tissues including skin, gastrointestinal tract or reproductive system. In 
humans, expression of at least eight variants of CRH1 mRNA (α, β, c, d, e, f, g and h) was 
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pathological factors including: growth conditions, onset of labor during pregnancy or 
exposure to ultraviolet irradiation (Michal et al., 2010). Of note, locally produced CRH can 
directly regulate steroid hormone production by adrenals and gonads. Furthermore, CRH in 
the immune cells can induce production and release of POMC derived ACTH and beta-
endorphin peptides. In vertebrates these peptides interact with membrane-bound CRH-R1 
and CRH-R2 (Grammatopoulos et al., 2002) (Hillhouse et al., 2002). Both receptor types 
belong to the group II subfamily of G protein-coupled receptors (GPCRs).  In human skin, 
CRH-R1 is the major receptor, expressed in both epidermal, dermal and subcutis with CRH-
R1α being the most prevalent isoform. The CRH-R2 gene was expressed solely in hair 
follicle keratinocytes and papilla fibroblasts, whereas CRH-R2 antigen was localized 
predominantly in hair follicles, sebaceous and eccrine glands, muscle and blood vessels 
(aSlominski et al., 2004). A hair follicle is a typical stress-responding mini organ with a 
peculiar immune system. The proximal epithelium of an anagen hair follicle is known to be 
an area of immune privilege within the hair follicle immune system, whose collapse may be 
crucial for the pathogenesis of alopecia areata (Christoph et al., 2000). 
3.3 HPA axis–immune system interactions 
It has been known for several decades that stress, whether inflammatory, traumatic or 
psychological, is associated with concurrent activation of the HPA axis. In the early 1990s, it 
also became apparent that cytokines and other humoral mediators of inflammation are 
potent activators of the central stress response, constituting the afferent limb of a feedback 
loop through which the immune/inflammatory system and the CNS communicate 
(Chrousos 1995). All three inflammatory cytokines, tumor necrosis factor-(TNF), interleukin-
1β and interleukin-6 (IL-6) can cause stimulation of the HPA axis alone, or in synergy with 
each other (Chrousos, 1995) (Tsigos et al., 1997). There is evidence to suggest that IL-6, the 
main endocrine cytokine, plays the major role in the immune stimulation of the axis, 
especially in chronic inflammatory stress. Some of the activating effects of cytokines on the 
HPA axis may be exerted indirectly by stimulation of the central catecholaminergic 
pathways. Conversely, activation of the HPA axis has profound inhibitory effects on the 
inflammatory/immune response because virtually all the components of the immune 
response are inhibited by cortisol. Alterations of leukocyte traffic and function, decreases in 
production of cytokines and mediators of inflammation, and inhibition of the latter's effects 
on target tissues are among the main immunosuppressive effects of glucocorticoids 
(Chrousos, 1995) (Elenkov, 1999).  
3.4 HPA: The field of psychoneuroimmunology   
Studies on stress-associated immune dysregulation have interested scientists and clinicians 
in the field of psychoneuroimmunology (PNI). This field focuses on the interactions among 
the central nervous system (CNS), the endocrine system and the immune system, and the 
impact these interactions have on health. Modulation of the immune response by the CNS is 
mediated by a complex network of signals that function in bi-directional communication 
among the nervous, endocrine and immune systems. HPA and SAM axes are the two major 
pathways through which immune function can be altered. The efferent 
sympathetic/adrenomedullary system apparently participates in a major fashion in the 
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interactions of the HPA axis and the immune/inflammatory reaction by being reciprocally 
connected with the CRH system, by receiving and transmitting humoral and nervous 
immune signals from the periphery, by densely innervating both primary and secondary 
lymphoid organs, and by reaching all sites of inflammation via the postganglionic 
sympathetic neurons. When activated during stress, the autonomic system exerts its own 
direct effects on immune organs, which can be immunosuppressive, or both 
immunopotentiating and antiinflammatory. CRH secreted by postganglionic sympathetic 
neurons at inflammatory sites has proinflammatory properties (immune CRH); one of its 
key actions is to degranulate mast cells (Elenkov, 1999).   
4. Overview of skin 
4.1 Skin (epidermal barrier homeostasis) 
The epidermis and its array of appendages undergo ongoing renewal by a process called 
homeostasis. Stem cells in the epidermis have a crucial role in maintaining tissue 
homeostasis by providing new cells to replace those that are constantly lost during tissue 
turnover or following injury (Blanpain et al., 2009). A homeostatic process involved in the 
maintenance of an internal steady state within a defined tissue of an organism, including 
control of cellular proliferation and death(apoptosis) and control of metabolic function. 
Mammalian epidermis is a stratified epithelium that retains the ability to self renews 
under both homeostatic and injury conditions by maintaining a population of mitotically 
active cells in the hair follicles and innermost basal layer (Niemann et al., 2002) (Ito et al., 
2005). The basic mechanisms and signalling pathways that orchestrate epithelial 
morphogenesis in the skin have been designed for protective effect of this organ. The 
stratum corneum is the outermost of the 5 layers of the epidermis and is largely 
responsible for the vital barrier function of the skin. The physical barrier localized 
primarily in the stratum corneum and consists of protein-enriched cells (corneocytes with 
cornified envelope and cytoskeletal elements, as well as corneodesmosomes) and lipid-
enriched intercellular domains. The nucleated epidermis, with its tight, gap and adherens 
junctions, additional desmosomes and cytoskeletal elements, also contributes to the 
barrier. Lipids are synthesized in the keratinocytes during epidermal differentiation and 
are then extruded into the extracellular domains, where they form lipid-enriched 
extracellular layers (Jensen et al., 2009). Activation of HPA axis with release of stress 
neuropeptides is essential for biological homeostasis and responses to external and 
internal challenges (Lotti et al., 1999) (bSlominski et al., 1996).       
4.2 Skin – Neuroendocrine organ 
More than ten years ago a comprehensive model of the skin acting as neuroendocrine organ 
has been proposed (Milstone et al., 1988) (aSlominski et al., 2000). For example, the skin 
synthesizes vitamin D, which enters the circulation and, upon activation, exerts profound 
metabolic and endocrine effects (Kragballe et al., 1996). Although the concept is still 
evolving, it relies on the skin capacity to communicate with the central system and to 
regulate global homeostasis through local production and/or systemic release of classical 
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4.3 Skin – Local stress (neuroendocrine activity) 
Skin as a neuroendocrine organ, is a relatively new addition to the field of cutaneous 
biology; it combines concepts from immunology, endocrinology, and neurobiology to 
unravel the multidirectional communications between brain, the endocrine and immune 
systems, and peripheral organs (Blalock, 1989) (Pennisi, 1997) (Turnbull et al., 1999). In 
this regard, the skin has a unique role because of its location, size, and relative functional 
diversity. Moreover, cutaneous signals sent to neuroendocrine centers may play 
modulatory roles, although peripheral intraorgan or inter systemic communications are 
also necessary to maintain global and local homeostasis. Thus precise stress-response 
coordination is an additional cutaneous function that appears to be served by locally 
expressed neuroendocrine activities (aSlominski et al., 2000) (bSlominski et al., 2000) 
(Slominski et al., 2001).   
4.4 Skin – Stress neuropeptides 
CRH/CRH-R1 system: Is it a cutaneous HPA system? 
Slominski and colleagues have extensively documented the nature of peripheral CRH, its 
receptors and their distribution in human and murine skin. They confirmed that skin stress–
response system was coordinated by a local cutaneous HPA axis-like system. They 
demonstrated that CRH, its receptors, the related neuropeptide urocortin and pro-
opiomelanocortin-derived peptides are expressed locally in normal skin, normal cycling hair 
follicle epithelium, benign and malignant melanocytic lesions and non-melanoma skin 
cancer (bSlominski et al., 2004). Corresponding functional receptors (CRH-R) in the same 
cells confirm paracrine or autocrine modes of action. In human skin, CRH-R1 mediates most 
phenotypic effects of CRH (Slominski et al., 2001) while the main adnexal location of CRH-
R2 indicates a role for this receptor in hair cycling (Kauser et al., 2006). Then a localized 
circuit regulates the peripheral functions of cutaneous CRH/CRH-R1, and the aberrant 
expression of CRH/CRH-R1 in the skin disturbs the local homeostasis and leads to 
abnormal differentiation and proliferation in keratinocytes. Because of the aberrant terminal 
differentiation of keratinocytes, psoriatic plaques have scale on the surface, which breaks in 
the protective barrier (Bowcock et al., 2005). However, dysfunction of keratinocytes may 
decrease CRH/CRH-R1 expression because of disharmony in differentiation and 
proliferation of keratinocytes. Zhou et al., in 2009 found a significant detuning CRH/CRH-
R1 system in psoriatic lesions, which suggests that an aberrant cutaneous HPA system 
might take part in the pathogenesis of psoriasis, especially the formation of plaque. Thus, 
they hypothesize that a cutaneous CRH/CRH-R1 system might be aberrant in lesions of 
psoriasis. The detuning of CRH/CRH-R1 regulation might contribute to the formation of 
plaque in psoriasis (zhou et al., 2009) (Slominski et al., 2005) (Fig. 2). 
POMC is a prohormone that produces various bioactive peptides via a series of enzymatic 
steps in a tissue-specific manner, including ACTH, α-melanocyte stimulating hormone (α-
MSH), and β-endorphin. POMC is expressed not only in the pituitary gland, but also in a 
variety of non-pituitary organs, including the skin (Millington 2006). The production of 
POMC peptides in keratinocytes and melanocytes was found to be under regulatory control 
(Schauer  et al., 1994) being stimulated by UVB, selected cytokines, and by disease 
processes(Slominski et al., 1996c, 1998, 1993a, 1993b)( Chakraborty et al., 1996) ( Winzen et 
al. 1996)( Wakamatsu et al., 1997).  
 




Fig. 2. The skin SNS are mediated via production of CRH and POMC peptides, and 
modulated by the local skin immune system (SIS). Signals originating in the latter and 
represented by proinflammatory cytokines perhaps stimulate production of CRH and 
POMC peptides. In turn, the signals generated by the interaction of CRH, ACTH, MSH, and 
β-endorphin, with their corresponding receptors, counteract the effect of local stress 
(Slominski et al., 2006).   
4.5 Skin – The field of psychoneuroimmunology 
Studies have shown that stress diminishes vaccine responses, exacerbates viral and bacterial 
pathogenesis, slows wound healing and alters autoimmune diseases (McCabe et al., 2000) 
(Padgett et al., 1998) (Teunis et al., 2002) (Dowdell et al., 1999). Because lymphocytes, 
monocytes or macrophages and granulocytes, exhibit receptors for many neuroendocrine 
products of the HPA and SAM axes, such as cortisol and catecholamines, which can cause 
changes in cellular trafficking, proliferation, cytokine secretion, antibody production and 
cytolytic activity .These studies have demonstrated that stress hormones inhibit the 
trafficking of neutrophils, macrophages, antigen-presenting cells, natural killer (NK) cells 
and T and B lymphocytes, suppress the production of proinflammatory cytokines and 
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adaptive immune responses and impair effector functions of macrophages, NK cells and 
lymphocytes. For example, treatment of peripheral blood leukocytes (PBLs) with 
catecholamines in vitro results in the suppression of interleukin-12 (IL-12) synthesis and an 
increase in IL-10 production (Elenkove et al., 1996). Data from both human and animal 
studies show that the connections between the neuroendocrine system and immune system 
provide a finely tuned regulatory system required for health. However, the immune cells 
and cytokines influencing keratinocyte function play a major role in the development and 
pathogenesis of psoriasis.  
5. Overview of psoriasis 
5.1 Psoriasis – Genetic 
It is generally accepted that the genetic background for psoriasis susceptibility is pivotal for 
the appearance of the symptoms. Intensive family studies since the early 1950s and linkage 
analysis studies pointed out several genetic loci that play a role in psoriasis (Bhalerao et al., 
1998). In the last decade, a molecular biology approach emerged to identify abnormally 
expressed genes and proteins contributing to psoriasis (Jackson et al., 1999) (Chen et al., 
2000). Two major genes under investigation are IL12B on chromosome 5q, which expresses 
interleukin-12B; and IL23R on chromosome 1p, which expresses the interleukin-23 receptor, 
and is involved in T cell differentiation. T cells are involved in the inflammatory process that 
leads to psoriasis. These genes are on the pathway that ends up upregulating tumor necrosis 
factor-α and nuclear factor κB, two genes that are involved in inflammation (Nestle et al., 
2009). Genome-wide association studies have also identified several new genomic loci, and 
compelling evidence has shown an interaction between the HLA-C and ERAP 1 loci, 
implicating pathways that integrate epidermal barrier dysfunction with innate and adaptive 
immune dysregulation in psoriasis (Strange et al., 2010).  
5.2 Psoriasis – Keratinocytes 
Psoriasis is a chronic inflammatory disease characterized by epidermal keratinocytic hyper 
proliferation and abnormal differentiation (Abdou et al., 2008). The upper most layer of 
skin, the epidermis, consists primarily of keratinocytes (>90% of all epidermal cells) (Sun et 
al., 1979). The keratin intermediate filament network is responsible for the extremely high 
keratinocyte stiffness and resilience. This could manifest into the rugged protective nature 
of the human epidermis (Lulevich et al., 2010). Therefore, keratinocytes form an effective 
barrier to the entry of protein antigens, chemical irritants, and infectious agents in to the 
body (Fuchs 1995), all while resisting environment stress, external pressure, and sheer force. 
The trigger of the keratinocyte response is thought to be activation of the cellular immune 
system, with T cells, dendritic cells and various immune-related cytokines and chemokines 
implicated in pathogenesis (Lowes et al., 2007).  
5.2.1 Keratinocytes – Dendritic & T cells  
Researchers have identified many of the immune cells involved in psoriasis, and the 
chemical signals they send to each other to coordinate inflammation. The immune system 
consists of an innate immune system, and an adaptive immune system. In the innate system, 
immune cells have receptors that have evolved to target specific proteins and other antigens 
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which are commonly found on pathogens. In the adaptive immune system, immune cells 
respond to proteins and other antigens that they may never have seen before, which are 
presented to them by other cells. The immune cells, such as dendritic cells (Dendritic cells 
are present in tissues in contact with the external environment, such as the skin: Once 
activated, they migrate to the lymph nodes where they interact with T cells and B cells to 
initiate and shape the adaptive immune response)  and T cells, move from the dermis to the 
epidermis, secreting chemical signals, such as tumor necrosis factor-α, interleukin-1β, and 
interleukin-6, which cause inflammation, and interleukin18, 22 which causes keratinocytes 
to proliferate (Banchereau et al., 1998) (Nestle et al., 2009). Recent studies indicate that 
various cytokines play an essential role in the induction and maintenance of psoriatic lesion.   
5.2.2 Keratinocytes – Cytokines   
Various inflammatory cytokines and growth factors have been shown to be strongly 
induced in keratinocytes in psoriatic lesion. Although it is thought that the induction of 
cytokine production is the consequence of the activation of infiltrating immune cells rather 
than a triggering factor for the inflammatory process (Lowes et al., 2007). Three types of 
cytokines elaborated by keratinocytes are of particular interest in this context: growth 
factors for keratinocytes, endothelial cells and neutrophil-attracting chemokines. Several 
growth factors are able to induce keratinocyte proliferation and have been found to be 
highly expressed in lesional psoriatic epidermis. Transforming growth factor α (Elder et al., 
1989) (Addison et al., 2010) and amphiregulin-epidermal growth factor (Cook et al., 1992) 
have been shown to induce epidermal proliferation and reproduce some aspects of the 
psoriatic phenotype when expressed in epidermal keratinocytes in transgenic animals (Cook 
et al., 1999) (Vassar et al., 1991). The epidermal growth factor (EGF) receptor ligand 
amphiregulin (AREG) has been implicated as an important autocrine growth factor in 
several epithelial malignancies and in psoriasis, a hyperproliferative skin disorder. In vitro, 
in vivo and clinical studies are well established the role of growth factors and neuropeptides 
in cutaneous innervation and there is substantial evidence that sensory neuropeptides 
contribute to the development of psoriasis (Saraceno et al., 2006).   
5.2.3 Keratinocytes & peripheral CRH/CRH-R1 
CRH is a central component of the local HPA axis, which has a functional equivalent in 
the skin. The ability of CRH to activate mast cells may explain its proinflammatory actions 
and the pathophysiology of certain skin conditions, which are precipitated or exacerbated 
by stress, such as atopic dermatitis, eczema, psoriasis, and urticaria (Theoharides et al., 
1998). Mast cells are derived from stem cells in the bone marrow and migrate into tissues 
where they are prominently located just below the dermal–epidermal junction; they 
mature, depending on the tissue, under the influence of stem cell factor (SCF), interleukin 
3 (IL-3), IL-4 and IL-9 (Wedemeyer et al., 2000). Mast cell infiltration and/or proliferation 
in the skin can be triggered by SCF released from fibroblasts and other immune cells, 
nerve growth factor (NGF) released from nerve endings, or RANTES (regulated on 
activation, normal T cells, expressed and secreted) (Conti et al., 1998) . Mast cells can also 
secrete SCF  (de Paulis et al., 1999) and NGF  (Xiang et al., 2000), thus affecting their own 
growth and activation (Gagari et al., 1997). The cytokines expressed by mast cells are 
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tumor necrosis factor α (TNF-α) (Wedemeyer et al., 2000). Human mast cells were recently 
shown to be particularly rich in both CRH and the structurally related peptide urocortin 
(Ucn) ( Kempuraj et al., 2004) and express multiple CRH receptor isoforms which suggests 
autocrine actions of CRH(Cao et al., 2003).  
5.2.4 Keratinocytes – CRH & Mast cells 
Skin and hypothalamic mast cells appear to have important physiological functions as 
sensors of stressful events with bidirectional regulation of the HPA axis; a local increase of 
the levels of CRH or Ucn in extracranial tissues under stress could adversely affect different 
disease states (Theoharides et al., 1998). Hypothalamic mast cells are located close to nerve 
endings that contain CRH and can be activated by acute stress (Rozniecki et al., 1999). Acute 
stress can trigger mast cell degranulation (Singh et al., 1999) and increased the number of 
skin mast cells and also can worsened delayed hypersensitivity, effects blocked by 
pretreatment with a CRH receptor antagonist (Kaneko et al., 2003). Neuropeptides can also 
activate mast cells in a receptor-independent manner by activating G proteins directly. 
Regardless of the mechanism of activation, mast cell-derived vasoactive, pro-inflammatory 
and neurosensitizing molecules could act on keratinocytes, endothelial cells or nerve 
endings to liberate additional molecules and lead to chronic inflammation and neuropathic 
hypersensitivity or pain. The Kempuraj et al., findings indicate that mast cells are not only 
the target, but also a potential source of CRH and Ucn that could have both autocrine and 
paracrine functions, especially in allergic inflammatory disorders (Kempuraj et al., 2004), 
atopic dermatitis and  psoriasis exacerbated by stress (Theoharides  et al., 2004).  
5.2.5 Keratinocytes – CRH & Stress 
The study of Mitsuma et al., in 2001 showed that CRH induces the proliferation of 
keratinocytes via interaction with CRH receptors (Mitsuma et al, 2001) and it may indicate 
the possible correlation of the proliferation of keratinocytes and the degree of stress. 
Therefore, activation of the stress system, via the direct and indirect effects of CRH, might 
affect the susceptibility of an individual to certain autoimmune, allergic, infectious, 
inflammatory or neoplastic diseases (Arbiser et al, 1999). The biological effects of CRH have 
been shown to include the inhibition of keratinocyte proliferation and regulation of 
adhesion molecules and cytokines (cSlominski et al, 2000)(Pisarchik et al., 2001)(Quevedo et 
al, 2001)(Zbytek et al, 2002). Dysregulation of the HPA and SAM systems has been proposed 
as one possible underlying cause of stress-induced flares of psoriasis (Heller et al., 2011). 
5.3 Psoriasis & stress 
Generally, in normal individuals, stress elevates stress hormones (i.e., increases cortisol 
levels). However, according to available studies, exposure to stress in psoriatic patients 
has been associated with diminished HPA responses and upregulated sympathic 
adernomedullary (SAM) responses (Richards et al., 2005). Evers et al., found psoriasis 
patients had significantly lower cortisol levels at moments when daily stressors are at 
peak levels. The study also reported that psoriasis patients with overall high levels of 
daily stressors exhibited lower mean cortisol levels, as compared to psoriatics with overall 
low levels of daily stressors (Evers et al., 2010) (Zangeneh et al., 2008). These blunted HPA 
 
Psoriasis and Stress – Psoriasis Aspect of Psychoneuroendocrinology 
 
199 
axis and elevated SAM system responses to stress may be crucial in better understanding 
the inflammatory characteristics of psoriasis, particularly in stress-responders. For 
instance, decreased secretion of cortisol and increased levels of epinephrine (Zangeneh et 
al., 2008) and norepinephrine may stimulate the release of mast cells, affect skin barrier 
function, and upregulate proinflammatory cytokines, which could thereby maintain or 
exacerbate psoriasis severity (Evers et al., 2010).  Some authors have commented that this 
decreased cortisol response may be similar to how psoriasis flares with steroid 
withdrawal, as evidenced by the well known phenomena of steroid-induced psoriasis 
rebound (Richards et al., 2005).  
5.3.1 Psoriasis & steroidogenic capabilities of keratinocytes 
Glucocorticoids are essential for maintaining barrier competency, as exemplified in GR−/− 
mouse, where loss of GR function led to incomplete epidermal stratification, 
hyperproliferation and abnormal differentiation (Bayo et al., 2008). In addition, the cortisol 
analogue dexamethasone has been shown to acutely influence expression of genes 
regulating cell proliferation, differentiation, apoptosis and inflammation in primary human 
keratinocytes (PHK) (Elias 2005) (Stojadinovic et al., 2007). Accordingly, cortisol 
(hydrocortisone) is regarded as the most potent therapy for many inflammatory skin 
conditions including psoriasis and atopic dermatitis. Keratinocytes contain an abundance of 
cholesterol, the precursor to all steroids, as they are capable of synthesizing cholesterol de 
novo (Menon et al., 1985). Additionally, the cholesterol transporter, steroidogenic acute 
regulatory (StAR) protein has been identified in human epidermis by immunofluorescence 
histochemistry (bSlominski, et al., 2004) (Tuckey 2005). Evers's study in 2010 is the first 
longitudinal study of patients with psoriasis to show a relationship between cortisol levels 
and daily stressors, these results suggest that patients who continuously experience higher 
levels of daily stressors are characterized by persistently lower cortisol levels and might thus 
be more vulnerable to the effects of stress on their disease (Everse et al., 2010). Hannen et al., 
in 2011 demonstrated that primary human Keratinocytes (PHK) express all the elements 
required for cortisol steroidogenesis and metabolite pregnenolone through each 
intermediate steroid to cortisol. They showed that normal epidermis and cultured PHK 
express each of the enzymes (CYP11A1, CYP17A1, 3βHSD1, CYP21 and CYP11B1) that are 
required for cortisol synthesis. Collectively these data show that PHK are capable of extra-
adrenal cortisol synthesis, which could be a fundamental pathway in skin biology with 
implications in psoriasis and atopic dermatitis (Hannen et al., 2011). 
5.3.2 Psoriasis & stress axis 
HPA axis is a critical adaptive system that maximizes survival potential in the face of 
physical or psychological challenge. The principal end products of the HPA axis, 
glucocorticoid hormones, act on multiple organ systems, including the brain, to maintain 
homeostatic balance. The brain is a target of stress, and the hippocampus is the first brain 
region, besides the hypothalamus, to be recognized as a target of glucocorticoids (Zangeneh 
et al., 2009). There is increasing evidence that the experience of stressful events is associated 
with the course of chronic inflammatory skin diseases. Buske-Kirschbaum et al., reported 
attenuated responsiveness of the  HPA axis and further, an increased reactivity of the SAM 
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2006) and psoriasis (Buske-Kirschbaum et al., 2010). It has been indicated that the 
redistribution of leukocytes in response to acute stress is mediated by the SAM, since 
adrenalectomy or blockade of β-adrenergic receptors has been found to mitigate this effect 
(Dhabhar et al., 1995) (Engler et al., 2004).  It is widely accepted that the SAM system 
represents a major immunoregulatory system that controls various aspects of immunity 
(Sanders et al., 2002).  
5.3.3 Psoriasis & SAM system: Aspect of psychoneuroimmunology 
It has been suggested that a dysfunctional sympathoadernomedulatory (SAM) system may 
increase the risk of an aberrant immune response, especially under stressful conditions 
when the system is activated. In fact, altered leukocyte distribution to acute stress, for 
example, increased numbers of NK cells, monocytes, CD4+ and CD8+ cells have been 
reported in psoriasis patients (Schmid-Ott et al., 2001). Under non-pathological conditions, 
this process may optimize immunoprotection in the case of wounding or infection. 
However, in the psoriatic patient, leukocyte trafficking to the (chronically inflamed) skin has 
been found to be a major step in the development of psoriatic eruption (Mehlis et al., 2003). 
Thus, the finding of a stress-induced increase of leukocyte trafficking with a potentially 
increased influx of leukocytes into the skin could be of clinical significance, and could at 
least partly explain the often observed stress-induced exacerbation of psoriatic lesions.  
However, there is growing evidence that T cell mediated autoimmune processes and action 
of proinflammatory cytokines cause hyperproliferation of keratinocytes and assume the 
psoriatic phenotype (Krueger et al., 2005). When exposed to psychosocial stress, psoriasis 
patients showed increased monocyte and (activated) T cell number when compared to 
healthy controls. Further, a shift towards a TH1-derived cytokine profile could be identified. 
These findings suggest that in psoriasis patient's stress may change immune functions 
towards a pathological relevant immune profile which could explain the often observed 
aggravation of psoriatic plaques in psoriasis patients under stressful conditions. Just as in 
many dermatologic conditions, psoriasis appears to worsen with stress in a significant 
segment of patients. For example, more than half of patients with psoriasis retrospectively 
report having experienced stressful life events before an exacerbation of the disease (Gupta 
et al., 1989) (Fortune et al., 1998). Studies report that the proportion of psoriasis patients who 
are “stress responders” ranges from 37% to 78% (Picardi et al., 2001).   
5.3.4 Psoriasis & “stress responders” 
Does stress cause or exacerbate psoriasis? 
The answer is both, because the stress response disrupts physiological homeostasis and 
body function and contributes to disease production (Burchfield, 1979). This disruption of 
physiological homeostasis in the skin barrier is the trigger and stressors may contribute 
directly to the production of psoriasis disease or it contributes to the development of stress 
behavior, which increases the risk of disease. Stress has been indicated as a trigger in many 
dermatologic conditions and with each of these conditions, one encounters both patients 
who experience a close chronologic association between stress and exacerbation of their skin 
disease, and patients for whom their emotional states seem to be unrelated to the natural 
course of their cutaneous disorder. These two groups are considered “stress responders” 
 
Psoriasis and Stress – Psoriasis Aspect of Psychoneuroendocrinology 
 
201 
and “non-stress responders,” respectively (Koo 1995).   Psoriasis itself can serve as a stressor 
for patients. Psoriasis can be a disfiguring skin disease causing social stigma. Accordingly, 
patients often suffer significant interpersonal and psychological distress. Patients commonly 
experience difficulties in social interactions, especially in meeting new individuals and 
forming romantic relationships. In general, most patients demonstrate adverse 
psychological consequences, including poor self-esteem, anxiety, depression, and for some, 
even develop suicidal ideation (Russo et al 2004). As psoriasis can cause considerable stress 
for patients and increased levels of stress are likely to exacerbate psoriasis, the disease 
process, thus, becomes a self-perpetuating, vicious cycle (Kimball et al., 2005). Therefore, 
treatment considerations for psoriasis stress responders should integrate methods of 
psychotherapy and pharmacotherapy that can decrease stress.   
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2006) and psoriasis (Buske-Kirschbaum et al., 2010). It has been indicated that the 
redistribution of leukocytes in response to acute stress is mediated by the SAM, since 
adrenalectomy or blockade of β-adrenergic receptors has been found to mitigate this effect 
(Dhabhar et al., 1995) (Engler et al., 2004).  It is widely accepted that the SAM system 
represents a major immunoregulatory system that controls various aspects of immunity 
(Sanders et al., 2002).  
5.3.3 Psoriasis & SAM system: Aspect of psychoneuroimmunology 
It has been suggested that a dysfunctional sympathoadernomedulatory (SAM) system may 
increase the risk of an aberrant immune response, especially under stressful conditions 
when the system is activated. In fact, altered leukocyte distribution to acute stress, for 
example, increased numbers of NK cells, monocytes, CD4+ and CD8+ cells have been 
reported in psoriasis patients (Schmid-Ott et al., 2001). Under non-pathological conditions, 
this process may optimize immunoprotection in the case of wounding or infection. 
However, in the psoriatic patient, leukocyte trafficking to the (chronically inflamed) skin has 
been found to be a major step in the development of psoriatic eruption (Mehlis et al., 2003). 
Thus, the finding of a stress-induced increase of leukocyte trafficking with a potentially 
increased influx of leukocytes into the skin could be of clinical significance, and could at 
least partly explain the often observed stress-induced exacerbation of psoriatic lesions.  
However, there is growing evidence that T cell mediated autoimmune processes and action 
of proinflammatory cytokines cause hyperproliferation of keratinocytes and assume the 
psoriatic phenotype (Krueger et al., 2005). When exposed to psychosocial stress, psoriasis 
patients showed increased monocyte and (activated) T cell number when compared to 
healthy controls. Further, a shift towards a TH1-derived cytokine profile could be identified. 
These findings suggest that in psoriasis patient's stress may change immune functions 
towards a pathological relevant immune profile which could explain the often observed 
aggravation of psoriatic plaques in psoriasis patients under stressful conditions. Just as in 
many dermatologic conditions, psoriasis appears to worsen with stress in a significant 
segment of patients. For example, more than half of patients with psoriasis retrospectively 
report having experienced stressful life events before an exacerbation of the disease (Gupta 
et al., 1989) (Fortune et al., 1998). Studies report that the proportion of psoriasis patients who 
are “stress responders” ranges from 37% to 78% (Picardi et al., 2001).   
5.3.4 Psoriasis & “stress responders” 
Does stress cause or exacerbate psoriasis? 
The answer is both, because the stress response disrupts physiological homeostasis and 
body function and contributes to disease production (Burchfield, 1979). This disruption of 
physiological homeostasis in the skin barrier is the trigger and stressors may contribute 
directly to the production of psoriasis disease or it contributes to the development of stress 
behavior, which increases the risk of disease. Stress has been indicated as a trigger in many 
dermatologic conditions and with each of these conditions, one encounters both patients 
who experience a close chronologic association between stress and exacerbation of their skin 
disease, and patients for whom their emotional states seem to be unrelated to the natural 
course of their cutaneous disorder. These two groups are considered “stress responders” 
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and “non-stress responders,” respectively (Koo 1995).   Psoriasis itself can serve as a stressor 
for patients. Psoriasis can be a disfiguring skin disease causing social stigma. Accordingly, 
patients often suffer significant interpersonal and psychological distress. Patients commonly 
experience difficulties in social interactions, especially in meeting new individuals and 
forming romantic relationships. In general, most patients demonstrate adverse 
psychological consequences, including poor self-esteem, anxiety, depression, and for some, 
even develop suicidal ideation (Russo et al 2004). As psoriasis can cause considerable stress 
for patients and increased levels of stress are likely to exacerbate psoriasis, the disease 
process, thus, becomes a self-perpetuating, vicious cycle (Kimball et al., 2005). Therefore, 
treatment considerations for psoriasis stress responders should integrate methods of 
psychotherapy and pharmacotherapy that can decrease stress.   
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1.1 Skin diseases and psychological factors 
It has been known since antiquity that a connection exists between the skin and the mind. In 
fact, the first documented case of psychodermatosis dates to 1700 BC, when the physician to 
the prince of Persia speculated that the prince’s psoriasis was caused by anxiety over 
succeeding his father to the throne (Shafii & Shafii, 1979). However, it was not until 1891 
that Brocq and Jacquet coined the term neurodermatitis and hypothesised that there was a 
pathological association between the skin and the autonomic nervous system, given that 
itching precipitates the appearance of lesions (Braun-Falco, Plewig, Wolff, & Winkelmann). 
A further 62 years passed before “Emotional Factors in Skin Disease” (Wittkower & Russell, 
1953) was published. Since then, physicians, and dermatologists in particular, have been 
steadily becoming aware of the impact of an individual’s emotional state on skin disease 
and how this organ can reflect, like a mirror, their psychological state. It should come as no 
surprise that these two structures have a common origin in the ectoderm. 
Psychological factors have traditionally been associated with the onset, development, and 
persistence of skin disease (Alexander, 1951) and there is evidence to suggest an association 
between stress and the exacerbation of skin lesions (Kimyai-Asadi & Usman, 2001; Robles, 
2007; Vileikyte, 2007). Recent longitudinal studies of a general hospital population show the 
involvement of psychological factors, such as stress, depression, and anxiety, in individuals 
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outbreaks of psoriasis. In 1998, the National Psoriasis Foundation (NPF) published the 
preliminary results of a survey that had been answered by 18,000 psoriasis patients who 
were members of the NPF. When they were asked to identify the factors that aggravate 
psoriasis, 52% answered that emotional stress was the most frequent trigger. Some 41% 
attributed outbreaks to seasonal changes, 9% to chemical substances, 8% to medications, 8% 
to certain food or diets, 7% to alcohol, and 29% did not know (Annual Report, 1998). Thus, 
emotional stress was considered the most important factor by more of half of the sample. 
Subsequently, their findings were published in a scientific journal (Krueger et al., 2001). 
The high percentage of dermatological patients who need psychiatric care is also striking. 
This ranges from 25.2% reported in a sample of 2579 patients attending a dermatology unit 
(Picardi, Abeni, Melchi, Puddu, & Pasquini, 2000) to 95% of the dermatological patients who 
fulfilled the criteria for a psychiatric disorder and were referred to a psychosomatic 
medicine specialist (Woodruff, Higgins, Du Vivier, & Wessely, 1997). A study that reviewed 
the prevalence of psychiatric symptoms in psoriasis patients found a higher rate of 
psychiatric disorders than in the healthy population (Russo, Ilchef, & Cooper, 2004). 
Similarly, another study found that the prevalence of psychiatric disease among psoriasis 
patients was less than in psychiatric patients but higher than in healthy controls 
(Chaudhury, Das, John, & Ramadasan, 1998). Psoriasis patients experience a greater number 
of stressful events (Jankovic et al., 2009; Malhotra & Mehta, 2008; Picardi et al., 2003). A 
prospective study which measured daily stressors in psoriasis patients found a direct 
association between disease severity and increased itching on days perceived as more 
stressful, but not on days of medium or low stress (Verhoeven et al., 2009). 
It is generally accepted that psoriasis patients experience reduced quality of life (Hong, Koo, 
& Koo, 2008). Compared to healthy subjects, psoriasis patients experience greater physical 
discomfort, mood swings, poor body image and self image, and restricted daily and social 
activities due to their lesions (De Korte, Sprangers, Mombers, & Bos, 2004). Other authors 
have found a stronger association between quality of life and psychological variables and 
fear of rejection than with the physical characteristics of the disease, such as the extent of the 
lesions and their visibility (Kimball, Jacobson, Weiss, Vreeland, & Wu, 2005). In an 
intermediate position, some authors suggest that the relationship between psoriasis and 
psychiatric symptoms could be reciprocal (Devrimci Ozguven, Kundakci, Kumbasar, & 
Boyvat, 2000). 
1.2 Personality, stress, and skin 
Given the role of the skin as the interface between the external and internal environment, 
the personality would be the psychological construct fulfilling the same role between the 
internal and external environment. That is, the personality would be the psychological 
analogue of the skin.  
The term personality represents the different behavioural styles that individuals present in 
their habitual habitats or environments (Davis, 1999). In other words, the personality would 
be the means of responding to the environment. According to Darwinian theory, individuals 
behave in the way that is most conducive to reproductive success. Millon selected several 
characteristics present in all living beings and, based on these, generated a dimensional 
system to classify the way individuals adapt to their environment, thus matching the 
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personality categories presented in DSM-IV (American Psychiatric Association [DSM-IV-
TR], 2000). 
The healthy personality, conceived of in this way, would reflect the specific adaptation 
modes that individuals find effective in their environment. In turn, personality disorders 
would be represented by the various maladaptive response styles that can be attributed to 
deficiencies, imbalances, or conflicts in an individual’s capacity to relate to his or her 
environment (Millon, 2001). In the context of Millon’s evolutionary theory, strategies that 
favour individual survival and reproductive are equivalent to the personality (Million, 
1990). 
Million compared the personality to the immune system. According to this perspective, the 
personality can be studied as an interface between the outer and inner world, as described 
by Freud (Quiroga, 2003), and between the social and biological levels. Just as in the 
biological perspective the skin or immune system protects the individual from external 
attacks and maintains the internal environment in homeostasis, similarly, Million suggested 
that within the framework of the DSM-IV, axis I (clinical disorders due to anxiety or 
depression, etc), would be equivalent to cough or fever, axis II (personality disorders) would 
represent a coping style equivalent to the immune system, and axis IV (psychological and 
social stressors, such as marital or economic conflict) would be analogous to infectious 
agents. 
Personality would be a complex behavioural system that evolved due to the need to deal 
with a threatening environment undergoing constant change (Million, 1990; Millon, 1999). 
Million suggested that the different ways of dealing with the environment may be more or 
less adaptative. It is of interest to apply these ideas to dermatology. Adaptive personality 
styles could modulate external events and ensure, with increased likelihood, the 
maintenance of physiological states that may allow the skin to function in a healthy way. 
However, individuals who experience difficulty in adaptation can be more vulnerable to 
stressful events and their impact on health. That is, biological differences may not only be 
due to genetic factors but to an entire group of environmental factors (Davidson, 2001). 
Studies have shown how certain personality variables can modulate response to stress. 
Associations have been found between the tendency to experience positive or negative 
emotions and extraversion or neuroticism (personality variables), respectively (Ng, 2009). 
These tendencies may modulate the effect that emotional responses to stressful events have 
on the physiology of the skin (Mardaga Solange, 2006). 
In general, psychological stress has been frequently described as a variable that triggers skin 
disease, and has been commonly associated with high levels of sympathetic activation and 
difficulties in regulating emotions (Arck & Paus, 2006; Berg, Svensson, Brandberg, & 
Nordlind, 2008; Gupta, 2008; Gupta & Gupta, 2004; Mastrolonardo, Alicino, Zefferino, 
Pasquini, & Picardi, 2007; Arck, 2006; Picardi, Pasquini, Cattaruzza, Gaetano, Melchi, et al., 
2003; Wright, Cohen, & Cohen, 2005).  
It has also been proposed that patients with skin disease usually present psychological traits 
that would make them vulnerable to stress (Cordan Yazici et al., 2006; Kim et al., 2006; 
Papadopoulos, 2003). In fact, psoriasis-associated psychological vulnerability has been 
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hypothalamic-pituitary-adrenal axis has been found in patients with this disease (Richards, 
Ray, et al., 2005); thus, the link between stressful events and psychological vulnerability may 
play an important role in the development of skin disease (Laguna, Pena Payero, & 
Marquez, 2006).  
Higher levels of alexithymia have been found among psoriasis patients and other skin 
diseases than in control groups (Gupta, 2006). One study assessed alexithymia before and 
after patients received PUVA therapy which led to lesion regression. The level of 
alexithymia did not vary and thus this disorder could not be a response to the severity of the 
lesions or the degree of discomfort occasioned by them (Richards, Fortune, Griffiths, & 
Main, 2005). The authors suggested that alexithymia could be understood as a stable 
internal psychological trait more than as a strategy to cope with the lesions. Other 
researchers have not found higher levels of alexithymia in patients with skin disease 
(Picardi, Pasquini, Cattaruzza, Gaetano, Baliva, et al., 2003). 
Taking this into account, it is not surprising that some authors have proposed psoriasis as a 
psychosomatic disease due to the close link between stress and the exacerbation of psoriasis 
lesions (Ginsburg, 1995; Kilic, Gulec, Gul, & Gulec, 2008). One of the most valuable, 
rigorous, and exhaustive studies of psoriasis concluded that the disease is caused by genetic 
and environmental factors, influenced by psychological stress, and where the patients’ 
attitudes, knowledge of, and behavior towards their disease have a profound effect on its 
course and severity (Ginsburg, 1995). The author suggested that psoriasis, by attacking the 
skin, attacks the individual’s sense of identity. Thus, the relationship between skin and 
identity is implicit. In a survey of NPF members conducted by Jobling, 84% of respondents 
stated that the worst aspect of having psoriasis was the difficulty involved in establishing 
relationships. What is striking is that few respondents had experienced avoidance or 
exclusion, such that the problem was more related to their constant anticipation of this 
occurring rather than it being a real event (Jobling, 1976). 
Doodley and Finlay attempted to define social adjustment in psoriasis patients by 
examining the relationship between subjective experience and various social situations, such 
as wearing a swimming suit (Dooley & Finlay, 1990). They found no correlation between 
chronicity, the natural course of the disease, visibility, and the various measures of social 
adjustment taken by the experimental group compared to the control group. 
In an attempt to provide an in-depth account of the patients’ subjective experience, 
Ginsburg and Link assessed 100 patients using the concept of stigma defined as a negative 
social or biological mark that sets a person off from others and changes how they interact 
with other people due to the anticipation of rejection, among other reasons. Although 
bleeding is not one of the main symptom of psoriasis, it is strongly correlated with stigma. 
This may be caused by scratching scales or their removal that leads to punctate bleeding 
spots known as Auspitz’s sign. Regarding all the aspects of the disease, bleeding lesions was 
the strongest predictor of feelings of being stigmatized and despair. Thus, feelings of 
despair and stigmatization may lead to non-compliance with treatment, possibly 
aggravating the disease (Ginsburg & Link, 1989). 
In relation to feelings of stigmatization, evidence suggests that psoriasis patients fear being 
rejected or negatively labelled, regardless of physical lesions (Richards, Fortune, Griffiths, & 
Main, 2001). This could be modulated by personality variables (Schmid-Ott et al., 2005), as is 
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the case among patients with other skin diseases such as acne (Krejci-Manwaring, Kerchner, 
Feldman, Rapp, & Rapp, 2006). All the evidence suggests that the patients themselves are 
one of the main sources of stigmatization and despair and that these feelings are not caused 
by the disease. 
It has been suggested that psoriasis patients have a particular way of reacting to feelings of 
stigmatization and that their feelings are divided and denied, to the point that the fact of 
being rejected due to psoriasis significantly predicted alcohol consumption, without the 
patient being consciously aware of feeling stigmatized because of the disease. Thus, the 
patients act out their feelings without being aware of their relationship to behaviour 
(Ginsburg & Link, 1993). 
To sum up, psoriasis, as well as other skin diseases, has frequently been associated with 
emotional disturbances, vulnerability to stress, and difficulty in expressing emotions. 
However, up to the present, no personality differences between psoriasis patients and the 
healthy population have been found. Matussek, Agerer & Seibt reported differences in 
personality traits between healthy individuals and those with psoriasis (Matussek, 
Agerer, & Seibt, 1985), but this was not corroborated in later studies conducted by 
Doodley and Finlay (Dooley & Finlay, 1990), Ginsburg et al. (Ginsburg & Link, 1993) and 
Gupta et al. (Gupta et al., 1989). Although some studies have identified personality traits 
associated with the development or exacerbation of skin disease, including psoriasis 
(Magin, Pond, Smith, Watson, & Goode, 2008), no differences have been found between 
the healthy population and the psoriatic population or the findings have not been 
conclusive (Pérez et al., 2000; Willemsen, Roseeuw, & Vanderlinden, 2008). Therefore, 
more research is required on the way personality traits modulate the course of skin 
disease (Verhoeven et al., 2008). For example, the hypothesis that individuals with 
psoriasis share common personality traits that are related to the exacerbation of 
symptoms has only been partially upheld.  
Despite some evidence suggesting that psoriasis patients have poor quality of life, 
experience emotional disturbances, are vulnerable to stressful events, suffer feelings of 
stigmatization that are independent of lesion severity, and possibly share nonfunctional 
personality traits, it cannot be asserted beyond doubt that these patients have personality 
traits that differ from the healthy population.  
2. Is there a different personality profile in psoriasis? 
To test this hypothesis a study including 36 psoriasis patients attending the Reina Sofía 
University Hospital (Murcia, Spain) was conducted. The inclusion criterion was the 
presence of psoriasis as diagnosed by a dermatologist who agreed to participate in the 
study. Patients were recruited between October 2005 and June 2009. 
The exclusion criteria were as follows: severe psychological disorders such as psychosis, 
factitious or simulation disorders, neurological disorders, etc. Given that the Million Index 
of Personality Styles (MIPS) is designed to evaluate the personality of individuals more than 
18 years old, younger patients were excluded. 
Regarding comorbidity, high levels of depression and anxiety are often observed in 
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clinical diagnosis of depression or anxiety. They had never been admitted to a psychiatric 
unit due to either of these disorders, and therefore the results obtained are unlikely to be 
attributable to psychiatric syndromes. 
The Spanish version of the MIPS was used to evaluate the participants’ personality styles 
(Millon, 2001). This index measures the healthy personality and analyzes 24 personality 
dimensions, including a clinical index that measures an individual’s level of adaptation to 
their environment. This instrument has been previously used with dermatological patients 
and has demonstrated sensitivity to differences with a non-dermatological sample (Martín-
Brufau, Corbalán Berná, Ramirez Aandreo, Brufau Redondo, & Limiñana Gras, 2010). The 
instrument consists of different bipolar scales divided into three dimensions: motivating, 
thinking, and behaving styles.  
For details of the participants and the selection procedure, see above. The questionnaires 
were given to the participants by the dermatologist who explained the purpose of the 
research, the requirements for participation and any consequences  for the patients. The 
dermatologist obtained prior consent from the participants. 
The Spanish version of the MIPS was validated using a normative sample of 1184 
individuals (643 women and 541 men) who were used as the control group. The test showed 
good psychometric properties. 
The control group did not present chronic, severe or disfiguring skin disease. It was 
assumed that the sociocultural characteristics of both populations were similar. This 
methodology has been previously used to evaluate personality styles in patients with other 
disorders (Limiñana Gras, Corbalán Berná, & Sánchez López, 2009) and skin diseases 
(Martín-Brufau et al., 2010). 
The Student t-test was used to analyse mean differences between groups and each 
personality scale was compared individually. Those items that did not fulfil the reliability 
index or that the participants did not fill in properly were excluded for the analysis. Mean t 
values were obtained for the 24 personality scales of the MIPS. The SPSS version 17.0 
software package for Mac was used for data analysis. 
The social and demographic data for both groups are shown in Table 1. 
 
Characteristics Mean/percentage psoriasis N=36 
Mean/percentage healthy group 
N=1184 
Female gender, n (%) 22 (59.5%) 634 (54.31%) 
Mean age/range (y) 42.59/(24-86) 37.60/(18-65) 
Table 1. Sociodemographic Data. 
Differences in personality were found between the two groups in the following variables: 
Self-indulging, Other-nurturing, Intuition, Innovation-seeking, Dissenting, Dominating, and 
Acquiescent. The results are shown in Table 2. 
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Personality trait Psoriasis Mean Healthy Mean Student t-test P 
1. (1A) - Pleasure-Enhancing 57.67 62.05 -1.155 .256 
2. (1B) - Pain-Avoiding 43.75 39.86 0.981 .333 
3. (2A) - Actively Modifying 44.56 50.52 -1.371 .179 
4. (2B) - Passively Accommodating 55.89 51.63 0.980 .334 
5. (3A) - Self-Indulging* 41.72 52.14 -2.390 .022 
6. (3B) - Other-Nurturing 60.19 51.64 1.916 .064 
7. (4A) - Externally Focused 46.41 48.59 -0.482 .633 
8. (4B) - Internally Focused 48.67 51.45 -0.570 .572 
9. (5A) - Realistic/Sensing 61.42 58.39 0.859 .396 
10. (5B) - Imaginative/Intuiting* 35.22 42.82 -2.529 .016 
11. (6A) - Thought-Guided 44.25 49.46 -1.251 .219 
12. (6B) - Feeling-Guided  57.83 51.36 1.486 .146 
13. (7A) - Conservation-Seeking  49.67 50.30 -0.155 .878 
14. (7B) - Innovation-Seeking*  33.22 42.67 -2.396 .022 
15. (8A) - Asocial/Withdrawing 55.83 50.60 1.379 .177 
16. (8B) - Gregarious/Outgoing 44.36 51.04 -1.680 .102 
17. (9A) - Anxious/Hesitating 49.47 46.32 0.672 .506 
18. (9B) - Confident/Asserting  44.44 50.89 -1.554 .129 
19. (10A) - Unconventional/Dissenting* 36.97 43.62 -2.170 .037 
20. (10B) - Dutiful/Conforming 59.31 51.93 1.739 .091 
21. (11A) - Submissive/Yielding 45.92 45.33 0.162 .872 
22. (11B) - Dominant/Controlling* 34.47 44.65 -2.436 .020 
23. (12A) - Dissatisfied/Complaining 39.50 44.62 -1.06 .296 
24. (12B) - Cooperative/Agreeing*** 77.58 59.18 5.269 .000 
 Clinical Index** 43.13 50.69 3.111  .004 
*p> .05; ** p>.01; ***p>.000. 
Table 2. Differences Between Psoriasis Patients and the Healthy Sample. 
3. And if so, how do they differ from the normal population? 
Individuals with psoriasis have a tendency towards complying with the wishes of other 
individuals as a motivating style. This tendency is reinforced by the fact that their self-
motivation or self-drive is low. 
Regarding thinking styles, psoriasis patients had lower scores on the intuition scale than the 
healthy population, suggesting that they are more oriented toward practical thinking rather 
than abstract thinking. In addition, they had a tendency not to employ innovative or creative 
ways of thinking. 
In relation to behaving styles, psoriasis patients are more conventional than the reference 
group. They were less dominating and more acquiescent. Overall, they tend to seek 
cooperation and agreement and avoid disagreement as a way of bonding with others. They 
may be dependent, submissive, and lack initiative or their own opinion. In general, the 
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with lower satisfaction with life (Díaz Morales & Sánchez López, 2002). The graph in Figure 
1 depicts these differences. 
 
Fig. 1. Graphical representation of psoriasis (red) and non-dermatological (blue) profiles. 
*p> .05; ** p>.01; ***p>.000. 
The results of our study indicate that individuals with psoriasis tend to avoid distancing 
themselves from others or disagreeing with them. This is suggested by their high scores on 
acquiescence, low dissatisfaction and low dominance, which could be interpreted as a 
protective mechanism used by psoriasis patients due to their fear of being rejected or 
discriminated against (Ulnik, 2007; Ginsburg & Link, 1989; Lu, Duller, van der Valk, & 
Evers, 2003; Schmid-Ott et al., 2005). This is reflected in an increased tendency to be 
externally focussed, as shown by other studies: psoriasis patients have low scores on 
narcissistic traits, are more altruistic and more orientated towards others, and are less 
aggressive in the face of criticism (Bahmer, 2007). Whereas Matussek et al. (Matussek et al., 
1985) found that psoriasis patients presented greater aggressivity toward others compared 
to the healthy population, the findings in our study are compatible with later studies which 
reported a decreased ability to express anger toward others (Ginsburg & Link, 1993) and a 
greater tendency among psoriasis patients who were more sensitive to stress to seek 
approval, to avoid expressing negative emotions and to avoid being rejected (Gupta et al., 
1989). Other studies have also reported that these patients show difficulties in expressing 
feelings of anger and being assertive, which may be a factor making them vulnerable to 
stress (Devrimci Ozguven et al., 2000), and could explain the higher level of acquiescence 
observed in the psoriasis sample. The most relevant aspect of this is that, in contrast to the 
healthy population, individuals with psoriasis change the way they present themselves in 
relation to others, and this may correspond to a given personality profile. Patients may 
behave in this manner to reduce emotional and behavioural conflicts that could damage 
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their relationship with others. It has been found that these patients present attentional bias 
and are more responsive to subtle signs of rejection (Fortune et al., 2003). The tendency to 
avoid rejection is compatible with other findings which suggest that the only association 
with decreased quality of life in psoriasis patients was due to the fear of being rejected 
rather than to the physical characteristics of the lesions, their localization, or severity 
(Fortune, Main, O’Sullivan, & Griffiths, 1997).  
The available data also shows that psoriasis patients have lower scores in self-directedness, 
which reinforces the tendency to be non-dominant and suggests that they are dependent, 
sociable and easily influenced, as reported by other authors (Kilic et al., 2008). However, our 
results indicate that individuals with psoriasis do not have a greater tendency to avoid pain, 
unlike the findings of Kilic who reported that psoriasis patients had higher scores on the 
harm-avoidance item. The high vulnerability to stress found in these patients (Valverde et 
al., 2005) may reinforce their tendency to avoid conflict with others, and may be related to 
the avoidance behavior reported in other studies (da Silva et al., 2006; Magin, Adams, et al., 
2009). Some authors have explained these differences as being a way to compensate for 
poorly regulated emotions that may modulate outbreaks of psoriasis plaques (Picardi et al., 
2005) and which has been confirmed by other studies (Richards, Fortune, et al., 2005). These 
personality traits suggest that, regardless of stressful events or lesion severity, psoriasis may 
be negatively affected by difficulties in managing emotions. 
Concerning the clinical index, psoriasis patients as a group have lower scores than the 
healthy population. This decreased level of adjustment has also been found in other studies 
(Dooley & Finlay, 1990). Given that a low clinical index has been associated with lower life 
satisfaction in general (Díaz Morales & Sánchez López, 2002), this could indicate why 
psoriasis patients have less quality of life than the healthy population (Van Voorhees & 
Fried, 2009), as well as accounting for the psychological disturbances, such as anxiety, 
depression and sexual problems, that have been reported in other studies (eg, Mercan, 
2008). The foregoing suggests that the personality variables measured by MIPS are poorly 
adjusted in the psoriasis population, which probably underlies the psychiatric vulnerability 
reported by other studies (Mastrolonardo et al., 2007; Picardi et al., 2005; Richards, Ray, et 
al., 2005; Valverde et al., 2005). Therefore, as suggested by other authors (Gieler, Niemeier, 
Brosig, & Kupfer, 2002; Melamed & Yosipovitch, 2004), psychological variables should be 
assessed in these patients, who should be referred to mental health specialists (Ginsburg, 
Prystowsky, Kornfeld, & Wolland, 1993; Schneider et al., 2006; Woodruff et al., 1997; 
Yosipovitch & Samuel, 2008). 
4. Controversy 
No consensus exists on the personality of dermatological patients. Buske-Kirschbaum 
suggests that these patients have a common psychological profile (Buske-Kirschbaum et al., 
2004). Despite the existence of features found in such patients, other authors do not accept 
the existence of a profile that differentiates them from the healthy population (Verhoeven et 
al., 2008). Similarly, research on personality variables in a Spanish dermatological 
population (Antuña-Bernardo, 2000), who were assessed using the Eysenck Personality 
Questionnaire, found that there were no differences between the healthy population and 
patients with various skin diseases, including psoriasis. However, they were found to have 
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There may be several reasons why no personality differences have been found between the 
healthy population and psoriasis patients. Firstly, by including all skin diseases, those less 
associated with psychological variables may have obscured the influence of distinctive 
personality patterns, thus hindering the detection of differences between the 2 populations. 
Second, few studies have analyzed the strategies used or differences in the way psoriasis 
patients manage their emotions compared to the healthy population (Fortune, Richards, 
Main, & Griffiths, 2002), whereas, in comparison, psychological research on dermatologic 
patients has mainly focussed on variables such as stress, anxiety and depression. By placing 
too much emphasis on variables such as depression and anxiety, or on psychopathological 
abnormalities based on diagnostic categories, there is an increased risk of losing specificity 
in the search for potential differences between the healthy population and psoriasis patients. 
An increase in psychiatric disorders can be observed in the latter group, but it would be 
more useful to know how these abnormalities arise, how are they qualitatively different, 
and what characterizes this group of patients. The relevance of personality may have 
become lost as a research aim, leading to a reduction in the number of empirical studies 
investigating personality in this group of patients. Finally, another possibility is that 
instruments used in the past to assess personality were not designed to measure specific 
personality variables in this group or were not sufficiently sensitive to detect subtle 
differences. This could explain why some studies have failed to find any differences; 
questionnaires were used that were not designed to assess profound personality structures. 
According to some authors, sensitive instruments are now available for assessing the 
association between personality and disease (Friedman, 1990).  
5. Conclusions 
The most important conclusion is that personality differences were found between the 
healthy population and psoriasis patients. These differences suggest that there is a greater 
tendency among psoriasis patients to be acquiescent and to restrain the expression of 
negative emotions in order to bond with others. The literature and the results from the study 
presented here shows a decreased capacity to adjust to the environment, which could, due 
to poor stress management, increase the risk of suffering psoriasis in susceptible 
individuals.  
The number of subjects in the study presented here was sufficient to establish differences 
between psoriasis patients and healthy participants and the results are consistent with those 
obtained by other authors; however, further studies are needed that include a greater 
number of psoriasis patients, thereby providing stronger support to the results obtained 
here, as well as a greater degree of generalizability. 
If we wish to understand the psychological characteristics of psoriasis patients and their 
characteristic personality styles, future studies should compare the personality of psoriasis 
patients to that of patients with other skin diseases associated with psychological traits in 
order to identify the different adaptation styles, if any.  
Finally, the relevance of these findings lies in their deepening our understanding of the 
psychological problems of psoriasis patients. 
If psychopathological abnormalities, such as depression and anxiety, are observed in 
dermatological patients as a group, then this should lead to investigating potential 
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differences between specific subgroups of dermatological patients, particularly in relation to 
what qualitatively characterizes psoriasis patients as one such subgroup.  
There are few personality studies on dermatological patients, and on psoriasis patients in 
particular, indicating a need for further research in personality psychology and psycho-
dermatology. Such studies would lead to a better understanding of this group of patients 
and to help them better manage stress and the impact this has on their disease, quality of 
life, and their relationships with others. 
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instruments used in the past to assess personality were not designed to measure specific 
personality variables in this group or were not sufficiently sensitive to detect subtle 
differences. This could explain why some studies have failed to find any differences; 
questionnaires were used that were not designed to assess profound personality structures. 
According to some authors, sensitive instruments are now available for assessing the 
association between personality and disease (Friedman, 1990).  
5. Conclusions 
The most important conclusion is that personality differences were found between the 
healthy population and psoriasis patients. These differences suggest that there is a greater 
tendency among psoriasis patients to be acquiescent and to restrain the expression of 
negative emotions in order to bond with others. The literature and the results from the study 
presented here shows a decreased capacity to adjust to the environment, which could, due 
to poor stress management, increase the risk of suffering psoriasis in susceptible 
individuals.  
The number of subjects in the study presented here was sufficient to establish differences 
between psoriasis patients and healthy participants and the results are consistent with those 
obtained by other authors; however, further studies are needed that include a greater 
number of psoriasis patients, thereby providing stronger support to the results obtained 
here, as well as a greater degree of generalizability. 
If we wish to understand the psychological characteristics of psoriasis patients and their 
characteristic personality styles, future studies should compare the personality of psoriasis 
patients to that of patients with other skin diseases associated with psychological traits in 
order to identify the different adaptation styles, if any.  
Finally, the relevance of these findings lies in their deepening our understanding of the 
psychological problems of psoriasis patients. 
If psychopathological abnormalities, such as depression and anxiety, are observed in 
dermatological patients as a group, then this should lead to investigating potential 
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differences between specific subgroups of dermatological patients, particularly in relation to 
what qualitatively characterizes psoriasis patients as one such subgroup.  
There are few personality studies on dermatological patients, and on psoriasis patients in 
particular, indicating a need for further research in personality psychology and psycho-
dermatology. Such studies would lead to a better understanding of this group of patients 
and to help them better manage stress and the impact this has on their disease, quality of 
life, and their relationships with others. 
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1. Introduction 
Psoriasis is a chronic immune-mediated skin disease with a intricate pathogenesis and a 
strong genetic background (Nickoloff et al., 2007a), that affects approximately 1–3% of the 
worldwide population, with an equal sex distribution (Stern  et al., 2004). The main type of 
psoriasis is chronic plaque psoriasis (Cpp) accounting for approximately 85–90% of all cases. 
The Cpp is characterized by erythematous scaly plaques, usually on elbows, knees, scalp 
and buttocks. Plaque size can diverge from minimal to the involvement of the entire skin 
surface (erythrodermic psoriasis) (C. E. Griffiths et al., 2007; Nestle et al., 2009). Other forms 
of psoriasis comprise guttate psoriasis, inverse, palmoplantar and  generalized pustular 
psoriasis (C. E. Griffiths & Barker, 2007; Nestle et al., 2009). 
The concept of psoriasis as “the disease of healthy people” has long been surpassed,  
nowadays we know that during the time course of this disease, as a consequence of 
dysregulated immunity and ensuing inflammation, certain conditions may appear at 
somewhat unpredictable time points in a progressive fashion;  these so-called co-
morbidities, although targeting different organs, share common pathogenetic factors. They 
often become manifest years after the onset of skin manifestations and are often observed in 
severe forms of psoriasis. 
Psoriatic Arthritis (PsA) is traditionally included among common co-morbidities, even if it 
should be rather considered a component of the clinical spectrum of psoriatic disease. PsA 
involves peripheral joints, the axial skeleton, sacroiliac joints, nails and enthuses, and is 
frequently associated with psoriatic skin lesions. The prevalence of PsA ranges from 5 to 
40% among psoriatic patients lesions (D. D. Gladman, 2009; Nograles et al., 2009).  
Recently, co-morbidities like cardiovascular disease, obesity and metabolic syndrome have 
been found to be associated with psoriasis, raising the idea that psoriasis might not be only a 
skin disorder (Gerdes & Mrowietz, 2009; Kimball et al., 2008a; Menter et al., 2008). 
Psoriasis patients suffer also from considerable psychological and financial burdens 
resulting in a significantly impaired quality of life (Rapp, et al., 1999); likewise traditional 
systemic psoriasis therapies (methotrexate [MTX], cyclosporin A, retinoids or PUVA 
therapy) have a potential for long-term toxicity and cannot always provide plenty disease 
improvement (Pathirana et al., 2009; Smith  et al., 2009). Thus, the development of agents 
efficiently targeting key steps in the pathogenesis of psoriasis and co-morbidities is clearly 
an important goal. 
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psoriasis is chronic plaque psoriasis (Cpp) accounting for approximately 85–90% of all cases. 
The Cpp is characterized by erythematous scaly plaques, usually on elbows, knees, scalp 
and buttocks. Plaque size can diverge from minimal to the involvement of the entire skin 
surface (erythrodermic psoriasis) (C. E. Griffiths et al., 2007; Nestle et al., 2009). Other forms 
of psoriasis comprise guttate psoriasis, inverse, palmoplantar and  generalized pustular 
psoriasis (C. E. Griffiths & Barker, 2007; Nestle et al., 2009). 
The concept of psoriasis as “the disease of healthy people” has long been surpassed,  
nowadays we know that during the time course of this disease, as a consequence of 
dysregulated immunity and ensuing inflammation, certain conditions may appear at 
somewhat unpredictable time points in a progressive fashion;  these so-called co-
morbidities, although targeting different organs, share common pathogenetic factors. They 
often become manifest years after the onset of skin manifestations and are often observed in 
severe forms of psoriasis. 
Psoriatic Arthritis (PsA) is traditionally included among common co-morbidities, even if it 
should be rather considered a component of the clinical spectrum of psoriatic disease. PsA 
involves peripheral joints, the axial skeleton, sacroiliac joints, nails and enthuses, and is 
frequently associated with psoriatic skin lesions. The prevalence of PsA ranges from 5 to 
40% among psoriatic patients lesions (D. D. Gladman, 2009; Nograles et al., 2009).  
Recently, co-morbidities like cardiovascular disease, obesity and metabolic syndrome have 
been found to be associated with psoriasis, raising the idea that psoriasis might not be only a 
skin disorder (Gerdes & Mrowietz, 2009; Kimball et al., 2008a; Menter et al., 2008). 
Psoriasis patients suffer also from considerable psychological and financial burdens 
resulting in a significantly impaired quality of life (Rapp, et al., 1999); likewise traditional 
systemic psoriasis therapies (methotrexate [MTX], cyclosporin A, retinoids or PUVA 
therapy) have a potential for long-term toxicity and cannot always provide plenty disease 
improvement (Pathirana et al., 2009; Smith  et al., 2009). Thus, the development of agents 
efficiently targeting key steps in the pathogenesis of psoriasis and co-morbidities is clearly 






Psoriasis is thought to be a complex condition  resultant by  a combination of genetic and 
environmental factors. The acute forms of psoriasis, guttate and generalized pustular 
psoriasis (von Zumbusch psoriasis), are both associated with infections (typically b-
haemolytic streptococcal or a viral infection). Other triggering factors which may elicit 
psoriasis in predisposed individuals include trauma (Koebner phenomen) (Eyre & G. G. 
Krueger, 1984), HIV infection (Reveille et al., 1990), psychogenic stress (Gupta et al., 1989) 
and definite drugs (e.g. lithium, beta-blockers, interferons and high dose corticosteroids) 
(Abel et al., 1986).  
Histological examination of psoriatic plaques reveals hyperproliferation of keratinocytes 
(Kcs) with parakeratosis, increased angiogenesis and dermal infiltration of immune cells, 
predominantly T cells, neutrophils, macrophages and dendritic cells (DCs) (Figure 1) 
(Nestle et al., 2009; Nickoloff et al. 2007b).  
 
Fig. 1. Psoriatic skin lesions evolution. Different stimuli (e.g. infections, etc.) can trigger an 
initial episode of psoriasis in genetically predisposed individuals. After starting, the earliest 
events driving the inflammatory eruption are the secretion of INF- from pDCs (plasmacytoid 
dendritic cells) and the production of TNF- by immune cells of both innate and adaptive 
response. Large amounts of IFN- induce activation of the local immune effector cells that 
secrete pro-inflammatory cytokines. TNF- is a very active cytokine of the inflammatory 
infiltrate and is principally secreted by activated macrophages (M), dermal DCs, 
keratinocytes and T cells. The elevated levels of TNF- lead to the maturation of DCs into 
forceful APCs (antigen presenting cells) and, with other cytokines, up-regulates the expression 
of endothelial E-selectin and ICAM-1 attracting further CLA+ T cells in the skin. Also, the 
panel of cytokines released by T cells contributes to the stimulation of epidermal keratinocytes 
and is at least, in some measure, responsible for typical psoriasis skin changes. They induce the 
expression of ICAM-1, CD40 and MHC-II and trigger keratinocyte hyper-proliferation.  
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The increased dermis vascularity is driven by angiogenic factors, such as VEGF (vascular 
endothelial growth factor ), highly present in psoriasis plaques (Detmar et al., 1994). Also,  
the interaction between VEGF and the angiopoietin/Tie signaling pathway is modulated by 
TNF-a (Tumour necrosis factor-a), that together with interleukin 12 (IL-12) and IL-23 are 
well known to be crucial immunological mediators in psoriasis. (Holash et al., 1999; Kuroda 
et al., 2001). Whereas IL-12 induces Th1 (T helper 1) differentiation and thus increases the 
production of TNF-a, IL-23 stimulates primarily Th17 cells, which secrete most importantly 
pro-inflammatory cytokines such as IL-17 and IL-22 (Nestle et al., 2009; Toichi et al., 2006; 
Torti & Feldman, 2007). 
Increased concentrations of TNF-a and IL-12/IL-23 have been found as in psoriatic skin 
(Nestle et al., 2009) as in the synovial fluid and tissue of patients with PsA (FitzGerald & 
Winchester , 2009; Ritchlin et al, 1998). Their role in psoriasis genesis  is highlighted by the 
successful treatment of psoriasis by agents blocking these cytokines (Boker et al., 2007; 
Mössner et al., 2008; Scalon et al., 2009). In addition, polymorphisms of IL-23 receptor gene 
and gene encoding the shared p40 subunit of IL-12 and IL-23 have been linked to psoriasis 
development (Elder et al., 2010; Hüffmaier  et al., 2009; Nestle et al., 2009). 
3. Genetics of psoriasis 
Family studies have shown that psoriasis has a strong genetic component although the 
inheritance pattern is still unclear. 71 % of patients with childhood psoriasis have a positive 
family history (Morris et al., 2001) and  analysis of concordance rates in twin studies show a 
threefold increased risk of psoriasis in monozygotic twins compared to dizygotic twins 
(Brandrup et al., 1978; Pisani & Ruocco, 1984).  
At least ten chromosomal loci have been identified showing statistically significant evidence  
for linkage to psoriasis (PSORS 1-10). However, the only region that has consistently been 
identified in genetic screens of families with psoriasis is the major-histocompatibility 
complex (MHC) region on chromosome 6 named PSORS1 (Capon et al., 2008; Nair et al., 
2006), that is responsible for up to 50 % of genetic susceptibility to psoriasis. Within PSORS1 
the human leukocyte antigen-C (HLA-C) gene which is the strongest candidate gene for 
psoriasis ,  precisely its allele HLACw6 (HLA-Cw*0602) the predominant risk allele (Nair et 
al., 2006): individuals with this allele have a 10-20-fold increased risk of developing psoriasis 
(Mallon et al., 1999).  
HLA-Cw6 positive and negative psoriasis patients may exhibit distinctive clinical 
phenotypes (Henseler & Christophers, 1985): guttate psoriasis is mostly confined to HLA-
Cw6+ patients meanwhile psoriatic nail disease, palmoplantar pustulosis and psoriatic 
arthritis are more common in HLA-Cw6- patients (Fan et al., 2007; Gudjonsson et al., 2006). 
Furthermore, partial or total remission during pregnancy is much more frequent in HLA-
Cw*0602+ women (Gudjonsson et al., 2006).  
Despite this strong association, the functional role of HLA-Cw6 remains unknown; as far as 
we know  HLACw6 may exert its effect through the specific or the innate immune system 
(Figure 2): HLA-Cw6 may act via the adaptive immune system by its antigen presenting 
capacity and the fact that guttate psoriasis (sturdily associated with HLA-Cw6) is triggered 
by streptococcal pharyngitis (J. C. Prinz, 2001), supports this hypothesis. HLA-Cw6 may 
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like receptors) of natural killer (NK) and natural killer T (NKT) cells, which are implicated, 
in psoriasis pathogenesis (Nickoloff, 1999a). KIRs recognize different types of HLA-C 
molecules leading to either an overall activating or inhibitory immune response. KIRs have 
been associated with psoriasis and PsA (Martin et al., 2002). HLA-Cw6 is a natural ligand 
for KIR2DL1 (an inhibitory receptor) and it is possible that interaction between HLA-Cw6 
and PaKIR2DL1 would lead to aberrant function of lymphoid cells in psoriasis 
pathogenesis. 
 
Fig. 2. Hypothetical regulating role  of HLA-Cw6 in both specific and innate immune 
responses. 
HLA-Cw6 expressed on APCs can trigger specific immune responses by presentation of 
processed antigen to the TCR of CD8+ T cells. Also, innate immune response can be elicited 
by interaction of HLA-Cw6 with its natural Killer immunoglobulin-like receptors expressed 
on NK and NKT cells. 
A new psoriasis susceptibility gene ZNF313/RNF114, which may regulate T cell activation 
through ubiquitin ligase activity, has been identified (Capon et al., 2008). All these data 
further supports the concept that multiple gene products share a role in the immune 
regulation of psoriasis, contributing to disease pathogenesis.  
4. Immune response 
Although the initial event triggering a psoriatic lesion is still unknown many factors have 
been shown to play a role in the pathogenesis of psoriasis:  physical trauma, infections, 
stress, drugs, alcohol and smoking can all trigger an initial episode of psoriasis in 
individuals with genetic predisposition (Bowcock & J. G. Krueger, 2005). 
This initial trigger activates dendritic cells, favoring their migration to skin-draining lymph 
nodes, where antigen-specific T cells (primed by DCs) differentiate into effector T cells, 
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which  then traffic to the skin where they induce – in concert with other cells, especially 
dermal DCs – the creation of a primary psoriatic plaque. During this step some T cells and 
DCs start to infiltrate the epidermis, where stimulating KCs support  the typical epidermal 
changes (Bowcock & J. G. Krueger, 2005). 
Epidermal keratinocytes are able to recruit and activate T cells and most T cells infiltrating 
psoriatic skin are divided into Th1 (CD4+) and T cytotoxic 1 (Tc1; CD8+) subsets (J. G. 
Krueger, 2002). Two further T cell subtypes, Th17 cells (McKenzie et al., 2006) and 
regulatory T cells (Treg) (Sugiyama et al, 2005) have been identified as important 
contributors to the pathogenesis of autoimmune diseases such as psoriasis (Figure 3).  
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Th1 and Th17 pro-inflammatory cytokines mediate keratinocyte hyperproliferation and 
trigger a ‘vicious cycle’ of inflammation. IL-23 secreted principally by keratinocytes, 
dendritic cells and macrophages  is critical for maintenance of Th17 function. Low levels of 
anti-inflammatory cytokines released by Th2 and Tregs potentially counteract but cannot 
balance the effects of Th1/Th17 cytokines.  
From the foregoing it is clear that the contribution of both innate and adaptive immune 
responses are important in mediating the inflammatory psoriasis cascade (Gaspari, 2006) 
(Figure 1). 
4.1 Aberrant activation of the innate fraction of the skin immune system 
The present knowledge of the possible role of innate immunity cells (Kcs, Dcs, neutrophils, 
macrophages, NK and NKT cells) in psoriasis will be discussed.  
4.1.1 Keratinocytes in psoriasis 
Over the last 20 years it has been regularly discussed if psoriatic skin lesions arise from a 
primary alteration in epidermal keratinocytes or in T cells (Figure 1); the current view is that 
infiltrating T cells initiate and maintain psoriasis. In this vision, cytokines (e.g., IL-1, IL-6 
and IFN-) secreted by T cells and other inflammatory cells (DCs, macrophages and 
neutrophils) would trigger KCs hyperproliferation,   inducing epidermal hyperplasia (J. G. 
Krueger, 2002). In particular, IL-23, whose expression is increased in psoriatic lesion (Piskin 
et al., 2006), has been implied in the development of epidermal acanthosis, most likely 
through the induction of IL-22 (Zheng et al., 2007); injection of  IL-23 into mouse dermis 
induces as dermal inflammation as epidermal hyperplasia similarly to features seen in 
psoriasis (J. R. Chan et al., 2006).  
Previous studies (J. G. Krueger, 2002) suggested an additional explanation for the chronic 
epidermal hyperplasia in psoriatic lesions: the migration of T cells in the epidermis would 
firstly break the basement membrane, which has been shown to have large areas with 
reduced staining intensity for collagen IV and laminins (Fleischmajer et al., 2000), and 
secondly disrupt desmosome connection between KCs. These two events could be 
interpreted by KCs as an injury and therefore induce a wound repair response. As a 
consequence many mitogenic cytokines would be released by KCs triggering a regenerative 
epidermal growth. Hence, T cells in psoriatic epidermis would be responsible for the chronic 
hyperplasia as by releasing pro-inflammatory cytokines as by disrupting epidermal 
integrity. 
Another evidence against the fundamental role of T cells in psoriasis arise from the 
observation that HIV+ patients (which usually have reduced number of CD4+ T cells) 
develop psoriasis with similar frequency as the rest of the population (Namazi, 2004).  
Finally, in 2005 Zenz et al. reported an interesting animal model with psoriasis-like features 
(Zenz et al., 2005); They knocked out JunB and c-Jun, two components of the AP-1 
transcription factor, which control cell proliferation and differentiation , cytokine 
production, and stress responses in the skin. The importance of this animal model lies in the 
fact that JunB is located in the PSORS6 locus, which has been shown to be a psoriasis 
susceptibility region (Hensen et al., 2003). Interestingly, these mice developed not only 
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inflammatory skin lesions but also a form of destructive arthritis. This evidence suggested 
that alteration in the epidermal Jun-pathway may be sufficient to induce inflammatory 
reactions in the skin as well as in the joints. At the skin level these mice showed typical 
hallmarks of psoriasis: hyperkeratosis, enlarged blood vessels, infiltration of T cells and 
neutrophils, and up-regulation of pro-inflammatory cytokines.  
The most intriguing aspect was the examination of the T cells role in development of 
psoriasis in a genetic model: upon deletion of JunB and c-Jun proteins in Rag2-deficient mice 
(mice deficient of  T/B cells), skin changes like in psoriasis were still induced, though they 
were milder. These data suggest a minor role for T cells in the etiology of psoriasis-form 
skin inflammation, and that primary alterations in KCs were sufficient to drive psoriasis-
form changes in the mice skin. But before stating that KCs instigate psoriasis in humans, the 
relevance of this model must be discussed further. A recent study (Haider et al., 2006) 
showed that the JunBwas expression increased in psoriatic plaques instead of 
decreased/deleted as in the Zenz mouse model, suggesting a role for JunB as a 
transcriptional activator of disease-related genes in psoriatic KCs.  
The ongoing discussion about the primary instigator of psoriasis reflects the complexity of 
this disease and the still elusive interplay between KCs and immune cells in driving 
psoriasis. 
This problem was further addressed in a another mouse model, in which STAT-3 was 
constitutively activated in basal KCs under the control of the keratin 5 promoter (K5.Stat3C) 
(Sano et al., 2005). As in human psoriatic plaques, induced lesions of K5.Stat3C mice shown 
a considerable number of CD4+ T and CD8+ T cells in the epidermis. For psoriasis 
development, this model required both activated STAT-3 in KCs and activated T cells in the 
dermis and epidermis of the transgenic rodents, suggesting the theory that KCs and T cells 
could act together in psoriasis pathogenesis. 
4.1.2 Neutrophilic granulocytes 
Early studies in psoriasis (Jablonska, 1986), in which the initial (pre-pinpoint) lesions  were 
studied histologically,indicated that the primary abnormality in a developing lesion of 
psoriasis is the perivascular accumulation of neutrophils as well as their epidermis invasion 
(Kogoj  phenomenon). Next, these neutrophils accumulations lead to microscopically 
detectable microabscesses (Munro abscesses). In many patients with psoriasis, these 
micropustules may enlarge and become clinically visible as sterile 2–3-mm pustules. In some 
patients, pustules are the primary visible abnormality, often on an erythematous base. 
The presence of neutrophils must be important for the formation of psoriatic skin lesions, in 
fact agranulocytosis has been reported to result in the remission of psoriasis (Toichi et al., 
2000). Next, neutrophils can contribute to the hyperproliferation of keratinocytes by the 
effects of human leucocyte-derived elastase (Rogalski et al., 2002). 
4.1.3 Natural killer T cells  
The potential role of cells expressing NK receptors in psoriatic skin was firstly  proposed by 
Nickoloff  (Nickoloff et al., 1999b); in further experiments, he showed that a CD94+/CD161+ 
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The presence of neutrophils must be important for the formation of psoriatic skin lesions, in 
fact agranulocytosis has been reported to result in the remission of psoriasis (Toichi et al., 
2000). Next, neutrophils can contribute to the hyperproliferation of keratinocytes by the 
effects of human leucocyte-derived elastase (Rogalski et al., 2002). 
4.1.3 Natural killer T cells  
The potential role of cells expressing NK receptors in psoriatic skin was firstly  proposed by 
Nickoloff  (Nickoloff et al., 1999b); in further experiments, he showed that a CD94+/CD161+ 





mouse, gave rise to creation of psoriatic plaque characterized by diffuse keratinocyte 
expression of CD1d, CD161+ T cells infiltration and marked presence of mRNA for IFN-c 
and IL-15 (Nickoloff et al., 2000). 
In line with these data, it seems that constitutive CD1d expression on prepsoriatic skin 
keratinocytes represents a primary prerequisite that ensures their contact with the CD161 
molecule on NKT cells. This interaction might also represent one of the critical events in the 
triggering of psoriasis as CD1d-bearing keratinocytes can present endogenous (self) or 
exogenous (bacterial, viral) glycolipids to NKT-cells. Consequently to the recognition of 
glycolipid antigens, NKT cells produce large amounts of IFN-c which induces stronger 
keratinocyte expression of CD1d; in this way the pathogenic mechanism of psoriatic plaques 
is not only initiated but also maintained. 
Numerous studies have addressed the issue of NKT cells in the lesional skin of psoriasis 
patients and a constant result evidenced by independent groups of investigators is that 
CD161+ T cells appear in greater numbers in lesional skin of patients with psoriasis than in 
normal healthy skin and/or prepsoriatic skin (Bonish  et al., 2000; Cameron et al., 2002; 
Curry et al., 2003; Vissers et al., 2004a).  
However, Curry group shown a greater frequency of CD161+ T cells yet in the prepsoriatic 
skin in comparison with the normal skin, suggesting that certain immune response 
dysregulations exists in the uninvolved skin and creates a milieu, promoting the psoriatic 
lesions onset  (Curry et al., 2003). 
A flow cytometric analysis of psoriatic tissue-infiltrating T cell demonstrated the presence of 
CD3+ cells expressing also CD16, CD56, CD158b, CD94 or NKG2A and CD4–CD8–, the 
majority of these is a subset of NKT cells (Liao et al., 2006). In addiction a recent study (Zhao 
et al., 2008) confirmed that NKT cells as well as CD1d molecules were increased within 
psoriatic skin. 
The supposed pathogenic role of NKT cells in psoriasis is also supported by the effects of 
different pharmacological treatments, that decreases NKT cell numbers in psoriatic plaques, 
in particular the clinical efficacy of  betamethasone dipropionate (Bovenschen et al., 2007; 
Vissers et al., 2004b, 2008;) and similarly of alefacept that induce an improvement in plaque 
severity accompanied by significant reductions of dermal CD94+ and CD161+ (Bovenschen 
et al., 2007). 
In general, these data strongly indicate that lesional CD94+ and CD161+ NKT cells actively 
participate in the development and/or maintenance of psoriatic lesions, but the relative 
relevance of each of these subsets remains elusive. However, it might be hypothesized that 
epidermal NKT cells play a major pathogenic role due to their direct interaction with CD1d+ 
keratinocytes and the resulting hyperproliferation while the dermal component of NKT cells 
participates in the immune response through the interaction with CD1d-bearing dermal 
dendritic cells and monocytes. 
Likewise other Th1-mediated autoimmune diseases, psoriasis is associated with decreased 
numbers of circulating NKT cells (Cameron et al., 2003; Koreck et al., 2002; van der Vliet et 
al., 2001;); Koreck reported that decreased percentage of NKT cells population in blood of 
psoriasis patients tended to be even lower in those with frequently relapsing (Koreck et al., 
2002). Moreover, different systemic therapy regimens resulted in the recovery of these cells, 
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but their percentage remained significantly lower in comparison with healthy control 
subjects. In contrast, Langewouters group showed that the number of circulating CD94+ an 
CD161+ cells was significantly higher in patients with moderate-to-severe as compared to 
patients with mild psoriasis (Langewouters et al., 2008). It has been also reported that 
circulating CD161+ NKT cells in people with severe psoriasis belong to Th1 cells (W. L. Chan 
et al., 2003) and that treatment with alefacept or efalizumab causes significant reduction in 
their number (Larsen et al., 2007; van Lingen et al., 2008). These observations imply that 
distinct subsets of NKT cells differentially regulate immune responses and that their relative 
imbalance might be of importance in the psoriasis pathogenesis, but the precise impact of 
these findings remains unclear. 
4.1.4 Accessory cells (Dendritic cells and macrophages) 
DCs are involved in the development of tolerance (Steinman et al., 2003) and are the unique 
professional antigen-presenting able to take up antigen in the tissue they reside in and to 
migrate to the draining lymph nodes; here activate naive T cells, generating specific T-cell 
responses (Teunissen, 2005).  
In the peripheral tissues DCs receive all kinds of microenvironment signals, that influence 
the their maturation process, determining the phenotype and function of mature DCs and 
their type 1 type 2 polarizing potential. In case of risk (e.g. infection, cancer), DCs will 
transform into strong stimulatory antigen presenting cells, whereas under non pathological 
steady-state conditions DCs do not reach full maturation and they will present self-peptides 
MHC complexes in the presence of insufficient costimulatory molecules, inducing  T-cell 
anergy or expansion of regulatory T cells (peripheral tolerance). If this delicate balance of 
immune reactivity vs. tolerance is broken, chronic inflammatory diseases, like psoriasis, 
may develop. 
In the absence of pathogenic substances, stress signals from neighbouring cells (e.g. necrotic 
cells) can activate DCs enabling them to stimulate naive T cells (Gallucci et al., 1999). In 
relation to this, Krueger has expressed an remarkable view concerning traumatic injuries 
(breaches in the basement membrane and disruption of desmosome connections between 
adjacent keratinocytes) caused by migrating T cells and DCs in the epidermis, that are 
possibly involved in the development of psoriasis lesions (J. G. Krueger, 2002). 
Keratinocytes will respond to these defects by overproduction of cytokines, among others 
TNF-a, a key cytokine to induce DC migration/maturation.  
Another exciting point to mention is the observation that DC development is also affected 
by mutual interaction with NKT cells (Taniguchi et al., 2003): weak responses by NKT cells 
to glycolipid CD1d complexes can be enhanced by DC-derived IL-12, resulting in up-
expression  of IFN-c by NK T cells. This interaction may be relevant in psoriasis. 
DCs are numerous in the dermal part of psoriasis skin  and many of them exhibit an 
activated phenotype (CD80+, CD83+, CD86+ and DC-LAMP+) (Abrams et al., 2000; 
Teunissen, 2005) and may be an important source of TNF-a (Nickoloff et al., 1991; Zhou et 
al., 2003).  
Recent evidences from different genetic mouse models show that also the macrophages can 
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and in particular the data from the CD18hypo PL/J psoriasis mouse model demonstrate 
(Wang et al., 2009) that the psoriasis-form inflammatory skin disorder critically depends on 
an appropriate activation of macrophages, with ample release of TNF-a.  
In human psoriasis, the number of epithelium-lining macrophages was reported to increase 
in lesional skin. These macrophages can play a role in the regulation of epidermal 
proliferation and differentiation (van den Oord & de Wolf-Peeters, 1994);  also vigorous 
interactions between macrophages and keratinocytes (Djemadji-Oudjiel et al., 1996) may be 
involved in the psoriasis pathogenesis (van den Oord & de Wolf-Peeters, 1994).  
Macrophages, under different conditions, secrete various pro-inflammatory cytokines: TNF-
, IL-1b, IFN-, IL-6, IL-10, IL-12, and IL-18, (Willment et al., 2003) and notably, in a recent 
study CD68+ macrophages  were identified as important TNF-source in human psoriasis 
and upon treatment with anti-TNF- antibody macrophage levels decreased in the plaque 
psoriasis, with clinical psoriasis resolution (Marble et al., 2007). In according to this finding, 
it is also showed that CD68+ macrophages as important TNF- source in human psoriatic 
skin, which had distinctly decreased number and TNF- concentration following bath-
PUVA therapy (Wang et al., 2009). This was also found in a T-cell-independent mouse 
model, with an increase of TNF- in macrophages (Stratis et al., 2006). 
Based on literature data, an emerging model of psoriasis pathogenesis in humans suggests 
that dermal macrophages, activated by T-cell cytokines, produce large amounts of TNF-, 
leading to skin changes (Clark & Kupper, 2006). 
4.2 Dysfunction of the adaptive immune response cells 
Until the 1990s, psoriasis was thought to be a disease of disordered keratinoctye 
proliferation and differentiation (G. G. Krueger et al., 1984) and  epidermal hyperplasia was 
the most prominent clinical and histological feature. For this reason, the old psoriasis 
treatments using antimetabolites including methotrexate which limit epidermal 
hyperproliferation. However, successive evidence from clinical studies and, experimental 
models support the theory that psoriasis is a T cell-mediated inflammatory skin disease 
(Lew et al., 2004) affecting genetically predisposed individuals and the epidermal 
hyperplasia is an effect of cellular immune infiltration. 
4.2.1 Role of T cells 
The first evidence resulting in psoriasis being widely considered as a T cell mediated 
autoimmune disease came from the success in the psoriasis treatment of T cell-targeted 
therapies such as cyclosporine (Baker et al., 1987), tacrolimus (Jegasothy et al., 1992) or CD4-
specific monoclonal antibodies (Moabs) (J. Prinz et al., 1991).  
A pivotal study involved the testing of IL-2-diphtheria-toxin fusion protein in psoriasis 
patients (S. L. Gottlieb et al., 1995). This agent selectively depleting activated T cells that 
express IL-2 receptors from psoriasis skin lesions and resulted in clinical remission of 
psoriasis vulgaris.  
Subsequently, administration of another fusion protein, cytotoxic T-lymphocyte antigen 4 
(CTLA4)-antibody, was shown to reverse the clinical and cellular features of psoriasis 
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(Abrams et al., 1999). This agent blocks T cell co-stimulation mediated by DCs without 
directly deplete T cells. Its effectiveness indicated that continuing T cell co-stimulation is 
required to sustain psoriasis disease activity, including the excessive infiltration of T cells 
and DCs into the skin (Abrams et al., 2000). All these clinical results confirmed that lesion-
associated T cells are central to sustaining disease activity in psoriasis.  
Additional evidence highlighting the implication of T cells in psoriasis pathogenesis have 
been reviewed (Nestle et al., 2009) including the appearance of clonal T cells in psoriatic 
lesions (Menssen et al., 1995); the development of psoriasis-form phenotype within 
symptomless psoriatic skin after transplantion onto the xenotransplantation AGR 129 mouse 
model again underlines the importance of epidermal T cells in psoriasis genesis  (Conrad et 
al., 2007).  
Also, based on the findings that expansion of skin resident T cells is important in psoriasis 
progress in the xenotransplantation AGR mouse model, the function of tissue-specific 
factors in activation and expansion of resident T cells has been further explored (Conrad et 
al., 2007). T cells need to pass through the dermo-epidermal junction in order to go into the 
epidermis and collagen fibrils are an essential part of the dermo-epidermal junction. The 
most important basement membrane collagen is collagen IV and long-term activation of T 
cells results in the expression of a receptor for collagen IV, the heterodimeric integrin . 
It has been shown that epidermal accumulation of + Th1 and Tc1 cells correlate with 
psoriasis development. Blocking  with a neutralizing Moab prevents epidermal T cell 
accumulation and subsequent psoriasis development in the xenotransplantation AGR 
mouse model.  expression can act as a checkpoint for entry of T cells into epidermis 
with + epidermal T cells potentially playing an important role in psoriatic lesion 
formation.  
In conclusion, targeting of these integrins may offer new and effective therapeutic 
approaches in psoriasis. 
4.2.2 The IL-23/Th17 pathway  
The IL-23/Th17 pathway is an exciting area in psoriatic pathology (Figure1) because it has 
led to the development of promising innovative treatments which specifically target this 
pathway (D'Elios et al., 2010). The development, characterization and function of Th17 cells 
and the role of IL-23 in Th17-cell dependent chronic inflammation in psoriasis have been 
recently reviewed (Di Cesare et al., 2009). Briefly, IL-23 is a heterodimeric cytokine 
(Oppmann et al., 2000) composed of the subunits IL-23p19 and  IL-12p40 (an IL-12 subunit). 
Intradermal injection of IL-23 in mice resulted in the development of a psoriasis-form 
phenotype with histopathological features (Chan et al., 2006). IL-23 can mediate epidermal 
hyperplasia, acanthosis, hyperparakeratosis and orthohyperkeratosis by way of TNF-, IL-
20R2 and IL-22 (Chan et al., 2006; Zheng et al., 2007). These data are supported by findings 
in humans including an mRNA over-expression of IL-23p19 and IL-12p40 seen in psoriatic 
skin lesions, compared to uninvolved skin. Further other results indicate that IL -23 
production  occurs at inflammatory skin sites and is mediated by tissue-resident and/or 
recruited immune cells, such DCs and KCs (Piskin et al., 2006).  
The pathogenic role of IL-23 in psoriasis is strongly supported by the clinical findings that 
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(Abrams et al., 1999). This agent blocks T cell co-stimulation mediated by DCs without 
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23 level caused by cyclosporin A, UV therapy and biological agents correlates to clinical 
improvements in psoriasis patients (A. L. Gottlieb et al., 2005; Haider et al., 2008; Piskin et 
al., 2004). 
Transforming growth factor (TGF)-1, IL-6 and IL-21 are all required to transform naïve T 
cells into cells expressing the unique lineage-specific transcription factor, RORC variant 2 
and IL-23 receptors with subsequent binding of IL-23 resulting in differentiation into Th17 
cells. 
Th17 cells in turn produce the pro-inflammatory  cytokines IL-17A, IL-17F, IL-22 and IL-26 
(Langrish et al., 2005) that activate KCs leading to hyperproliferation and production  of  
proinflammatory cytokines / chemokines, which recruit and activate other immune cells in 
the inflamed skin, enlarging the inflammatory response and consequently the clinical 
disease features. Another support for a role of the IL-23/Th17 pathway in psoriasis comes 
from whole genome studies showing that genetic variants of the IL-23 receptor are 
associated with psoriasis (Capon et al., 2007).  
Regarding the clinical relevance of the IL-23/Th17 pathway, targeting the common subunit 
p40 of IL-12 and IL-23 demonstrated clinical improvement in psoriasis. Two anti-IL-12p40 
Moabs, ustekinumab and ABT-874, have been recently developed as psoriasis cures. As we'll 
see in more detail later, ustekinumab and ABT-874 are humanized IgG1 Moabs that binding 
to the p40 subunit of human IL-12 and IL-23, prevents interaction with IL-12Rb1. Phase I 
(Kauffman et al., 2004)  and phase II (Kimball et al., 2008b; G. G. Krueger et al., 2007)  studies  
supported the use of both antibodies as effective treatments for psoriasis.  
The safety profile of ustekinumab in psoriasis has been evaluated in 2 phase III studies. Of 
these, PHOENIX I assessed the efficacy and safety of ustekinumab 45 and 90 mg 
administered subcutaneously at weeks 0, 4, and then every 12 weeks over 76 weeks of 
treatment (Leonardi et al., 2008). 67.1 % and 66.4 % of patients who received ustekinumab 
45mg and 90 mg respectively, achieved PASI-75  at week 12 compared to placebo control 
(3.1 %). The observed adverse events were mild, non-life threatening and not significantly 
different from the placebo group. The most commonly reported adverse events were 
upper respiratory tract infections, nasopharyngitis, headache, and arthralgia. The 
PHOENIX II trial (Papp et al., 2008) was conducted to further assess if dosing 
intensification would increase the response to treatment in partial responder patients 
(between PASI-50 and PASI-75). It was found that dosing intensification resulted in 
increased clinical efficacy only in patients receiving 90mg, but not 45mg, of ustekinumab 
every 8 weeks (PASI-75 in 68.8 % of patients receiving 90mg every 8 weeks versus 33.3 % 
of patients receiving 90 mg every 12 weeks). The incidence and type of adverse events 
observed did not differ between PHOENIX I and II studies. Ustekinumab is also effective 
in the treatment of psoriatic arthritis and this study again confirmed that ustekinumab is 
well tolerated (A. Gottlieb et al., 2009). 
4.2.3 Regulatory T cells 
Regulatory T cells (Tregs) are characterized by their ability to suppress the activation and 
proliferation of  effector T cells (CD4+/CD8+)  by direct contact with antigen presenting cells 
(Gondek et al., 2005) or by releasing IL-10 (Annacker et al., 2003) and/or TGF-1 (Nakamura 
et al., 2004) (Figure 3).  
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Tregs express CD4, height CD25 and Foxp3 and are about the 1-5 % of the total population 
of peripheral CD4+ cells.  
Dysfunction of Tregs has been implicated in the pathogenesis of various autoimmune 
diseases such as multiple sclerosis and rheumatoid arthritis (RA) and in psoriasis; where 
Treg function and proliferation are both defective (Sugiyama et al., 2005). This combination 
may result in a failure to limit the activation and proliferation of pathogenic T cells, 
contributing to the ongoing inflammation seen in psoriasis; for this reason strategies that 
correct Treg function or increase the Treg/pathogenic T cell ratio may be potential 
treatments for psoriasis (Sugiyama et al., 2005). Phototherapy, for example,  might induce 
Treg type suppressor cells as well as eliminate pathogenic T cells (Baadsgaard et al., 1990), 
supporting a possible role of Treg cells in protection against psoriasis. 
5. Principal co-morbidities 
Today we know that during the time course of psoriasis, certain conditions may appear at 
somewhat unpredictable time points in a progressive fashion. These so-called co-
morbidities, often become manifest years after the onset of skin manifestations and are 
frequently observed in severe forms of psoriasis. 
5.1 Psoriatic arthritis  
PsA is traditionally included among common co-morbidities of psoriasis, even if it should 
be rather considered a component of the clinical spectrum of psoriatic disease. Skin 
manifestations occur before the onset of arthritis in the large majority of patients (A. B. 
Gottlieb et al., 2006), and in general, the prevalence of arthritis in psoriasis patients is 
estimated to be approximately 30% (Gisondi et al., 2005; Zachariae et al., 2002).  
In PsA pathogenesis the TNF- plays a key role, promoting osteoclastogenesis and bone 
resorption by stimulating the receptor-activator of NFkB, expressed in bone marrow 
osteoclast precursors (Abu-Amer et al., 2000; Keffer et al., 1991). Moreover, TNF- has been 
noted to increase DKK-1 (dickkopf-1), a glycoprotein able to inhibit the bone apposition 
process by obstructing osteoblast growth (Baron & Rawadi, 2007; Diarra et al., 2007).  
Numerous clinical observations support these experimental data, particularly a number of 
clinical trials showed a significant inhibition of joint damage in patients who underwent 
anti-TNF therapy, confirming the role of TNF in altered bone remodeling. 
Approximately 20% of PsA patients are estimated to suffer from a severe and destructive 
form of arthritis, that leads to overall increased disability (D. D. Gladman et al., 1990; 
Queiro-Silva et al., 2003). Interestingly, different results indicate that the DMARDs (disease-
modifying antirheumatic drugs) might not be able to inhibit disease progression and 
osteoarticular damage, even though they are generally useful in providing relief of clinical 
symptoms (Kana et al., 2003). 
There is also convincing evidence of increased mortality in PsA patients, which seems to be 
related to disease activity, characterized by high erythrosedimentation rate, high medication 
level, and significant radiological damage at early patient visits (D. D. Gladman et al., 1998). 
Fortunately, as we shall see later, the mortality in PsA patients has gradually improved by 
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5.2 Inflammatory bowel disease (IBD) 
IBD commonly refers to ulcerative colitis (UC) and Crohn’s disease (CD), which are 
chronic inflammatory diseases of the gastrointestinal tract with unknown etiology. UC 
and CD have significant clinical differences, however, both diseases share similar 
pathogenic mechanisms and many extra-intestinal manifestations, and frequently respond 
to the same treatments. 
Many data indicate a stringent correlation between CD and psoriasis (Najarian & A. B. 
Gottlieb, 2003). Firstly, CD patients have been found to have a seven-fold higher risk of 
developing psoriasis than control subjects (Mrowietz et al., 2006). This association may be 
related to the following observations: a) it has been shown that TNF- has a key role in both 
conditions, valuing the hypothesis of common inflammatory pathways. This point has been 
further supported by the therapeutic efficacy of anti-TNF- antibodies; b) genetic evidences, 
such as polymorphisms in the TNF- promoter region and the close position of the 
susceptibility loci, link psoriasis to CD (Najarian & A. B. Gottlieb, 2003). In particular, a 
recent study demonstrated a significant association between CD and the IL-23 receptor gene 
(Duerr et al., 2006) and, as reported previously,  IL-23 /IL-17 pathway is involved in 
psoriasis pathogenesis (Blauvelt, 2008; Rizzo et al., 2011). 
On the other hand, the association between psoriasis and UC has been described in only in 
recent studies, even if the first studies regarding this connection trace back to the 60s and 
early 70s (Brewerton et al., 1974; McEwen et al., 1971). Most recently, Cohen et coll. (Cohen 
et al., 2009), in a case-control study with 12,502 psoriasis patients, demonstrated that even 
though not as high as CD (odds ratio 2.49), UC association is statistically significant and far 
from being negligible (odds ratio 1.64). This often undervalued correlation is biologically 
conceivable because chronic systemic inflammation and TNF- constitute core features of 
UC, as well as psoriasis (Torres & Rios 2008). 
5.3 Metabolic Syndrome (MS) and Cardiovascular Diseases (CVD) 
Different overlapping guidelines have been proposed to define the MS: the cardiometabolic 
risk factors of obesity, impaired glucose tolerance (or type 2 diabetes), insulin resistance, 
dyslipidemia, and hypertension (Alberti et al., 2006; Grundy et al., 2005; Johnson & 
Weinstock, 2006). Just like psoriasis, MS is characterized by a pro-inflammatory state, 
characterized by a complex cytokines network. 
In response to various metabolic signals the adipose tissue release the adipokines that 
modulate flogosis, lipid metabolism, and insulin sensitivity. A cluster of these adipokines is 
represented by pro-inflammatory cytokines (TNF-, IL-8 and IL-6) whose overproduction 
drives the psoriasis pathogenesis, as well as of certain basic features of MS like insulin 
resistance and diabetes (Arican et al., 2005; Nickoloff & Nestle, 2004; Rondinone, 2006). 
Consistent with this common pathophysiology, different studies have demonstrated that 
psoriasis patients show an increased risk of developing the metabolic syndrome (Henseler & 
Christophers, 1995; Neimann et al., 2006). 
The multiple conditions that constitute the MS could very well be the main reasons for CVD 
in psoriasis patients. 
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However, in various studies involving patients with psoriasis, the latter was identified as an 
independent risk factor for myocardial infarction regardless of the presence of the complete 
MS and an independent risk factor for coronary artery calcification (Gelfand et al., 2006).  
Indeed, as of today there is forceful evidence that psoriasis, much like other systemic pro-
inflammatory conditions (e.g. RA, SLE), may predispose to an increased CVD risk, 
following a nontraditional pathway to atherogenesis and premature vascular damage 
(Kimball et al., 2008c; Saphiro et al., 2007).  
In conclusion, basic inflammatory activity in psoriasis could act independently of traditional 
risk factors, MetS included, and can increase the risk of CVD through its own underlying 
biological mechanisms (inflammation-driven atherogenesis). 
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Recently, some studies have also shown that in psoriasis patients, the increased risk for 
myocardial infarction varies by age (higher in younger individuals) and disease severity 
(higher in severe forms) (Gelfand et al., 2006; Kremers et al., 2007; Mallbris et al., 2004). As 
such, a young patient with severe psoriasis is burdened by a CVD risk comparable with 
what is seen in the presence of traditional risk factors such as diabetes and hypertension. 
Moreover, a variety of data indicates that psoriasis and CVD (mostly atherosclerosis) share 
common pathogenic features: both Th1 mediated, with an up-regulation of Th1 cytokines 
(TNF-, IFN-) and a systemic expression of adhesion molecules, neoangiogenesis factors, 
and superantigens, these latter potentially able to activate the T cells (Biedermann et al., 
2004; Ettehadi et al., 2004; Gudjonsson et al., 2004). The table 1 summarizes the 
consequences of the TNF- over-expression in promoting inflammatory conditions such as 
psoriasis and atherogenesis.  
Overlapping of genetic susceptibility loci between psoriasis and atherosclerosis is also worth 
mentioning, even though its role has yet to be fully understood (Becker et al., 1998).  
Lastly, the two conditions also show similar histological aspects, mainly involving T cells, 
macrophages, mast cells  and connective tissue matrix. (Nickoloff et al., 2007a;  Nickoloff et 
al., 2007b).  
Alongside the similar pathogenesis, other indirect factors might be responsible for psoriasis-
CVD association; in fact some authors have found that a number of conventional systemic 
psoriasis treatments  (e.g. methotrexate, acitretin, cyclosporine) might increase the effects of 
specific CVD risk factors (Katz et al., 1994; Strober & Menon, 2005; Taler et al., 1999). 
6. Disease evaluation 
To assess the severity of psoriasis and PsA (baseline/in response to treatment), a number of 
tools are now available, of which the Psoriasis Activity and Severity Index (PASI) is the most 
frequently used (Fredriksson & Pettersson, 1978). The PASI combines assessments of the 
extent of body surface involvement in four anatomical regions (head, trunk, arms and legs) 
and the severity of desquamation, erythema and plaque induration (thickness) in each 
region, yielding an overall score of 0 (no psoriasis) to 72 (severe psoriasis) (Fredriksson & 
Pettersson, 1978). PASI 75 is defined as a 75% reduction in PASI compared with baseline, 
instead a PASI score of >10 is defined as moderate to severe disease, necessitating systemic 
therapy (PUVA, UVB 311, MTX, cyclosporin A or biological drugs) (Pathirana et al., 2009)  
An additional tool to assess the psoriasis severity is the physician’s global assessment 
(PGA). The PGA takes into account the involvement of the body surface area, induration, 
scaling and erythema and grades the patient’s psoriasis overall, relative to baseline, as 1 
(clear), 2 (excellent), 3 (good), 4 (fair), 5 (poor) or 6 (worse) (Pathirana et al., 2009).  
In trials investigating patients with PsA, the American College of Rheumatology Criteria 
(ACR) are most commonly used. The ACR clinical response criteria are defined as 
percentage reduction [20% (ACR 20), 50% (ACR50) and 70% (ACR 70)] in tender and 
swollen joint counts and in 3 of the, remaining, 5 ACR core items (patient and physician 
global assessments, pain, disability and an acute phase reactant) (Montecucco, 2006; Radtke 
et al., 2009).  
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A supplementary tool to evaluate clinical remission in psoriatic patients is the Disease 
Activity Score (DAS) comprising the number of swollen and tender joints, the erythrocyte 
sedimentation rate and the general health of the patient (measured on a visual analogue 
scale) (Montecucco, 2006). The DAS measures 44 swollen joints, whereas the modified DAS 
28 measures only 28 swollen and tender joints (Prevoo et al., 1995). The effect of psoriasis on 
the patient’s quality of life is measured by the 10-item Dermatology Life Quality Index 
(DLQI) questionnaire. DLQI scores range from 0 (not at all) to 30 (very much) (Pathirana et 
al., 2009). 
7. Biological drugs 
Biological therapies for the treatment of psoriasis are defined by their mode of action and 
are classified into 3 groups, the inhibitors of TNF- (adalimumab, certolizumab, etanercept, 
golimumab, and infliximab), the T-cell modulating agents (such as alefacept) and the 
inhibitors of IL-12 and IL-23 (ustekinumab and briakinumab). 
7.1 TNF- inhibitors 
The TNF- inhibitors adalimumab, etanercept and infliximab have been approved by the 
FDA and EMEA for psoriasis and PsA treatment; they have been reviewed quite extensively 
in the past and the table 2 summarizes the clinical outcome for primary endpoints (e.g. PASI 
and ACR) in randomized controlled studies.  
In this chapter, instead will focus on the new TNF- blockers such as golimumab and 
certolizumab (Mössner et al., 2008; Pathirana et al., 2009).  
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Recently, some studies have also shown that in psoriasis patients, the increased risk for 
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certolizumab (Mössner et al., 2008; Pathirana et al., 2009).  
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Up to now, treatment with  MoaB anti-TNF-has proven to be effective and relatively safe 
in patients with  psoriasis and PsA (Lima et al., 2009).  
Since TNF- has showed an osteoclast stimulating effect, alongside being synergic with 
DKK-1 in reducing osteoblasts maturation, anti-TNF- drugs should improve PsA-related 
bone altering processes, as confirmed by significant inhibition of radiographic progression 
during treatment with etanercept or infliximab (Antoni et al., 2008; Mease et al., 2006b; van 
der Heijde et al., 2007).  
Equally importantly, anti-TNF- therapy might have a preventive effect on PsA overlapping 
in psoriasis patients. In fact, in a case-control study, Gisondi group (Gisondi et al., 2008) has 
demonstrated that lower limb enthesopathy can be documented in asymptomatic psoriasis 
patients without any clinical sign of arthropathy. Similar findings were reported in the past 
concerning entheseal abnormalities (De Filippis et al., 2005) and increased Achilles tendon 
thickness (Ozcakar et al., 2005); all of which were detected in asymptomatic patients. 
Different evidences have proved that anti-TNF- treatments infliximab and adalimumab are 
effective in controlling gut inflammation, whereas etanercept is not (Bosani et al., 2009).  
There are reports of CD development in patients with ankylosing spondylitis or PsA (Song 
et al., 2008) and treated with etanercept. However, it is well-known that such patients are 
burdened with a high risk of chronic IBD development. It is therefore hard to assess 
whether these cases of CD were really a consequence of anti-TNF- therapy or rather a 
coincidental event in predisposed patients.  
The reason for the discordant effect of anti-TNF- treatments on IBD probably lies in 
different pharmacodynamic features of these drugs, and a number of hypotheses have been  
expressed in this regard.  
Firstly, it has been noted that etanercept, unlike anti-TNF- Moabs, doesn’t induce 
apoptosis of activated lymphocytes in CD patients (Van den Brande et al., 2003). Given the 
existing results, it is reasonable to conclude that etanercept has no potential to control or to 
prevent gut inflammation and hence IBD appearance. A preventive role of anti-TNF- 
Moabs against the IBD development in susceptible psoriasis patients cannot be rule out 
considering the effectiveness of these drugs in both conditions. 
About the effects of anti-TNF-a Moabs in MS and CVD, studies regarding the consequence 
on blood lipids have shown  unclear results. A study of RA patients reported a significant 
decreased atherogenic index of low-density lipoprotein (LDL)/high-densitiy lipoprotein 
(HDL) ratio after 6 months of therapy with anti-TNF-a (Spanakis et al., 2006); another 
showed increased HDL levels and reduced C-reactive protein (CRP) and IL-6 levels after 2 
weeks (Popa et al., 2005). In contrast, in some cases anti-TNF-a therapy has resulted in a pro-
atherogenic effect in RA and PsA patients, with increase of LDL/ HDL ratio and 
triglycerides levels (Dahlqvist et al., 2004). Another study demonstrated a sudden reduction 
in HDL levels the day after infliximab infusion, but without any significant variation in the 
HDL profile (Irace et al., 2004).  
No conclusions can be drawn from these inconsistent findings regarding long-term clinical 
outcomes. As a consequence, many authors seem to agree on the fact that despite the 
prominent role of TNF- on lipid regulation, the emerging efficacy of anti-TNF- therapy  
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on CV morbidity and mortality is likely independent of the induced blood lipid variations 
(Soubrier et al., 2008). 
Results derived from studies about the effects of anti-TNF- drugs on insulin resistance in 
psoriasis patients, appear to show an improvement in insulin sensitivity (Marra  et al., 2007). 
This outcome seems to confirm the beneficial effects of anti-TNF- Moabs already 
documented in many RA studies (Huvers et al., 2007; Yazdani-Biuki et al., 2004). In 
particular, infliximab has proved capable of enhancing insulin sensitivity after the infusion 
to up to one year (Huvers et al., 2007). Lastly, there have been few isolated cases of psoriasis 
patients with diabetes developing unpredictable hypo- or hyperglycemia after commencing 
treatment with TNF inhibitors (Boulton & Bourne, 2007; Wu & Tsai 2008).  
In the table 3 are reported the side effects of  adalimumab, etanercept and infliximab 
treatment in psoriasis patients. 
7.1.1 Golimumab (CNTO148) 
Golimumab is a human immunoglobulin G1K Moab binding both soluble and 
transmembrane forms of TNF-, thereby neutralizing their bioactivity by blocking the 
interaction with receptor (Kavanaugh et al., 2009; Xu et al., 2009). 
In a study with 337 patients, the pharmacokinetics of subcutaneously administered 
golimumab (50 or 100 mg every 4 weeks) were analyzed (Xu et al., 2009) and the following 
golimumab pharmacokinetic parameters were found: apparent clearance = 1.38 ± 0.04 L per 
day, apparent volume of distribution = 24.9 ± 1.04 L and absorption rate constant = 0.908 ± 
0.121 per day. Significant covariants on apparent clearance were identified as body weight, 
baseline C-reactive protein level and smoking habits. However, only body weight was 
found to be a significant covariant on apparent volume of distribution. In addition, 
golimumab concentrations in patients (50 mg golimumab every 4 weeks) not receiving MTX 
were 30% lower as compared with patients receiving MTX (Xu et al., 2009). So far, no 
possible explanation for the different effects of MTX on the serum golimumab 
concentrations has been provided (Xu et al., 2009). 
A randomized, double-blind, placebo-controlled phase III multicenter study was conducted 
to evaluate the safety and efficacy of golimumab from week 0 to 20 in 405 patients with 
active PsA (Kavanaugh et al., 2009).  
Active PsA was defined as at least three swollen joints and three tender joints as well as 
active plaque psoriasis with a qualifying lesion of at least 2 cm in diameter. Concomitant 
MTX, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids were permitted 
at stable doses. 
A significant reduction in PASI 75 among patients receiving golimumab 50 or 100 mg at 
week 14 (40 and 58%) was observed when compared with patients receiving placebo (3%). 
PASI 75 scores in patients with golimumab (50 and 100 mg) further improved at week 24 in 
both golimumab groups (56 and 66%), whereas only 1% of patients in the placebo group 
reached a PASI 75 (Kavanaugh et al., 2009). 
Golimumab significantly (P < 0.001) improved signs and symptoms of PsA compared with 
patients treated with placebo (Kavanaugh et al., 2009). An ACR 20 response at week 14 
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could be achieved in 51% of patients treated with golimumab 50 mg and in 45% of patients 
receiving golimumab 100 mg versus only 9% in the placebo group. At week 24, an ACR 20 
response was observed in 52% in the golimumab 50-mg group and in 61% in the golimumab 
100-mg group versus 12% in the placebo group (P < 0.001). ACR 50 and 70 responses were 
also significantly higher in both golimumab groups than in the placebo group. At week 104, 
91.4% of patients in the 50-mg group and 73.1% in the 100-mg group achieved an ACR 20 
(Kavanaugh et al., 2009). A good or moderate DAS 28 response was significantly (P < 0.001) 
more often achieved in the golimumab 50 and 100-mg recipients than in the placebo group 
at week 14 (66 and 67% vs. 24%) and at week 24 (64 and 78% vs. 24%) (Kavanaugh et al., 
2009). Assessment of physical function and health-related quality of life were measured by 
the Health Assessment Questionnaire (HAQ) and Short Form 36 Health Survey (SF-36) and 
significantly improved in both golimumab groups compared with the placebo group (P < 
0.001 for HAQ and SF-36 at all comparisons at week 24).Thus, in this study golimumab 
improved significantly the clinical signs and symptoms of PsA as well as the physical 
function and quality of life (Kavanaugh et al., 2009). 
About the of safety of this treatment, Kavanaugh and coll. (Kavanaugh et al., 2009) reported 
that 8.6% of patients treated with golimumab shown a serious adverse event up to week 104: 
serious infectious adverse events comprised sepsis/cholecystitis and abscess formation. 
about the cancers registered: one basal cell carcinoma, one colon cancer and one small lung 
cell carcinoma in the golimumab 50-mg group. In the golimumab 100-mg group, three basal 
cell carcinomas, one prostate cancer and one small lung cancer occurred.  
As for adverse events, infections of the upper respiratory tract and nasopharyngitis were 
most frequently reported. 
7.1.2 Certolizumab pegol (CDP870) 
Certolizumab pegol, a pegylated Fab-9 fragment of a humanized anti-TNF-a Moab, has been 
approved for the treatment of patients with CD (Bourne et al., 2008) and it has also been 
investigated in RA patients (Barnes & Moots, 2007). 
It binding to TNF-, blocks the interaction with specific receptors. Whereas adalimumab, 
etanercept and infliximab contain an IgG1 Fc region, which can induce antibody-dependent 
cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), 
certolizumab lacking this Fc region, isn’t able of inducing ADCC and CDC (European 
Medicines Agency [EMEA], 2008). 
Pharmacokinetic analysis in the CDP870 trial showed a bioavailability of 85% (EMEA, 2008). 
Peak plasma concentrations were attained between 54 and 171 h after subcutaneous 
injection. The mean serum concentration (Cmax) after the subcutaneous administration of 
400-mg certolizumab ranged from 46.3 ± 13.1 to 49.5 ± 8.2 mg· mL-1. An increase of Cmax 
and area under the curve (AUC) was observed with higher doses in a dose-proportional 
manner. The half-life of certolizumab was found to be approximately 14 days (EMEA, 2008)  
Certolizumab pegol has been investigated in patients with moderate to severe psoriasis. In a 
phase II trial, patients were randomized to receive certolizumab pegol 200 mg, 400 mg or 
placebo subcutaneously every 2 weeks up to week 12. At week 12, significantly more 
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could be achieved in 51% of patients treated with golimumab 50 mg and in 45% of patients 
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certolizumab lacking this Fc region, isn’t able of inducing ADCC and CDC (European 
Medicines Agency [EMEA], 2008). 
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and area under the curve (AUC) was observed with higher doses in a dose-proportional 
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Certolizumab pegol has been investigated in patients with moderate to severe psoriasis. In a 
phase II trial, patients were randomized to receive certolizumab pegol 200 mg, 400 mg or 
placebo subcutaneously every 2 weeks up to week 12. At week 12, significantly more 





group (74.6 and 82.8% vs. 6.8%) (Ortonne et al., 2007). The most frequently reported adverse 
events comprised headache, nasopharyngitis and pruritus. The frequency of adverse events 
was similar across all three groups. However, serious adverse events were more common in 
the 400-mg group (7.0%) than in the 200-mg group (3.3%) and in the placebo-group (1.7%) 
(Ortonne et al., 2007). According to the data from the phase II study, PASI 75 results and 
side effects were comparable with those observed in patients treated with the approved 
TNF- blockers adalimumab and infliximab. So far, no phase III studies or studies in 
patients with PsA have been conducted. 
7.2 T-cell modulators 
In 2003, alefacept and efalizumab were the first biological agents to be approved by the 
Food and Drug Administration (FDA) for the treatment of psoriasis (Pathirana et al., 2009). 
In the European Union, only efalizumab was approved for the psoriasis therapy (Pathirana 
et al., 2009). In 2009, efalizumab was withdrawn from the market in Europe and the United 
States (EMEA, 2009; Food and Drug Administration [FDA], 2009). 
7.2.1 Alefacept 
Alefacept, a recombinant dimeric fusion protein, is made up of the terminal portion of 
leukocyte function antigen-3 (LFA-3). It binds to extracellular human CD2 and the Fc 
portion of human immunoglobulin IgG1 (Sugiyama et al., 2008). Alefacept blocks signalling 
between LFA-3 on antigen presenting cells and the CD2 molecule on T cells (primarily 
CD45RO+). 
Subsequently, the activation and proliferation of CD45RO+ T cells, which account for 
approximately 75% of T lymphocytes in psoriatic lesions, are inhibited. Furthermore, 
alefacept decreases the number of pathogenic T cells by binding CD2 on CD45RO+ T cells to 
the FcgIII receptor on natural killer cells, resulting in granzyme-mediated apoptosis of T 
cells (Gordon et al., 2003; Sobell et al., 2009; Sugiyama et al., 2008). Using a dosage of 15 mg 
alefacept administered intramuscularly QW, PASI 75 scores at week 12 were found to range 
between 21 and 35% (Gordon et al., 2003; Pathirana et al., 2009; Sugiyama et al., 2008). 
Recently, patients receiving alefacept in combination with MTX were shown to improve 
significantly in ACR 20 at week 24 compared with patients treated with MTX and placebo 
alone (54% vs. 23%; P < 0.001) (Mease et al., 2006a). 
7.3 IL-12/IL-23 antagonists 
Briakinumab and ustekinumab are both IL-12/IL-23 antagonists. Whereas briakinumab is 
currently under investigation for the psoriasis treatment in several phase III studies, 
ustekinumab was recently approved by the EMEA for the therapy of chronic plaque 
psoriasis. 
7.3.1 Briakinumab (ABT874) 
Briakinumab is a recombinant fully human, IgG1 Moab targeting the shared p40 subunit of 
IL-12 and IL-23 (Kimball et al., 2008b). It binds to soluble forms of IL-12 and IL-23, leading to 
a decreased secretion of pro-inflammatory cytokines: IL-12, IL-6, IFN- and TNF-, as 
shown in CD patients (Ding et al., 2008).  
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In a phase I trial with 64 healthy controls, the pharmacokinetics of briakinumab (0.1–5.0 
mg·kg-1 subcutaneously or intravenously) were evaluated. A linear relationship between the 
Cmax and AUC (concentration-time) was found with increasing doses. The terminal phase 
half-life time was about 9 days. No dose dependency was found for the volume distribution 
at steady state and the clearance of the drug. Subcutaneous and intramuscular application 
achieved an absolute bioavailability of 42 and 63% respectively (Ding et al., 2008). 
A phase II study with briakinumab was conducted (Kimball et al., 2008b) in patients with 
psoriasis. Patients were randomized in groups of  30 to receive either only one dose of 
briakinumab 200 mg at week 0, 100 mg briakinumab every other week for 12 weeks, 200 mg 
weekly for 4 weeks, 200 mg every other week for 12 weeks and 200 mg every week for 12 
weeks, or placebo respectively(Kimball et al., 2008b).  
PASI 75 was significantly (P < 0.001) more often reached in patients in all five briakinumab 
treatment groups (63, 93, 90, 93, and 90% respectively) compared with the placebo group 
(3%). Statistically significant improvement to briakinumab therapy was rapid and could be 
registered in the briakinumab groups as early as at week 1. During the 12-week period, 
improvement could be sustained in briakinumab-treated patients even for patients in the 
briakinumab 200 mg x 1 and 200 mg x 4 dosage groups. 
Besides injection site reactions, other common side effects the trial study comprised 
nasopharyngitis and upper respiratory infections. In addition, non-infectious serious 
adverse events reported in this study included costal chondritis in one patient. Significantly 
more patients in the briakinumab groups (36%) experienced adverse events compared with 
the placebo group (10%) (Kimball et al., 2008b). 
7.3.2 Ustekinumab (CNTO1275) 
Ustekinumab is a human monoclonal antibody binding with high affinity to the p40 subunit 
of IL 12 and IL 23 and therefore inhibiting the binding to specific receptor (IL-12Rb1) 
expressed on various cells.  
In a phase I study, patients with constant 70% PASI improvement at weeks 8, 12 and 16 shown 
significant decreases in mRNA expression of different cytokines (IL-8, IL-18 and IFN-) as 
early as week 1 (P < 0.05), whereas, in patients without PASI improvement, no significant 
reduction of cytokine mRNA expression was observed(Wittig, 2007). 
The pharmacokinetics of ustekinumab were assessed in different studies (A. B. Gottlieb et 
al., 2007; Kaufmann et al., 2004; Wittig, 2007): after a single subcutaneous injection, 
ustekinumab was slowly absorbed into the systemic circulation (mean Tmax about 12 days) 
and was afterwards slowly eliminated from the circulation (mean t1/2 around 20 days) (A. 
B. Gottlieb et al., 2007; Wittig, 2007). 
The terminal half-life (t1/2) was dose dependent and was found to range from 14.9 ± 4.6 
days (0.27 mg·kg-1 dose group) to 28.6 ± 9.3 days (2.7 mg·kg-1 dose group) (A. B. Gottlieb et 
al., 2007). Similar results were also observed for t1/2 by Kaufman (Kaufmann et al., 2004), 
ranging from 18.5 ± 3.6 in the 0.3-mg group to 25.9 ± 3.7 in the 1.0-mg group. An increase of 
Cmax and AUC was observed with superior dosages (A. B. Gottlieb et al., 2007; Kaufmann 
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In the clinical trial conducted by Kaufman (Kaufmann et al., 2004), 18 psoriasis patients 
were enrolled in four dose groups: 0.1, 0.3, 1.0 and 5.0 mg per kg to assess the clinical 
response and the safety of a single intravenous administration of ustekinumab. At week 12, 
PASI 75 was reached in 25, 50, 60 and 100% of patients respectively. In patients responding 
to ustekinumab treatment, the expression of pro-inflammatory cytokines and chemokines 
IFN-, CXCL-8, CCR2, TNF-, IL-12p40 and IL-23p19 subunits was decreased, compared 
with baseline levels (Reddy et al., 2007; Toichi et al., 2006). 
In a second double-blind, placebo-controlled study, patients were randomized to receive 
either a single subcutaneous injection of 0.27, 0.675, 1.35 or 2.7 mg·kg-1 ustekinumab or 
placebo (A. B. Gottlieb et al., 2007). For a second time, patients treated with ustekinumab 
showed a dose-dependent improvement of their psoriasis. PASI 75 was achieved in 60% of 
the 0.27 mg·kg-1 group, 100% in the 0.675 mg·kg-1 group, 50% in the 1.35 mg·kg-1 group and 
100% in the 2.7 mg·kg-1 group, but in none of the patients receiving placebo during the 
whole study period. 
Krueger (G. G. Krueger et al., 2007) evaluated in a double-blind, placebo controlled trial, 
four subcutaneous dosing regimens of ustekinumab in patients with psoriasis; 320 patients 
were randomized to receive one of the following treatment regimens: one 45-mg dose, one 
90-mg dose, four weekly 45-mg doses and four weekly 90-mg doses of ustekinumab or 
placebo. The primary endpoint of the study was a 75% improvement in the PASI at week 12. 
PASI 75 was achieved in 52% of patients receiving ustekinumab 45 mg, in 59% receiving 
ustekinumab 90 mg, in 67% receiving four weekly 45-mg doses and in 81% of patients 
receiving four weekly 90-mg doses, whereas only 2% of patients in the placebo group 
achieved a PASI 75. 
Another  placebo-controlled double blind randomized crossover study was conducted to 
evaluate the efficacy of ustekinumab in 146 patients suffering from PsA (A. Gottlieb et al., 
2009). Patients were either randomized to receive ustekinumab 90 or 63 mg every week for 4 
weeks (weeks 0–3) followed by placebo at weeks 12 and 16 (76 patients, group 1) or placebo 
(weeks 0–3) and ustekinumab (63 mg) at weeks 12 and 16 (70 patients, group 2). ACR 20 at 
week 12 (taken as the primary endpoint of the study) was achieved by 42% of patients in 
group 1 and by 14% in group 2 (P = 0.0002). Significantly more patients in group 1 achieved 
PASI 75 compared with group 2 in week 12 (52% vs. 5%, P < 0.0001). However, one should 
note that the dosages of ustekinumab used in the study were higher (90 and 63 mg, 
respectively) than those recommended for patients of normal weight (45 mg) with psoriasis 
(Leonardi et al., 2008). 
In conclusion, we report the results of  the two double-blind, placebo-controlled phase III 
studies (Phoenix 1 and Phoenix 2) in patients with psoriasis were performed parallel in USA 
and Europe. Primary outcome in both studies was PASI 75 at week 12 (Leonardi et al., 2008; 
211,). 766 patients of  Phoenix 1 trial were randomly assigned to receive either ustekinumab 
45 mg or 90 mg at weeks 0 and 4 and afterwards every 12 weeks or placebo at weeks 0 and 4 
and to cross over at week 12 to ustekinumab (Leonardi et al., 2008; Papp et al., 2008). 
Furthermore, patients initially receiving ustekinumab and reaching a PASI 75 at weeks 28 
and 40 were re-randomized at week 40 to either continue therapy with ustekinumab or to 
withdrawal of the study drug until loss of response. Significantly more patients in both 
ustekinumab groups (45 and 90 mg) received a PASI 75 at week 12 compared with the 
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placebo group. Patients receiving maintenance therapy up to week 76 significantly better 
sustained PASI 75 than patients randomized to the drug withdrawal group (P < 0.0001).  
The design of the Phoenix 2 study closely resembles that of the Phoenix 1 trial (Papp et al., 
2008). Of the 1230 patients, 409 patients were randomized to receive ustekinumab 45 mg, 
411 to receive ustekinumab 90 mg and 410 to receive placebo at weeks 0 and 4. The efficacy 
analysis at week 12 revealed the following results for the three groups. The primary 
endpoint was achieved in 66.7% of the ustekinumab 45-mg group, 75.7% of the ustekinumab 
90 mg and 3.7% of the placebo group (P < 0.0001 for both ustekinumab 45 and 90 mg vs. 
placebo). 
Quality of life was significantly improved in the patients treated with ustekinumab 
compared with the placebo groups (P < 0.0001) in both Phoenix trials. Patients randomized 
to maintenance therapy in the Phoenix 1 study were able to sustain improved DLQI scores 
until the end of the study, whereas in patients withdrawn from the study drug, the DLQI 
deteriorated again (Leonardi et al., 2008; Papp et al., 2008). 
In a randomized active-controlled, parallel three-arm trial (ACCEPT trial), ustekinumab (45 
and 90 mg, respectively) was compared versus the anti-TNF- etanercept (50 mg twice 
weekly) (C. E. M. Griffiths et al., 2008). The primary endpoint of the study was PASI 75 at 
week 12. 903 patients were randomized in 3 treatment-arms as follows: 347 patients received 
etanercept 50 mg subcutaneously twice weekly, 209 patients received ustekinumab 45 mg 
subcutaneously at weeks 0 and 4, and 347 patients received ustekinumab 90 mg 
subcutaneously at weeks 0 and 4. PASI 75 at week 12 was achieved by 56.8% of patients in 
the etanercept group, by 67.5% in the ustekinumab 45-mg group and 73.8% in the 
ustekinumab 90-mg group. A greater proportion of patients receiving ustekinumab (45 or 90 
mg) achieved PASI 75 when compared with the etanercept group (P = 0.012 for 
ustekinumab 45 mg, P < 0.001 for ustekinumab 90 mg). Interestingly, PASI 75 values at 
week 12 in patients receiving etanercept were better than those published in previous 
studies (Leonardi et al., 2008; Papp et al., 2008). 
The table 4 resume the major results obtained using the briakinumab and ustekinumab in 
psoriasis treatments. 
About the major side effects of treatments with ustekinumab; in the phase I studies, no 
serious adverse events were reported (A. B. Gottlieb et al., 2007; Kaufmann et al., 2004). 
Adverse events included headaches, abdominal pain and common cold symptoms. Adverse 
events were comparable in the phase II studies between ustekinumab and placebo groups 
(79% vs. 72%) (G. G. Krueger et al., 2007). Serious adverse events in patients treated with 
ustekinumab were infections (2 patients), myocardial infarctions (2 patients), a 
cerebrovascular accident (1 patient), non-melanoma skin cancer (2 patients) and prostate 
cancer (1 patient). 
In the placebo group, one patient had a basal cell carcinoma and one patient experienced 
aggravation of his psoriasis requiring hospitalization. In the PsA trial conducted by Gottlieb, 
the following serious adverse events were reported in the ustekinumab groups: syncope (1 
patient), respiratory tract infection (1 patient), haemorrhage (1 patient), stroke (1 patient), 
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sustained PASI 75 than patients randomized to the drug withdrawal group (P < 0.0001).  
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analysis at week 12 revealed the following results for the three groups. The primary 
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90 mg and 3.7% of the placebo group (P < 0.0001 for both ustekinumab 45 and 90 mg vs. 
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ustekinumab 90-mg group. A greater proportion of patients receiving ustekinumab (45 or 90 
mg) achieved PASI 75 when compared with the etanercept group (P = 0.012 for 
ustekinumab 45 mg, P < 0.001 for ustekinumab 90 mg). Interestingly, PASI 75 values at 
week 12 in patients receiving etanercept were better than those published in previous 
studies (Leonardi et al., 2008; Papp et al., 2008). 
The table 4 resume the major results obtained using the briakinumab and ustekinumab in 
psoriasis treatments. 
About the major side effects of treatments with ustekinumab; in the phase I studies, no 
serious adverse events were reported (A. B. Gottlieb et al., 2007; Kaufmann et al., 2004). 
Adverse events included headaches, abdominal pain and common cold symptoms. Adverse 
events were comparable in the phase II studies between ustekinumab and placebo groups 
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ustekinumab were infections (2 patients), myocardial infarctions (2 patients), a 
cerebrovascular accident (1 patient), non-melanoma skin cancer (2 patients) and prostate 
cancer (1 patient). 
In the placebo group, one patient had a basal cell carcinoma and one patient experienced 
aggravation of his psoriasis requiring hospitalization. In the PsA trial conducted by Gottlieb, 
the following serious adverse events were reported in the ustekinumab groups: syncope (1 
patient), respiratory tract infection (1 patient), haemorrhage (1 patient), stroke (1 patient), 





patient), gastric ulcer haemorrhage/abdominal pain/back pain (1 patient) and basal cell 
carcinoma (1 patient) respectively (A. Gottlieb et al., 2009). Two serious infections occurred 
during the placebo-controlled phase of the two large phase III trials: one case of cellulitis 
and one case of herpes zoster (both in the ustekinumab 90-mg group) (Ding et al., 2008; 
Ortonne et al., 2007). 
During the placebo-controlled phase of the Phoenix 2 study, a squamous cell carcinoma in a 
patient in the placebo group and a basal cell carcinoma in a patient in the ustekinumab 90-
mg group were observed (Ding et al., 2008). Comparing patients on maintenance therapy 
with patients randomized to the withdrawal group in Phoenix 1 study did not reveal an 
increased infection rate between the two groups (Ortonne et al., 2007).  
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However, as Th1 and Th17 blockade by ustekinumab might impair cell-mediated immunity, 
normal KCs host immunity and defence against malignancies, close monitoring in patients 
on long-term treatment with ustekinumab seems to be appropriate (O’Neill & Kalb, 2009). In 
the ACCEPT trial, serious adverse events have been observed in 1.2% of patients in the 
etanercept group, 1.9% in the ustekinumab 45-mg group and 1.2% of patients in the 
ustekinumab 90 mg group respectively. These included 4 patients in each treatment group: 
etanercept group: abdominal pain, bacterial meningitis, nephrolithiasis, rotator cuff 
syndrome; 45-mg ustekinumab group: alcoholic pancreatitis, chest pain/hypertension, 
psychotic disorder, breast cancer; ustekinumab 90-mg group: urosepsis/renal failure, 
uveitis, appendicitis and gastroenteritis from food poisoning (C. E. M. Griffiths et al., 2008). 
8. Conclusion 
Based on  a large series of studies, that we discuss in the different paragraphs, current 
evidence indicates the importance of T cells during psoriasis pathogenesis and demonstre 
that T cell expansion precedes the development of typical psoriatic changes; the more 
reasonable conclusion is that psoriasis is the outcome of an inappropriate T cell-based 
activation event, together with a defect in KCs, whose combination results in the full 
psoriatic phenotype. 
Once recognized the primary role of T cells in  psoriasis pathogenesis, several biological 
therapies have been developed and proposed to counteract immune T response. These 
treatments consist  in blocking the actions of several T cell cytokines that play a key role in 
sustain the pathogenesis of early and late events of psoriasis, e.g. anti-IL23 and anti-TNF-. 
So far, considering published data from the clinical trials, the new biological agents have 
been shown to be efficient treatment options for patients suffering from psoriasis and the 
major comorbidities disease-associated, primarily PsA. 
These new biological agents  seem to have proven a good risk/benefit ratio. As psoriasis is 
considered a life-long disease and no causal therapy for the disease is yet available, long-
term studies on safe and efficacious treatments are needed and are of major importance. 
Taking into account the possibility that uncommon adverse events or events occurring 
during long-term exposure to these drugs might emerge in the future (e.g. the development 
of progressive multifocal leukoencephalopathy in long-term patients treated with 
efalizumab), vigilant and careful post-marketing surveillance in patients treated with 
biological agents is strongly recommended. 
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1. Introduction 
Psoriasis is a disease with frequently severe impairment of quality of life. Traditional 
therapies (topical treatments, UV, cyclosporine, acitretin, methotrexate...) are widely used 
but are not always sufficient, and may be poorly tolerated or contra-indicated. Among 
biologicals, firsts on the European dermatological market were etanercept and infliximab. 
Alefacept use was restricted to the United States of America. Byafter, adalimumab and 
ustekinumab were launched. 
Among all these biotherapies, infliximab is considered a little bit different : known to be one 
of the most efficient, infliximab treatment requires a mode of administration quite repulsive 
for some practitioners. It is an intravenous drug, needing a medicalized center of care with 
good experience and equipment. Infliximab is also known to induce some adverse event, 
particularly infusion hypersensitivity. 
To verify these sentences, we intended to examine our patient cohort treated by infliximab 
in our Dermatology Unit, with a retrospective study of the first 50 patients beginning 
infliximab therapy in our Department (excluding patients in phase II or III clinical trials). 
Aims : 
- to evaluate the proportion of noticeable adverse events, and particularly the therapy 
discontinuation for adverse events. 
- to evaluate in 'real life' the dose and frequency of treatments 
- to evaluate the clinical relapses (loss of drug efficacy) and the medical attitude towards 
this 
- to evaluate the reasons for therapy drop-out and/or drug switches 
- to evaluate the patient point of view and wishes : drug holidays ? Continuous 
treatment : good or bad concept for patient psychology ? 
- to evaluate the number of temporarily-discontinued treatments and the consequence for 
re-introduction : adverse event ? Systematic prevention ? 
Limitations : 
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- no comparison is possible 
- real life context induces more drop-outs, drug switches and lost to follow-up than 
controlled clinical studies 
2. Retrospective study 
2.1 Patients and methods 
This is a retrospective study. We revised the list of patients affected with moderate and 
severe psoriasis and treated with infliximab in our Department since April 2006. Only the 
first 50 patients were kept, in order to ensure a sufficient trial and analysis period (one year 
minimum). Four patients were excluded, who were initially treated in the Department but 
subsequently received follow-up in another hospital. 46 patient files were analyzable in 
total. Of these, the PASI follow-up data were complete for 41 patients. Analysis of the files 
was carried out respecting privacy laws, according to the procedures in force for 
retrospective analyses. 
2.2 Results 
 Patients were 13 women and 33 men. 
 Age range was 19 to 72 years. 
 As prior treatment for psoriasis, all patients but 2 (44/46) previously received PUVA 
therapy and cyclosporine and methotrexate, according to Belgian regulations for the 
prescription of biological therapy. Two patients did not receive cyclosporine: one due to 
an absolute renal contra-indication and another who had begun biological therapy in a 
country where prior treatment with cyclosporine was not required. 
 Concerning biological therapy, 15 patients began infliximab as first-line treatment 
(biotherapy naive patients). 31 took infliximab as second- or third-line treatment. 
 The average length of infliximab therapy on day of analysis was 604 days (14 – 1666) 
 Best results obtained were PASI 100 (19 patients), PASI 90 (6), PASI 75 (6), PASI 50 (4), 
PASI <50 (6). Among the 19 patients who achieved PASI 100, 4 had a complete relapse, 
and 6 a partial relapse. 9 maintained a complete response. Of the patients scoring 
between 50 and 99%, 8 completely relapsed, and 3 partially. 
 As significant adverse events, we noticed 2 cases of arthritis and atypical lupus, 2 
typical lupus syndromes, 2 true anaphylactic reactions. We did not see any significant 
infection. The lupus syndromes required hospitalization and took six months to 
disappear. 
 In clinical follow-up, we did not notice any global tendency to weight loss or gain and 
no change in blood pressure. 
 In the serie, we have one death, by suicide, deemed to be unrelated to the treatment 
 Infliximab was used in monotherapy in 41 cases; 5 in combination with methotrexate 
 Dosage was secondarily adapted in 8 cases (3 increases in frequency due to insufficient 
response, 5 dose reductions due to complete and sustained clinical response) 
 Temporary interruption and subsequent reintroduction were observed in 10 cases: for 
non-compliance (2), personal choice (1), intercurrent illness (1), waiting to settle social 
security (1), extended trip (1), clinical trial (1), temporary treatment switch (3). The 
reintroduction was accompanied by manifestations of hypersensitivity in one case only. 
 





Our patients' demographic data is unremarkable: average weight, alcohol and tobacco 
habits, comorbidity, and concurrent medication appear to be similar to the general 
population of psoriasis patients. Only the sex ratio would seem to be non-standard: there 
are significantly less women than men in our series (13 vs 33). Even if it is not consistent 
with the general psoriasis sex ratio, it is in accordance with other infliximab case series. 
For legal, and social security reimbursement reasons, we do not prescribe infliximab to 
children and adolescents; our youngest patient is aged 19 years. Subject to a safeguarded 
general condition, we did not set an upper limit; the oldest patient was aged 72. 
3.2 Prior systemic treatment 
Prior treatments received for psoriasis are stereotypical: before authorizing biological 
therapy, Belgian regulations require patients to have tried three therapeutic channels: PUVA 
therapy, cyclosporine, and methotrexate. It is noted that this refers to PUVA therapy proper, 
and not just UVB treatment. For cyclosporine, a 'minimum of 2 months of therapy' is 
stipulated, 'at a minimum of 2.5 mg/kg.day'. For methotrexate, a minimum of 3 months is 
required, at 15 mg minimum per week. Infringements to either requirement can be made 
only in the case of documented intolerance or absolute contra-indication. 
Among the 46 patients, one was Argentinian and had been able to begin biological therapy 
in his country without going through the three prior steps; the Belgian authorities therefore 
authorized him to take infliximab immediately. Another patient had mild renal insufficiency 
and unstable blood pressure despite the treatment, which was deemed sufficient to certify 
contra-indication to cyclosporine. The remaining 44 patients all received the three standard 
treatments, in some cases also UVB, acitretin, or spa treatments. None received fumaric acid 
(not used in Belgium). Reasons for discontinuing prior treatments included the absence of 
sufficient clinical results, or an intolerance to the treatment, as well as the prevention of side 
affects after reaching an excessive cumulative dose. Note: one of the patients had renal 
insufficiency induced by prolonged cyclosporine therapy. 
3.3 Choice of biological therapy 
No regulations lay down the use of a specific first-line biological therapy. It would no doubt 
be logical to begin with a TNF inhibitor, before considering an anti-interleukin, such as 
ustekinumab, however no objective data exists to support this affirmation. This rationale lies 
merely in a lack of experience and appraisal with ustekinumab, as opposed to the years of 
experience with TNF inhibitors, infliximab in particular. There is no way to choose one 
product over another among TNF inhibitors. Suggestions to begin with etanercept are based 
on certain data emerging from records, but these are not sufficiently back-up. In the end, the 
choice of first-line biological therapy currently depends on the habits of the prescriber and 
discussions with the patient. 
In our case series, 15 patients have received infliximab as first-line treatment. The choice was 
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advantages and disadvantages. Many patients appreciate the simplicity of infliximab's 
dosage schedule: half a day in hospital every eight weeks seems much easier than more 
regular injections at home. Patients often say: "at least, with the drip, I can forget about 
psoriasis and its treatment completely for two whole months". Patients do not have to go to 
the pharmacy on a regular basis, keep boxes in the family refrigerator, or have a nurse 
repeatedly visit their house (figure 1). 
 
Fig. 1. Infusion in specialized unit 
On the other hand, some patients fear the hospital environment and prefer treatments they 
can manage independently. This explains the figure of 31 patients who began infliximab as 
second- or third-line treatment. Of these patients, the majority had begun with etanercept, 
with a clinical response deemed insufficient. Some had begun with adalimumab, with a 
subsequent secondary clinical relapse. Some patients used these two products before 
beginning infliximab. One patient had received ustekinumab, with a good clinical result, but 
the development of a paradoxical eczematous reaction. 
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When we compared the response to infliximab in biotherapy naive and non-naive patients, we 
found no significant difference, contrary to our expectations. The two groups have the same 
numbers of complete responses and there is no difference in the subsequent relapse rate. 
3.4 Duration of treatment 
The average duration of treatment (stopped on the day of database analysis) is 604 days, with 
extremes of 14 and 1666 days. This duration is long enough to draw conclusions, at least 
partial ones. The 14-day duration corresponds to a treatment stopped due to side effects. 
3.5 Efficacy of infliximab 
Clinical response is often excellent. Primary response must be distinguished from more 
long-term response. Primary response is immediate efficacy, generally deemed at 10 weeks 
for infliximab. The more long-term response is the persistence of efficacy, without relapse; 
there is no defined timeframe for measuring this. We will therefore talk about a 1-year or 2-
year response, etc. For this study, we analyzed the long-term response according to the 
clinical practice at the time of file analysis, so 1 to 4 years after the beginning of treatment. 
 
Fig. 2. W0, baseline 
A review of the literature indicates excellent clinical response rates to infliximab after 10 
weeks: around 80% at PASI 75 (Chaudhari et al., 2001). In other words: four patients out of 
five achieve a three-quarter response at minimum (reduce their initial PASI by 75% 
minimum). In our series, this was true for 31 out of 41 assessable patients, so 76%. 19 
patients (46%) had a complete response (total clearance of lesions) (table 1). 6 patients 
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percentage between 75 and 89%. Just 4 remained with an improvement of ‘only’ between 50 
and 74%. 6 patients are considered to have a primary resistance to treatment as they have 
never obtained a 50% reduction in their initial severity. These six patients cannot be 
distinguished from the others on the basis of age, sex, comorbidity, or prior treatments 
received. No characteristics predictive of response emerged from our series. 
 
Fig. 3. W10, complete response 
 
 Initial clinical response 
PASI improvement 100% 90-99% 75-89% 50-74% < 50% 
Number of patients 19 6 6 4 6 
%, of patients (46%) (15%) (15%) (10%) (15%) 
Table 1. Clinical response at 10-12 weeks 
Although the initial clinical response is therefore very good, there are concerns about its 
persistence in the medium and long term. Indeed, in our series there were numerous 
relapses: of the 35 responders, 12 (34%) experimented complete relapse, and 9 partial losses 
of efficacy (26%) (table 2). By relapse, we mean relatively rapid or gradual return to initial 
clinical severity. Each case must be confirmed in time in order to exclude spontaneous 
fluctuations of the illness. True relapses rarely pose diagnostic problems, and justify 
treatment abandonment. In contrast, for partial loss of efficacy, the absence of external 
factors must first be verified. In our series, several patients experienced periods of 
aggravation, which should be seen in relation to increased alcohol consumption; hygienic, 
dietary, and psychosomatic care improved several cases. The use of contributory drugs 
should also be systematically researched. 
 




Fig. 4. W46, partial relapse 
 
 Clinical response upon completion (after 1 to 4 years) 
Response evolution Stable Partial loss Complete relapse 
Initial responders 100% (19) 9 (47%) 6 (32%) 4 (21%) 
Initial responders 
50-99% (16) 5 (31%) 3 (19%) 8 (50%) 
Total (35 pat.) 14 (40%) 9 (26%) 12 (34%) 
Table 2. Clinical response at long-term 
Our series shows more relapses than the literature initially reported, but the latter was often 
based on short observation time periods, or a more frequent combination with methotrexate. 
However, the most recent publications are in line with our observations. Thus, a Brazilian 
series demonstrates numbers similar to ours: 32% maintain efficacy, 44% partially recur, 
17% completely relapse, and another 6% of patients had a relapse corrected by infusion 
every six weeks (Duarte et al., 2011). In a series of 120 patients, 93% of patients had an initial 
response achieving at least PASI 90, however 87% required a higher frequency of treatment 
than the normal regimen of 5 mg/kg every 8 weeks (Kamili et al., 2011). 
In our series, complete relapses occurred most commonly after between 8 and 12 months of 
treatment; partial relapses could appear up to three years after the start. The responders are 
highly satisfied and intend to continue treatment, with an improvement in quality of life 
consistently nearing 100%. We should note that 9 out of 35 patients (26%) maintain a 
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Initial responders 100% (19) 9 (47%) 6 (32%) 4 (21%) 
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Total (35 pat.) 14 (40%) 9 (26%) 12 (34%) 
Table 2. Clinical response at long-term 
Our series shows more relapses than the literature initially reported, but the latter was often 
based on short observation time periods, or a more frequent combination with methotrexate. 
However, the most recent publications are in line with our observations. Thus, a Brazilian 
series demonstrates numbers similar to ours: 32% maintain efficacy, 44% partially recur, 
17% completely relapse, and another 6% of patients had a relapse corrected by infusion 
every six weeks (Duarte et al., 2011). In a series of 120 patients, 93% of patients had an initial 
response achieving at least PASI 90, however 87% required a higher frequency of treatment 
than the normal regimen of 5 mg/kg every 8 weeks (Kamili et al., 2011). 
In our series, complete relapses occurred most commonly after between 8 and 12 months of 
treatment; partial relapses could appear up to three years after the start. The responders are 
highly satisfied and intend to continue treatment, with an improvement in quality of life 
consistently nearing 100%. We should note that 9 out of 35 patients (26%) maintain a 





An interesting observation is the difference for the long-term result between complete and 
partial initial responders. Among complete initial responders, half patients maintain the 
response, and 21% have a complete relapse. In comparison, among partial initial responders, 
31% have a stable efficacy, and 50% have a complete relapse.  
3.6 Infliximab and methotrexate 
We commonly propose infliximab in monotherapy. It is the most common method for treating 
plaque psoriasis, in contrast to other indications, where combination with methotrexate is 
systematic. The aim is therefore both to increase treatment efficacy, and to prevent the 
formation of neutralizing anti-drug antibodies (Poulhalon etal., 2007). The question of more 
frequently combining infliximab and methotrexate in dermatology has already been raised but 
never resolved. In our series, 4 patients take methotrexate in parallel with infliximab; they 
began it after around four months on infliximab, to compensate for insufficient efficacy. 1 
other patient began infliximab immediately in parallel with methotrexate. 
3.7 Practical attitude in case of relapse 
In case of partial relapse, after removing the aggravating factors mentioned above, we 
usually suggest continuing treatment, this time in combination with methotrexate. The 
dosage of the latter is in line with usual regulations, adapted to the patient's weight 
(between 55 and 135 kg, for the present four patients). The medical practice is initially to 
diminish the dosage relative to methotrexate taken alone, but the clinical facts then dictate 
the procedure to follow. Tolerance posed no particular problems for three patients. The 
fourth patient experiences biological perturbations in the liver, which require frequent dose 
reductions; gastroenterology results are reassuring and allow treatment to be continued, 
which is furthermore essential due to the severity of the psoriasis and its impact on the 
patient's life. 
We did not try to combine infliximab with other treatments for psoriasis. 
Another option would have been to adapt the dosage of infliximab; an increase in frequency 
has demonstrated success (an infusion every 6 weeks instead of every 8) (Duarte et al., 
2011). In Belgium, this is impossible in common practice due to Social Security 
reimbursement regulations. 
If relapse is complete, a combination with methotrexate is not sufficient and the 
continuation of infliximab is not justified. It could even be deleterious, by analogy with 
other observations (Korswagen et al., 2011). Among patients with relapse (complete or 
partial, severe and resistant), 16 were treated with ustekinumab: after a minimum of 10 
months, 5 responses at 100%, 7 satisfactory responses (50-99%), and 4 failures were 
observed. Please note: a naive patient of biological therapy for whom infliximab has never 
produced a significant improvement (primary non-responder), has then responded 
optimally to adalimumab. 
4. Adaptation of dosage 
The official dosage is 5 mg/kg, every eight weeks, after the induction phase. We adapted it 
in 8 cases. For 3 patients, we increased the frequency of infusions to 1x/6 weeks to try and 
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respond to the loss of efficacy observed. For two of them, response improved temporarily, 
however the dosage frequency would have had to be increased more, which was not 
possible. In contrast, for 5 patients, the dose had to be reduced; the clinical response had 
been complete and stable for 18 months, and these patients questioned the usefulness of 
continuing the treatment, at least at the initial dosage. Four patients out of the five thus 
continued their treatment at a reduced dose, without loss of efficacy. In practice, a reduction 
to 4, and then 3 mg/kg was suggested to them. 
4.1 Medical follow-up 
The medical follow-up we propose follows English guidelines (Smith et al., 2009): essentially 
clinical and anamnestic, it is also based on a blood sampling every six months and particular 
monitoring for tuberculosis risk. For our patients, we have not observed a tendency for 
weight gain or loss, nor change in blood pressure. 
4.2 Adverse events 
Few adverse events were observed, but these were occasionally severe. 
One death by suicide, of a 30 year old man. The patient had been depressed for a long time, 
with a first suicide attempt long before the infliximab treatment. The psychological follow-
up was good, but the patient was unable to cope with a failed love affair. The doctor 
considered this suicide as unrelated to the infliximab treatment. Similarly, a 67 year old 
patient reported an aggravated impotence problem since the first infliximab infusions. He 
decide to stop the treatment, which left the effect on erectile function unclear. He had 
reported the same problem during methotrexate treatment, with recovery after 
discontinuation. Urological examination results were normal. 
Overall, we did not observe any significant infection. Specifically, we did not note any 
opportunistic infection or any tuberculosis. There were no severe infections to justify a 
deferral of the infliximab infusion, and anti-infective treatment did not need to be increased 
in any case. 
One patient suspended their treatment during cardiac surgery on the mitral valve (condition 
pre-existing the infliximab treatment). 
For six patients, the obligation to discontinue treatment was more acute (see table 3). 
The two cases of induced lupus were severe and required hospitalization. Remission was 
slow. The first patient had already been treated with infliximab, with an excellent initial 
clinical response but a relapse after one year. The treatment was stopped for 9 months, but 
the administration of adalimumab was not conclusive, and the patient wished to try 
infliximab again. Ten days after the first re-introduced infusion, the patient experienced 
joint pain and swelling, with rapidly-progressive functional disability leading to an 
incapacity to move, and hospitalization. The second patient, on methotrexate from the start, 
developed signs of articular lupus from the 9th month of infliximab treatment, with 
seroconversion. After the 11-month infusion, the seizure was acute, incapacitating, requiring 
hospitalization and the use of corticosteroids, and then even thalidomide. It was possible to 
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Table 3. Observed adverse events 
For patient 3 (see table), resistant to adalimumab from the start, adverse effects arose from 
the first infliximab infusion: chest pain with normal tracing on the ECG, unremarkable 
blood pressure and pulse. The second infusion had to be stopped (faintness) and resumed 
the following week, with premedication. On the following three days, the patient had to 
visit the emergency department for incapacitating inflammatory joint pain. The patient was 
off work for 24 hours. The clinical result was good (PASI reduced to 80%). The third 
infusion gave rise to the same joint pains, increased, diffused, with headaches. The 
treatment was discontinued and replaced with ustekinumab, with no tolerance problem. 
Patient 4, who was resistant to etanercept, initially showed an excellent response to 
infliximab (98% PASI improvement). After around 10 months, the recurrence preceding 
each infusion came earlier and earlier. The treatment was discontinued after 17 months, 
after it had lost all effect and inflammatory, atypical joint pain had developed for several 
days and then weeks following the last two infusions, despite the use of methotrexate 
(begun very late). 
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For patients 5 and 6, the anaphylactic reactions were true. For the first patient, the shock 
arose on the 2nd infusion after treatment reintroduction. The patient had participated in the 
Centocor EXPRESS clinical trial (C0168T38) in 2003 and 2004. The treatment had been 
stopped for 2 years, with use of etanercept. The infliximab treatment could be restarted after 
the anaphylactic shock, with systematic preventive measures, progressively reduced, but 
without the possibility of complete cessation. Clinical efficacy was reduced: less complete 
response, and period of 8 weeks between two infusions became too long. This justified the 
discontinuation of infliximab 4½ years later. The reaction was less severe for the second 
patient. The treatment was also continued, with prevention, but a clinical relapse appeared, 
which became complete six months later (no improvement after infusion). This patient 
currently has a partial response to ustekinumab. 
4.3 Drug holidays 
10 patients experienced temporary interruptions to treatment. The reasons varied widely. 
Two patients were not compliant: they forgot appointments on several occasions and 
canceled due to 'lack of time'. Several times, this led to delays of up to three months. This 
did not affect tolerance for either patient, but one of the two had an insufficient clinical 
response. The doctor therefore suggested a treatment more in line with their lifestyle. 
One patient personally chose to have a drug holiday; he was able to restart treatment 
successfully and without adverse events, after recurrence of psoriasis. 
One patient (already mentioned above) had to interrupt infliximab for nearly six months 
due to repeated heart surgery. 
One patient interrupted treatment for several months, as his Social Security status was 
unsettled, and he was no longer allowed to claim his treatment fees. 
One patient had to go on a extended trip abroad. 
One patient interrupted treatment for a clinical drug trial. 
Several patients who had received infliximab therapy for several years recently expressed 
interest in switching to a biological therapy administered subcutaneously, which they had 
heard about and considered easier to manage. However, the beginning of treatment is 
often difficult (partial recurrence following the discontinuation of infliximab), and efficacy 
of the new treatment is not always immediate. Three patients experienced the change 
badly and tolerated the beginning of the recurrence poorly. Despite medical explanations 
and the concern for avoiding drug ‘shopping’, they returned to their prior infliximab 
treatment. The reintroduction was accompanied by manifestations of hypersensitivity in 
one case only. 
4.4 Adherence to treatment 
Infliximab treatment usually involves strong adherence by the patient. When efficacy is 
maintained in the long-term, the patient is especially grateful for this invariability. All 
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inconvenience of hospitalized infusion is deemed negligible by most patients. For many, this 
aspect of full care is even deemed to be positive. One possible problem, in psychological 
terms, is that the infusions take place in hospitals which treat other ambulatory patients, in 
particular patients undergoing cancer chemotherapy. This co-existence can be difficult to 
experience for some patients affected with psoriasis. It is easier to manage in large hospitals, 
which can organize their wards accordingly. 
4.5 Quality of life 
We did not have systematically evaluate a score of quality of life. Thus, no analyzis is 
possible. Only one patient has stopped the treatment because considered too heavy to 
manage. Four patients complain about the need of hospital infusion. All others were 
satisfecied by the treatment. 
As for other psoriasis treatments, erythematous scars occuring after initial improvement 
may be of transitory bad perception by the patient (figure 5).  
The major problem is to psychologically and medically manage losses of clinical response. 







Fig. 5. W6, PASI75 response with erythematous sequelae 
 




From this series of 50 patients treated by infliximab, we can confirm the efficacy of the 
product: PASI 100 (46%), PASI 90-99 (15%), PASI 75-89 (15%), PASI 50-74 (10%). In around 
half the cases, this efficacy is reduced over time (26%), or completely lost (34%); it is 
maintained in 40% of cases. In this study, we have a tendency for a more sustained response 
among complete initial responders in comparison with partial initial responders (47 vs 31%). 
We always present infliximab to new patients as the most effective therapy in principle, 
warning them however about this risk of efficacy loss. The concurrent use of methotrexate 
could be considered, having proved its worth in indications other than plaque psoriasis 
(Kamili et al., 2011). Patient satisfaction is increased, despite the need for infusions in 
specialized and equipped centers. The occurrence of hypersensitivity reactions during 
infusion must be monitored and the risk of arthritic and lupus reactions must be known. 
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1. Introduction 
Cyclosporin was isolated in 1970, by Jean François Borel at Sandoz Laboratories (Basel, 
Switzerland), from the soil fungus Tolypocladium inflatum (Borel et al., 1995; Amor et al., 
2010). The compound was initially identified as a possible antifungal agent, but it was 
subsequently shown to have limited antifungal activity. However, in 1976, the drug 
demonstrated potent immunosuppressive properties, and two years later, it was 
successfully shown to prevent renal allograft rejection in renal transplant recipients. A year 
later, a pilot study showed that cyclosporin improved psoriasis in patients treated for  
rheumatoid and psoriatic arthritis. Ultimately, in the early 1990s, cyclosporin was approved 
in Europe for the treatment of psoriasis and atopic dermatitis. In 1997, the United States 
Food and Drug Administration approved a microemulsion formulation of cyclosporin 
(Neoral®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) for the treatment 
of severe psoriasis in adults. Worldwide, cyclosporin has been used extensively in various 
dermatological disorders: e.g. pyoderma gangrenosum, and refractory chronic idiopathic 
urticaria (Amor et al., 2010; Vena et al., 2006). 
Despite such a distinguished clinical history, some dermatologists have been rather hesitant 
to use cyclosporin because of concerns about possible adverse effects (Amor et al., 2010; 
Ryan et al., 2010); however a ‘framework’ of detailed clinical data now widely supports the 
effective and safe use of cyclosporin within dermatologists’ prescribing guidelines, 
especially when the drug is used as a ‘rescue’, or intermittent short-term treatment for 
severe psoriasis, psoriatic arthritis, or atopic dermatitis (Amor et al., 2010). 
Another particularly pertinent consideration is that ‘conventional’ and generic (including 
generic microemulsion) formulations of cyclosporin are associated with marked intra- and 
interindividual variability in absorption, thus creating the potential for subtherapeutic 
dosing at one extreme and toxicity at the other (Colombo & Egan, 2010; Ryan et al., 2010). 
For this reason, generic formulations have not yet been approved in several countries. 
Conversely, the microemulsion Neoral® preparation is associated with low intra- and 
interpatient variability in cyclosporin absorption and with a consistent dose-exposure 
relationship. This highlights the importance of prescribing the most clinically appropriate 
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cyclosporin preparation, and of avoiding any confusion between the various cyclosporin 
formulations available (Colombo & Egan, 2010). Indeed, a Canadian survey reported that up 
to 20% of new cyclosporin recipients may be given a cyclosporin formulation different from 
that actually prescribed (Davies & Gupta 2000). 
This chapter will review the following with respect to psoriasis treatment: 
 The mechanism of cyclosporin action 
 The pharmacokinetic properties of cyclosporin 
 The efficacy of cyclosporin in well-designed, randomised controlled trials, with 
important economic information from certain key clinical trials 
 The role of cyclosporin in current combination therapy 
 Side effects of the compound. 
2. Mechanism of action 
Cyclosporin, an 11-amino acid, cyclic polypeptide produced from the fungal species 
Beauveria nivea, is a calcineurin inhibitor that acts selectively on T cells (Amor et al., 2010). 
Cyclosporin binds to the intracellular immunophilin cyclophilin to form a complex, which 
then binds to and inhibits the enzymatic activity of calcineurin phosphatase, a serine- 
  
Fig. 1. Mechanism of cyclosporine action. Cyclosporine (CsA) binds to cyclophylin (CpN), 
forming a complex that  binds and blocks the function of the enzyme calcineurin (CaN). As a 
result, CaN fails to dephosphorylate the cytoplasmic component of the nuclear factor of 
activated T cells (NF-ATc), and the transport of NF-ATc to the nucleus and the binding of 
NF-ATc to the nuclear component of the nuclear factor of activated T cells (NF-ATn). The 
NF-ATc–NF-ATn complex binds to the promoter of the interleukin 2 (IL-2) gene and 
initiates IL-2 production. Consequently, T cells do not produce IL-2, which is necessary for 
full T-cell activation.(Modified from Stepkowski, S.M. 2000) 
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threonine phosphatase that depends on calcium and calmodulin for activity (Amor et al., 
2010; Giese et al., 2004; Stepkowski 2000). Consequently, calcineurin cannot 
dephosphorylate an important transcription factor: the cytoplasmic component of nuclear 
factor of activated T cells (NF-ATc) [Fig.1]. Transport of NF-ATc to the cell nucleus, and 
binding of NF-ATc to the promoter region of the IL-2 gene nuclear component of NF-AT 
(NF-ATn), is therefore blocked and T cells can no longer produce IL-2, a cytokine required 
for complete activation of the T-cell pathway, granulocyte-macrophage colony-stimulating 
factor, and interferon-γ production (Amor et al., 2010; Giese et al., 2004). The consequences 
of cyclosporin action include (Amor et al., 2010): 
 Depletion of lymphocytes and macrophages in the epidermis and dermis 
 Downregulation of cellular adhesion molecule expression in the dermal capillary 
endothelium 
 Restricted activation of antigen-presenting cells, natural killer cells, and T cells 
 Inhibition of keratinocyte hyperproliferation 
 Restricted release of histamine from mast cells. 
3. Pharmacokinetic properties 
Cyclosporin is a lipophilic molecule that is poorly absorbed from ‘conventional’ orally 
administered formulations, with major variations in intra- and inter-patient bioavailability 
(Ryan et al., 2010). A microemulsion preparation (Neoral®; Novartis, East Hanover, New 
Jersey, USA) was therefore developed with greater hydrophilicity, and higher 
bioavailability (Colombo & Egan, 2010). There is marked variability among conventional 
formulations, and for the microemulsion vs conventional formulations : oral forms of 
cyclosporin are generally not bioequivalent,(Colombo & Egan, 2010) except for Neoral® soft 
gelatin capsules and Neoral® oral solution, which are bioequivalent (Novartis 
Pharmaceuticals UK Ltd 2011). Conventional and generic (including generic microemulsion) 
formulations of cyclosporin are characterised by considerable intra- and inter-individual 
variability in absorption (Colombo & Egan, 2010; Ryan et al., 2010). By contrast, there is low 
variability in cyclosporin absorption from the microemulsion Neoral® preparation, which 
provides a consistent dose-exposure relationship (Colombo & Egan, 2010). 
Peak plasma cyclosporin concentrations are attained 1–6 hours after administration of a 
conventional soft gelatin capsule formulation (Sandimmune®; Novartis Pharmaceuticals 
Corporation, East Hanover, New Jersey, USA), but 1.5–2.0 hours after oral administration of 
the microemulsion formulation (Neoral®) (Novartis Pharmaceuticals Corporation 2009; 
Novartis Pharmaceuticals UK Ltd 2011). Mean peak plasma cyclosporin concentration (Cmax) 
after administration of the microemulsion versus conventional preparation is 40–106% 
greater, and mean area under the plasma concentration versus time curve (AUC) is 20–50% 
greater (Novartis Pharmaceuticals Corporation 2009; Novartis Pharmaceuticals UK Ltd 
2011). After 4 weeks’ administration of Neoral® at a mean dosage of 2.48 mg/kg/day in 18 
patients with psoriasis, mean Cmax was 655 ng/mL and mean AUC was 2324 
ng•h/mL.(Novartis Pharmaceuticals Corporation 2009) 
Cyclosporin is extensively distributed throughout the body, in plasma (33–47% of an 
administered dose), lymphocytes (4–9%), granulocytes (5–12%), and erythrocytes (41–58%) 
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to proteins (~90%), primarily lipoproteins,(Novartis Pharmaceuticals Corporation 2009) and 
transfer of the drug may occur between various lipoprotein subfractions, and between 
albumin and lipoproteins (Ryan et al., 2010). Cyclosporin is excreted in breast milk, such 
that mothers treated with the compound should not breastfeed (Novartis Pharmaceuticals 
Corporation 2009). 
Cyclosporin is metabolised by the cytochrome P450 (CYP) system, primarily by isozymes 
CYP3A4 and CYP3A5 in the liver and small intestine; the p-glycoprotein pump also has a 
major influence on cyclosporin bioavailability and clearance (Novartis Pharmaceuticals 
Corporation 2009; Ryan et al., 2010).  Cyclosporin is eliminated primarily via the bile. The 
terminal half-life of cyclosporin in plasma has varied from 6–24 hours in various 
populations,(Novartis Pharmaceuticals UK Ltd 2011; Ryan et al., 2010) but in patients with 
psoriasis, the value is probably closer to the lower end of this range (Berth-Jones 2005). 
4. Clinical efficacy 
Cyclosporin is one of the most effective antipsoriatic agents available because of its rapid 
onset of effect and potent immunosuppressive activity against disease flares (Amor et al., 
2010; Ryan et al., 2010). Thus, in patients with severe psoriasis refractory to other agents, 
cyclosporin can produce rapid remission and serve as a useful ‘bridge’ to other treatments 
(Menter et al., 2009). 
The efficacy of cyclosporin is dose-dependent, and times to psoriasis remission are shorter at 
higher doses (Faerber et al., 2001; Timonen et al., 1990). Results from key dose-finding 
studies and meta-analyses for cyclosporin in psoriatic patients are shown in Table 1. In 
patients treated with cyclosporin 1.25–5 mg/kg/day for 10–36 weeks, the PASI70 or PASI75 
response rate (i.e. the proportion of patients with a decrease in Psoriasis Area and Severity 
Index [PASI] score of ≥70% or ≥75% from baseline, or with a decrease to a PASI score of ≤8)  
 















et al., 1992 r, df 217 1.25–5 12–36 wks 18–56 - 
Ellis et al., 
1991 r, db 85 3–7.5 16 wks - 59–77 
Faerber et al., 
2001 ma 597 1.25–5 10–12 wks 16–50
c - 
Timonen et 
al., 1990 ma 457 1.25–5 3 mos 24–88 - 
a Proportion of patients with a decrease in Psoriasis Area and Severity Index (PASI) score of ≥75% from 
baseline, or with a PASI score ≤8. 
b Percentage decrease in score from baseline. 
c PASI70 response. 
db = double-blind; df = dose-finding; ma = meta-analysis; mos = months; r = randomised; wks = weeks. 
Table 1. Key dose-finding studies and meta-analyses for cyclosporin in psoriatic patients. 
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was 16–88% (Christophers et al., 1992; Faerber et al., 2001; Timonen et al., 1990). Moreover, 
in a 16-week study in 85 patients with severe psoriasis, cyclosporin 3–7.5 mg/kg/day 
reduced global disease severity score by 59–77% (Ellis et al., 1991); however, although major, 
additional efficacy benefits can be obtained at cyclosporin doses >5 mg/kg/day, these 
benefits are offset by increased toxicity (Amor et al., 2010). 
Psychological distress is common in psoriatic patients (Colombo et al., 2010c; Finzi et al., 
2007). A large, observational, follow-up study of more than 1500 psoriatic patients (the 
PSYCHAE study) revealed that methotrexate and topical corticosteroids were associated 
with a significantly increased risk of minor psychological distress, whereas cyclosporin 
significantly reduced such distress, perhaps because of patients’ overall perceptions of 
efficacy and tolerability (Colombo et al., 2010c). This finding has potentially major clinical 
significance, since it outlines the possibility for markedly improved quality of life during 
cyclosporin therapy, but the possibility for detrimental effects on quality of life for certain 
other psoriasis treatments. Additional, comparative investigations are now warranted to 
clearly define the relative effects of cyclosporin and other antipsoriatic agents on quality of 
life (see section 8). 
4.1 Intermittent short-term therapy 
Intermittent short-term therapy for 12–16 weeks is the most widely recommended dosing 
schedule for psoriasis: that is, short courses of cyclosporin are administered until marked 
improvement is evident, whereupon treatment is stopped; if relapse manifests, cyclosporin 
is re-started at the dosage that was earlier effective (Menter et al., 2009). 
 
Fig. 2. Maintained efficacy of intermittent short-term cyclosporin therapy during a large, 1-
year, multicentre, randomised trial in patients with plaque psoriasis (Ho et al., 1999). Values 
shown are the probability of a PASI75 response after 12 weeks’ treatment with cyclosporin 
2.5–5 mg/kg/day. 
In a large, multicentre, randomised trial (the Psoriasis Intermittent Short Courses of Efficacy 
of Sandimmun Neoral® [PISCES] study), 400 patients with plaque psoriasis were initially 
treated with cyclosporin 2.5–5 mg/kg/day until clearance of psoriasis, or for a maximum of 
12 weeks; patients were then randomised to abruptly or gradually discontinue (dosage 
reduction of 1 mg/kg/day each week) cyclosporin therapy. If relapse occurred, patients 
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received 3 cyclosporin courses, and 26 had received 4. After the first treatment course, 
abrupt versus gradual cessation of cyclosporin therapy was associated with a slightly, but 
significantly, shorter time to disease relapse (median 109 vs 113 days; p=0.038). Overall, the 
Kaplan-Meier probability of achieving a ≥75% decrease in disease area after 12 weeks’ 
treatment was 83% after the first cyclosporin course, 76% after the second, 73% after the 
third, and 66% after the fourth [Fig. 2] (Ho et al., 1999). 
In an extension of the PISCES trial, 76 patients were followed-up for a total of 2 years. The 
time in remission during the follow-up period was not significantly different between 
patients stopping cyclosporin therapy abruptly versus gradually (time in remission: 56.2% 
vs 61.8%); overall, the mean proportion of follow-up for which patients received cyclosporin 
was 42.8%. After the first treatment course, the median time to relapse was 115.5 days, but 
this became progressively shorter with an increasing number of cyclosporin courses (Ho et 
al., 2001). 
4.1.1 Prevention of relapse 
The well-designed PREWENT study assessed the efficacy of microemulsion cyclosporin 5 
mg/kg/day, administered each weekend for 24 weeks in a total of 243 adults with chronic 
plaque psoriasis. The primary study endpoint in this multicenter, randomised, double-blind, 
placebo-controlled trial was relapse rate at 24 weeks: thus, 66.9% of cyclosporin-treated 
patients versus 53.2% of placebo recipients (p=0.072) had no worsening of psoriasis (i.e. no 
increase in PASI score to ≥75% of the value recorded before 8–16 weeks’ induction therapy 
with cyclosporin). Although this difference only approached statistical significance, the time 
to first relapse was significantly longer in the cyclosporin than placebo group (p=0.0233), 
and in a post hoc analysis of patients with mild-to-moderate psoriasis, significantly more 
cyclosporin-treated patients than placebo recipients had no worsening of psoriasis (69.9% vs 
46.3%; p=0.011) [Fig. 3] (Colombo et al., 2010a). 
 
Fig. 3. Weekend cyclosporin therapy (5 mg/kg/day) prevents relapse in patients with mild-
to-moderate psoriasis: results from the PREWENT trial (Colombo et al., 2010a). 
p=0.011 
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4.2 Rescue therapy 
Short-term cyclosporin therapy has a rapid onset of effect, and can therefore be 
administered as a rescue or bridging treatment for severe disease flares: that is, until a 
different maintenance therapy is started. As a bridging therapy, cyclosporin can be 
‘dovetailed’ with the new maintenance regimen (e.g. biological therapy, methotrexate) to 
avoid clinical deterioration while the new schedule is taking effect. Cyclosporin can then be 
stopped without a risk of flares, and with a limited risk of adverse effects for only the short 
time that the cyclosporin bridging schedule and the new maintenance regimen are 
dovetailed (Amor et al., 2010). 
Rescue cyclosporin therapy is especially effective in patients with erythrodermic, 
generalised, or suberythrodermic pustular psoriasis; a reducing-dosage strategy is 
employed after starting treatment at 5 mg/kg/day (Menter et al., 2009; Pathirana et al., 
2009). In a study of 33 patients with erythrodermic psoriasis, the initial intervention was 
cyclosporin 4.2 mg/kg/day; after remission, the dosage was reduced by 0.5 mg/kg/day 
every 2 months. At 2–4 months, two-thirds of patients had attained complete remission, and 
marginally more than one-quarter had attained significant clinical improvement (Rosenbach 
et al., 2010). 
4.3 Long-term therapy 
European guidelines recommend that the maximum period of continuous cyclosporin 
therapy in patients with psoriasis should be no more than 2 years (Griffiths et al. 2004; 
Menter et al. 2009; Pathirana et al. 2009). This is primarily because the incidence of renal 
dysfunction and nonmelanoma skin cancer may increase markedly with high doses of 
cyclosporin administered for longer periods (Paul et al. 2003; Ryan et al. 2010). In addition, 
any cyclosporin-related hypertension or renal dysfunction is generally reversible if the dose 
is maintained at ≤5 mg/kg/day and treatment duration at ≤2 years (Ryan et al. 2010). 
Long-term cyclosporin therapy (for up to 2 years or more) maintains its efficacy in most 
psoriatic patients; however, the principal goal of maintenance therapy is not routine 
attainment of clinical remission, but rather attainment of marked clinical improvement with 
the minimum cyclosporin dosage — generally 3–3.5 mg/kg/day (Griffiths et al., 2000). 
Rather surprisingly, given the long-term nature of psoriasis, and in contrast to European 
guidelines, US guidelines stipulate that the duration of cyclosporin therapy should be 
restricted to ≤1 year in psoriatic patients (Amor et al. 2010; Menter et al. 2010). This 
restriction appears rather strange when it is considered that, only with longer-term 
treatment (3–5 years or more) may a substantial proportion of patients experience 
glomerulosclerosis (Menter et al. 2010). 
In a large-scale study involving 285 patients with psoriasis, cyclosporin 1.25–5 mg/kg/day 
administered continuously for 6–30 months reduced mean PASI scores by approximately 
75–94% from baseline, but after cyclosporin cessation, approximately 50% of patients 
experienced a relapse requiring antipsoriatic therapy (Mroweitz et al., 1995). Similarly, in 
another large-scale study (n=181), 86% of patients treated with cyclosporin at a dosage of ~5 
mg/kg/day for 16 weeks had a PASI70 response, and subsequent maintenance therapy with 
cyclosporin 3 mg/kg/day was associated with a significantly longer median time to relapse 
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Fig. 3. Weekend cyclosporin therapy (5 mg/kg/day) prevents relapse in patients with mild-
to-moderate psoriasis: results from the PREWENT trial (Colombo et al., 2010a). 
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4.2 Rescue therapy 
Short-term cyclosporin therapy has a rapid onset of effect, and can therefore be 
administered as a rescue or bridging treatment for severe disease flares: that is, until a 
different maintenance therapy is started. As a bridging therapy, cyclosporin can be 
‘dovetailed’ with the new maintenance regimen (e.g. biological therapy, methotrexate) to 
avoid clinical deterioration while the new schedule is taking effect. Cyclosporin can then be 
stopped without a risk of flares, and with a limited risk of adverse effects for only the short 
time that the cyclosporin bridging schedule and the new maintenance regimen are 
dovetailed (Amor et al., 2010). 
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the minimum cyclosporin dosage — generally 3–3.5 mg/kg/day (Griffiths et al., 2000). 
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restriction appears rather strange when it is considered that, only with longer-term 
treatment (3–5 years or more) may a substantial proportion of patients experience 
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In a large-scale study involving 285 patients with psoriasis, cyclosporin 1.25–5 mg/kg/day 
administered continuously for 6–30 months reduced mean PASI scores by approximately 
75–94% from baseline, but after cyclosporin cessation, approximately 50% of patients 
experienced a relapse requiring antipsoriatic therapy (Mroweitz et al., 1995). Similarly, in 
another large-scale study (n=181), 86% of patients treated with cyclosporin at a dosage of ~5 
mg/kg/day for 16 weeks had a PASI70 response, and subsequent maintenance therapy with 
cyclosporin 3 mg/kg/day was associated with a significantly longer median time to relapse 





treated with cyclosporin 3 mg/kg/day compared with 84% of placebo recipients had 
relapsed (Shupack et al., 1997). 
A recent, retrospective evaluation of 193 patients with moderate-to-severe psoriasis revealed 
that cyclosporin 1.5–3.1 mg/kg/day (mean dosage) administered for 12–36 (mean 14) 
months reduced mean PASI score from 23.3 to 5.6; the PASI75 response rate was 73.9%. In 
this trial, 83/193 patients (43%) received cyclosporin monotherapy, whereas the remainder 
received polytherapy. Among monotherapy recipients, the physician’s judgement of 
therapeutic success (total clearance of lesions) was 71% of patients, whereas that of clinical 
remission (clearance of lesions with some remaining pigmentation) was 19% of patients. 
Costs to the Italian healthcare system, based on a mean 1.5 cyclosporin courses administered 
over 14 months, were estimated at €2,984 per patient overall; the direct costs of cyclosporin 
acquisition were €2,058 per patient, which are approximately 4½–7 times less than annual 
treatment courses of etanercept and infliximab (Colombo et al., 2010b). To support and 
extend these cost findings, the design and execution of comparative economic evaluations of 
cyclosporin versus biological therapies in patients with moderate-to-severe psoriasis would 
now be particularly pertinent (see section 8). 
In smaller studies, continuous versus intermittent cyclosporin therapy was significantly 
more effective over a 1-year period in 51 patients with chronic plaque psoriasis (PASI75 
response rate: 92% vs 62%, p=0.008), although the mean cumulative annual dose of 
cyclosporin was 1.4-fold greater for continuous therapy (Chaidemenos et al., 2007). 
Furthermore, 60 patients with clearance or near clearance of psoriasis during cyclosporin 
induction therapy (3–7.5 mg/kg/day for 4 months) subsequently received cyclosporin 
maintenance therapy 1.5 or 3 mg/kg/day, or placebo, for up to 4 months (Ellis et al., 1995). 
Mean time to relapse was significantly longer in the higher-dose versus lower-dose 
cyclosporin group (12 vs 9 weeks; p=0.04), and in the higher-dose group versus placebo 
recipients (12 vs 7 weeks; p=0.002). At study completion, markedly fewer patients in the 
higher-dose versus lower-dose versus placebo group had relapsed: 43% vs 79% vs 95% (Ellis 
et al., 1995). 
4.4 Rotational therapy 
Rotational therapy with various systemic agents (e.g. acitretin, fumaric acid esters, 
methotrexate, mycophenolate mofetil) has occasionally been advocated as a means of 
reducing the duration, and any potential toxicity, of cyclosporin therapy (Amor et al., 2010). 
While most patients require additional antipsoriatic therapy after cyclosporin cessation 
(Amor et al., 2010), some patients may have an extended period of remission after 
cyclosporin therapy (Ho et al., 1999, 2001). 
5. Indications/dosage 
In Europe, cyclosporin is indicated for the treatment of severe psoriasis in patients for whom 
conventional therapy is ineffective or inappropriate. After starting treatment with oral 
cyclosporin, psoriatic patients should not be switched to another oral cyclosporin 
formulation without relevant monitoring of plasma cyclosporin levels, creatinine levels, and 
blood pressure; indeed, except for Neoral® soft gelatin capsules and Neoral® oral solution, 
which are bioequivalent, the various oral forms of cyclosporin are not bioequivalent. To 
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avoid any possible confusion among healthcare professionals, and to avoid any potential for 
major fluctuations in cyclosporin bioavailability, cyclosporin should be prescribed by brand 
(Neoral® SPC, 2011). 
To induce remission of psoriasis, the recommended starting dosage of oral cyclosporin is 2.5 
mg/kg actual bodyweight each day, administered in two divided doses; however, when a 
rapid initial response is required, a starting dosage of 5 mg/kg/day can be used (Neoral® 
SPC, 2011). If no improvement is evident after 1 month of 2.5 mg/kg/day, the dosage can be 
gradually increased in 0.5–1 mg/kg increments, at intervals of 2–4 weeks, up to a maximum 
of 5 mg/kg/day (Menter et al., 2009; Neoral® SPC, 2011). Cyclosporin should be stopped if 
the response is inadequate after 6 weeks’ administration of 5 mg/kg/day. However, after an 
initially good response, the cyclosporin dosage can be reduced for maintenance therapy in 
steps of 0.5–1 mg/kg, at intervals of 2 weeks, until the lowest effective dosage level is 
attained (Amor et al., 2010; Neoral® SPC, 2011). Intermittent cyclosporin therapy may be 
appropriate for some psoriatic patients: that is, when an initial satisfactory response has 
been attained, cyclosporin therapy can be stopped and any subsequent relapses treated with 
reintroduction of cyclosporin at the previously effective dosage (Neoral® SPC, 2011). 
Before starting cyclosporin therapy, baseline renal function and blood pressure should be 
measured. Plasma creatinine should be measured every month. If an increase in plasma 
creatinine occurs to ≥30% above baseline, cyclosporin dosage should be reduced by 25–50%, 
even if levels are within the reference range (see section 7.2.2). If such dosage reduction does 
not successfully reduce plasma creatinine within 1 month, cyclosporin should be stopped. 
Similarly, if elevated blood pressure occurs and cannot be controlled by cyclosporin dosage 
reduction, or by intervention with antihypertensive therapy, cyclosporin cessation is 
advocated (Neoral® SPC, 2011). 
6. Combination therapy 
6.1 Topical treatments 
To improve clinical efficacy, cyclosporin has been administered with various topical 
therapies (e.g. corticosteroids, dithranol, vitamin D3 analogues [e.g. calcipotriol]) (Amor et 
al., 2010). However, data supporting such strategies stem mainly from small-scale, 
uncontrolled studies (Gottlieb et al., 1995; Griffiths et al., 1989). For example, in 12 
psoriatic patients treated with cyclosporin 5 mg/kg/day for up to 18 weeks, and who 
applied topical dithranol to plaques on half of their bodies, improved clinical efficacy (e.g. 
significantly reduced severity index) was noted for combination therapy in 58% of 
patients (Gottlieb et al., 1995). In 13 patients with severe persistent psoriasis, cyclosporin 
1–4 mg/kg/day was administered for 12–25 months, and an 81% decrease was noted in 
mean PASI score; 85% of the patients had received topical corticosteroid therapy after the 
first 3 months of cyclosporin (Griffiths et al., 1989). A larger randomised, double-blind, 
placebo-controlled trial in 69 cyclosporin-treated (2 mg/kg/day) patients with severe 
chronic plaque psoriasis revealed clinical improvement in a significantly greater 
proportion of patients who used concomitant calcipotriol 50 µg/g ointment versus 
vehicle: 50% vs 12% of patients (p=0.0019) had complete clearing of psoriasis or a ≥90% 
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6.2 Systemic treatments 
Combination schedules of cyclosporin plus other systemic antipsoriatic agents (e.g. fumaric 
acid esters, methotrexate, mycophenolate mofetil) have been used in patients with severe 
psoriasis to facilitate cyclosporin dosage reduction and to reduce the risk of potential 
adverse effects (Amor et al., 2010). For instance, in small-scale, uncontrolled trials: 
 Cyclosporin plus methotrexate was administered for a mean of up to about 3½ years in 
19 patients with severe recalcitrant psoriasis, and the combination schedule produced 
good control of psoriasis using lower doses of each agent than would have been used 
for monotherapy; however, 6 patients developed renal impairment, which normalised 
(n=3), or which improved but did not normalise (n=3), after cyclosporin dosage 
reduction (Clark et al., 1999). 
 Cyclosporin 2.5 mg/kg/day plus mycophenolate mofetil 3 g/day led to moderate or 
good clinical improvement over 3–11 months’ follow-up in 78% of patients with severe 
recalcitrant psoriasis (Ameen et al., 2001). 
Interestingly, in a retrospective assessment of 193 cyclosporin-treated patients with 
moderate-to-severe plaque psoriasis, 110 patients (57%) had received concurrent therapy 
with systemic methotrexate or retinoids, or topical and/or phototherapy. In the physician’s 
judgement, a clinical response (therapeutic success or clinical remission) occurred in 80% of 
combination therapy recipients (Colombo et al., 2010b). Cyclosporin was also investigated in 
combination with phototherapy. In a study comparing sequential cyclosporin and narrow-
band (NB) UVB phototherapy versus NB UVB phototherapy alone in patients with severe 
psoriasis, both treatments were effective and well tolerated, but the sequential therapy 
showed a greater efficacy on lesions of UV-shielded body areas and on itching (Calzavara-
Pinton et al., 2005). The increased efficacy of the sequential therapy allowed for the 
reduction of NB UVB dosage and exposure. Nonetheless, it should be remembered that 
psoriatic patients previously treated with psoralen and ultraviolet A (PUVA), and to a lesser 
extent UVB, have increased risks of skin malignancies during cyclosporin therapy. Psoriatic 
patients receiving cyclosporin should not receive concomitant PUVA or UVB therapy 
(Neoral® Prescribing Information, 2009). 
7. Side effects 
Side effects, such as hypertension and renal impairment, may be associated with continuous 
cyclosporin therapy and appear related to treatment duration and dose (Colombo et al., 
2010a). Generally, such side effects are reversible after cyclosporin discontinuation, although 
rarely chronic renal impairment and structural abnormalities in the kidneys may persist and 
be irreversible (Ryan et al., 2010). To minimise the risk of nephrotoxicity, the most widely 
recommended cyclosporin regimen in psoriasis is a short-term schedule of 2.5–5.0 
mg/kg/day for 12–16 weeks (see section 5); this short course is repeated if subsequent 
disease flares occur (Amor et al., 2010; Griffiths et al., 2004). Adhering to present guidelines 
about appropriate dosage and monitoring protocols for cyclosporin use in psoriatic patients 
will substantially reduce the risk of side effects (Griffiths et al., 2004; Menter et al., 2009; 
Pathirana et al., 2009). 
Although the mechanisms for many cyclosporin-related adverse effects have not been 
clearly defined, immunophilin inhibition (especially inhibition of immunophilins involved 
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in the regulation of mitochondrial ion channels) and mitochondrial dysfunction may have 
significant pathogenetic roles (Ryan et al., 2010). Adverse effects reported in large-scale 
randomised controlled trials and meta-analyses of short-term or longer-term cyclosporin 



















No. of patients 85 579 285 631 88 181 
Dosage 
(mg/kg/day) 3–7.5 1.25–5 1.25–5 1.25–5 1.25–5 1.5–6 
Duration 16 wks 10–12 wks 12–36 wks 12 wks–16 mos 6–30 mos 40 wks 
AEs requiring 
discontinuation 4.7 4.1 1.6–3.2 5.9 5.7 7.0–11.0 
Renal dysfunction 18e ≤8 1–13 na 5 17–43 
Hypertension na 5–14 11–26 na 8 9f 
GI side effects 28–55 3–8 4–5 12 22 12f 
Headache 20–53 2–4 ≤5 6 3 30f 
Tremor 4–25 na ≤2 1 2 na 
Paraesthesias 16–40 na ≤1 11 na 18f 
Hypertrichosis 24–27 ≤5 1–2 7 2 17f 
Hypercholesterolaem
ia na na 12–25 na na na 
Hypertriglyceridaem
ia na na 20–53 na 13 na 
CV symptomsb 5–8 na na na na na 
CNS symptomsc 7–25 1–6 na na na na 
Fatigue 12–20 ≤4 1–2 3 na 11f 
Influenza-like 
symptoms 5–20 na na na 9 na 
Infectiond 20–27 na 2 na na na 
Gum hypertrophy 8–15 na 1–2 4 2 na 
a Percentage of patients, unless otherwise stated. 
b Chest pain, premature ventricular contraction, tachycardia. 
c Anxiety, depression, dizziness, insomnia, nervousness, syncope, visual changes, transient ischaemic 
attack. 
d Non-influenza-like viral, bacterial, and fungal infections. 
e ≥15% decrease in glomerular filtration rate. 
f During 16-wk induction phase (5 mg/kg/day). 
AE = adverse effect; CNS = central nervous system; CV = cardiovascular; GI = gastrointestinal; mos = 
months; na = not available; wks = weeks. 
Table 2. Principal side effects reported in large-scale, well-designed clinical trials and meta-
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studies of up to 16 weeks’ duration, about 4–5% of cyclosporin-treated patients had adverse 
effects requiring treatment discontinuation (Ellis et al., 1991; Faerber et al., 2001). In a meta-
analysis of 3 major German studies in approximately 600 patients with severe plaque 
psoriasis, and across the dosage range 1.25–5.0 mg/kg/day, the principal side effects were 
hypertension (5–14% of patients), renal dysfunction (≤8%), and gastrointestinal problems (3–
8%); increased plasma creatinine levels required intervention in only 3.4% of the total 756 
cyclosporin treatment cycles (Faerber et al., 2001). 
In longer-term studies of up to 30 months’ duration, but across the same dosage range 1.25–
6 mg/kg/day, up to 11% of patients discontinued cyclosporin because of adverse effects; 
hypertension occurred in 8–26% of patients, gastrointestinal problems in 1–22%, and renal 
dysfunction in 1–43%. Lipid disorders also manifested: hypercholesterolaemia in 12–25% of 
patients, and hypertriglyceridaemia in 13–53% of patients (Christophers et al., 1992; Krupp 
& Monika, 1990; Mrowietz et al., 1995; Shupack et al., 1997). 
Interestingly, in a recent, well-designed evaluation of relapse rates in patients with chronic 
plaque psoriasis who had achieved clinical remission after continuous cyclosporin therapy, 
243 patients were randomised to 24 weeks of weekend cyclosporin microemulsion therapy 5 
mg/kg/day or placebo (the Psoriasis Relapse Evaluation with Week-End Neoral Treatment 
[PREWENT] study) (Colombo et al., 2010a). In this investigation in a ‘real-life’ clinical 
setting, rather than in a group of carefully selected psoriatic patients, cyclosporin was well 
tolerated: no significant difference was evident in the incidence of adverse events between 
cyclosporin and placebo recipients (38.4% vs 21.5%). Only one patient (a cyclosporin 
recipient) had a serious adverse event (breast mass), but this was considered unrelated to 
study treatment. Furthermore, at no time during the study were mean plasma creatinine 
levels, or systolic and diastolic blood pressure values, different between the two groups; the 
incidence of plasma creatinine levels >30% above baseline was similar in the two groups 
(5.0% vs 3.8% of patients) (Colombo et al., 2010a) 
In a retrospective assessment of 193 patients with moderate-to-severe psoriasis who had 
received a mean cyclosporin dosage of 1.5–3.1 mg/kg/day for 14 months, 83 patients (43%) 
received cyclosporin as monotherapy (Colombo et al., 2010b). Altogether, marginally more 
than one-third of patients experienced at least one adverse event. The most frequent events 
were hypertension (17.6% of patients), hypercholesterolaemia (14.0%), raised plasma 
creatinine level to >30% above baseline (6.7%), and gastrointestinal symptoms (6.2%). The 
clinician’s assessment of cyclosporin tolerability was ‘very good’ or ‘good’ in 90% of cases 
(Colombo et al., 2010b). 
Overall, the possibilities of cyclosporin-induced hypertension and renal dysfunction are 
perhaps the major tolerability concern among prescribers, and might explain a certain 
degree of cyclosporin ‘under-utilisation’ by dermatologists (Ryan et al., 2010). These two 
side effects are discussed in more detail below, whereas other potential tolerability issues 
are addressed relatively briefly. 
7.1 Hypertension 
The incidence of new-onset hypertension during cyclosporin administration to psoriatic 
patients has varied somewhat in short-term studies (5-14% of patients) and longer-term 
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trials (8–26%; Table 2). Such hypertension is generally reversible after the cyclosporin 
dosage is reduced, or after antihypertensive medications are added (Ho et al., 1999; Ryan et 
al., 2010). Importantly, besides specific drug therapy, psoriasis per se may contribute to an 
increased risk of hypertension, since psoriatic patients have increased incidences of obesity 
and metabolic syndrome (Gelfand et al., 2006). 
Pooled data from 10 studies involving 563 patients with severe psoriasis revealed an 
overall incidence of new-onset hypertension of 10.6% during cyclosporin therapy (Feutren 
et al., 1990). However, the occurrence of hypertension was not dose-related (10.0% of 
patients at 2.5 mg/kg/day; 11.9% at 5.0 mg/kg/day) (Feutren et al., 1990), and this 
finding agrees with that of several randomised trials (Ryan et al., 2010). The implication, 
therefore, is that a subset of psoriatic patients exists with heightened sensitivity to 
cyclosporin, and enhanced susceptibility to hypertension, even at low cyclosporin doses 
(Ryan et al., 2010). Thus, cyclosporin-induced hypertension may best be managed with 
antihypertensive therapy rather than with a reduced cyclosporin dosage (Feutren et al., 
1990; Ryan et al., 2010). 
7.1.1 Management of hypertension 
Psoriatic patients have an increased risk of cardiovascular morbidity and mortality (Gelfand 
et al., 2006). Regular blood pressure monitoring (e.g. weekly self-monitoring) is therefore 
important in cyclosporin-treated patients with psoriasis. If hypertension occurs, current 
guidelines advocate a cyclosporin dosage reduction of 25–50%, or commencement of 
antihypertensive therapy (Griffiths et al., 2004; Pathirana et al., 2009). Dihydropyridine 
calcium-channel blockers (e.g. amlodipine, isradipine) are generally the interventions of 
choice, since they confer some degree of nephroprotection (Ryan et al., 2010). 
7.2 Renal dysfunction 
Though renal dysfuntion is recognized as a cyclosporin-related side effect, the real impact of 
cyclosporin on kidney function may need to be reassessed. The experience in transplant 
patients, particularly in kidney transplant recipients where cyclosporin is used at higher 
doses in life-long regimens shows, that these regimens are well tolerated (Cho & Terasaki, 
1988; Opelz, 1994). An Italian study conducted in 573 kidney transplant recipients showed 
that creatinine plasma levels remain constant and around 1.5 mg/dl over 15 years after the 
intervention, a clear indication of stable kidney function ( Sandrini, data presented at SIN 
2003 Bologna).  
When renal dysfunction persists during cyclosporin therapy, it is usually related to higher 
doses (>5 mg/kg/day) or extended treatment (>2 years), and both of these factors may lead 
to structural renal damage. Renal dysfunction may also comprise functional impairment (i.e. 
vascular or tubular dysfunction), which may be evident soon after starting treatment. The 
consequences of vascular dysfunction are reduced glomerular filtration rate and renal blood 
flow, and reduced creatinine clearance, whereas the consequences of tubular dysfunction 
may include hypomagnesaemia, reduced plasma bicarbonate levels, hyperuricaemia, and 
hyperkalaemia. Acute functional impairment is generally reversible when cyclosporin 
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cyclosporin therapy is prescribed in psoriasis, since such therapy is associated with 
normalisation of renal function between treatment courses (Ryan et al., 2010). 
Besides raised plasma creatinine levels, other predictors of cyclosporin-related 
nephropathy include advanced age, obesity, new-onset or pre-existing hypertension or 
renal disorders, and other nephrotoxic treatments. Altogether, as relatively low 
cyclosporin dosages are now used in psoriasis, tubulopathic changes are rare and 
reversible (Ryan et al., 2010). 
7.2.1 Management of renal dysfunction 
If plasma creatinine levels are ≥30% above baseline on two consecutive occasions, 2 weeks 
apart, the cyclosporin dosage should be reduced by 25–50% for at least 4 weeks; this applies 
even if creatinine values are within the normal reference range (Griffiths et al., 2004; Menter 
et al., 2009; Pathirana et al., 2009). After 4 weeks of reduced-dosage treatment, if plasma 
creatinine levels remain elevated, cyclosporin should be discontinued (Neoral® SPC, 2011). 
As a preventive measure against renal dysfunction, it is recommended that psoriatic 
patients receiving long-term cyclosporin therapy should have glomerular filtration rate 
measured at least once each year (Griffiths et al., 2004; Pathirana et al., 2009). Guidelines 
from the European Association of Dermatology and Venereology and from the British 
Association of Dermatology stipulate that the maximum period of continuous cyclosporin 
therapy in psoriatic patients should not exceed 2 years (Griffiths et al., 2004; Menter et al., 
2009; Pathirana et al., 2009). As a comparison, it should be reminded that in graft recipients, 
life-long regimens with higher cyclosporin doses are routinely used in clinical practice and 
have proved well tolerated after many years of use. 
Generally, if the cyclosporin dosage is ≤5 mg/kg/day, and if patients are closely monitored 
so that plasma creatinine levels remain ≤30% above baseline, any renal side effects will be 
wholly reversible after cyclosporin treatment is stopped (Ryan et al., 2010). 
7.3 Central nervous system effects 
Headache may occur in up to 53% of cyclosporin-treated patients with psoriasis, 
paraesthesias in up to 40%, and tremor in up to 25% (Table 2). The latter two effects 
generally occur during the first few weeks of cyclosporin administration and dissipate after 
a decrease in cyclosporin dosage; hypomagnesaemia has been postulated as a cause of these 
effects (Ryan et al., 2010). 
Seizures have been reported rarely during cyclosporin therapy, but cyclosporin does have 
the potential to reduce seizure threshold in epileptic patients; the seizure risk is increased in 
patients taking concurrent, high-dose corticosteroid therapy. Furthermore, patients taking 
antiepileptic drugs may have reduced circulating cyclosporin levels because of increased 
metabolism by the cytochrome P450 system (Ryan et al., 2010). 
7.4 Gastrointestinal effects 
The rates of cyclosporin-induced gastrointestinal side effects (e.g. abdominal pain, 
diarrhoea, dyspepsia, nausea, and vomiting) vary markedly: however, a meta-analysis 
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involving 631 psoriatic patients reveals rates of 2.3%, 2.0%, 2.0%, 3.8%, and 1.1%, 
respectively (Krupp & Monka, 1990). 
7.5 Gingival hyperplasia 
Gingival hyperplasia may occur in up to 30% of patients taking cyclosporin and is often 
linked with poor oral hygiene (Ryan et al., 2010). Thanks to increased oral health awareness, 
improved oral hygiene, and better public health service this condition occurs rarely in 
developed countries. If it occurs, this side effect usually manifests within the first 3–6 
months of treatment. 
7.6 Hyperlipidaemia 
Hypertriglyceridaemia (>750 mg/dL) occurs in approximately 15% of cyclosporin-treated 
patients, and hypercholesterolaemia in <3% (Neoral® Prescribing Information, 2011). 
Importantly, hyperlipidaemia normalizes when cyclosporin therapy is stopped (Shupack 
et al., 1997). 
Severe psoriasis is associated with increased cardiovascular morbidity and mortality (see 
section 7.1.1); thus, hyperlipidaemia should be actively managed in cyclosporin-treated 
patients with psoriasis. If cyclosporin therapy is continued, the initial intervention is a lipid-
lowering diet. If this is unsuccessful, the cyclosporin dosage should be reduced, or treatment 
with a lipid-lowering agent started. Fluvastatin was shown to be well tolerated in 
association with cyclosporin (Holdaas et al., 1995; Launay-Vacher 2005). In general, 
however, statins should be used with caution because of the risk, albeit very low, of 
rhabdomyolysis, as reported in a few cases of transplanted patients treated with cyclosporin 
and lovastatin or simvastatin (Ryan et al., 2010; Corpier et al., 1988).  
7.7 Hypertrichosis 
In large-scale clinical trials and meta-analyses in cyclosporin-treated patients with psoriasis, 
the incidence of hypertrichosis has varied widely from 1–27% (Table 2); the cause of this 
side effect is unclear, but it is  unlikely to be an altered endocrine status (Ryan et al., 2010). 
7.8 Infections 
Cyclosporin-induced infections occur rarely, and are rarely severe; controlled studies in 
psoriasis report no difference in the incidence of infections between cyclosporin and placebo 
recipients. Moreover, an overview of 20 years’ safety data for cyclosporin in dermatology 
patients revealed no increases in the risks of opportunistic infections or tuberculosis 
reactivation (Ryan et al., 2010). 
7.9 Malignancies 
7.9.1 Lymphomas 
B- and T-cell lymphomas have rarely been reported in cyclosporin-treated patients with 
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in a large-scale trial (Krupp & Monka, 1990), whereas no increase in the incidence of 
lymphomas was noted in another large-scale trial (Paul et al., 2003). Significantly, psoriasis 
itself leads to chronic immunological overactivation, and to greater risks of lymphoma and 
other malignancies than in the general population (Ryan et al., 2010).  
7.9.2 Nonmelanoma skin cancers 
In 1252 patients with severe psoriasis, low-dosage cyclosporin (2.7–3.1 mg/kg/day) was 
associated with a 6-fold increase in cutaneous squamous cell carcinomas after up to 5 
years’ follow-up. The greatest risks of these nonmelanoma skin cancers were in patients 
treated with cyclosporin for >2 years, in patients previously exposed to PUVA, and in 
patients exposed to other immunosuppressants or methotrexate (Paul et al., 2003). In 
another large-scale study, 6/842 psoriatic patients (0.7%) developed premalignant or 
malignant skin lesions during cyclosporin therapy, but nearly all of these patients had 
received previous treatment with PUVA, ultraviolet B, or methotrexate (Krupp & Monka, 
1990). 
The current recommendation is that if phototherapy is considered in psoriatic patients, 
narrowband ultraviolet B should be the first choice; cyclosporin can then be reserved for 
future therapy, if necessary (Griffiths et al., 2004; Pathirana et al., 2009). Cyclosporin 
should not be used together with phototherapy, or immediately before or after PUVA (see 
section 5); in patients with a high total dose of PUVA, or with a history of squamous cell 
carcinoma or melanoma, cyclosporin should be avoided (Griffiths et al., 2004; Pathirana et 
al., 2009). 
7.9.3 Solid organ tumours 
Numerous case reports exist of solid organ tumours developing during cyclosporin 
treatment in dermatology patients (Ryan et al., 2010). However, no increase in the incidence 
of solid organ tumours was noted in a study of 1252 psoriatic patients treated with 
cyclosporin (Paul et al., 2003), and although another large-scale study reported solid organ 
tumours in 5/842 patients (0.6%), the lead investigator considered any relationship between 
these tumours and cyclosporin to be unlikely (Krupp & Monka, 1990). Large case-control 
studies suggest that cyclosporin plus other immunosuppressive therapies may actually have 
immunoprotective effects against, and reduce the risks of, some tumour types (e.g. breast 
and rectal cancers) (Ryan et al., 2010). 
7.10 Other side effects 
Fatigue and influenza-like symptoms may occur in up to 20% of cyclosporin-treated patients 
(Table 2), and joint pain and muscle aches are also frequently reported (10–40% of patients) 
(Pathirana et al., 2009). 
Hyperbilirubinaemia manifests in up to one-third of cyclosporin recipients (Pathirana et al., 
2009), but this effect is usually dose-related, and does not require further investigation if 
other liver function abnormalities are absent (Ryan et al., 2010). Transaminase elevations 
may also occur in up to one-third of cyclosporin-treated patients. If plasma bilirubin or 
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transaminase levels are >2 x the upper limit of normal, the cyclosporin dosage should be 
reduced by 25% (Pathirana et al., 2009). 
8. Drug interactions 
Several drug interactions have been documented for cyclosporin, which is extensively 
metabolised by the CYP 3A system in the liver and small intestine. Some of the key 
interactions include the following: (Novartis Pharmaceuticals Corporation 2009; Ryan et 
al., 2010) 
 Erythromycin should be used with caution in cyclosporin-treated patients with infected 
eczema, since the former compound can increase cyclosporin toxicity. 
 Grapefruit juice inhibits cyclosporin metabolism and should be avoided in cyclosporin 
recipients. 
 Heavy alcohol ingestion should be avoided, as it can increase cyclosporin levels. 
 Nephrotoxic drugs, including aminoglycosides, ciprofloxacin, clotrimazole, fibrates, 
and nonsteroidal anti-inflammatory drugs (NSAIDs), should not be administered, if at 
all possible, to cyclosporin-treated patients. NSAIDs, especially in dehydrated patients, 
are likely to potentiate the deleterious effect of cyclosporin on renal function, and 
importantly, intermittent NSAID use is often not disclosed by patients. 
 Cyclosporin may restrict the metabolism of many drugs (e.g. diclofenac, digoxin, 
methotrexate, prednisolone, repaglinide, simvastatin), thus increasing plasma levels 
and toxicity. 
 Cyclosporin should not be used concomitantly with potassium-sparing diuretics 
because of the risk of hyperkalaemia, and care should also be exercised if cyclosporin is 
administered concurrently with potassium-sparing drugs such as angiotensin-
converting enzyme inhibitors or angiotensin II receptor antagonists. 
9. Conclusions 
Cyclosporin was first approved for the treatment of severe psoriasis in the 1990s, and 
indeed, it is one of the most effective antipsoriatic agents available because of its fast onset 
of action and potent immunosuppressive activity. Besides psoriasis, other dermatological 
disorders — most notably, pyoderma gangrenosum and refractory chronic idiopathic 
urticaria — have seen substantial off-label cyclosporin use in recent years. Nonetheless, 
concerns remain among some dermatologists about the safety of cyclosporin, even though a 
growing evidence base exists of a favourable benefit : risk profile for the compound, 
especially in the management of psoriasis, psoriatic arthritis, and atopic dermatitis. 
Perhaps the most frequent safety concerns, and those potentially explaining under-
utilisation of cyclosporin by some dermatologists, are hypertension and renal impairment. 
However, it should be remembered that psoriasis itself is associated with increased 
cardiovascular morbidity, and any new hypertension emerging during cyclosporin therapy 
can be managed effectively by dosage reduction and/or antihypertensive therapy. 
Moreover, persistent renal dysfunction during cyclosporin therapy is usually associated 
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may also occur in up to one-third of cyclosporin-treated patients. If plasma bilirubin or 
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transaminase levels are >2 x the upper limit of normal, the cyclosporin dosage should be 
reduced by 25% (Pathirana et al., 2009). 
8. Drug interactions 
Several drug interactions have been documented for cyclosporin, which is extensively 
metabolised by the CYP 3A system in the liver and small intestine. Some of the key 
interactions include the following: (Novartis Pharmaceuticals Corporation 2009; Ryan et 
al., 2010) 
 Erythromycin should be used with caution in cyclosporin-treated patients with infected 
eczema, since the former compound can increase cyclosporin toxicity. 
 Grapefruit juice inhibits cyclosporin metabolism and should be avoided in cyclosporin 
recipients. 
 Heavy alcohol ingestion should be avoided, as it can increase cyclosporin levels. 
 Nephrotoxic drugs, including aminoglycosides, ciprofloxacin, clotrimazole, fibrates, 
and nonsteroidal anti-inflammatory drugs (NSAIDs), should not be administered, if at 
all possible, to cyclosporin-treated patients. NSAIDs, especially in dehydrated patients, 
are likely to potentiate the deleterious effect of cyclosporin on renal function, and 
importantly, intermittent NSAID use is often not disclosed by patients. 
 Cyclosporin may restrict the metabolism of many drugs (e.g. diclofenac, digoxin, 
methotrexate, prednisolone, repaglinide, simvastatin), thus increasing plasma levels 
and toxicity. 
 Cyclosporin should not be used concomitantly with potassium-sparing diuretics 
because of the risk of hyperkalaemia, and care should also be exercised if cyclosporin is 
administered concurrently with potassium-sparing drugs such as angiotensin-
converting enzyme inhibitors or angiotensin II receptor antagonists. 
9. Conclusions 
Cyclosporin was first approved for the treatment of severe psoriasis in the 1990s, and 
indeed, it is one of the most effective antipsoriatic agents available because of its fast onset 
of action and potent immunosuppressive activity. Besides psoriasis, other dermatological 
disorders — most notably, pyoderma gangrenosum and refractory chronic idiopathic 
urticaria — have seen substantial off-label cyclosporin use in recent years. Nonetheless, 
concerns remain among some dermatologists about the safety of cyclosporin, even though a 
growing evidence base exists of a favourable benefit : risk profile for the compound, 
especially in the management of psoriasis, psoriatic arthritis, and atopic dermatitis. 
Perhaps the most frequent safety concerns, and those potentially explaining under-
utilisation of cyclosporin by some dermatologists, are hypertension and renal impairment. 
However, it should be remembered that psoriasis itself is associated with increased 
cardiovascular morbidity, and any new hypertension emerging during cyclosporin therapy 
can be managed effectively by dosage reduction and/or antihypertensive therapy. 
Moreover, persistent renal dysfunction during cyclosporin therapy is usually associated 





at ≤5 mg/kg/day, and if renal function is monitored closely so that plasma creatinine levels 
remain ≤30% above baseline, any renal side effects occurring during cyclosporin therapy 
will be reversible when treatment is stopped. 
Safety concerns may also exist about possible malignancies during cyclosporin 
administration. Again, however, it should be emphasised that the disease itself leads to 
long-term immunological overstimulation, such that psoriatic patients have greater risks of 
lymphoma and other malignancies compared to the general population. Any risk of 
nonmelanoma skin cancer during cyclosporin administration appears to be minimised if the 
duration of continuous therapy is kept to ≤2 years, and if PUVA is avoided; and some 
studies suggest that cyclosporin plus other immunosuppressant therapy may actually 
reduce the risks of some cancers (e.g. breast, rectal). 
Additional well-designed assessments of various cyclosporin schedules are now warranted 
in the treatment of psoriasis. Such assessments should include: 
 Comparative studies — i.e. vs traditional treatments (e.g. methotrexate) and/or newer 
agents (e.g. etanercept, infliximab). 
 Measures of economic and quality-of-life endpoints, such that relative cost-utility and 
cost-effectiveness, and important considerations such as effects on psychological 
distress, can be quantified and clarified. 
 Careful evaluation of the clinical potential of specific combination therapy schedules 
(e.g. cyclosporin plus topical calcipotriol; low-dose cyclosporin plus mycophenolate 
mofetil, with a possible view to the development of a fixed-dose combination ‘pill’ with 
enhanced tolerability). This is particularly pertinent given that most studies of 
combination therapy to date have been small-scale, uncontrolled evaluations. 
 Long-term studies  of ≥2 years’ duration. 
In summary, the immunosuppressive properties of cyclosporin in the transplant and non-
transplant settings have been widely recognised for approximately 3½ decades. As such, 
there is much clinical knowledge and experience of cyclosporin use in non-dermatological 
settings, but in the dermatological arena, clinical experience is ‘catching up’. Cyclosporin 
has now been used in the treatment of psoriasis for almost 15 years, and with the relatively 
low doses used, dermatologists appear to be moving beyond any potential safety concerns 
about the compound, and are increasingly embracing the established antipsoriatic efficacy 
of the drug. As further clinical, economic, and quality-of-life data accrue from well-
conducted clinical trials of cyclosporin monotherapy and combination therapy schedules, 
dermatologists, policy makers, and patients are likely to gain even more confidence in the 
favourable efficacy and tolerability profiles of cyclosporin in the treatment of psoriasis and 
other dermatological disorders. 
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1. Introduction 
Psoriasis is a chronic and recurring inflammatory condition of the skin that affects 
approximately 2% of the western population (Nestle et al., 2009). The most common form is 
plaque type psoriasis, the treatment of which is the focus of this chapter. Patients with 
psoriasis often present with scaly, painful and disfiguring skin lesions (Nestle et al., 2009). 
Although, it is seldom life-threatening, psoriasis is associated with a high degree of 
morbidity - patients are embarrassed about the appearance of their skin. There are 
significant psychosocial issues affecting these patients, often they experience social isolation, 
stigmatization, alcoholism and depression. In addition, patients with psoriasis, like those 
with other major medical disorders, have reduced levels of employment and income as well 
as a decreased quality of life (Horn et al., 2007). The combined costs of long-term therapy 
and social costs of the disease have a major impact on healthcare systems and on society in 
general. There are several co-morbidities that have been linked to psoriasis and it has been 
hypothesized that psoriasis as a disease has important systemic manifestations (Nestle et al., 
2009). The shared conditions include the metabolic syndrome, depression, and cancer. 
Psoriasis can also occur in association with inflammatory bowel disease (Wolf et al., 2008), 
diabetes mellitus (Wolf et al., 2008) and HIV infection (Maurer, 2005). Although cases have 
been reported, it is unclear whether cancer particularly lymphoma and skin cancer, is 
related to psoriasis or the long term consequences of its treatment (Gelfand et al., 2006a). 
The relationship between psoriasis and the risk of cardiovascular disease is of emerging 
significance (Gelfand et al., 2006b). While patients with mild psoriasis appears to be in no 
excess risk, the moderate and severe form of the disease is associated with an increase in 
frequency of myocardial infarction and an increase in mortality, in large part because of 
cardiovascular events (Gelfand et al., 2006b). If confirmed, these findings would have major 
implications for future preventive and therapeutic strategies. Further, it is estimated that a 
significant population of juvenile guttate psoriasis cases are preceded by streptococcal 
infections (Campalani & Barker, 2005). 
For treatment purposes, psoriasis can be categorized into localized and generalized forms, 
based upon body surface area (BSA) involvement. For localized, mild to moderate disease, 
usually defined as lesions covering <10% of body surface area, topical therapy is often 
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sufficient (Nestle et al., 2009). For generalized disease, systemic therapy approaches such as 
oral therapy, immunotherapy and UVB phototherapy are effective treatment options. In any 
case, the treatment plan should include obtaining rapid control of the disease and 
maintaining that control. In this chapter, the authors provide an overview of current 
guidances for topical management of psoriasis, novel mono- and combination topical 
therapies as well as combination regimens of topical and phototherapy. Several of the well-
established traditional topical medications such as coal tar, salicylic acid and anthralins are 
only briefly reviewed here. Interested readers are referred to the following references (Su & 
Fang, 2008; Witman 2001) for information. An overview of the topical antipsoriatic 
medications is summarized in Table 1. Most of the trade names used throughout this 
chapter represent those marketed in United States (US).  
 
Drug Formulation Disease Type 
Monotherapy 
Corticosteroids 
Clobetasol   propionate Ointment, spray, foam, lotion, 
shampoo 
Plaque and scalp psoriasis 
Halobetasol propionate Ointment Plaque psoriasis 
Betamethasone Cream, gel, lotion, foam Plaque and scalp psoriasis 
Mometasone Cream, ointment, gel Plaque  and scalp psoriasis 
Vitamin D3 analogues 
Calcipotriol Ointment, cream, solution Plaque, scalp and nail 
psoriasis 
Calcitriol Ointment Plaque psoriasis 
Tacalcitol Ointment Plaque psoriasis 
Retinoids 
Tazarotene Gel, cream Plaque psoriasis 
Coal tar Ointment, gel, solution, shampoo, 
soap 
Plaque and scalp psoriasis 
Anthralin Ointment, cream Plaque psoriasis 
Calcineurin inhibitors (investigational use) 
Tacrolimus Ointment Face, genitelia and 
intertriginous psoriasis 
Pimecrolimus Cream Intertriginous psoriasis 
PDE4 inhibitors 





Ointment Plaque, scalp and nail 
psoriasis 
Betamethasone 
dipropionate +  salicylic 
acid 
Ointment, cream, lotion Plaque, scalp and nail 
psoriasis 
Table 1. A summary of topical medications for psoriasis. 
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2. Guidances for effective management of psoriasis 
Although there is no cure for psoriasis, several available therapies can help control skin 
lesions and associated symptoms. Some treatments can also induce remission for months or 
longer. Despite availability of numerous topical and systemic treatment options, there is a 
lack of patient satisfaction with the available treatments and high rates of non-compliance. 
In order to optimize topical treatment of psoriasis, guidelines have been developed for more 
effective management of psoriasis. Some of the available guidances for topical treatment are 
discussed in this section: 
The American Academy of Dermatology (AAD) has published a six part series of guidelines 
in 2009, on the management of psoriasis and psoriatic arthritis. The third section of this 
series discusses the use of topical medications for the treatment of psoriasis (Menter et al., 
2009). This guidance discusses the efficacy and safety of as well as offer recommendations 
for the use of topical corticosteroids such as vitamin D analogues, tazarotene, tacrolimus, 
pimecrolimus, emollients, salicylic acid, anthralin, coal tar, as well as combination therapy. 
The authors concluded that patients with localized psoriasis can be treated with topical 
agents, which generally provide a high efficacy-to-safety ratio. Topical agents may also be 
used adjunctively in patients with more extensive psoriasis who are undergoing therapy 
with either ultraviolet light, systemic or biologic medications. However, the use of topical 
agents as monotherapy in the generalized form of the disease or in the setting of limited, but 
recalcitrant, disease was not recommended.  
The Cochrane Skin Group in UK published a review of topical therapies for chronic plaque 
psoriasis following examination of 131 studies (Mason et al., 2009). They concluded that 
vitamin D analogues showed similar efficacy as potent or very potent corticosteroids when 
used on the body, whereas topical corticosteroids proved the most effective treatment for 
scalp psoriasis. Combination of topical corticosteroids and vitamin D analogues were more 
effective than either agent as single formulation. Although the overall safety of topical 
therapies was high, topical corticosteroids were associated with lower incidence of local 
adverse events than vitamin D analogues. Warren et. al. (Warren et al., 2010) has published 
a review summarizing the guidances on the use of topical, systemic and biological therapies 
for the treatment of psoriasis; co-morbidities associated with psoriasis; and complementary 
therapies for psoriasis. The UK National Health Service provides an annual evidence update 
on psoriasis and has included new guidelines and systematic reviews on psoriasis published 
or indexed from November 2008 to October 2009 in the 2009 Annual Evidence Update on 
Psoriasis from NHS Evidence – Skin Disorders.  
In Germany, Nast et. al. have developed an evidence based guidelines for topical treatment 
(Nast et al., 2007). The guidelines focus on induction therapy in cases of mild, moderate, and 
severe plaque-type psoriasis in adults and contain a series of therapeutic recommendations. 
A similar guideline is also available for systemic treatment of psoriasis (Pathirana et al., 
2009).  
A guide has also been developed to optimize and harmonize the amount of topical 
medications to be applied on children (Long et al., 1998). Study conducted in children aged 
between 6 months to 9 years, showed that the amount of an ointment applied on children 
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3. Topical antipsoriatic medications 
3.1 Corticosteroids 
Topical corticosteroids, particularly high-potency corticosteroids, have been a mainstay in 
the topical treatment of psoriasis for decades (Bagel 2009). Their efficacy may be attributed 
to multiple mechanisms of action, including their anti-inflammatory, immunosuppressive 
and antiproliferative effects. Topical corticosteroids are often classified into seven classes in 
United States and four in UK and Germany based on potency. A detailed classification 
system has been discussed else where (Horn et al., 2010). In the United States, topical 
corticosteroids are classified as following: class I (superpotent), class II (potent), class III 
(upper mid strength), class IV (mid strength), class V (lower mid strength), class VI (mild) 
and class VII (least potent). Typically corticosteroids of lower potency are mainly used on 
the face and groin, and in infants and children. Mid-potency corticosteroids are typically 
used as initial therapy on all other areas in adults. Potent and superpotent corticosteroids 
are often used for stubborn, cutaneous plaques or lesions on the scalp, extremities, including 
palms, and/or soles as well as for initial therapy to achieve quick resolution of lesions. In 
this section detailed discussion of a few representative steroids are provided, however there 
are several other corticosteroids which are effective against psoriasis topically. Some 
steroids which are widely used in topical psoriasis treatment but have not been discussed in 
this section include, methylprednisolone aceponate (Ruzicka 2006), which has shown good 
efficacy against chronic therapy-resistant psoriasis, including both progressive and 
stationary phases. Although topical corticosteroids are effective in maintenance of the 
disease, these therapies can cause many potential local adverse effects including cutaneous 
atrophy, formation of telangiectasia, development of striae, steroid rosacea, perioral 
dermatitis, and skin infections (Horn et al., 2010). Risks of systemic adverse effects increase 
with prolonged use, or use of higher potency steroids, particularly with greater percent of 
BSA to which the topical steroid drug is applied. These risks include metabolic disturbances 
such as hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing like syndrome, 
osteonecrosis of the hip and immunosuppression are other rare but possible serious adverse 
events. Tachyphylaxis or tolerance often occurs with prolonged use, leading to less durable 
potency or lower effectiveness of topical steroids. Therefore, several strategies have been 
proposed to improve safety for long-term use of topical corticosteroids (Horn et al., 2010) 
such as, 1) using rotational treatment regimens that minimize side effects, 2) combination 
with other topical medications, 3) following package inserts on the maximum usage per 
week, and 4) caution when using in vulnerable body areas (such as face) and in children. 
3.1.1 Clobetasol 
Clobetasol propionate is a super high-potency glucocorticosteroid, initially approved for 
treatment of steroid-responsive dermatosis. Clobetasol propionate is traditionally 
formulated in an ointment base for treatment of psoriasis. However, several novel 
formulation of clobetasol propionate are now available such as spray, foam, lotion, and 
shampoo formulations, which may provide for improved convenience and acceptance in 
many patients with similar efficacy, safety, and tolerability as the traditional ointment and 
cream formulations (Feldman and Yentzer, 2009). While there are very few direct clinical 
comparison studies between clobetasol propionate in different vehicles, the efficacy rates of 
obtaining clear or almost clear of psoriasis are high for the novel formulations with most 
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patients achieving success after 2-4 weeks of treatment in well controlled clinical trials, but 
the response rates are similar for all presentations. Small differences in vasoconstrictor 
potency or cutaneous absorption have been noted among the formulations, but the clinical 
significance of these observations is difficult to discern.  
The development of a foam formulation of clobetasol propionate 0.05% (e.g. Olux®) 
provides an effective and cosmetically appealing treatment option for patients with plaque-
type psoriasis because it spreads easily and is cosmetically elegant. Olux is based on 
VersaFoam® platform, a thermolabile and low-residue foam. A randomised, placebo-
controlled, double-blinded study of 279 patients aged 18 years or older with mild-to-
moderate plaque-type psoriasis demonstrated the efficacy and tolerability of clobetasol 
propionate foam (Gottlied et al., 2003). After 2 weeks of twice-daily applications of 
clobetasol propionate foam versus vehicle foam, 68% of patients in the active treatment arm 
were clear of lesions versus 21% of patients receiving placebo. The treatment was well 
tolerated with 5% of patients receiving clobetasol propionate foam and 7% of those receiving 
placebo reported burning at the site of application. Although the efficacy of the clobetasol 
propionate foam can partially be attributed to patient adherence, the foam also delivers the 
active drug more efficiently than other formulations that have been compared. This may be 
due to the easier spread of foam onto the skin. In in vitro skin penetration studies, 
application of foam to donor skin resulted in higher drug accumulation and increased rate 
of permeation into skin layers (Huang et al., 2005). 
A study comparing two novel formulations containing 0.05% clobetasol propionate, Clobex® 
spray and Olux® foam clearly highlighted the difference in efficacy from two products 
containing the same active ingredient (Mraz et al., 2008). In a study of 77 randomized 
patients aged 18 years or older with moderate to severe plaque psoriasis the products were 
applied as per the product labeling. At the end of the treatment period (2 weeks for foam 
and 4 weeks for spray), patients treated with clobetasol propionate spray showed a 
significantly greater median reduction in affected body surface area compared to the 
clobetasol propionate foam. Improvements in quality of life were statistically significantly 
greater at all time points for patients treated with clobetasol propionate spray compared to 
patients treated with the foam formulation. The majority of adverse events for both products 
were mild in severity (Mraz et al., 2008).  
Clobex® shampoo containing 0.05% clobetasol propionate is a once-daily, short-contact, 
shampoo treatment for moderate-to-severe scalp psoriasis (Feldman & Yentzer, 2009). The 
efficacy and safety of clobetasol propionate 0.05% shampoo was evaluated in a randomized, 
double-blind, vehicle-controlled clinical trial of 142 patients aged 12 years and older with 
moderate-to-severe scalp psoriasis (Jarratt et al., 2004). Patients applied clobetasol 
propionate shampoo or vehicle shampoo once daily for 15 minutes for four weeks. 
Treatment success (defined as a global psoriasis rating of "clear" or "minimal") was obtained 
for 42% of patients who used clobetasol propionate shampoo versus 2% of patients who 
used vehicle shampoo. Recurrence of the scalp psoriasis, assessed during a two week 
follow-up period, showed that the clobetasol propionate shampoo was more effective than 
the vehicle shampoo in preventing recurrence after treatment was discontinued. Similar 
safety profile was established between the clobetasol propionate shampoo and vehicle 
shampoo. No skin atrophy, telangiectasia, acne or severe adverse events were noted for 
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Mometasone furoate (Elocon® cream) is a potent synthetic glucocorticoid, which is 
commonly used in dermatological conditions (Prakash & Benfield 1998). It is available as 
cream, ointment and lotion formulations for the treatment of patients with atopic dermatitis, 
seborrhoeic dermatitis, scalp psoriasis and psoriasis vulgaris. Although mometasone 
demonstrates greater anti-inflammatory activity and a longer duration of action than 
betamethasone, it has low potential to cause adverse systemic effects such as suppression of 
the hypothalamic-pituitary-adrenal (HPA) axis. Moreover, its atrophogenic potential is low 
and no greater than that of other glucocorticoids in its class, such as betamethasone valerate. 
Transient, mild to moderate, local adverse effects such as burning, stinging, folliculitis, 
dryness, acneiform eruptions and signs of skin atrophy have been reported with 
mometasone. Mometasone has shown a low risk of primary sensitization and cross-
reactions in preliminary patch test studies. 
In clinical studies with patients aged between 12 and 90 years, with moderate to severe scalp 
psoriasis (Swinehart et al., 1989; Vanderploeg et al., 1989) or psoriasis vulgaris (Bressinck et 
al., 1988; Svensson et al., 1992), who had not used topical glucocorticoids for 2 weeks or 
taken systemic glucocorticoids for 6 weeks prior to enrolment showed that in general, 
mometasone (0.1% lotion, ointment or cream applied once or twice daily) was significantly 
superior to topical glucocorticoid preparations of similar and weaker potency. The ointment 
formulation of mometasone was significantly superior to once-daily hydrocortisone 1.0% 
ointment (Bressinck et al., 1988; Katz et al., 1989), twice-daily betamethasone valerate 0.1% 
ointment (Svensson et al., 1992; Medansky et al., 1987), triamcinolone acetonide 0.1% 
ointment (Medansky et al., 1988), and 3 times daily fluocinolone acetonide 0.025% ointment 
(Medansky et al., 1988).  
The effectiveness of alternate-day treatment with mometasone 0.1% ointment in 
maintenance therapy of psoriasis vulgaris was evaluated in a randomized, double-blind, 3-
week study in 48 adult patients with moderate psoriasis vulgaris. After 1 week (n = 48) of 
once-daily application of mometasone 0.1% ointment, patients either continued with daily 
application (n = 25) or applied mometasone 0.1% ointment on alternate days (n =19) for 2 
weeks. At the end of the study period both regimens were effective in treating disease signs 
and symptoms with no detectable difference between the treatment groups (Prakash & 
Benfield 1998). 
In patients with scalp psoriasis, the effects of mometasone lotion were significantly superior 
to those of twice-daily application of betamethasone valerate 0.1% lotion or triamcinolone 
acetonide 0.1% lotion (Swinehart et al., 1989; Vanderploeg et al., 1989). 
A study in 24 patients with moderate to severe psoriasis evaluated the response to 
mometasone 0.1% ointment applied once daily on the face and intertriginous areas and 
other affected body areas (Lebwohl et al., 1993) After 2 weeks, the face and intertriginous 
areas showed a quicker and significantly superior response to treatment as compared with 
other body areas (Lebwohl et al., 1993). 
3.1.3 Betamethasone 
Betamethasone dipropionate (BDP, Diprolene®) is a mid-potency synthetic fluorinated 
corticosteroid and is commonly used in combination with vitamin D3 analogues (Saraceno 
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et al., 2009). Betamethasone dipropionate is commonly formulated as a gel. Several attempts 
have been made to increased betamethasone dipropionate skin permeation by encapsulating 
in liposomes. The liposomal formulations achieved improved corticosteroid dermal delivery 
(Fresta & Puglisi 1997). However, in a double blind randomized trial comparing a liposomal 
formulation containing 0.039% betamethasone dipropionate against the gel containing 
0.064% betamethasone dipropionate, showed that the gel was more effective in reducing 
psoriatic plaques than the liposome after application for 14 days (Korting et al., 1990). 
Hence, liposome encapsulation of betamethasone dipropionate may increase the anti-
inflammatory action but not the antiproliferative effect. 
Betamethasone valerate (BMV) is also available as a foam formulation (Luxiq®) containing 
0.12% betamethasone valerate for use as a treatment for psoriasis affecting the scalp 
(Feldman et al., 2001) and non-scalp (Stein et al., 2001) regions of the body. Betamethasone 
valerate foam formulated in a thermolabile hydroethanolic foam vehicle is absorbed more 
rapidly, and demonstrated 2-fold greater skin penetration in a human cadaver skin model, 
than the betamethasone valerate lotion (Franz et al., 1999). Safety and efficacy of the 
betamethasone valerate foam was evaluated in a randomized, multicenter, double-blind, 
active- and placebo-controlled trial in adult patients with moderate to severe scalp psoriasis 
(Franz et al., 1999). At the end of 28-days of treatment, patients on betamethasone valerate 
foam showed significantly better clearing of plaques than those on betamethasone valerate 
lotion and placebo. Further, there was no evidence of increased toxicity for betamethasone 
valerate foam (Franz et al., 1999). 
3.1.4 Halobetasol 
Halobetasol propionate (HP) is a high potency corticosteroid available as 0.05% ointment 
and cream (Rivera & Hsu 2005). Halobetasol is a synthetic trihalogenated corticosteroid 
structurally similar to clobetasol propionate but with an additional fluorine atom (Rivera & 
Hsu 2005). 
The efficacy and safety of 0.05% halobetasol ointment (Ultravate) in the treatment of 
patients aged 18 years or older with moderate plaque psoriasis was demonstrated in two 
multicenter, randomized, double-blind, and placebo controlled studies in 204 patients 
(Bernhard et al., 1991). In both studies the medication and placebo were applied twice daily 
for 2 weeks. At the end of the treatment period, 0.05% halobetasol ointment was found to be 
more effective over placebo. No systemic adverse events or findings of skin atrophy were 
reported in these studies. Reports of “stings” or “burns” were equally divided between 
halobetasol formulation and its vehicle. These two studies demonstrated that 0.05% 
halobetasol ointment was clinically beneficial and without evidence of significant adverse 
events during the treatment period. 
Three clinical studies separately compared the 0.05% halobetasol propionate ointment to 
0.05% clobetasol propionate ointment (Goldberg et al., 1991), 0.05% betamethasone 
dipropionate (BDP) ointment (Mensing et al., 1991) and 0.1% betamethasone valerate (BMV) 
ointment (Blum & Yawalkar 1991) in plaque psoriasis. The efficacy of the halobetasol 
propionate ointment was significantly superior to those of the other products in these studies. 
Neither skin atrophy nor systemic adverse effects were observed for halobetasol propionate 
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13% of patients, the daily application of halobetasol propionate should be limited to a 
maximum of 14 days with a maximum dose of 50 g per 2 weeks (Rivera & Hsu 2005). 
3.2 Vitamin D3 analogues 
The active form of vitamin D3 is known to play an important role in the regulation of 
intestinal calcium absorption, bone mineralization and the prevention of rickets. In addition 
to these actions, vitamin D3 has several additional biological effects including the 
stimulation of cellular differentiation, inhibition of proliferation and immunomodulation 
(Muller & Bendtzen, 1996). This makes vitamin D3 a potential candidate for treatment of 
psoriasis. However, parent vitamin D3 might not be suitable for treating psoriasis due to 
potential for hypercalcemia. Hence, several vitamin D3 analogues have been developed for 
treatment of psoriasis (Tanghetti 2009). Vitamin D analogues bind to the vitamin D receptor, 
thus causing biological actions on both corneocytes and on immune-competent cells in the 
skin. Analogues such as calcipotriol, calcitriol, tacalcitol and maxacalcitol inhibit corneocyte 
proliferation and stimulate corneocyte differentiation in vitro. In addition, these analogues 
have only minimal effects on calcium levels and calcium excretion (Barker et al., 1999). 
However, due to concerns with elevating the serum calcium levels with extensive 
application to large body surface area, these analogues usually have a limit on total amount 
used per week. 
3.2.1 Calcipotriol (Calcipotriene) 
Calcipotriol is a synthetic vitamin D3 analogue formulated as a cream and scalp solution 
(Dovonex) at a drug loading of 0.005%. The calcipotriol cream is effective in treatment of 
plaque psoriasis and statistically significantly better than the placebo alone (Staberg et al., 
1989). In addition, a solution has been developed for scalp psoriasis (Klaberg et al., 1994), 
and calcipotriol ointment has also been investigated for nail psoriasis (Tosti et al., 1998).  
A comparison of calcipotriol ointment with a combination of betamethasone dipropionate 
and salicylic acid ointment (Diprosalic) showed that calcipotriol was as effective as the 
combination product for treating nail psoriasis (Tosti et al., 1998). Comparisons of 0.005% 
calcipotriol ointment and 5% coal tar ointment in conjunction with sun exposure in 10 adult 
patients with stable plaque psoriasis showed that both calcipotriol and coal tar ointment had 
comparable efficacies in treating stable plaque psoriasis when used simultaneously with sun 
exposure, although the initial response to calcipotriol was faster (Kaur et al., 2001). 
The calcipotriol cream formulation is less greasy than the ointment formulation and hence 
has better patient acceptability. It was the impression that the effect of calcipotriol is more 
pronounced on lesional infiltration and scaling, whereas the effect is less pronounced on the 
vascular component of psoriasis, as determined by redness. Finally, the therapeutic 
response to calcipotriol ointment can be increased by occlusion with a polyethylene film 
(Boyrke et al., 1993). 
3.2.2 Calcitriol 
Calcitriol is a synthetic form of the active metabolite of vitamin D3. It has anti-proliferative, 
prodifferentiating and immunomodulating effects on human keratinocytes (Lehmann 2009). 
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A calcitriol ointment (Vectical) for mild-to-moderate plaque psoriasis was approved by the 
US Food and Drug Administration (FDA) in 2009 (Kowalzick 2009). Multicenter and 
randomized clinical trials have shown calcitriol ointment to be efficacious, safe and 
cosmetically acceptable as compared to placebo and other topical psoriasis therapies (Kircik 
2009). Pharmacokinetic studies in patients with psoriasis and healthy control subjects have 
demonstrated that topical calcitriol ointment produced minimal systemic absorption of 
calcitriol and does not alter systemic calcium homeostasis significantly even when applied 
to approximately one third of the body surface area (Kircik 2009). However, the Vectical 
prescribing information limits the use to 200 gm per week due to concern of disturbance in 
calcium metabolism. The efficacy and safety of topical calcitriol ointment were examined in 
two placebo-controlled, randomized, multicenter, parallel-group double blind clinical trials 
of identical design in a total of 839 patients aged 18 years or older with mild-to-moderate 
plaque psoriasis (Lebwohl et al., 2007). Both studies showed that at the end of the treatment 
period, the patients in the calcitriol group showed significantly better clearing of psoriatic 
plaques than those in the vehicle group. The incidence of treatment related adverse events 
such as mild skin discomfort, pruritus, and erythema was similar for the calcitriol and the 
vehicle groups in both studies (Lebwohl et al., 2007). 
3.3 Retinoids 
Retinoids provide a distinct class of treatment option within antipsoriatic therapies, which 
are largely dominated by immunomodulatory effects. The mechanism of action of retinoids 
in psoriasis may include direct suppression of inflammation as well as inhibition of 
proliferation and normalization of differentiation in the epidermal layer (van de Kerkhof 
2006). In the US topical retinoid for psoriasis is approved as tazarotene gel and cream 
(Tazorac) available in 0.05% and 0.1% formulations. It is recommended that treatment 
commences with the 0.05% formulation, and the concentration increased if necessary and 
tolerated. Tazarotene is applied once daily in the evening. All formulations and strengths 
can be used for plaque psoriasis. In general, gels and the more-concentrated strengths tend 
to have higher incidences of irritation, pruritus, erythema, stinging and desquamation 
(Yamauchi et al., 2004). The cream formulations are being marketed as less irritating (Linden 
& Weinstein 1999). A recent improvement in tazarotene therapy was a reduction of skin 
irritation by short contact applications or concurrent steroid use (Veraldi & Schianchi 2003). 
These side effects are most apparent on initial application, but are generally alleviated with 
continued usage. Tazarotene is contraindicated in pregnant women and in women who are 
not taking adequate birth control in view of its teratogenic potential, category X pregnancy 
status. In addition, tazarotene use should be avoided in nursing women, and patients who 
have substantial sun exposure, who do not use adequate sun protection and who use 
photosensitisers or have photodermatitis (Veraldi & Schianchi 2003). 
The efficacy of once-daily topical tazarotene has been studied in four randomized, double or 
single blinded clinical trials; two trials on the tazarotene gel formulation (Lebwohl et al., 
1998; Weinstein et al., 1997) and two trials on tazarotene cream formulation (Weinstein et al., 
2003) in patients at least 18 years old and having plaque psoriasis in at least 2% of the total 
body surface area. The duration of active treatment was 12 weeks and an additional 12 
weeks follow-up period without active treatment was incorporated in these studies. These 
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significant improvement as compared to the vehicle, with the 0.05% tazarotene formulations 
showing statistically significant improvement at week 4. Twelve weeks after the 
discontinuation of therapy (post-treatment phase), both 0.1% and 0.05% tazarotene cream 
were significantly better as compared to the vehicle (Weinstein et al., 2003). Comparative 
studies between calcipotriol and tazarotene monotherapy have been carried out, showing 
superior efficacy of calcipotriol during the first 8 weeks but equal efficacy after 12 weeks' 
treatment (Tzung et al., 2005). The penetration of tazarotene through human skin is limited. 
The systemic availability after topical tazarotene 0.05% or 0.1% gel is < 1% after single 
application, and 2.6% and 5.3%, respectively, after once-daily applications following 
2 weeks of treatment. After 12 weeks of treatment, the systemic availability of tazarotene 
0.05% was 1.8% and for the 0.1% tazarotene preparation it was 3.9% (Tang-Liu et al., 1999). 
3.4 Other topical agents 
While tars, anthralins and salicylic acid containing products have been used for decades in 
the United States for the treatment of plaque psoriasis, recent innovative delivery 
technologies have provided new versions of these products, offering the prospect of 
enhanced tolerability, convenience and compliance. Some of these novel topical products 
are discussed in this section. 
3.4.1 Anthralins 
A timed-release cream of anthralin (Psoriatec®) has been developed with the potential to 
reduce skin irritations that are sometimes observed with generic anthralin. Psoriatec can be 
a relatively convenient formulation to reduce side effects, such as irritation and skin 
staining, by following instructions for short contact anthralin therapy (SCAT).  
3.4.2 Coal tar 
An emollient foam formulation of coal tar (Scytera™) has been developed for convenient 
usage to relief of the symptoms of psoriasis. This formulation is neither intended for use for 
prolonged periods nor in areas such as rectum, genital area, or eyes. As with other tar 
containing products, skin exposure to sunlight should be avoided after application and it 
has the potential to stain clothing, contact lenses, and hair. Some tar products are also 
available as co-packaged kits, one such example is Clobeta Plus. This product is co-
packaging of clobetasol cream and coal tar solution.  
3.4.3 Salicylic acid 
Salicylic acid as a topical agent aids in the removal of excessive keratin in hyperkeratotic 
skin disorders, including psoriasis (including body, scalp, palms and soles) (Beani 2002). 
Salicylic acid has been shown to produce desquamation of the horny layer of skin while not 
effecting qualitative or quantitative changes in the structure of the viable epidermis. It has 
been used as monotherapy or as combination therapy to reduce the size and scale of 
psoriatic plaques. Recent development of foam formulations of salicylic acid such as Salvax® 
and Salkera® may lead to broader use of this agent. In children under 12 years of age and 
those patients with renal or hepatic impairment, the area to be treated should be limited and 
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the patient monitored closely for signs of salicylate toxicity. Contact with eyes and other 
mucous membranes should be avoided. 
4. Novel agents for topical treatment of psoriasis 
4.1 Calcineurin Inhibitors 
These agents inhibit the activity of calcineurin phosphatase, an enzyme important for the 
translocation of the pluripotent transcription factor, nuclear factor of activated T cell, from 
the cytoplasm to the nucleus where it activates a number of proinflammatory cytokines 
associated with T-cell activation. Hence, these agents have potential for treatment of skin 
diseases mediated by calcineurin phosphatase (Luger & Paul 2007). Currently these 
calcineurin inhibitors are approved for use in mild to moderate atopic dermatitis only, any 
use in psoriasis is off-label, and therefore not within approved US-FDA prescribing 
information. A black box warning has been added to the labels of these medications stating 
that the long-term safety of topical calcineurin inhibitors has not been established and that 
rare cases of cancer have been reported in patients who used the medications, although a 
causal relationship in human beings has not been established. Apart from topical tacrolimus 
and pimecrolimus, another new oral calcineurin inhibitor, voclosporin is also in clinical 
development for treatment of plaque psoriasis (Papp & Carey 2010). 
4.1.1 Tacrolimus 
Tacrolimus is an immunosuppressive drug whose main use is after allogenic organ 
transplant to reduce the activity of the patient's immune system and hence reduce the risk of 
organ rejection. It is also used in a topical ointment preparation (Protopic) for the treatment 
of severe atopic dermatitis, vitiligo and psoriasis. Tacrolimus ointment was approved in the 
United States in 2000, and Europe in 2001 for atopic dermatitis. However, new research has 
proven the potential use of tacrolimus in psoriasis (Luger & Paul 2007; Beck 2005). The 
introduction of tacrolimus ointment marked the advent of a new, nonsteroidal drug class, 
topical immunomodulators, for the management of inflammatory dermatoses.  
Tacrolimus ointment seems most effective in treating psoriasis where the skin is thin, that is 
on the face, genitelia and intertriginous areas (Martín Ezquerra et al. 2006). In one study 21 
patients with facial psoriasis lesions applied tacrolimus (0.1%) ointment twice a day for 4 
weeks without occlusion. A complete or good response was obtained in majority of the 
patients (Yamamoto & Nishioka 2003). 
The efficacy and tolerability of tacrolimus ointment has also been investigated for the 
treatment of male genital psoriasis (Bissonnette et al., 2008). In an open-label study in 12 
adult male patients with genital psoriasis, patients received topical tacrolimus 0.1% 
ointment twice daily for 8 weeks followed by a 4-week observational period. Psoriasis 
severity also improved significantly for the glans, shaft of the penis, and scrotum. The 
ointment was very well tolerated, with only mild pruritus or burning sensation of limited 
duration reported (Bissonnette et al., 2008).  
The safety and efficacy of tacrolimus (0.1 %) ointment for the treatment of psoriasis on the 
face, intertriginous areas, or both were evaluated in an open-label, clinical trial of 21 patients 





significant improvement as compared to the vehicle, with the 0.05% tazarotene formulations 
showing statistically significant improvement at week 4. Twelve weeks after the 
discontinuation of therapy (post-treatment phase), both 0.1% and 0.05% tazarotene cream 
were significantly better as compared to the vehicle (Weinstein et al., 2003). Comparative 
studies between calcipotriol and tazarotene monotherapy have been carried out, showing 
superior efficacy of calcipotriol during the first 8 weeks but equal efficacy after 12 weeks' 
treatment (Tzung et al., 2005). The penetration of tazarotene through human skin is limited. 
The systemic availability after topical tazarotene 0.05% or 0.1% gel is < 1% after single 
application, and 2.6% and 5.3%, respectively, after once-daily applications following 
2 weeks of treatment. After 12 weeks of treatment, the systemic availability of tazarotene 
0.05% was 1.8% and for the 0.1% tazarotene preparation it was 3.9% (Tang-Liu et al., 1999). 
3.4 Other topical agents 
While tars, anthralins and salicylic acid containing products have been used for decades in 
the United States for the treatment of plaque psoriasis, recent innovative delivery 
technologies have provided new versions of these products, offering the prospect of 
enhanced tolerability, convenience and compliance. Some of these novel topical products 
are discussed in this section. 
3.4.1 Anthralins 
A timed-release cream of anthralin (Psoriatec®) has been developed with the potential to 
reduce skin irritations that are sometimes observed with generic anthralin. Psoriatec can be 
a relatively convenient formulation to reduce side effects, such as irritation and skin 
staining, by following instructions for short contact anthralin therapy (SCAT).  
3.4.2 Coal tar 
An emollient foam formulation of coal tar (Scytera™) has been developed for convenient 
usage to relief of the symptoms of psoriasis. This formulation is neither intended for use for 
prolonged periods nor in areas such as rectum, genital area, or eyes. As with other tar 
containing products, skin exposure to sunlight should be avoided after application and it 
has the potential to stain clothing, contact lenses, and hair. Some tar products are also 
available as co-packaged kits, one such example is Clobeta Plus. This product is co-
packaging of clobetasol cream and coal tar solution.  
3.4.3 Salicylic acid 
Salicylic acid as a topical agent aids in the removal of excessive keratin in hyperkeratotic 
skin disorders, including psoriasis (including body, scalp, palms and soles) (Beani 2002). 
Salicylic acid has been shown to produce desquamation of the horny layer of skin while not 
effecting qualitative or quantitative changes in the structure of the viable epidermis. It has 
been used as monotherapy or as combination therapy to reduce the size and scale of 
psoriatic plaques. Recent development of foam formulations of salicylic acid such as Salvax® 
and Salkera® may lead to broader use of this agent. In children under 12 years of age and 
those patients with renal or hepatic impairment, the area to be treated should be limited and 
 
Topical Therapies for Psoriasis 
 
319 
the patient monitored closely for signs of salicylate toxicity. Contact with eyes and other 
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introduction of tacrolimus ointment marked the advent of a new, nonsteroidal drug class, 
topical immunomodulators, for the management of inflammatory dermatoses.  
Tacrolimus ointment seems most effective in treating psoriasis where the skin is thin, that is 
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severity also improved significantly for the glans, shaft of the penis, and scrotum. The 
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clearance at day 57 (end of treatment). Only 2 patients reported adverse events, which were 
limited to itching and the feeling of warmth at the application site (Freeman et al., 2003). 
4.1.2 Pimecrolimus 
Pimecrolimus is a non-steroidal immunosuppressant derived from ascomycin. Pimecrolimus 
1% cream (Elidel) was approved in the United States, the European Union, and Japan as 
second-line therapy for the short-term and non-continuous chronic treatment of mild to 
moderate atopic dermatitis in patients, who have failed to respond adequately to other topical 
prescription treatments, or when those treatments are not advisable (Fabroni & Wollina 2009). 
Pimecrolimus also has an enormous potential as topical treatment for numerous inflammatory 
skin diseases like psoriasis and dermatitis (Fabroni & Wollina 2009).  
Pimecrolimus is not effective in plaque-type psoriasis when used as the commercially 
available formulation without occlusion (Wollina et al., 2006). However, pimecrolimus has 
been shown to be effective in intertriginous psoriasis (Wollina et al., 2006). A double-blind, 
randomised, vehicle-controlled study was performed in 57 patients aged 18 years or older 
with moderate-to-severe intertriginous psoriasis. By week 8 of treatment, 82% of patients 
using pimecrolimus scored their disease as being equally well, or completely controlled, 
compared with 41% of the vehicle group. The pimecrolimus treatment was also well 
tolerated (Gribetz et al., 2004). 
4.2 Phosphodiesterase 4 (PDE4) Inhibitors 
PDE4 is the predominant cyclic AMP degrading enzyme, present in a variety of 
inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes. 
In addition, this enzyme is expressed in non-immune cells such as keratinocytes and 
fibroblasts. Due to the broad anti-inflammatory and immuno-modulatory action of PDE4 
inhibitors, it has been proposed that PDE4 inhibitors might also be efficacious for skin 
disorders such as psoriasis and atopic dermatitis (Bäumer et al., 2007). These PDE4 
inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis 
in mice, in the arachidonic acid induced skin inflammation in mice and in ovalbumin 
sensitized guinea pigs. The determination of cytokines in skin homogenates revealed that 
both Th1 as well as Th2 cytokines are suppressed by PDE4 inhibitors, indicating an anti-
inflammatory activity in both the Th2 dominated acute phase as well as the Th1 dominated 
chronic phase of atopic dermatitis. Due to the suppression of Th1 cytokines, activity can also 
be expected in psoriasis (Bäumer et al., 2007). Consequently PDE4 inhibitors are currently in 
clinical development for treatment of psoriasis both topically (AN-2728 from Anacor 
Pharmaceuticals) and orally (CC-10004 from Celgene Corporation).  
4.2.1 AN-2728 
A recent publication gives a comprehensive summary of preclinical, phase I and phase II 
data for topical AN-2728 (Nazarian & Weinberg 2009). Till date 3 phase IB, 1 Phase IIA and 1 
phase IIB trials have been completed for AN-2728, and results suggest that AN-2728 is well 
tolerated with significantly better efficacy in plaque psoriasis as compared to placebo 
controls. A phase IIB, randomized, double-blind, placebo-controlled, parallel-assignment, 
single-center, safety and efficacy clinical trial assessed AN-2728 ointment (5% bid for 12 
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weeks) in 30 patients with plaque psoriasis (Nazarian & Weinberg 2009). Preliminary data 
revealed that psoriatic plaques treated with AN-2728 exhibited a reduced overall target 
plaque severity score compared with plaques treated with vehicle alone at 8 weeks of 
treatment. In addition, AN-2728 topical therapy has also been reported to be well tolerated. 
In the phase IIA trial, no treatment-related adverse events or laboratory anomalies were 
reported; one patient reported mild gingivitis and diarrhea, but these effects were not 
considered to be related to the trial medication (Nazarian & Weinberg 2009). 
4.3 Janus-Associated Kinase (JAK) inhibitors 
The JAK family is composed of four tyrosine kinases - JAK1, JAK2, JAK3, and tyrosine 
kinase 2 (TYK2) (Fridman et al., 2011). Members of the JAK family are essential for signaling 
by many cytokines and growth factors following their binding to specific receptors on the 
cell surface. The interaction activates one or more JAKs, JAKs in turn activate the signal 
transducer and activator of transcription (STAT) proteins that transmit the growth and 
activation signals to the nucleus. JAK signaling is involved in a number of biologic 
processes, including the formation and development of blood cells and the regulation of 
immune function. Hyperactivation of JAKs has been associated with a number of disease 
states, including chronic myeloproliferative disorders and inflammatory diseases such as 
rheumatoid arthritis (RA) and psoriasis (Fridman et al., 2001). As a result, JAK inhibitors are 
currently in clinical development for treatment of psoriasis both topically (INCB18424 from 
Incyte Corporation) and orally (Tofacitinib from Pfizer).  
A 28-day phase Ib/IIa dose escalation trial of topical INCB18424 in patients with mild-to-
moderate psoriasis demonstrated rapid onset of action, reduction in total lesion area, and 
improvement in lesion thickness, erythema, and scaling (Mesa 2010).  
5. Combination topical therapies 
The commonly used topical medications described in this chapter provide efficacy through 
varying and divergent pathways. As these agents act through different mechanisms, there is 
a scientific rationale for their use in combination therapy. The rationale assumes that agents 
are selected on the basis of their individual mechanisms of action, which may offer the 
possibility of additive or synergistic efficacy, reduction in the dose of either or both 
products, and reduction in the occurrence of side effects (Norris 2005). Several studies have 
proven the advantages of using a combination of topical medications for treatment of 
psoriasis. Recently, a fixed dose combination ointment containing 50 μg/g calcipotriol and 
0.5 mg/g betamethasone dipropionate (approved in US as Taclonex®) was found to be 
effective against psoriasis vulgaris (Claréus et al., 2009). This ointment formulation 
combines the keratinocyte differentiation and antiproliferative action of the vitamin D3 
analogues (calcipotriol) with the anti-inflammatory effect of steroids (betamethasone 
dipropionate), thus enhancing effectiveness while reducing the side-effect profile of the 
individual agents (Saraceno et al., 2009). It was found that the combination product had a 
more rapid onset of action (Papp et al., 2003) than calcipotriol or betamethasone alone and 
was more effective (Douglas et al., 2002) than calcipotriol or betamethasone alone. In a 
clinical trial with 1605 randomized patients aged 18 years or older showed that the 
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calcipotriol and placebo. The local adverse reactions were also low compared to the other 
drugs. It was concluded that two different treatment regimens (i.e. application once or twice 
daily) employing the two-compound product provided rapid and marked clinical efficacy as 
compared to calcipotriol or betamethasone alone and also were safe therapies for psoriasis 
vulgaris (Saraceno et al., 2009). Combination of calcipotriol and betamethasone has also 
been shown to have significant advantages in treatment of scalp and nail psoriasis (Saraceno 
et al., 2009). More recently, a combination of 0.005% calcipotriol and 0.064% betamethasone 
dipropionate (Taclonex Scalp in US and Xamiol in Europe) has been approved for the 
treatment of moderate to severe scalp psoriasis vulgaris in adults. This once-daily therapy 
has a quick onset of action and greater efficacy than monotherapy with either ingredient. At 
8 weeks, the combination product had a safety profile comparable with betamethasone 
dipropionate and was associated with significantly fewer adverse events than calcipotriol 
(Guenther 2009). 
A combination of betamethasone dipropionate and salicylic acid (Diprosalic) is available as 
ointment and lotion formulations. Faster improvement in scaling, itching, and redness has 
been observed with Diprosalic as compared to betamethasone dipropionate alone 
(Guenther 2004). It has also been shown that the combination ointment has similar efficacy 
to clobetasol and calcipotriene (calcipotriol) ointments.  
A multicentre, randomised, double-blind, vehicle-controlled, parallel-group study was 
carried out to study the effect of the addition of calcipotriol ointment to methotrexate in 
patients aged 18 years or older with psoriasis vulgaris (De Jong 2003). From this study, it 
was concluded that the combined use of calcipotriol with methotrexate resulted in a 
methotrexate-sparing effect, while still maintaining the efficacy. Calcipotriol treatment 
increased the time to relapse of psoriasis following discontinuation of methotrexate. The 
combination of calcipotriol and methotrexate was safe and well tolerated. The combination 
resulted in lower cumulative doses of methotrexate as compared to monotherapy, thus 
significantly reducing the risk of methotrexate side effects (De Jong 2003). 
The combination of calcipotriol ointment (twice daily) and tazarotene gel (once daily) was 
compared with clobetasol ointment (twice daily) in the treatment of psoriasis (Bowman et 
al., 2002). The vitamin D3 analogue plus retinoid treatment had comparable efficacy to that 
of the potent topical steroid. Similarly a comparison of twice-daily calcipotriol ointment 
against the combination of tazarotene gel and 0.1% mometasone furoate cream was superior 
during the first 2 weeks of treatment. However, by 8 weeks of treatment, both groups 
exhibited similar responses (van de Kerkhof 2006). 
6. Combination of topical therapy with phototherapy 
Phototherapy for psoriasis includes narrowband and broadband UVB phototherapy; 
psoralens combined with UVA, targeted excimer laser phototherapy, and combination 
treatments (Nguyen et al., 2009). The combination of phototherapy with topical products 
has long been used for treatment of plaque psoriasis. In the 1920s, William Goeckerman 
combined the use of UVB phototherapy with topical application of tars (Su & Fang 2008; 
Witman 2001). This in-patient psoriasis regimen, known as the Goeckerman regimen, is still 
occasionally used in major dermatologic centers.  
 
Topical Therapies for Psoriasis 
 
323 
Psoralen photochemotherapy uses a combination of topical application (or ingestion) of 8-
methoxypsoralen followed by exposure of the affected skin area to long-wavelength UV 
(320 – 400 nm) (Nguyen et al., 2009). Other psoralen derivatives such as 5-methoxypsoralen 
and 4,5,8-trimethylpsoralen are also used in topical PUVA therapy. Bath psoralen UVA 
combination involves immersion of either localised areas (such as the hands or feet) or the 
whole body in water containing dissolved 8-methoxypsoralen prior to UVA exposure 
(Nguyen et al., 2009). 
Photodynamic therapy is another non-invasive technique used in the treatment of skin 
diseases. 5-aminolevulinic acid is a prodrug that is metabolized intracellularly to form the 
photosensitizing molecule protoporphyrin IX. When protoporphyrin IX is activated by light, 
cytotoxic reactive oxygen species and free radicals are generated. This phototoxic effect may 
be used for treatment of malignant and non-malignant hyperproliferative tissue (Gupta & 
Ryder 2003). Photodynamic therapies using 5-aminolaevulinic acid in plaque psoriasis has 
also been reported (Gupta & Ryder 2003), however these are not approved regimens. Side 
effects of the aforementioned regimens include short and long term adverse effects of visible 
and UV light, such as acute phototoxicity, and longer term effects such as photoaging and 
photocarcinogenesis. Protective clothing, sunblock and sunglasses should be used to protect 
unaffected areas of the body. 
7. Sequential therapy 
Sequential therapy is a strategy to treat psoriasis using a specific combination of therapeutic 
agents in a particular sequence with the aim of achieving initial efficacy followed by a safe 
maintenance regimen (Koo 1999). This treatment strategy maximizes efficacy of each 
medication while minimizing long term side effects. The strategy involves three main steps 
– 1) clearing phase, 2) transitional phase and 3) maintenance phase (Koo 1999). A 
combination of topical, systemic and phototherapy agents can be used to achieve the desired 
outcome, depending on the severity of the disease (Lebwohl et. al., 2004). 
The clearing phase involves the use of a rapid acting agent such as a potent or super-potent 
topical steroid at the maximum dermatologic dose with the main aim of promptly 
controlling an acute outbreak of psoriasis. This is followed by the transitional phase, in 
which a well tolerated maintenance agent such as acitrein or vitamin D analogue is 
introduced and administered along with the clearing agent. The clearing agent is slowly 
tapered off in this phase of treatment. The transitional phase can be challenging as it 
requires prevention of breakthrough of the disease, while tapering off the clearing agent and 
adjusting dose of the maintenance agent to ensure long term control with minimal side 
effects. Finally, in the third phase of the treatment, the patient is retained on the 
maintenance therapy, with additional therapy such as phototherapy, as needed (Koo 1999).  
Several combinations of therapeutic agents and regimen for sequential therapy have been 
proposed in literature (Lebwohl et. al., 2004; Bhutani et. al., 2011). However the choice of 
treatment agents needs careful consideration based on the severity and type of the disease, 
and the need to balance safety and efficacy. Recently, a sequential treatment regimen of 
clobetasol and calcitriol has been shown to be efficacious and safe for the management of 
moderate-to-severe plaque psoriasis (Brodell et. at., 2011). In a multicentre, open-label study 
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Psoralen photochemotherapy uses a combination of topical application (or ingestion) of 8-
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maintenance regimen (Koo 1999). This treatment strategy maximizes efficacy of each 
medication while minimizing long term side effects. The strategy involves three main steps 
– 1) clearing phase, 2) transitional phase and 3) maintenance phase (Koo 1999). A 
combination of topical, systemic and phototherapy agents can be used to achieve the desired 
outcome, depending on the severity of the disease (Lebwohl et. al., 2004). 
The clearing phase involves the use of a rapid acting agent such as a potent or super-potent 
topical steroid at the maximum dermatologic dose with the main aim of promptly 
controlling an acute outbreak of psoriasis. This is followed by the transitional phase, in 
which a well tolerated maintenance agent such as acitrein or vitamin D analogue is 
introduced and administered along with the clearing agent. The clearing agent is slowly 
tapered off in this phase of treatment. The transitional phase can be challenging as it 
requires prevention of breakthrough of the disease, while tapering off the clearing agent and 
adjusting dose of the maintenance agent to ensure long term control with minimal side 
effects. Finally, in the third phase of the treatment, the patient is retained on the 
maintenance therapy, with additional therapy such as phototherapy, as needed (Koo 1999).  
Several combinations of therapeutic agents and regimen for sequential therapy have been 
proposed in literature (Lebwohl et. al., 2004; Bhutani et. al., 2011). However the choice of 
treatment agents needs careful consideration based on the severity and type of the disease, 
and the need to balance safety and efficacy. Recently, a sequential treatment regimen of 
clobetasol and calcitriol has been shown to be efficacious and safe for the management of 
moderate-to-severe plaque psoriasis (Brodell et. at., 2011). In a multicentre, open-label study 





clobetasol propionate (0.05% spray) twice daily for up to four weeks. At the end of four 
weeks, if the patient's overall disease severity was assessed as clear, almost clear, mild or 
moderate, the patients were treated with calcitriol (3 μg/g ointment) twice daily for an 
additional eight weeks (upto week 12) or unless the patient's disease was assessed as severe 
or returned to the baseline score, at which time the treatment was discontinued. Patients 
were evaluated at baseline and at 2, 4, 8 and 12 weeks. In 84% of the patients who completed 
the 12 week study, this treatment resulted in at least one grade improvement in disease 
severity and hence was considered successful as per predefined criteria. There was a 
significant decrease in the percent body surface area affected, from 7.1% at baseline to 3.9% 
at week 12. The sequential treatment regimen was also well tolerated with no unexpected 
adverse events. Most reported adverse events and skin irritations were mild in severity 
(Brodell et. at., 2011). 
8. Challenges in developing topical medications for psoriasis 
The unique nature of drug delivery across the skin also presents with several unique 
challenges in development of topical products, such as:  
1. Optimization of both drug property and formulation composition to enhance the rate 
and extent of drug diffusion through the stratum corneum;  
2. Reduced drug concentration and increase in data variability due to presystemic 
metabolism in the skin;  
3. Switch of topical formulations during clinical development that can be very 
challenging, hence only minimal formulation changes can be usually made during 
development;  
4. No control on deep tissue penetration through formulation approaches, which is 
primarily influenced by protein binding and dermal blood flow;  
5. Lack of confidence in dose projection due to difficulty in establishing robust skin 
pharmacokinetic-pharmacodynamic relationship;  
6. High variability in in vitro and in vivo skin permeability remains a major obstacle in 
using these tools in formulation development; 
7. Guidances from regulatory agencies often call for clinical comparisons of innovative 
drugs with approved active comparators, thus increasing the challenges for 
development and licensure of novel products; 
8. Regulatory standards call for demonstration of benefit for each component within a 
fixed dose combination product, the so-called "Combination Rule", another challenge in 
development of a combination product. 
In addition to these general challenges in topical formulation development, there are 
several challenges specific to psoriasis and the development of antipsoriatic topical 
products, such as:  
1. Psoriatic lesions can have both thickened and markedly thinned epidermis, this 
heterogeneity in the skin morphology can increase the variability in drug permeation 
and systemic absorption, thus increasing challenges in formulation development;  
2. A significant number of psoriasis patients feel that the current therapies are either not 
sufficiently efficacious or aggressive. Hence, a primary challenge is to develop new 
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therapies which can be once daily application and show quick response, such as within 
the first four weeks of treatment;  
3. Effective management of psoriasis frequently necessitates combining therapies in order 
to achieve optimum response while minimizing any side-effects. Thus any new topical 
therapy should have appropriate safety and efficacy when used in combination with 
another topical medication, systemic therapy and/or phototherapy;  
4. In order to increase patient adherence to therapy, new topical formulations should have 
appropriate cosmetic elegance such as ease of use, no or minimal staining potential on 
clothing and bedding, quick absorption on application and being less greasy;   
5. Formulations which can be used on many areas of the body including hair-bearing sites 
are preferred as patients often have psoriasis plaques in multiple areas;  
6. Due to the availability of a wide variety of therapies and presence of generic products 
in the market, competitive cost of any new medication is paramount in influencing 
physician's and patient's choice of product. 
9. Conclusion  
As is summarized in this chapter, there are several treatment options for psoriasis and 
exciting novel targets (e.g. PDE4 and JAK) are being investigated as potential topical 
treatment options. Also, combination topical products and combination of topical and 
phototherapy have been shown to provide more effective treatment options. The epidermal 
hyperproliferation in psoriatic patients may increase the variability in drug penetration 
across the skin. Hence novel drug delivery approaches such as liposomes, iontophoresis, 
and electroporation are being investigated for improved delivery. Recent research has 
emphasized the importance of treatment adherence in the management of psoriasis. 
Adherence to treatment is likely to be a far more important determinant of success than are 
small differences in drug delivery, especially in actual clinical use as opposed to the well 
controlled environment of clinical trials. Several guidances have been developed to optimize 
topical treatment of psoriasis and hence enable more effective management of psoriasis. 
Since patients prefer a less messy vehicle, adherence and outcomes are likely to be better 
with the more novel formulation options such as foams and sprays compared with the 
traditionally recommended ointment.  
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1. Introduction 
Psoriasis is a chronic inflammatory skin disorder affecting 1–3% of the general population 
worldwide. Up to one-third of psoriatic patients have concomitant psoriatic arthritis (Gerdes 
et al, 2009). Multiple studies and clinical trials support an important role for dysregulation 
of the immune system in the development of psoriasis. In recent years, the improved 
understanding of the molecular basis underlying psoriasis has led to the introduction of 
biological drugs, providing a new effective treatment option for this disease. Biologics target 
key steps in the pathogenesis of psoriasis, and can be classified into three main categories: 
TNF inhibitors, T cell inhibitors and IL-12/IL-23 inhibitors (Weger, 2010). In this chapter 
we discuss the state of the art of biological therapies for psoriasis and psoriatic arthritis and 
give a brief overview of the new biological approaches that are currently undergoing 
evaluation for the treatment of both diseases. 
2. TNF Inhibitors 
TNF is a proinflammatory cytokine that plays key roles in both innate and adaptive 
immunity. At high concentrations, it can trigger an excessive inflammatory response ending 
in organ damage. The development of anti-TNF biologics originated from a study by 
Brennan et al., which showed that the expression of pro-inflammatory cytokines by 
synoviocytes in  rheumatoid arthritis patients was inhibited by TNF-neutralizing antibodies 
(Brennan et al, 1989). To date, the role of TNF in psoriasis and psoriatic arthritis has been 
fully investigated (Schottelius et al, 2004). Increased levels of TNF and a differential 
expression of TNF receptors I and II have been found in lesional psoriatic skin compared 
with normal-appearing skin; in addition, in psoriatic patients, the plasma concentration of 
TNF is higher and the mRNA expression of this cytokine is increased in peripheral blood 
                                                 
* Valeria Iansante1, Mariafausta Fischietti1, Daniela Verzella1, Maria Concetta Fargnoli2, Ketty Peris2, 
Roberto Giacomelli3, Francesca Zazzeroni1 and Edoardo Alesse1 
1Department of Experimental Medicine, University of L’Aquila, L’Aquila, Italy 
2Department of Sciences and Biomedical Technology, University of L’Aquila, L’Aquila, Italy 





Svensson A, Reidhav, Gisslen, H. (1992). A comparative study of mometasone furoate 
ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. 
Curr Ther Res, 52, 390-396. 
Swinehart JM, Barkoff JR, Dvorkin D, Fisher G, Peets E. (1989). Mometasone furoate lotion 
once daily versus triamcinolone acetonide lotion twice daily in psoriasis. Int J 
Dermatol, 28, 680-681. 
Tang-Liu DD, Matsumoto RM, Usansky JI. (1999). Clinical pharmacokinetics and drug 
metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin 
Pharmacokinet, 37, 273-287. 
Tanghetti EA. (2009). The role of topical vitamin D modulators in psoriasis therapy. J Drugs 
Dermatol, 8, Suppl, s4-8. 
Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE, Benelli C. (1998). 
Calcipotriol ointment in nail psoriasis: a controlled double blind comparison with 
betamethasone dipropionate and salicylic acid. Br J Dermatol, 139, 4, 655-659. 
Tzung TY, Wu JC, Hsu NJ. (2005). Comparison of tazarotene 0.1% gel plus petrolatum once 
daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque 
psoriasis. Acta Derm Venereol, 85, 236-239.  
van de Kerkhof PC. (2006). Update on retinoid therapy of psoriasis in an update on the use 
of retinoids in dermatology. Dermatol Ther, 19, 252-263. 
Vanderploeg DE, Cornell RC, Binder R. (1989). Clinical trial in scalp psoriasis. Mometasone 
furoate 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied 
twice daily. Acta Ther, 15, 145-152. 
Veraldi S, Schianchi R. (2003). Short contact therapy with tazarotene in psoriasis vulgaris. 
Dermatology, 206, 347-348. 
Warren RB, Brown BC, Grindlay DJC, Griffiths CEM. (2010). What’s new in psoriasis? Analysis 
of the clinical significance of new guidelines and systematic reviews on psoriasis 
published in 2008 and 2009. Clinical and Experimental Dermatology, 35, 7, 688-692. 
Weinstein GD, Krueger GG, Lowe NJ. (1997). Tazarotene gel, a new retinoid, for topical 
therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of 
therapeutic effect. J Am Acad Dermatol, 37, 85-92. 
Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, 
Sefton J, Gibson JR, Walker PS; (2003). Tazarotene cream in the treatment of 
psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of 
the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 
12 weeks. J Am Acad Dermatol, 48, 5, 760-767. 
Witman PM. (2001). Topical therapies for localized psoriasis. Mayo Clin Proc, 76, 943-949.  
Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, Worthington J, Griffiths 
CE, Mathew CG, Barker JN, Capon F, Trembath FC. (2008). Psoriasis is associated 
with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. 
J Med Genet, ;45, 2, 114-116. 
Wollina U, Hansel G, Koch A, Abdel-Naser MB. (2006). Topical pimecrolimus for skin 
disease other than atopic dermatitis. Expert Opin Pharmacother, 7, 1967-1975. 
Yamamoto T, Nishioka K. (2003). Topical tacrolimus: an effective therapy for facial psoriasis. 
Eur J Dermatol, 13, 471-473. 




Biotech on the Rise: The Treatment  
of Psoriasis with Biological Drugs  
Daria Capece et al.* 
Department of Experimental Medicine, 
University of L’Aquila, L’Aquila 
 Italy 
1. Introduction 
Psoriasis is a chronic inflammatory skin disorder affecting 1–3% of the general population 
worldwide. Up to one-third of psoriatic patients have concomitant psoriatic arthritis (Gerdes 
et al, 2009). Multiple studies and clinical trials support an important role for dysregulation 
of the immune system in the development of psoriasis. In recent years, the improved 
understanding of the molecular basis underlying psoriasis has led to the introduction of 
biological drugs, providing a new effective treatment option for this disease. Biologics target 
key steps in the pathogenesis of psoriasis, and can be classified into three main categories: 
TNF inhibitors, T cell inhibitors and IL-12/IL-23 inhibitors (Weger, 2010). In this chapter 
we discuss the state of the art of biological therapies for psoriasis and psoriatic arthritis and 
give a brief overview of the new biological approaches that are currently undergoing 
evaluation for the treatment of both diseases. 
2. TNF Inhibitors 
TNF is a proinflammatory cytokine that plays key roles in both innate and adaptive 
immunity. At high concentrations, it can trigger an excessive inflammatory response ending 
in organ damage. The development of anti-TNF biologics originated from a study by 
Brennan et al., which showed that the expression of pro-inflammatory cytokines by 
synoviocytes in  rheumatoid arthritis patients was inhibited by TNF-neutralizing antibodies 
(Brennan et al, 1989). To date, the role of TNF in psoriasis and psoriatic arthritis has been 
fully investigated (Schottelius et al, 2004). Increased levels of TNF and a differential 
expression of TNF receptors I and II have been found in lesional psoriatic skin compared 
with normal-appearing skin; in addition, in psoriatic patients, the plasma concentration of 
TNF is higher and the mRNA expression of this cytokine is increased in peripheral blood 
                                                 
* Valeria Iansante1, Mariafausta Fischietti1, Daniela Verzella1, Maria Concetta Fargnoli2, Ketty Peris2, 
Roberto Giacomelli3, Francesca Zazzeroni1 and Edoardo Alesse1 
1Department of Experimental Medicine, University of L’Aquila, L’Aquila, Italy 
2Department of Sciences and Biomedical Technology, University of L’Aquila, L’Aquila, Italy 





mononuclear cells. Currently, four TNF antagonists are approved for the treatment of 
psoriasis and/or psoriatic arthritis, namely etanercept, infliximab, adalimumab and 
golimumab; a new TNF inhibitor (certolizumab pegol) is currently undergoing a phase III 
trial for the treatment of psoriatic arthritis. 
2.1 Etanercept  
Etanercept is a recombinant human fusion protein consisting of a dimer of the extracellular 
portion of TNF receptor II linked to the Fc portion of IgG1 (Amgen, Inc, 2011). Etanercept 
binds to both the trimeric form of soluble TNF and to the transmembrane form, 
antagonizing their biological actions (Bachmann et al, 2010). Several studies reported a 
reduction of different inflammatory cell types in psoriatic lesions during etanercept 
treatment, such as T cells, natural killer cells, neutrophils, macrophages and plasmocytoid 
dendritic cells (de Groot et al, 2010). Etanercept also blocks downstream T-cell mediated 
events inducing apoptosis of CD11c+ myeloid dendritic cells (Malaviya et al, 2006). In 
addition, etanercept has been shown to down-regulate Th17 cell markers, as well as Th17 
cell products and effector molecules (Antiga et al, 2010; Zaba et al, 2007). Etanercept is FDA- 
and EMA-approved for the treatment of psoriasis and psoriatic arthritis. It is also approved 
for the treatment of other autoimmune conditions such as rheumatoid arthritis, juvenile 
idiopathic arthritis and ankilosing spondilytis (Amgen, Inc., 2011). 
2.1.1 Administration 
Etanercept is administered subcutaneously at a dose of 50 mg twice a week in patients with 
plaque psoriasis or at 25 mg twice a week in patients with psoriatic arthritis during the first 
12 weeks of treatment. After the initiation phase, the dosage for plaque psoriasis is reduced 
to 25 mg twice a week or 50 mg weekly during the maintenance phase (Amgen, Inc., 2011). 
Etanercept can be administered either continuously or intermittently. Gordon et al reported 
no loss of efficacy with intermittent therapy, with a similar response between retreatment 
and initial therapy in psoriatic patients (Gordon et al, 2006a). However, a multicenter 
European open-label study showed that both regimens provide a significant improvement 
in quality of life, with a greater improvement in the continuous treatment group (Dauden et 
al, 2009). Non-neutralizing anti-etanercept antibodies have been observed by several 
authors, but the relevance of them is still debated (Bachmann et al, 2010). 
2.1.2 Clinical efficacy 
Several high-quality clinical trials (Cassano et al, 2010; Gottlieb et al, 2003; Leonardi et al, 
2003, 2010; Papp et al, 2005; Tyring et al, 2007; van de Kerkhof et al, 2008) have evaluated 
both the short-term and long-term efficacy of etanercept in the treatment of psoriasis. In 
clinical trials, the severity of psoriasis is assessed by the Psoriasis Area and Severity Index 
(PASI). PASI 75 is defined as a 75% reduction in PASI score compared with baseline. An 
initial randomized, double-blind, placebo-controlled, multicenter trial of 112 patients 
demonstrated a PASI 75 response in 30% of patients receiving 25 mg etanercept twice a 
week compared with 2% of placebo-treated patients after 12 weeks. After 24 weeks, PASI 75 
response increased to 56% in the etanercept-treated arm compared with 5% in the placebo 
group (Gottlieb et al, 2003). Leonardi et al. demonstrated that the efficacy of etanercept  is 
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dose-related, reporting a PASI 75 response in 34% and 49% of patients treated with 25 mg 
and 50 mg twice weekly after 12 weeks of treatment, respectively. The improvement 
continued through week 24, with 44% and 59% of patients achieving a PASI 75, respectively 
(Leonardi et al, 2003).  The same high-dose etanercept regimen was used in a recent study 
by Griffiths et al., who reported a PASI 75 response in 57% of patients after 12 weeks of 
treatment (Griffiths et al, 2010). In a further multicentre 24-week study, the efficacy of 
etanercept during the initial treatment phase and after dose reduction were evaluated (Papp 
et al, 2005). Patients were treated with a dose of 50 mg etanercept, 25 mg etanercept or 
placebo twice weekly for the first 12 weeks. During the second 12 weeks of treatment, the 
dosage was reduced to 25 mg twice weekly. Papp et al. reported a PASI 75 in 49% of 
patients treated with 50 mg twice weekly and in 34% of patients receiving 25 mg twice 
weekly of etanercept compared with 3% in the placebo group at week 12, and demonstrated 
that the effect obtained with the higher dose could be preserved in most patients after dose 
reduction (Papp et al, 2005). A further increase of the dose of etanercept to 100 mg did not 
demonstrate an improvement in efficacy (Cassano et al, 2006). Recent data by van de 
Kerkhof et al. demonstrated that etanercept 50 mg once weekly for 24 weeks was effective, 
with a PASI 75 response of 38% after 12 weeks, which increased to 71% after 24 weeks 
(van de Kerkhof et al, 2008). Similar results were reported by Sterry et al. (Sterry et al, 
2010). Regarding long-term efficacy, etanercept response has been demonstrated to last up 
to 96 weeks, resulting in a statistically significant improvement (Tyring et al, 2007; 
Esposito et al, 2010). Etanercept is the only biological drug that has shown efficacy and 
safety in pediatric patients with moderate to severe plaque psoriasis (Paller et al, 2008). 
Paller et al. reported a PASI 75 response in 57% of children and adolescents treated with 
etanercept (0.8 mg/kg body weight) compared with 11% in placebo patients after 12 
weeks. The efficacy of the treatment was maintained through 96 weeks (Paller et al, 2010). 
Treatment with etanercept also provides  an improvement in the quality of life of patients, 
as measured by the Dermatology Life Quality Index (DLQI) (Leonardi et al, 2003; van de 
Kerkhof et al, 2008).  
Two pivotal studies have demonstrated the efficacy of etanercept in the treatment of 
psoriatic arthritis. In these studies, the American College of Rheumatology (ACR) criteria is 
the most frequently parameter used to assess the severity of psoriatic arthritis. A double-
blind, placebo-controlled study enrolling 60 patients suffering from psoriatic arthritis 
showed achievement of ACR 20, ACR 50 and ACR 70 response in 73%, 50% and 13% of 
patients after 12 weeks of treatment with etanercept, compared with 13%, 3% and 0% in the 
placebo group (Mease et al, 2000). Furthermore, the same authors reported an additional 
double-blind, placebo-controlled clinical trial in 250 patients with psoriatic arthritis. At 12 
weeks, an ACR 20 response was observed in 59% of etanercept-treated patients compared 
with 15% of the placebo group. This study also reported an improvement in quality of life 
measured by the Health Assessment Questionaire (HAQ) (Mease et al, 2004). The 
improvements observed were maintained for up to 2 years (Mease et al, 2010). A recent 
study by Saougou et al. reported a PASI 90 response in 68% of etanercept-treated patients 
affected by psoriatic arthritis after 5 years (Saougou et al, 2011).   
Although highly effective as monotherapy, few studies have been published on the 
combination of etanercept with cyclosporine, narrowband UVB, acitretin and methotrexate 
(reviewed in Foley et al, 2010). Preliminary data from short-term analysis support the use of 
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toxicities. This provides an attractive option for patients inadequately responding to 
monotherapy. However, further long-term studies are needed to confirm the safety of 
combination therapy.     
2.2 Infliximab 
Infliximab is a chimeric IgG anti-TNF monoclonal antibody constiting of a human constant 
(75%) region and murine variable (25%) regions (Centocor Ortho Biotech, Inc., 2011). In vivo, 
infliximab binds to human TNF and forms stable complexes, resulting in the loss of 
biological activity of this pro-inflammatory cytokine (Scallon et al, 1995). Infliximab is able 
to neutralize both soluble and trans-membrane TNF and induces the elimination of TNF 
bearing cells, such as macrophages, dermal dendritic cells, and T cells (Gisondi et al, 2004; 
Zaba et al, 2007). Recently, it has been suggested that infliximab induces p53-related 
keratinocytes apoptosis, highlighting another effect of this drug in psoriasis (Raho et al, 
2011). Infliximab is FDA- and EMA-approved for the treatment of psoriasis, psoriatic 
arthritis, rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease 
and ulcerative colitis (Centocor Ortho Biotech, Inc., 2011). 
2.2.1 Administration 
Infliximab is administered as a 2-3 hour intravenous infusion at a dose of 5mg/kg. The 
infusions are given at weeks 0, 2 and 6 (induction period) and then every 8 weeks 
(maintenance period) (Centocor Ortho Biotech, Inc., 2011). The efficacy of continuous 
versus intermittent treatment was evaluated in the clinical trial EXPRESS II, reporting that 
continuous treatment achieved better results than intermittent therapy to maintain PASI 
response and to reduce the occurrence of anti-infliximab antibodies, the most common 
cause of decreased drug efficacy (Haraoui et al, 2006; Menter et al, 2007; Vena & Cassano, 
2007). 
2.2.2 Clinical efficacy 
Several pivotal clinical trials demonstrated the clinical efficacy of infliximab in the treatment 
of plaque psoriasis (Chaudhari et al, 2001; Gottlieb et al, 2004; Reich et al, 2005, 2006). Two 
phase II studies evaluated the efficacy of infliximab at different doses, 5 and 10 mg/kg and 3 
and 5 mg/kg, respectively (Chaudhari et al, 2001; Gottlieb et al, 2004). In the first study of 33 
psoriatic patients, a PASI 75 response was observed in 82% and 73% of patients receiving 5 
and 10 mg/kg of infliximab, respectively, and in 8% of the patients receiving placebo after 
10 weeks. In the second study (SPIRIT) of 249 plaque psoriasis patients,  72% and 88% of 
patients receiving 3 and 5 mg/kg of infliximab, respectively, achieved PASI 75 at week 10 
compared with 6% of the placebo-treated patients. These results demonstrated a high short-
term efficacy of infliximab and identified 5 mg/kg as the ideal dosage regimen in the 
treatment of psoriasis. The rapid response induced by infliximab decreased after 50 weeks 
(Reich et al, 2005). The phase III multi-center, double-blind, placebo-controlled trial 
EXPRESS enrolled 378 patients with plaque psoriasis and showed a PASI 75 response in 80% 
of the patients after 10 weeks compared with 3% in placebo group. The response was 
maintained through week 24 and decreased to 61% by week 50. Nevertheless, the 
retrospective analysis of the EXPRESS trial showed that infliximab continuous therapy for 1 
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year resulted in a sustained improvement in PASI score (Reich et al, 2010). Moreover, 
infliximab provides a substantial improvement in quality of life, with a meaningful decrease 
in DLQI both in short-term and long-term treatment (Feldmann et al, 2005; Gottlieb et al, 
2004; Menter et al, 2007; Reich et al, 2006, 2010).  
The IMPACT trial evaluated the efficacy of infliximab in 104 patients with psoriatic arthritis 
(Antoni et al, 2005a). At week 16, 65% of patients achieved ACR 20 compared with 10% of 
the placebo group and 46% and 29% achieved ACR 50 and ACR 70, respectively. The 
efficacy of infliximab has been evaluated in a larger cohort of patients (n=200) in the 
IMPACT 2 trial. At week 14, 64% of infliximab-treated patients showed a PASI 75 response 
and 58% achieved ACR 20; in addition ACR 20 criteria were maintained up to 1 year 
(Antoni et al,  2005b; Kavanaugh et al, 2007).  The long-term efficacy of infliximab was 
evaluated by a two-year extension of the IMPACT trial (Antoni et al, 2008). At week 98, 
maintenance of the ACR 20 criteria was observed in 68% of infliximab-treated patients and 
64% of them achieved PASI 75. 
Regarding combination therapy, the concomitant administration of methotrexate has been 
reported to prolong the long-term efficacy of infliximab by decreasing the development of 
human anti-infliximab neutralizing antibodies (Klotz et al, 2007).  
2.3 Adalimumab 
Adalimumab is the first fully humanized recombinant anti-TNF monoclonal antibody. 
Adalimumab is able to bind both soluble and membrane-bound TNF in a dose-dependent 
manner (Abbott Laboratories, 2011). It has been shown that adalimumab lyses TNF-
bearing cells in the presence of complement and induces apoptosis in vitro; in addition 
adalimumab affects the biological responses controlled by TNF, such as the expression of 
adhesion molecules, serum concentration of cytokines, reactive oxygen species and dendritic 
cells in psoriatic plaques (Papoutsaki et al, 2007). Moreover, adalimumab is able to modulate 
Toll-like receptors expression on basal keratinocytes (De Pità et al, 2011). Adalimumab is 
FDA- and EMA-approved for the treatment of psoriasis, psoriatic arthritis, rheumatoid 
arthritis, Crohn’s disease, juvenile idiopathic arthritis and ankylosing spondylitis (Abbott 
Laboratories, 2011).    
2.3.1 Administration 
Adalimumab is administered as a subcutaneous injection and the recommended dose for 
psoriasis is a loading dose of 80 mg at week one, followed by 40 mg at week two and 
continuous 40 mg injection every other week (eow) for maintenance. In psoriatic arthritis 
the ideal dosage regimen is 40 mg every second week (Abbott Laboratories, 2011). The 
continuous therapy with adalimumab seems to be more effective than intermitted therapy 
to provide a sustained response (Menter et al, 2008).  Recently, encouraging results have 
been obtained in the retreatment of patients who relapsed after interruption of 
adalimumab therapy (Papp et al, 2011) and patients who lost efficacy during treatment 
with another TNF antagonist (Van et al, 2008). Development of anti-adalimumab 
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2.3.2 Clinical efficacy 
The clinical efficacy of adalimumab was analyzed by three main clinical trials (Gordon et al, 
2006b; Menter et al, 2008; Saurat et al, 2008). In an earlier phase II study enrolling 147 
psoriatic patients, two dose regimens of adalimumab were evaluated. Gordon et al. reported 
a PASI 75 improvement in 80% of patients treated with 40 mg weekly and in 53% of patients 
receiving 40 mg eow compared with 4% of patients in the placebo group at week 12. At 
week 60, PASI 75 response was observed in 64% and 56% of patients treated with 40 mg 
weekly or 40 mg eow, respectively (Gordon et al, 2006b). The phase III placebo-controlled 
randomized trial by Menter et al. of 1212 patients with plaque psoriasis evaluated the 
efficacy of adalimumab 40 mg eow. The authors reported a PASI 75 response rate in 71% of 
the patients after 16 weeks and in 70% after 24 weeks of 40 mg eow adalimumab therapy; 
the efficacy decreased during weeks 33 to 52 (Menter et al, 2008). The first head-to-head trial 
CHAMPION compared adalimumab vs methotrexate and reported a PASI 75 response in 
80% of patients in the adalimumab 40 mg eow group, in 36% of patients in the methotrexate 
group and in 19% of those in the placebo group (Saurat et al, 2008). An improvement in 
DLQI after treatment with adalimumab has been reported by several studies (Menter et al, 
2010; Revicki et al, 2008; Saurat et al, 2008; Shikiar et al, 2007). 
The clinical efficacy of adalimumab in psoriatic arthritis has also been described (Genovese 
et al, 2007; Gladman et al, 2007; Mease et al, 2005, 2009). The ADEPT trial involving 315 
psoriatic arthritis patients tested the long-term clinical efficacy of adalimumab through 2 
years. Mease et al. reported that 58% of patients treated with adalimumab achieved the ACR 
20 after 12 weeks compared with 14% of the patients in the placebo group and that similar 
percentages were maintained up to week 104 (Mease et al, 2005, 2009). These data were 
confirmed by Genovese et al. who reported an ACR 20 response in 65% of adalimumab-
treated patients after week 24 (Genovese et al, 2007). 
Recently, the use of adalimumab in combination with traditional therapies was evaluated in 
psoriasis. Adalimumab with methotrexate results in a lower discontinuation rate of the 
TNF antagonist (Heiberg et al, 2008); the concomitant administration of adalimumab with 
phototherapy seems to be clinically effective, but further investigations in controlled clinical 
trials are needed (Bagel, 2011). The use of topical agents in combination with adalimumab 
results in a higher short-term efficacy that decreases after 4 weeks (Thaçi et al, 2010). 
2.4 Golimumab 
Golimumab is a new TNF antagonist and, like adalimumab, is a fully human anti-TNF 
IgG monoclonal antibody, which binds to both soluble and transmembrane forms of TNF. 
Golimumab has been recently FDA- and EMA-approved for the treatment of psoriatic 
arthritis as monotherapy or in combination with methotrexate. Golimumab is also approved 
for controlling symptoms of rheumatoid arthritis and ankylosing spondylitis (Centocor 
Ortho Biotech, Inc., 2010). 
2.4.1 Administration 
Golimumab is the first patient-administered once-monthly anti-TNF drug. The 
recommended dosage is 50 mg subcutaneously every 4 weeks (Centocor Ortho Biotech, 
Inc., 2010). 
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2.4.2 Clinical efficacy 
The phase III GO-REVEAL clinical trial evaluated the efficacy of golimumab in 405 patients 
suffering from active psoriatic arthritis (Kavanaugh et al, 2009a). Patients received 50 mg, 
100 mg or placebo once every 4 weeks. Achievement of ACR 20 criteria at week 14 was the 
primary end-point and was observed in 51% of patients treated with 50 mg, in 45% of 
patients receiving 100 mg of golimumab and in 9% of patients in the placebo group. At 24 
weeks, Kavanaugh et al. reported further improvement, with 52% and 61% of patients 
treated with 50 mg and 100 mg achieving ACR 20 criteria, respectively, compared with only 
12% of patients in the placebo group. At week 14, a PASI 75 was achieved in 40% and in 58% 
of patients receiving 50 mg and 100 mg golimumab, respectively, compared to 3% of 
patients receiving placebo (Kavanaugh et al, 2009a). Long-term efficacy of golimumab was 
evaluated in a 2-year trial (Kavanaugh et al, 2009b). At week 52, the percentage of patients 
treated with 50 mg of golimumab achieving ACR 20 and PASI 75 responses was 78% and 
62%, respectively. At week 104, the proportion of patients with the aforementioned clinical 
responses increased to 91% and 69%, respectively. With regard to the group of patients who 
received 100 mg of golimumab, Kavanaugh et al. observed an ACR 20 response in 81% and 
in 73% of patients at week 52 and 104, respectively. At the same time points, the percentage 
of patients achieving a PASI 75 was 70% and 76%, respectively (Kavanaugh et al, 2009b). 
The authors also reported an improvement in physical function and quality of life 
(Kavanaugh et al, 2009a). 
2.5 Certolizumab pegol 
Certolizumab Pegol is another TNF antagonist approved for the treatment of rheumatoid 
arthritis and Crohn’s disease (UCB, Inc., 2010). It is a pegylated Fab fragment of a 
humanized anti-TNF antibody. The presence of polyethylene glycol prolongs serum half-
life of the drug. Certolizumab pegol is unable to induce antibody-dependent cell-mediated 
cytotoxicity and complement-dependent cytotoxicity because of the lack of the Fc region 
(Bourne et al, 2008). Preliminary data from two phase II clinical trials showed that 
certolizumab pegol is effective in patients with moderate to severe plaque psoriasis 
(Ortonne et al, 2007, 2008a, 2008b). In these studies the efficacy and safety at two different 
dose regimens were evaluated. Patients were treated with 200 mg, 400 mg of certolizumab 
pegol or placebo every two weeks subcutaneously. At week 12, a PASI 75 response was 
observed in 74.6% of patients receiving 200 mg and in 82.8% of 400 mg treated-patients 
compared with 6.8% of patients in the placebo group (Ortonne et al, 2007). The same authors 
showed that at week 12 a higher number of patients achieved PASI 90 and had a greater 
improvement in health-related quality of life (Ortonne et al, 2008a, 2008b). A phase III trial 
of certolizumab pegol for psoriatic arthritis is ongoing (UCB, Inc., 2010).  
2.6 Safety of TNF inhibitors 
The aforementioned clinical trials show that TNF antagonists are well tolerated and safe. 
The commonest side effect associated with etanercept, adalimumab and golimumab 
treatment is a reaction at the site of injection, including redness, itching, bruising, pain, 
swelling and/or irritation as well as allergic reactions such as latex allergy (Kerbleski & 
Gottlieb, 2011). Treatment with infliximab is associated with infusion reactions, occurring in 
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treatment is a reaction at the site of injection, including redness, itching, bruising, pain, 
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reactions (Leman & Burden, 2008). For all TNF inhibitors, the primary concern is the 
increased risk for viral, bacterial and fungal infections, mainly of the upper respiratory tract 
(Kunz, 2009). Therapy with anti-TNF agents can lead to reactivation of latent tuberculosis, 
more frequently with infliximab (associated with the highest risk) and adalimumab than 
etanercept (Dixon et al, 2006). Another safety issue is the development of malignancies. The 
use of TNF inhibitors is associated with an increased risk of non-melanoma skin cancer 
(NMSC); the occurence of NMSC may be due to the previous use of phototeraphy and 
immunosuppressive agents, even if a potential risk to develop cancer after anti-
TNFtherapy cannot be excluded (Kerbleski & Gottlieb, 2011). A paradoxical side effect of 
anti-TNF therapies is the new onset and worsening of psoriasis, which have been reported 
in some cases (Ko et al, 2009). Infliximab, adalimumab and golimumab have been shown to 
cause hepatotoxicity (Kavanaugh et al, 2009a; Reich et al, 2005). On the contrary, etanercept 
seems to be effective and safe in the treatment of psoriatic patients with chronic hepatitis C 
virus-infection (Piccolo et al, 2008; Zeinn et al, 2005). Moreover, TNF inhibitors can 
potentially worsen congestive heart failure (Chung et al, 2009). The TNF blockade can lead 
to development of antinuclear antibodies and anti-double-stranded DNA antibodies. A 
lupus-like syndrome may occur with TNF antagonists, but it is a rare event that reverts after 
discontinuation of therapy (Ramos-Casals et al, 2008). Other rare events associated with 
TNF antagonists are the development of serious hematological diseases, such as leukopenia, 
neutropenia, thrombocytopenia, pancytopenia or aplastic anemia and the development or 
worsening of peripheral and central demyelinating disorders (Montane et al, 2007; Roberts 
& McColl, 2004). Rare dermatological diseases such as erythema multiforme, Steven’s 
Johnson syndrome and toxic epidermal necrolysis have been reported during etanercept, 
infliximab and adalimumab treatment (Kerbleski & Gottlieb, 2011).  
3. T-cell inhibitors 
Psoriasis is defined as a T cell-mediated autoimmune disease based on the advanced 
understanding of its pathogenesis. Primarily, a deregulated Th1/Th17 response has been 
reported in psoriatic skin (Lowes et al, 2008). Due to the primary role that T cells play in this 
disease, a new class of biologics has been designed to interfere with T-cell activation and 
functions. Currently, alefacept is the only T cell inhibitor drug approved for the treatment of 
psoriasis. Efalizumab was withdrawn from the market because of the associated risk of 
progressive multifocal leukoencephalopathy. Two other T-cell modulators are currently 
being evaluated for their use in psoriasis and psoriatic arthritis. 
3.1 Alefacept 
Alefacept is a recombinant human fusion protein consisting of the soluble lymphocyte 
function-associated antigen-3 (LFA-3) and the IgG1 Fc fragment (Biogen Inc., 2003). The 
LFA-3 portion binds to CD2, highly expressed on CD4+ and CD8+ memory-effector T cells 
(CD45RO+), while the IgG1 portion binds to Fc receptors on cytotoxic cells (da Silva et al, 
2002). Alefacept inhibits T-cell activation and proliferation, by interfering with the 
downstream activation of cytokines by interfering with the binding between CD2 on T 
lymphocytes and LFA-3 on antigen-presenting cells (da Silva et al, 2002). Since CD2 is 
highly expressed on CD45RO+ T cells, alefacept mainly inhibits memory-effector T cells, 
which represent the majority of T lymphocytes in psoriatic lesions, and preserves naïve cells 
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(Krueger, 2002). Alefacept also causes the depletion of CD45RO+ memory T cells via 
cytotoxic cell-mediated apoptosis; this occurs between CD2 on target T lymphocytes and Fc 
receptors, primarily FcRIII+, on natural killer cells and macrophages (Cooper et al, 2002). 
Alefacept was the first FDA-approved biologic agent in 2003 for the treatment of moderate 
to severe chronic plaque psoriasis in patients who are candidates for systemic treatment or 
phototherapy (Biogen Inc., 2003) but it is not currently approved for the treatment of 
psoriasis by EMA. It is also being investigated for the treatment of other conditions caused 
by T-cell dysregulation, such as psoriatic arthritis (Kraan et al, 2002; Mease & Reich, 2009). 
3.1.1 Administration 
The recommended administration of alefacept is a once-weekly 15 mg intramuscular 
injection (IM) for 12 weeks (Biogen Inc., 2003), although intravenous bolus injection (IV) has 
also been evaluated in several studies. A comparison of the pharmacokinetic and biologic 
activity of IM and IV administration showed that an adequate dose of IM alefacept leads to 
similar bioavailability and efficacy compared to IV administration and it is associated with 
minimal adverse effects (Vaishnaw & TenHoor, 2002). Retreatment with an additional 12-
week course may be initiated if CD4+ T-lymphocyte counts are within the normal range, 
and a minimum of a 12-week interval has passed since the previous course of treatment 
(Biogen Inc., 2003).  
3.1.2 Clinical efficacy 
A series of clinical trials showed significant improvement in the PASI score in patients 
treated with alefacept. The first multicenter, randomized, controlled phase II trial was 
conducted in 229 patients who received alefacept 0.025, 0.075 and 0.150 mg/kg IV or 
placebo weekly for 12 weeks, with a 12-week follow-up (Ellis & Krueger, 2001). Patients 
achieved a reduction in PASI by 38%, 53% and 53%, respectively, compared with 21% 
reduction by placebo. A significant improvement in quality of life was also reported, and 
long-term follow-up showed a sustained response for a median of 10 months (Ellis & 
Krueger, 2001).  
Two phase III clinical trials showed similar results (Krueger et al, 2002; Lebwohl et al, 2003). 
In these trials, patients with chronic plaque psoriasis received a once-weekly administration 
of alefacept IV or IM for 12 weeks, with a 12-week follow-up. In the first study (Krueger et 
al, 2002), a total of 553 patients was randomized to receive 7.5 mg of IV alefacept or placebo, 
while in the second trial (Lebwohl et al, 2003) 507 patients were treated with 10 or 15 mg of 
IM alefacept or placebo. Both trials showed a significant clinical improvement in psoriatic 
patients: a PASI 75 was achieved by 28% in IV-treated patients compared to 8% in placebo-
treated patients, and by 28% and 33% in 10 or 15 mg IM-treated patients, respectively, 
compared to 13% in the placebo group. Most responder patients maintained a 50% or 
greater reduction in PASI in the follow-up period. Other studies have been performed to 
investigate alefacept efficacy and safety in the long-term treatment of plaque psoriasis. 
Treatment of up to 5 courses provided incremental efficacy in responders, while 
maintaining the safety profile (Menter et al, 2006; Roberts et al, 2010). Although these 
studies are limited by the decreasing number of patients over multiple treatment courses or 
the lack of appropriate controls, but do they suggest that multiple courses of alefacept are 
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of alefacept IV or IM for 12 weeks, with a 12-week follow-up. In the first study (Krueger et 
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Several studies evaluated the effect of alefacept in combination with other therapies, 
including topical agents, methotrexate, cyclosporine, acitretin, systemic retinoids, or 
phototherapy (Krueger et al, 2008). The results suggest that the combination of alefacept 
with other psoriasis therapies is efficacious and well tolerated but larger studies are needed 
to confirm these results and evaluate long-term effects.  
3.1.3 Safety 
Alefacept is one of the safest biologic drugs for psoriasis. Clinical trials have demonstrated 
that it is well tolerated (Gottlieb, 2004; Krueger et al, 2002; Lebwohl et al, 2003; Roberts et al, 
2010). The main concern is T lymphocyte depletion so that monitoring of CD4+ T cells is 
required during treatment and administration should be withheld if the CD4+ T-cell count 
falls below 250 cells/mL (Biogen Inc., 2003). The most common side effects are pharyngitis, 
headache, rhinitis, bronchitis and flu (Ellis & Krueger, 2001; Gottlieb et al, 2003; Krueger et 
al, 2002; Lowe et al, 2003). These infections are not severe, and there is no evidence to date to 
suggest a predisposition to malignancies associated with alefacept.   
3.2 Abatacept 
Abatacept is a fusion protein composed of an Fc fragment of IgG1 and the extracellular 
domain of CTLA-4 (cytotoxic lymphocyte antigen-4) that inhibits T-cell costimulation. 
Abatacept is currently approved for the treatment of rheumatoid arthritis (Bristol-Myers 
Squibb, 2009). A phase II study has been terminated for psoriatic arthritis and it showed that 
10 mg/kg may be an effective treatment (Mease et al, 2011).   
3.3 Rituximab 
Rituximab is a chimeric monoclonal antibody that selectively binds the CD20 antigen of B 
cells. Rituximab is currently used in the treatment of non Hodgkin’s lymphoma and 
rheumatoid arthritis (Genentech USA, Inc., 2011). A phase I trial is ongoing to assess the 
efficacy and safety of rituximab in patients with psoriatic arthritis (Swedish Medical 
Center, 2009). 
4. IL-12/IL-23 inhibitors 
A third class of biologics classified as IL-12/IL-23 inhibitors has been developed for treating 
psoriasis. These two cytokines, mainly produced by activated dendritic cells, lead to 
differentiation of Th cells into the Th1 and Th17 subsets, respectively (Nestle et al, 2009). 
Moreover, elevated levels of IL-12 and IL-23 have been observed in psoriatic skin lesions 
(Yawalcar et al, 2009). Currently, ustekinumab is FDA- and EMA-approved for the 
treatment of chronic plaque psoriasis, whereas briakinumab, has recently had its approval 
application withdrawn in the US and Europe to conduct further analysis and clinical trials 
(Centocor Ortho Biotech, 2009; Kurzeia et al, 2011).  
4.1 Ustekinumab 
Ustekinumab is a fully human monoclonal antibody that binds to the p40 subunit that is 
shared by IL-12 and IL-23 (Centocor Ortho Biotech, 2009). IL-12 activates natural killer and T 
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cell responses, including CD4+ T cell differentiation toward the Th1 phenotype, while IL-23 
leads to Th17 differentiation, regulates T memory cells, and activates macrophages to 
maintain chronic autoimmune inflammation (Aggarwal et al, 2003; Trinchieri, 2003). 
Ustekinumab prevents the interaction of these cytokines with the IL-12Rβ1 receptor, 
neutralizing their  immune-mediated responses. A single administration of anti-IL-12p40 
demonstrated significant changes in psoriatic skin lesions after 2 weeks, including the 
reduction of a type 1 cytokine (IFN-) and chemokines (IL-8, IFN--inducible protein-10, and 
MCP-1), and a decrease of TNF and infiltrating T cells (Toichi et al, 2006). 
Ustekinumab was approved by the FDA in September 2009 for the treatment of adult 
patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or 
systemic therapy (Centocor Ortho Biotech, 2009). Early-stage clinical trials have also 
demonstrated its therapeutic potential  in psoriatic arthritis (Gottlieb et al, 2009).  
4.1.1 Administration 
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then at week 4, followed by one injection every 12 weeks as maintenance treatment 
(Centocor Ortho Biotech, 2009). Clinical response to ustekinumab is associated with serum 
ustekinumab concentration and patient body weight. Two phase III clinical trials 
demonstrated that efficacy of the 45 and 90 mg doses of ustekinumab was similar in patients 
weighing ≤100 kg, while the 90 mg dose was more effective than the 45 mg dose in patients 
weighing >100 kg (Leonardi et al, 2008; Papp et al, 2008). 
4.1.2 Clinical efficacy 
The first phase II trial was performed in 320 patients with moderate-to-severe plaque 
psoriasis who were randomized to receive one of four subcutaneous dosing regimens of 
ustekinumab (one 45 mg dose, one 90 mg dose, 4-weekly 45 mg doses, or 4-weekly 90 mg 
doses) or placebo (Krueger et al, 2007). At week 12, a PASI 75 was achieved by 52%, 59%, 
67%, and 81%, respectively, of the aforementioned groups, compared to 2% of placebo 
patients. Other measures of clinical outcome, including DLQI and Physician’s Global 
Assessment (PGA) showed significant improvements in responders compared with placebo 
patients at both weeks 12 and 24. Two important clinical trials for the assessment of 
ustekinumab efficacy and safety are PHOENIX-1 and PHOENIX-2. Both are large-scale, 
randomized, placebo-controlled phase III trials designed to evaluate the efficacy and safety 
of ustekinumab in patients with moderate-to-severe plaque psoriasis over a period of five 
years. In the PHOENIX-1 study, 766 patients were randomized to subcutaneous injections of 
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a PASI 75 was achieved by 67.1%, 66.4%, and 3.1% of patients receiving 45 mg, 90 mg or 
placebo, respectively. Results at week 28 demonstrated durable effects of ustekinumab with 
71.2% and 78.6% of patients treated with 45 mg or 90 mg achieving or maintaining a PASI 75 
score. Patients that achieved PASI 75 were re-randomized to maintenance ustekinumab or 
withdrawal from treatment at week 40. A PASI 75 response was better maintained in 
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treatment. The median time to loss of PASI 75 in patients withdrawn from therapy was 15 
weeks. The PHOENIX-2 study enrolled 1230 patients (Papp et al, 2008). Its design and 
results were similar to the PHOENIX-1 study: a PASI 75 was achieved by 66.7% of patients 
in the 45 mg group, by 75.7% in the 90 mg group, by 3.7% in the placebo group, at week 12. 
However, a dosing intensification was added for those subjects who did not respond fully to 
ustekinumab (PASI 50 to <75). At week 28, partial responders were re-randomized to 
continue dosing regimen every 12 weeks or to increase dosing frequency to every 8 weeks. 
In the 90 mg group, 22 of 33 partial responders achieved PASI 75 after increasing dosage 
frequency to every 8 weeks. Conversely, dosing intensification did not improve clinical 
outcomes in the 45 mg group. The authors concluded that intensification of dosing to once 
every 8 weeks with ustekinumab 90 mg might be necessary to achieve a full response in 
partial responders. The ACCEPT study is a randomized phase III clinical trial that directly 
compares ustekinumab to etanercept in 903 patients with psoriasis (Griffiths et al, 2010). 
Patients were randomized to receive ustekinumab 45 or 90 mg at week 0 and 4, or 
etanercept 50 g twice weekly for 12 weeks. At week 12 PASI 75 was achieved by 74% of the 
patients in the ustekinumab 90 mg group, by 68% of patients in the ustekinumab 45 mg 
group, and by 57% of those in the etanercept group. Patients who were unresponsive to 
etanercept were switched to ustekinumab, with almost a 50% response rate within the first 
12 weeks. There were no significant safety differences between ustekinumab and etanercept 
in the ACCEPT trial. Both drugs were generally well tolerated. This head-to-head 
comparison clearly showed a significant superiority of ustekinumab over etanercept for the 
treatment of patients with moderate-to-severe psoriasis. However, this trial only evaluated 
12 weeks of therapy, a  short period to have an adequate comparison of the drugs, especially 
for their safety profiles.  
4.1.3 Safety 
In general, ustekinumab is well tolerated with only mild adverse events experienced in 
clinical trials. The most common adverse events have been equally observed between the 
treatment and placebo groups and included upper respiratory infections, headache, 
nasopharyngitis, arthralgia, back pain, and injection site reactions (Leonardi et al, 2008; 
Papp et al, 2008). Safety concerns exist for risks of infection and suppression of tumor 
immune surveillance. Individuals congenitally deficient in IL-12p40 or IL-12R1 are known 
to have an increased susceptibility to intracellular pathogens, including tuberculosis and 
salmonella (Döffinger et al, 2002). However, in the PHOENIX 1 and 2 studies only two 
serious infections occurred in the ustekinumab group treated with the 90 mg dose. No 
mycobacterial or salmonella infections were reported. The risk of malignancy did not appear 
to be significant. Cutaneous malignancies were reported in two patients in the PHOENIX 2 
study, a squamous cell carcinoma in the placebo group and a basal cell carcinoma in the 90 
mg treatment group. No malignancies were reported in the PHOENIX 1 trial. The rate of 
malignancies reported in ustekinumab-treated patients was comparable to the rate in the 
general population. Patients with psoriasis have an increased risk of cardiovascular events. 
In the phase II trial of ustekinumab two patients experienced myocardial infarction and one 
suffered a stroke (Krueger et al, 2007). However, subsequent larger phase III studies 
revealed no apparent increased risk of cardiovascular side effects. Further studies are 
needed to assess long-term ustekinumab safety in patients treated for extended periods. 
 




Briakinumab is a recombinant fully human IgG1 monoclonal antibody directed against the 
shared p40 subunit of IL-12 and IL-23 (Kimball et al, 2008). Due to its binding to the aforesaid 
cytokines, briakinumab causes a decrease in secretion of IL-6, IL-12, INF- and TNF, as 
demonstrated in patients with Crohn’s disease (Ding et al, 2008). In a phase II study, 180 
patients suffering from psoriasis were treated with placebo or briakinumab at one of the 
following doses: one 200 mg dose at week 0, 100 mg eow for 12 weeks, 200 mg weekly for 4 
weeks, 200 mg eow for 12 weeks, 200 mg weekly for 12 weeks. At week 12, an improvement in 
PASI 75 was reported for all briakinumab-treated groups compared with placebo (Kimball et 
al, 2008). The retreatment efficacy and the long-term safety of briakinumab through 48 weeks 
have been evaluated by the same authors (Kimball et al, 2009). Kimball et al. reported that the 
efficacy of briakinumab was higher in the first 12 weeks compared with the re-treatment 
phase, although more patients showed a PASI 75 response during this period. The most 
frequent adverse events observed during the treatment with briakinumab were injection site 
reactions, upper respiratory infections and nasopharyngitis. 
5. Perspectives 
In the last decade, the detailed comprehension of the molecular mechanisms involved in 
psoriasis has led to the development of new biological drugs, such as monoclonal 
antibodies, recombinant proteins and small RNA drugs, which are currently under 
evaluation for psoriasis and/or psoriatic arthritis. 
5.1 Anti-interleukin 17 
IL-17 is a pro-inflammatory cytokine produced by Th17 T cells, one of the key players  in the 
pathogenesis of psoriasis. Due to its role in psoriasis, IL-17 is a new emerging target for 
biological therapy.  
AMG 827 is a fully human IgG2 anti IL-17 receptor monoclonal antibody investigated in 
phase II trials for psoriasis, rheumatoid arthritis and Crohn’s disease (Amgen, 2011). 
Preliminary data from a small study showed that psoriatic patients treated with 700 mg 
AMG 827 IV had a significant improvement in terms of histopathological features and PASI 
score (Russell et al, 2010). 
AIN457 is a recombinant fully human anti-IL-17 monoclonal antibody that selectively binds 
and neutralizes IL-17. The efficacy and safety of AIN457 has been evaluated in a phase II 
trial (Jancin, 2009) which enrolled 36 patients suffering from chronic plaque psoriasis. A 
PASI 75 response was observed in 44% of patients receiving 3 mg/kg AIN457 IV compared 
with 9% of placebo group. AIN457 is currently undergoing phase II studies for psoriasis, 
psoriatic arthritis and rheumatoid arthritis and a phase III study for uveitis (Novartis, 2010).  
LY2439821 is a new humanized IgG4 anti-IL-17 monoclonal antibody in a phase II trial for 
psoriasis and rheumatoid arthritis (Eli Lilly and Company, 2011).    
5.2 Anti-interleukin 22 
IL-22 is a pro-inflammatory cytokine produced by both Th17 and a new group of T cells 





treatment. The median time to loss of PASI 75 in patients withdrawn from therapy was 15 
weeks. The PHOENIX-2 study enrolled 1230 patients (Papp et al, 2008). Its design and 
results were similar to the PHOENIX-1 study: a PASI 75 was achieved by 66.7% of patients 
in the 45 mg group, by 75.7% in the 90 mg group, by 3.7% in the placebo group, at week 12. 
However, a dosing intensification was added for those subjects who did not respond fully to 
ustekinumab (PASI 50 to <75). At week 28, partial responders were re-randomized to 
continue dosing regimen every 12 weeks or to increase dosing frequency to every 8 weeks. 
In the 90 mg group, 22 of 33 partial responders achieved PASI 75 after increasing dosage 
frequency to every 8 weeks. Conversely, dosing intensification did not improve clinical 
outcomes in the 45 mg group. The authors concluded that intensification of dosing to once 
every 8 weeks with ustekinumab 90 mg might be necessary to achieve a full response in 
partial responders. The ACCEPT study is a randomized phase III clinical trial that directly 
compares ustekinumab to etanercept in 903 patients with psoriasis (Griffiths et al, 2010). 
Patients were randomized to receive ustekinumab 45 or 90 mg at week 0 and 4, or 
etanercept 50 g twice weekly for 12 weeks. At week 12 PASI 75 was achieved by 74% of the 
patients in the ustekinumab 90 mg group, by 68% of patients in the ustekinumab 45 mg 
group, and by 57% of those in the etanercept group. Patients who were unresponsive to 
etanercept were switched to ustekinumab, with almost a 50% response rate within the first 
12 weeks. There were no significant safety differences between ustekinumab and etanercept 
in the ACCEPT trial. Both drugs were generally well tolerated. This head-to-head 
comparison clearly showed a significant superiority of ustekinumab over etanercept for the 
treatment of patients with moderate-to-severe psoriasis. However, this trial only evaluated 
12 weeks of therapy, a  short period to have an adequate comparison of the drugs, especially 
for their safety profiles.  
4.1.3 Safety 
In general, ustekinumab is well tolerated with only mild adverse events experienced in 
clinical trials. The most common adverse events have been equally observed between the 
treatment and placebo groups and included upper respiratory infections, headache, 
nasopharyngitis, arthralgia, back pain, and injection site reactions (Leonardi et al, 2008; 
Papp et al, 2008). Safety concerns exist for risks of infection and suppression of tumor 
immune surveillance. Individuals congenitally deficient in IL-12p40 or IL-12R1 are known 
to have an increased susceptibility to intracellular pathogens, including tuberculosis and 
salmonella (Döffinger et al, 2002). However, in the PHOENIX 1 and 2 studies only two 
serious infections occurred in the ustekinumab group treated with the 90 mg dose. No 
mycobacterial or salmonella infections were reported. The risk of malignancy did not appear 
to be significant. Cutaneous malignancies were reported in two patients in the PHOENIX 2 
study, a squamous cell carcinoma in the placebo group and a basal cell carcinoma in the 90 
mg treatment group. No malignancies were reported in the PHOENIX 1 trial. The rate of 
malignancies reported in ustekinumab-treated patients was comparable to the rate in the 
general population. Patients with psoriasis have an increased risk of cardiovascular events. 
In the phase II trial of ustekinumab two patients experienced myocardial infarction and one 
suffered a stroke (Krueger et al, 2007). However, subsequent larger phase III studies 
revealed no apparent increased risk of cardiovascular side effects. Further studies are 
needed to assess long-term ustekinumab safety in patients treated for extended periods. 
 




Briakinumab is a recombinant fully human IgG1 monoclonal antibody directed against the 
shared p40 subunit of IL-12 and IL-23 (Kimball et al, 2008). Due to its binding to the aforesaid 
cytokines, briakinumab causes a decrease in secretion of IL-6, IL-12, INF- and TNF, as 
demonstrated in patients with Crohn’s disease (Ding et al, 2008). In a phase II study, 180 
patients suffering from psoriasis were treated with placebo or briakinumab at one of the 
following doses: one 200 mg dose at week 0, 100 mg eow for 12 weeks, 200 mg weekly for 4 
weeks, 200 mg eow for 12 weeks, 200 mg weekly for 12 weeks. At week 12, an improvement in 
PASI 75 was reported for all briakinumab-treated groups compared with placebo (Kimball et 
al, 2008). The retreatment efficacy and the long-term safety of briakinumab through 48 weeks 
have been evaluated by the same authors (Kimball et al, 2009). Kimball et al. reported that the 
efficacy of briakinumab was higher in the first 12 weeks compared with the re-treatment 
phase, although more patients showed a PASI 75 response during this period. The most 
frequent adverse events observed during the treatment with briakinumab were injection site 
reactions, upper respiratory infections and nasopharyngitis. 
5. Perspectives 
In the last decade, the detailed comprehension of the molecular mechanisms involved in 
psoriasis has led to the development of new biological drugs, such as monoclonal 
antibodies, recombinant proteins and small RNA drugs, which are currently under 
evaluation for psoriasis and/or psoriatic arthritis. 
5.1 Anti-interleukin 17 
IL-17 is a pro-inflammatory cytokine produced by Th17 T cells, one of the key players  in the 
pathogenesis of psoriasis. Due to its role in psoriasis, IL-17 is a new emerging target for 
biological therapy.  
AMG 827 is a fully human IgG2 anti IL-17 receptor monoclonal antibody investigated in 
phase II trials for psoriasis, rheumatoid arthritis and Crohn’s disease (Amgen, 2011). 
Preliminary data from a small study showed that psoriatic patients treated with 700 mg 
AMG 827 IV had a significant improvement in terms of histopathological features and PASI 
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inflammation via several transcription factors such as STAT3 (Nograles et al, 2009). ILV-094 
is a fully human anti IL-22 monoclonal antibody. A phase I study to evaluate the efficacy 
and safety of ILV-094 in psoriasis has been recently completed, while it is currently ongoing 
a phase II trial for rheumatoid arthritis  (Pfizer, 2010). 
5.3 Chaperonin 10 
Chaperonin 10 belongs to the heat shock proteins family and acts as a molecular chaperon, 
regulating protein folding. Several studies support its anti-inflammatory activity and its role 
in down-regulating the excessive immune response (van Eden, 2008). Recombinant 
Chaperonin 10 (Cpn10) mimics these activities and its efficacy in psoriasis has been 
evaluated by a single-center, double-blind exploratory study, showing a significant 
improvement in Cpn10-treated patients (Williams et al, 2008). Phase II trials have been 
completed for psoriasis, rheumatoid arthritis and multiple sclerosis (Golant & Gutman-
Yassky, 2011).  
5.4 Small RNA drugs 
The use of RNA interference as a drug is one of the possible therapeutic strategies to target 
the pro-inflammatory cytokines involved in psoriasis, as shown by several phase I and II 
ongoing clinical trials (reviewed in Jackson et al, 2006). On the basis of their role in psoriasis, 
suitable mRNA targets are TNF, IL-20 and IL-23. A recent study showed that local small 
RNA therapy against TNF provided amelioration in psoriasis in a xenograft 
transplantation model (Jakobsen et al, 2009). These results indicate that RNA interference is 
a potential therapy in the treatment of inflammatory skin diseases. Nevertheless the main 
challenge for this kind of therapy remains the delivery of small RNA.  
6. Conclusion 
The introduction of biological drugs in clinical practice has revolutionized the treatment of 
psoriasis and psoriatic arthritis in the last decade. Biologics have shown to be effective and 
to have an acceptable safety profile, but there is still a need to assess long-term toxicity 
through clinical experience and careful post-marketing surveillance.  
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transplantation model (Jakobsen et al, 2009). These results indicate that RNA interference is 
a potential therapy in the treatment of inflammatory skin diseases. Nevertheless the main 
challenge for this kind of therapy remains the delivery of small RNA.  
6. Conclusion 
The introduction of biological drugs in clinical practice has revolutionized the treatment of 
psoriasis and psoriatic arthritis in the last decade. Biologics have shown to be effective and 
to have an acceptable safety profile, but there is still a need to assess long-term toxicity 
through clinical experience and careful post-marketing surveillance.  
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1. Introduction 
Diet has been suggested to play a role in the etiology and pathogenesis of psoriasis (Araujo 
et al., 2009; Wolters, 2005). Periods of fasting, a hypocaloric and vegetarian diet have been 
associated with an improvement in symptoms due to changes in the metabolism of 
polyunsaturated fatty acids (PUFAs) and an influence on the profile of eicosanoids, leading 
to suppression of the inflammatory process (Lithell et al., 1983; Rucevic et al., 2003; Wolters, 
2005). The consumption of alcoholic beverages is prevalent among patients with psoriasis 
and is the greatest cause of the high mortality rate among individuals with moderate to 
severe forms of the disease and should therefore be avoided (Chistophers, 2001; Poikolainen 
et al., 1990; Smith & Fenske, 2000; Wolters, 2005). According to several authors, calcitriol (the 
active form of vitamin D) and its analogs have anti-proliferation, pro-differentiation and 
immune-regulating properties that may inhibit the growth and maturation of keratinocytes, 
with oral supplementation often suggested for patients who do not topically use calcitriol 
(Andorini, 2002; Holick, 2003; Wolters, 2005). 
The skin acts as an interface between the body and surrounding environment, thus the skin 
is constantly exposed to both endogenous and exogenous pro-oxidants, leading to the 
generation of harmful oxidant species. Oxidative stress and the generation of excessive free 
radicals have been related to skin inflammation in psoriasis. Patients with this condition 
have reduced plasma levels of β-carotene and α-tocopherol as well as a decline in serum 
selenium and high concentrations of malondialdehyde, which is a marker of lipid 
peroxidation in the plasma and red blood cells (Briganti & Picardo, 2003; Azzini et al., 1995; 
Serwin et al., 2003).  
Data from literature indicates that the topical application or oral administration of 
antioxidants is suggested as preventive therapy for the natural aging of the skin and cancer 
caused by ultraviolet rays (Briganti & Picardo, 2003). With regard to lipids, studies have 
demonstrated the anti-inflammatory effect of fish oil in individuals with psoriasis, as diets 
rich in omega 3 modify the metabolism of PUFAs, thereby influencing the profile of 
eicosanoids, which leads to the suppression of the inflammatory process (Smith & Fenske, 
2000). A number of authors report an association between latent sensitivity to gluten (pre-
celiac disease state) and different skin diseases, including psoriasis, suggesting a gluten-free 
diet may provide beneficial effects (Duggan, 2004; Humbert et al., 2006; Leffler et al., 2003; 
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The aforementioned data underscore the importance of studies on psoriasis, especially with 
regard to the influence of nutrition on the etiopathogenesis and treatment of this condition.  
2. Influence of calorie intake, periods of fasting and vegetarian diet 
A number of studies report that symptoms of inflammatory disease, such as rheumatoid 
arthritis, can improve with a hypocaloric diet or during periods of fasting (Muller et al., 
2001; Palmblad et al., 1991). Similarly, the prevalence and severity of psoriasis were shown 
to improve during periods of fasting and a hypocaloric diet,suggesting diet to be an 
important consideration for theprevention and treatment of the moderate non-pustular form 
of the disease (Rucevic et al., 2003; Wolters, 2005) 
While various mechanisms have been discussed, the direct cause of these positive effects on 
the symptoms of psoriasis remains unknown (Wolters, 2005). The most important reason is 
likely a reduction in arachidonic acid (AA) intake, resulting in a lower production of 
inflammatory eicosanoids. During the fasting state, a reduction in the activation of TCD4 
cells and an increase in the number and/or function of the anti-inflammatory cytokine 
interleukin 4 have been observed; Calorie restriction leads to a reduction in oxidative stress 
(Fraser et al., 1999; Wolters, 2005). However, the few studies that have addressed the effect 
of caloric restriction on psoriasis offer inconsistent data on the benefits of this conduct over a 
long period of time (Lithell et al., 1983; Rucevic et al., 2003). The results of evaluations 
carried out during World War I revealed that individuals with psoriasis experienced 
significant improvement during calorie restriction, with the recurrence of skin lesions after 
the reintroduction of a normal diet (Ricketts et al., 2010). 
A vegetarian diet may be beneficial to all patients with psoriasis due to the reduction in AA 
intake and consequent reduction in the formation of inflammatory eicosanoids (Fraser et al., 
1999). 
3. Polyunsaturated fatty acids 
Lipids are macronutrients that perform energy, structural and hormonal functions in 
organisms. Fatty acids are monocarboxylic acids with a hydrocarbon chain of variable size 
and double bonds between carbon atoms. These substances are classified as 
monounsaturated and polyunsaturated, depending on the number of double bonds they 
contain. Fatty acids are integral compounds of nearly all lipids. Two series of PUFAs are 
differentiated, depending on the location of the first double carbon bond at the methyl 
radical. Linoleic acid, which is an essential fatty acid, belongs to the omega 6 family and is 
found in a large quantity of oleaginous seeds; this acid can be converted into AA, which is 
prinicipally derived from meat and egg sources (Dutra-de-Oliveira, 2000). Eicosapentaenoic 
acid (EPA) and docosahexaenoic acid are the most abundant omega 3 fatty acids in food and 
are found mainly in cold-water fish, such as mackerel, sardine, salmon, herring, etc. 
(Wolters, 2005). 
Besides their function in the phospholipid membrane, PUFAs are needed for the formation 
of eicosanoids, which are metabolic regulators (Jones & Papamandjaris, 2001). AA is a 
precursor of prostaglandins, leukotrienes and other compounds that have important 
functions in inflammation and the regulation of immunity, whereas EPA derivatives exhibit 
anti-inflammatory properties (Calder, 2001). High concentrations of AA and its pro-
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inflammatory metabolites have been observed in psoriatic lesions as well as in other auto-
immune and inflammatory disorders. Therefore, one treatment option for psoriasis  may be 
the replacement of AA with an alternative fatty acid, especially EPA, which is metabolized 
through the same enzymatic pathways as AA (Mayser et al., 2002; Wolters, 2005). 
Fish oil (omega 3), has been observed to change the serum and lipid composition of 
epidermal and blood cell membranes, which rationalizes its use in the treatment of psoriasis.  
High levels of AA are found in psoriatic lesions and it is believed that its metabolite, 
leukotriene B4, may be the mediator of inflammation in psoriasis (Ricketts et al., 2010). Thus, 
when omega 3 fatty acids are metabolized by cyclooxygenase or lipoxygenase in place of 
AA in the cell membranes, these substances may assist in reducing inflammation (Ricketts et 
al., 2010). 
Conflicting results are reported regarding the effect of the oral supplementation of omega 3 
on this disease and there are no clear findings regarding the dose to be employed (Mayser et 
al., 2002; Wilkinson, 1990). In vitro studies report that the addition of fish oil to the diet of 
individuals with psoriasis leads to an increase in EPA in relation to AA in the plasma and 
platelets, with a significant reduction in the synthesis of leukotriene B4 (Ricketts et al., 2010) 
Initial studies involving different amounts of EPA ranging from 3.6 to 14 grams per day for 
periods of six weeks to six months report some clinical improvement with minimal side 
effects; however, lower doses for a shorter period of time are reported to offer no significant 
improvement (Maurice et al., 1987; Ziboh et al., 1986; Kragballe & Fogh, 1989; Kojima et al., 
1989). The majority of studies report positive results; however, less effective results are 
reported in randomized, controlled trials (Wolters, 2005). Despite the inconsistent results, 
the consumption of fish rich in omega 3 is recommended. Moreover, parenteral infusions of 
omega 3 may be beneficial to patients hospitalized with acute psoriasis (Wolters, 2005). 
4. Gluten 
Celiac disease is an enteropathy associated with different extra-intestinal manifestations, 
such as anemia, transaminase elevation, osteopenia, neurological conditions, emotional and 
psychiatric disorders, auto-immune disease and dermatological problems. This disease is  
characterized by an allergy to gluten (a protein found in wheat, oats, rye and barley), 
leading to malabsorption and atrophy of the intestinal villi, which improves with a gluten-
free diet (Abenavoli et al., 2006). 
This gluten-sensitive enteropathy tends to bemildly symptomatic and even  
asymptomatic, which may explain the association between latent gluten sensitivity and 
psoriasis (Wolters, 2005). A number of studies report an association between celiac disease 
and psoriasis (Michaelsson et al., 2000; Woo et al., 2004). According to some authors, 
however, this association is controversial due to currently limited data (Addolorato et al., 
2003; Collin & Reunal, 2003). Since both celiac disease and psoriasis are related to T helper 
1 (Th1) cytokines,  this association could be caused by the activation of Th1 by the 
interleukins IL1 and IL8, stemming from the rapid division of keratinocytes (Ojetti et al., 
2003). 
There is no consensus among current literature regarding the high prevalence of patients 
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is a need for prospective studies in order to determine the incidence of celiac disease and the 
real percentage of increased levels of antigliadin, antiendomysial and anti-tissue 
transglutaminase antibodies in patients with psoriasis (Ricketts et al., 2010). 
A gluten-free diet can improve skin lesions even in patients without celiac disease but with 
the antigliadin antibodies IgA and IgG, which are important to the diagnosis of celiac 
disease (Michaelsson et al., 2003). Likewise, studies indicate that a gluten-free diet leads to 
an improvement in rheumatoid arthritis, which is another chronic inflammatory disease 
(Hafstrom et al., 2001). Data remains scarce in regards to  the mechanisms involved in the 
association between celiac disease, psoriasis and a gluten-free diet in skin lesions. A number 
of hypotheses have been raised, such as an alteration in intestinal permeability, immune 
mechanisms and vitamin D deficiency (Abenavoli et al., 2006). 
5. Oxidative stress and antioxidants 
The skin is constantly exposed to oxidants, which leads to the formation of harmful reactive 
oxygen species (Briganti & Picardo, 2003). Oxidative stress and the increased formation of 
free radicals have been related to skin inflammation and are reported to be among the most 
important factors in the pathogenesis of psoriasis (Kiymat et al., 2003; Rocha et al., 2004; 
Relhan et al., 2002; Wolters, 2005). Studies demonstrate that individuals with psoriasis have 
high concentrations of malondialdehyde, OuvirLer foneticamentea marker of lipid 
peroxidation, and is compromised antioxidant status, with reduced levels of -carotene, -
tocopherol and selenium (Azzini et al., 1995; Briganti & Picardo, 2003; Serwin et al., 2003).  
High alcohol intake (stemming from the psychosocial impact of the disease) and either 
active or passive smoking are among some of the factors that can increase oxidative stress 
and reduce levels of natural antioxidants in individuals with a history of the disease for 
more than three years (Lecomte et al., 1994; Mckenzie, 2000; Monk & Neil, 1986; Naldi et al., 
1992). The consumption of fruit and vegetables may be beneficial to such individuals due to 
the high antioxidant content, such as karotenoids, flavonoids and vitamin C, as an adequate 
antioxidant status is considered useful to the prevention of imbalance between oxidative 
stress and antioxidant defense (Naldi et al., 1996; Wolters, 2005). However, few studies have 
investigated the effects of antioxidant supplementation on the symptoms of psoriasis 
(Wolters, 2005). 
6. Selenium 
Selenium is an essential trace element with immune-modulating and anti-proliferative 
properties, with an influence over the immune response whether through a change in the 
expression of cytokines and respective receptors or by making immune cells more resistant 
to oxidative stress (Celerier et al., 1995; Roy et al., 1992; Spallholtz et al., 1990). Moreover, 
data  indicates that patients with inflammatory skin diseases, skin cancer, malignant 
melanoma and cutaneous T-cell lymphoma have low concentrations of selenium (Clark et 
al., 1984; Deffuant et al., 1984; Hinks et al., 1987; Michaelsson & Edqvist, 1984).    
The low concentration of selenium found in patients with psoriasis may be a risk factor for 
the development of the disease. However, there are few studies on the role of this element in 
the pathogenesis (Hinks et al., 1987; Fairris et al., 1989; Michaelsson et al., 1989; Harvima et 
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al., 1993; Pinton et al., 1995; Azzini et al., 1995). Low levels of selenium are related to the 
severity of psoriasis and may occur due to low food intake or excessive flaking of the skin 
(Serwin et al., 2003). Serwin et al. (2003) found that selenium levels were significantly lower 
in patients with a diagnosis of psoriasis for more than three years in comparison to healthy 
volunteers (38.69 vs 48.41; p < 0.05).  
Kharaeva et al. (2009) demonstrated for the first time that the combination of conventional 
therapy and supplementation with vitamin E, co-enzyme Q10 and selenium resulted in an 
improvement in the clinical condition of patients with severe psoriasis as well as a reduction 
in oxidative stress. Supplementation using inorganic forms of selenium (sodium selenite 
and selenate) is also reported to lead to clinical improvement in patients with psoriasis 
(Fairris et al., 1989; Pinton et al., 1995). 
7. Vitamin D 
Vitamin D is a pro-hormone that can be produced from 7-dehydrocholesterol through the 
exposure of skin to ultraviolet B rays of the sun. Besides its importance in the homeostasis of 
calcium and bone metabolism, calcitriol (the active form of vitamin D) has effects on more 
than 30 types of tissue, including skin (Wolters, 2005). Vitamin D plays an important role in 
reducing the risk of a number of chronic diseases, such as auto-immune diseases, infectious 
diseases, cardiovascular diseases and some forms of cancer (breast, colon-rectal and prostate 
cancer) (Fu &Vender, 2011). 
Vitamin D plays an essential role in cell proliferation, differentiation, apoptosis and 
angiogenesis.Vitamin D also has beneficial effects on inflammatory diseases medicated by 
Th1 lymphocytes, such as diabetes, psoriasis, Crohn’s disease and multiple sclerosis 
(Cantorna et al., 2004; Holick, 2007; Ikeda et al., 2010). Vitamin D has proven to be highly 
effective in the treatment of psoriasis, as patients having received vitamin D for the 
treatment of osteoporosis exhibited an improvement in psoriasis (Abramovits, 2009; Smith 
et al., 2009; Van De Kerkhof, 2005). Due to the function of calcitriol and its analogs in 
psoriasis, oral supplementation with vitamin D should be considered in patients who do not 
make use of topical treatment with this vitamin, as vitamin D deficiency is frequent in these 
individuals (Holick, 2003; Wolters, 2005). 
8. Vitamin B12 
Data from the literature demonstrates the efficacy of using intramuscular and systemic 
vitamin B12 in patients with psoriasis in addition to the positive effects of topical vitamin 
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10. Alcoholic beverages 
The first studies on the association between psoriasis and the consumption of alcoholic 
beverages emerged in 1963. While some investigations have failed to demonstrate such an 
association, recent studies have shown a significant correlation (Wolf et al., 1999). Besides 
contributing to the development of psoriatic plaque, alcohol intake is involved in triggering 
periods of exacerbation, associated with a reduced response to treatment and the risk of 
liver toxicity associated to the use of methotrexate (Gupta et al., 1993; Higgins et al., 1994; 
Liu et al., 2010; Qureshi et al., 2010; Smith & Fenske, 2000). 
The exact mechanism by which alcohol causes or aggravates psoriasis is not yet fully 
clarified. Some authors propose that alcohol induces immunological dysfunction, leading to 
immunosuppression, and increases the production of inflammatory cytokines and cell cycle 
activators, such as cyclin D1 and keratinocyte growth factor, which could lead to epidermal 
over-proliferation (Farkas et al., 2003; Ockenfels et al., 1996; Smith & Fenske, 2000). 
Moreover, the greater susceptibility to superficial infection observed in alcoholics, such as 
those caused by Streptococcus and trauma, has also been suggested in the development of 
psoriasis (Farkas et al., 2003). 
Data from literature indicates that alcohol is a risk factor for psoriasis in young and middle-
aged men and, while not a risk factor in women, alcohol intake aggravates the condition in 
this gender (Poikolainen et al., 1994). Patients with psoriasis are recommended to exercise 
with caution when consuming alcohol, especially during periods of exacerbation. Moreover, 
due to all possible effects, a number of authors recommend abstention (Behnam et al., 2005; 
Wolters, 2005). Thus, identifying this risk factor in patients with psoriasis could contribute 
toward a reduction in episodes of exacerbation, thereby achieving better treatment results 
(Kazakevich et al., 2011). 
11. Obesity 
The first associations between psoriasis and obesity were reported in large epidemiological 
studies carried out in Europe (Duarte et al., 2010). A pioneering American study conducted 
in the state of Utah reports a 34% prevalence of obesity among individuals with psoriasis, 
which is much higher than the 18% reported in the general population (Herron et al., 2005) 
Obesity is known to cause a state of chronic inflammation, with high levels of TNF-α, IL-6 
and C-reactive protein, which are associated to the progressive increase in body mass index 
(BMI). In this state of chronic inflammation, alterations in resistance/sensitivity to insulin 
and greater oxidative stress, with the production of free radicals, lead to a greater likelihood 
of the development of diabetes and metabolic syndrome as well as the influence of these 
pro-inflammatory cytokines in the course and presentation of psoriasis (Hamminga et al., 
2006; Wakkee et al., 2007). The association between obesity and psoriasis has been well 
established, as obesity can increase the risk of developing psoriasis and preexisting psoriasis 
can increase the risk of patients becoming obese (Farías et al., 2011). 
Non-pharmacological treatment aimed at changes in lifestyle should be offered to all 
patients, especially those with a BMI ≥ 25 kg/m², for whom the goal is controlled, healthy 
weight loss (Farías et al., 2011). A low-calorie diet is recommended, following the Step I diet 
(Obesity Society, 2000) (Table 1), with a calorie restriction of 500 to 1000 kilocalories per day, 
based on the patient’s energy expenditure, which can be determined through measurement 
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techniques such as indirect calorimetry or through mathematical formulas such as the 
Harris-Benedict equation (Table 2) (Frankenfield et al., 1998).  For greater compliance to 
treatment and patient follow up, the participation of a nutritionist is needed to individualize 
the treatment, considering all socioeconomic and cultural aspects. Farías et al (2011) 
suggests the recommendations of the Nutrition Committee of the American Heart 
Association (Table 3 e Table 4). 
 
Nutrient Recommendation intake
Reducing calories Approximately 500 to 1,000 kilocalories / day 
Total fat < 30% of total calories 
Saturated fat 8 a 10% of total calories 
Monounsaturated fat ≤15% of total calories 
Polyunsaturated fat ≤10% of total calories 
Total cholesterol <300 mg / day 
Proteins Approximately 15% of total calories 
Carbohydrates At least 55% of total calories 
Sodium 100 mmol / day (approximately 2.4 g of sodium) 
Calcium 1.000 to 1.500 mg/Day 
Fiber 20 a 30 g/Day 
Table 1. Diet Step 1 (Obesity Society, 2000). 
 
Women BMR = 655 + (4.35 x weight in pounds ) + (4.7 x height in inches) - (4.7 x age in years) 
Men 66 + (6.23 x weight in pounds) +  (12.7 x height in inches) - (6.8 x age in years) 
Table 2. Basal metabolic rate according to the Harris  Benedict formula. 
 
Balance calorie intake and physical activity to achieve or maintain a healthy body weight. 
Consume a diet rich in vegetables and fruits.
Choose whole-grain, high-fiber foods
Consume fish, especially oily fish, at least twice a week.
Limit your intake of saturated fat to _7% of energy, trans fat to _1% of energy, and 
cholesterol to _300 mg per day by 
-Choosing lean meats and vegetable alternatives; 
— Selecting fat-free (skim), 1%-fat, and low-fat dairy products; and 
— Minimizing intake of partially hydrogenated fats. 
Minimize your intake of beverages and foods with added sugars. 
Choose and prepare foods with little or no salt.
If you consume alcohol, do so in moderation.
When you eat food that is prepared outside of the home, follow the AHA Diet and 
Lifestyle Recommendations. 
Table 3. Diet and Lifestyle Recommendations for Cardiovascular Disease  Risk 
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 Know your caloric needs to achieve and maintain a healthy 
weight. 
 Know the calorie content of the foods and beverages you 
consume. 
 Track your weight, physical activity, and calorie intake. 
 Prepare and eat smaller portions. 
 Track and, when possible, decrease screen time (eg, watching 
television, surfing the Web, playing computer games). 
 Incorporate physical movement into habitual activities. 
 Do not smoke or use tobacco products. 
 If you consume alcohol, do so in moderation (equivalent of no 
more than 1 drink in women or 2 drinks in men per day). 
Food choices and 
preparation 
 Use the nutrition facts panel and ingredients list when choosing 
foods to buy. 
 Eat fresh, frozen, and canned vegetables and fruits without high-
calorie sauces and added salt and sugars. 
 Replace high-calorie foods with fruits and vegetables. 
 Increase fiber intake by eating beans (legumes), whole-grain 
products, fruits, and vegetables. 
 Use liquid vegetable oils in place of solid fats. 
 Limit beverages and foods high in added sugars. Common forms 
of added sugars are sucrose, glucose, fructose, maltose, dextrose, 
corn syrups, concentrated fruit juice, and honey. 
 Choose foods made with whole grains. Common forms of whole 
grains are whole wheat, oats/oatmeal, rye, barley, corn, popcorn, 
brown rice, wild rice, buckwheat, triticale, bulgur (cracked 
wheat), millet, quinoa, and sorghum. 
 Cut back on pastries and high-calorie bakery products (eg, 
muffins, doughnuts). 
 Select milk and dairy products that are either fat free or low fat. 
 Reduce salt intake by 
- comparing the sodium content of similar products (eg, different 
brands of tomato sauce) and choosing products with less salt; 
- choosing versions of processed foods, including cereals and 
baked goods, that are reduced in salt; and 
- limiting condiments (eg, soy sauce, ketchup). 
 Use lean cuts of meat and remove skin from poultry before 
eating. 
 Limit processed meats that are high in saturated fat and 
sodium. 
 Grill, bake, or broil fish, meat, and poultry. 
 Incorporate vegetable-based meat substitutes into favorite 
recipes. 
 Encourage the consumption of whole vegetables and fruits in 
place of juices.
Table 4. Practical Tips to Implement AHA 2006 Diet and Lifestyle Recommendations. 
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12. Psoriasis and metabolic syndrome 
Metabolic syndrome is a set of metabolic alterations, particularly insulin resistance, which, 
together, lead to a greater risk of pro-inflammatory and pro-thrombotic alterations. A 
number of studies have suggested an increase in the prevalence of the components of 
metabolic syndrome in patients with psoriasis (Cohen et al., 2008; Neimann et al., 2006; 
Sommer et al., 2006). 
Patients with psoriasis have a greater prevalence of metabolic syndrome in comparison to 
those with other dermatological conditions (30.1% vs 20.6%; OR: 1.65; 95%CI: 1.16 to 2.35) 
(Gisondi et al., 2007). However, few studies have considered the possibility of associating 
the treatment for psoriasis with the components of metabolic syndrome (Fu &Vender, 
2011). A case report of a patient with psoriasis and metabolic syndrome suggests that the 
treatment program designed by nutritionists and endocrinologists through the 
modification of diet and treatment of comorbidities provided an improvement in blood 
glucose, cholesterol and BMI, along with a clinical improvement in psoriasis (Saraceno et 
al., 2008). 
13. Conclusion 
Diet is an important factor in the etiology and pathogenesis of psoriasis. Low-calorie and 
vegetarian diets may be beneficial to the treatment of this condition. Although the results 
regarding the oral supplementation of fish oil are inconsistent, patients are recommended 
to consume fish rich in omega 3 PUFAs and parenteral infusions of PUFAs are 
recommended for patients hospitalized with acute psoriasis. Further studies are needed to 
clarify the role of a gluten-free diet, which may improve the severity of the disease in 
patients with IgA and/or IgG antigliadin antibodies. Moreover, the consumption of fruit 
and vegetables may be beneficial due to their high antioxidant content. Vitamin D is an 
important treatment option due to its immuno-regulating and anti-proliferation activity. 
Patients with psoriasis should not consume alcoholic beverages in order to avoid 
exacerbation of the disease.  
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